

GUIDELINE

International Society for Heart and Lung Transplantation Guidelines for the Evaluation and Care of Cardiac Transplant Candidates—2024



Yael Peled, MD,^{1,2,a,*} Anique Ducharme, MD, MSc,^{3,a,**} Michelle Kittleson, MD, PhD,⁴ Neha Bansal, MD,⁵ Josef Stehlik, MD, MPH,⁶ Shahnawaz Amdani, MD,⁷ Diyar Saeed, MD, PhD,⁸ Richard Cheng, MD, MS,⁹ Brian Clarke, MD,¹⁰ Fabienne Dobbels, PhD,¹¹ Maryjane Farr, MD, MSc,¹² JoAnn Lindenfeld, MD,¹³ Lazaros Nikolaidis, MD,¹⁴ Jignesh Patel, MD, PhD,¹⁵ Deepak Acharya, MD,¹⁶ Dimpna Albert, MD, PhD,¹⁷ Saima Aslam, MD,¹⁸ Alejandro Bertolotti, MD,¹⁹ Michael Chan, MD,²⁰ Sharon Chih, MD,²¹ Monica Colvin, MD,²² Maria Crespo-Leiro, MD,²³ David D'Alessandro, MD,²⁴ Kevin Daly, MD,²⁵ Carles Diez-Lopez, MD, PhD,²⁶ Anne Dipchand, MD,²⁷ Stephan Ensminger, MD,²⁸ Melanie Everitt, MD,²⁹ Alexander Fardman, MD,³⁰ Marta Farrero, MD, PhD,³¹ David Feldman, MD, PhD,³² Christiana Gjelaj, DNP,³³ Matthew Goodwin, MD, MS,³⁴ Kimberly Harrison, PharmD, BCTXP,³⁵ Eileen Hsich, MD,³⁶ Emer Joyce, MB, BCH, PhD,³⁷ Tomoko Kato, MD,³⁸ Daniel Kim, MD,³⁹ Me-Linh Luong, MD,⁴⁰ Haifa Lyster, FRPharmS,⁴¹ Marco Masetti, MD,⁴² Ligia Neres Matos, RN,⁴³ Johan Nilsson, MD, PhD,⁴⁴ Pierre-Emmanuel Noly, MD, PhD,⁴⁵ Vivek Rao, MD, PhD,⁴⁶ Katrine Rolid, MSc, PhD,⁴⁷ Kelly Schlendorf, MD,⁴⁸ Martin Schweiger, MD,⁴⁹ Joseph Spinner, MD,⁵⁰ Madeleine Townsend, MD,⁵¹ Maxime Tremblay-Gravel, MD, MSc,⁵² Simon Urschel, MD,⁵³ Jean-Luc Vachieri, MD,⁵⁴ Angela Velleca, MHDS, RN,⁵⁵ Georgina Waldman, PharmD, BCTXP,⁵⁶ and James Walsh, BPhy, PhD⁵⁷

¹Leviev Heart & Vascular Center, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; ²Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel; ³Department of Medicine, Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada; ⁴Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA; ⁵Icahn School of Medicine at Mount Sinai, New York, New York, USA; ⁶Division of Cardiovascular Medicine, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA; ⁷Department of Pediatric Cardiology, Cleveland Clinic Children's, Cleveland, Ohio, USA; ⁸Heart Center Niederrhein, Helios Hospital Krefeld, Krefeld, Germany; ⁹Division of Cardiology, University of Washington, Seattle, WA, USA; ¹⁰Division of Cardiology, University of British Columbia, St Paul's Hospital, Vancouver, British Columbia, Canada; ¹¹Academic Centre for Nursing and Midwifery, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium; ¹²Division of Cardiology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX; ¹³Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN, USA; ¹⁴Baylor Scott & White Medical Center, Temple, TX, USA; ¹⁵Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA; ¹⁶Division of Cardiovascular Diseases, University of Arizona Sarver Heart Center, Tucson, Arizona, USA; ¹⁷Department of Paediatric Cardiology, Paediatric Heart Failure and Cardiac Transplant, Heart Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; ¹⁸Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, La Jolla, California, USA; ¹⁹Heart and Lung Transplant Service, Favaloro Foundation University Hospital, Buenos Aires, Argentina; ²⁰University of Alberta Hospital, Edmonton, Alberta, Canada; ²¹Heart Failure and Transplantation, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; ²²Department of Cardiology, University of Michigan, Ann Arbor, MI; ²³Scientific Registry of Transplant Recipients, Hennepin Healthcare Research Institute, Minneapolis, MN, USA; ²⁴Cardiology Department Complejo Hospitalario Universitario A Coruna (CHUAC), CIBERCV, INIBIC, UDC, La Coruna, Spain; ²⁵Massachusetts General Hospital, Boston; ²⁶Harvard School of Medicine, Boston, MA, USA; ²⁷Boston Children's Hospital & Harvard Medical School, Boston, MA, USA; ²⁸Advanced Heart Failure and Heart Transplant Unit,

Endorsed by the Pediatric Heart Transplant Society.

*Corresponding author: Yael Peled, MD, Sheba Hospital, Leviev Heart Center, Tel Hashomer, 5265601 Ramat Gan, Israel; email: Yael.Peled-Potashnik@sheba.health.gov.il.

**Corresponding author: Anique Ducharme, MD, MSc, Montreal Heart Institute, University of Montreal, 5000 Belanger east, Montreal (QC), Canada, H1T 1C8; email: anique.ducharme@umontreal.ca.

^a These authors contributed equally.

To inquire about reprints and permissions, please visit <https://www.medreprints.com/howto> or complete the contact form: <https://service.elsevier.com/app/contact/supporthub/permissions-helpdesk/>

1053-2498/© 2024 International Society for Heart and Lung Transplantation. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

<https://doi.org/10.1016/j.healun.2024.05.010>

Department of Cardiology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; ²⁷Division of Cardiology, Department of Paediatrics, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada; ²⁸Heart Center Lübeck, University Hospital, Lübeck, Germany; ²⁹Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA; ³⁰Leviev Heart & Vascular Center, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel; ³¹Department of Cardiology, Hospital Clínic, Barcelona, Spain; ³²Newark Beth Israel Hospital & Rutgers University, Newark, NJ, USA; ³³Department of Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA; ³⁴Division of Cardiothoracic Surgery, University of Utah, Salt Lake City, UT, USA; ³⁵Department of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, TN, USA; ³⁶Cleveland Clinic Foundation, Division of Cardiovascular Medicine, Cleveland, OH, USA; ³⁷Department of Cardiology, Mater University Hospital, Dublin, Ireland; School of Medicine, University College Dublin, Dublin, Ireland; ³⁸Department of Cardiology, International University of Health and Welfare School of Medicine, Narita, Chiba, Japan; ³⁹University of Alberta & Mazankowski Alberta Heart Institute, Edmonton, Alberta, Canada; ⁴⁰Division of Infectious Disease, Department of Medicine, University of Montreal Hospital Center, Montreal, Quebec, Canada; ⁴¹Department of Heart and Lung Transplantation, The Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Harefield, Middlesex, UK; ⁴²Heart Failure and Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; ⁴³Hospital Pró-Cardíaco, Rio de Janeiro, Brazil; ⁴⁴Department of Cardiothoracic and Vascular Surgery, Skane University Hospital, Lund, Sweden; ⁴⁵Department of Surgery, Montreal Heart Institute, Montreal, Quebec, Canada; ⁴⁶Division of Cardiac Surgery, University of Toronto, Toronto, Ontario, Canada; ⁴⁷Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway; ⁴⁸Division of Cardiology, Vanderbilt University Medical Center, Nashville, TN, USA; ⁴⁹University Children's Hospital, Zurich, Switzerland; ⁵⁰Section of Pediatric Cardiology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA; ⁵¹Division of Pediatric Cardiology, Stollery Children's Hospital, Edmonton, Alberta, Canada; ⁵²Department of Medicine, Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada; ⁵³Stollery Children's Hospital, University of Alberta, Edmonton, Alberta, Canada; ⁵⁴Department of Cardiology, Cliniques Universitaires de Bruxelles, Hôpital Académique Erasme, Bruxelles, Belgium; ⁵⁵Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA; ⁵⁶Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA; ⁵⁷Allied Health Research Collaborative, The Prince Charles Hospital, Brisbane; Heart Lung Institute, The Prince Charles Hospital, Brisbane, Australia.

The “International Society for Heart and Lung Transplantation Guidelines for the Evaluation and Care of Cardiac Transplant Candidates—2024” updates and replaces the “Listing Criteria for Heart Transplantation: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidates—2006” and the “2016 International Society for Heart Lung Transplantation Listing Criteria for Heart Transplantation: A 10-year Update.” The document aims to provide tools to help integrate the numerous variables involved in evaluating patients for transplantation, emphasizing updating the collaborative treatment while waiting for a transplant. There have been significant practice-changing developments in the care of heart transplant recipients since the publication of the International Society for Heart and Lung Transplantation (ISHLT) guidelines in 2006 and the 10-year update in 2016. The changes pertain to 3 aspects of heart transplantation: (1) patient selection criteria, (2) care of selected patient populations, and (3) durable mechanical support. To address these issues, 3 task forces were assembled. Each task force was cochaired by a pediatric heart transplant physician with the specific mandate to highlight issues unique to the pediatric heart transplant population and ensure their adequate representation. This guideline was harmonized with other ISHLT guidelines published through November 2023. The 2024 ISHLT guidelines for the evaluation and care of cardiac transplant candidates provide recommendations based on contemporary scientific evidence and patient management flow diagrams. The American College of Cardiology and American Heart Association modular knowledge chunk format has been implemented, allowing guideline information to be grouped into discrete packages (or modules) of information on a disease-specific topic or management issue. Aiming to improve the quality of care for heart transplant candidates, the recommendations present an evidence-based approach.

J Heart Lung Transplant 2024;43:1529–1628

© 2024 International Society for Heart and Lung Transplantation. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

KEYWORDS:

Heart transplant candidates; Durable mechanical circulatory support; Guideline-directed medical therapy; Pediatric heart transplant; Collaborative treatment

Contents

1.	INTRODUCTION	6
1.1.	Rationale	6
1.2.	Purpose and Structure of the Document	7
1.3.	Task Forces	8
1.3.1.	Task Force I: Evaluation for Heart Transplant Candidacy. Cochairs: Michelle Kittleson and Neha Bansal (Pediatric)	8
1.3.2.	Task Force II: Optimization of the Medical Surveillance of Patients on the Waitlist. Cochairs: Josef Stehlik and Shahnawaz Amdani (Pediatric)	8
1.3.3.	Task Force III: Considerations for Mechanical Circulatory Support Systems. Chair: Diyar Saeed	8
1.4.	Document Format: Modular Knowledge Chunk	8
1.5.	Grading the Evidence	8
1.6.	Abbreviations	9
2.	TASK FORCE I: EVALUATION FOR HEART TRANSPLANT CANDIDACY	10
2.1.	Listing Criteria for Heart Transplantation	10
2.1.1.	Indications for Heart Transplantation	10
2.1.2.	Comorbidities and Potential Contraindications to Heart Transplantation	12
2.1.2.1.	Age	13
2.1.2.2.	Obesity	13
2.1.2.3.	Cancer	14
2.1.2.4.	Diabetes	19
2.1.2.5.	Cerebral and Peripheral Vascular Disease	19
2.1.2.6.	Pulmonary Disease	20
2.1.2.7.	Pulmonary Hypertension	21
2.1.2.8.	Kidney Disease	23
2.1.2.9.	Liver Disease	24
2.1.2.10.	Connective Tissue Diseases and Sarcoidosis	26
2.1.2.11.	Infections and Vaccinations	26
2.1.2.12.	Frailty	29
2.1.2.13.	Surgical Risk	31
2.1.2.14.	Bone Disease	31
2.1.3.	Assessment of Transplant Eligibility in Special Populations	32
2.1.3.1.	Cardiac Amyloidosis	32
2.1.3.2.	Restrictive and Hypertrophic Cardiomyopathy	35
2.1.3.2.1.	Restrictive Cardiomyopathy	35
2.1.3.2.2.	Hypertrophic Cardiomyopathy	36
2.1.3.3.	Congenital Heart Disease	37
2.1.3.4.	Retransplantation	40
2.1.4.	Special Considerations Regarding Transplant Eligibility in Pediatric Patients	41
2.2.	Psychosocial Evaluation	42
2.2.1.	Evaluation of Substance Use	42
2.2.2.	Evaluation of Support, Adherence, and Mental Health	43
2.2.3.	Special Considerations in Pediatric Psychosocial Assessment	47
2.2.3.1.	High-risk Psychosocial Assessment in Pediatric Heart Transplant Candidates	47
2.2.3.2.	Cultural Considerations in the Pediatric Heart Transplant Candidate Evaluation	47
2.2.3.2.1.	Race/Ethnicity and Socioeconomic Status	47
2.2.3.2.2.	Religion	47
2.2.3.3.	Impact of Intellectual and Developmental Disabilities on Pediatric Heart Transplant Candidacy	47
2.2.3.4.	Parental Refusal of Vaccination	48
2.3.	Multidisciplinary Team Approach	48
3.	TASK FORCE II: OPTIMIZATION OF THE MEDICAL SURVEILLANCE OF PATIENTS ON THE WAITLIST	52
3.1.	Optimal Pharmacologic Management of Heart Transplant Candidates	52
3.1.1.	Standard Heart Failure Guideline-Directed Medical Therapies	52
3.1.2.	Diuretics and Volume Management	53
3.1.3.	Antianginal Therapy	53

3.1.4.	Pulmonary Hypertension Therapy	54
3.1.5.	Anticoagulant and Antiplatelet Therapy	55
3.1.6.	Systemic Disease Modifying Therapies	56
3.1.7.	Special Considerations for Combined Organ Transplant Candidates	56
3.1.8.	Special Considerations for Pediatric Heart Failure Patients	57
3.2.	Nonpharmacologic Management of Cardiac Transplant Candidates: Approaches to Be Considered	58
3.2.1.	Percutaneous Interventional Procedures in Heart Transplant Candidates	58
3.2.2.	Heart Rhythm Considerations in Heart Transplant Candidates	59
3.2.3.	Nonpharmacologic Management of Pediatric Transplant Candidates	61
3.3.	Surveillance and Management on the Waitlist	61
3.3.1.	Serial Evaluation (Guidelines for Repeat Testing on the Waitlist)	61
3.3.1.1.	Cardiac Catheterization to Assess Hemodynamic Stability	61
3.3.1.2.	Exercise Capacity: Frequency of Assessment	62
3.3.1.3.	Assessment of Extracardiac Organ Function (Renal and Liver Function)	63
3.3.1.4.	Updating Vaccinations and Screening for Infections on the Waitlist.	63
3.3.1.5.	Frequency of Malignancy Screening	64
3.3.1.6.	Dynamic Psychosocial Evaluation	66
3.3.1.7.	Evaluation of Malnutrition and Frailty on the Waitlist.	67
3.3.1.8.	Monitoring of HLA and ABO Sensitization while Awaiting Transplantation	68
3.3.1.9.	Role of Biomarkers.	69
3.3.1.10.	Improvement and Removal from the Waitlist	70
3.3.2.	Acute Decompensation on the Waitlist	70
3.3.2.1.	Considerations for Status Upgrade on the Waitlist	70
3.3.2.2.	Inotropic and Vasoactive Therapy	71
3.3.2.3.	Cardio-Renal Syndrome	73
3.3.2.4.	End-of-Life Care and Removal from the Waitlist.	73
3.3.3.	Managing Special Populations on the Waitlist	74
3.3.3.1.	Retransplant and Multiorgan Transplant	74
3.3.3.2.	Pediatric and Congenital Heart Disease Considerations	75
3.4.	Preoperative Preparation of the Patient for Transplantation.	76
3.4.1.	Standard and Specialized Preoperative Measures	76
3.4.2.	Infectious Disease Considerations.	78
3.4.2.1.	Hepatitis B and C Viral Infections	78
3.4.2.2.	Coronavirus Disease 2019	81
3.4.2.3.	Human Immunodeficiency Viral Infection	83
3.4.3.	Donor-Recipient Matching Considerations.	84
3.4.4.	Recommendations for Preoperative Preparation of Pediatric Patients for Transplantation.	85
3.5.	Ethical Considerations	85
4.	TASK FORCE III: CONSIDERATIONS FOR MECHANICAL CIRCULATORY SUPPORT SYSTEMS.	86
4.1.	Scope of the Problem	86
4.1.1.	Trends in Utilization of Durable Mechanical Support Devices	86
4.1.2.	Waitlist Outcomes	86
4.1.3.	Indications for Durable Mechanical Support Devices	86
4.1.4.	Indications for Durable Mechanical Support Devices in Pediatric Patients	87
4.2.	Candidate Selection for Durable Mechanical Circulatory Support	88
4.2.1.	Patient Evaluation and Risk Factors	88
4.2.2.	Pediatric Patients.	90
4.3.	Surgical Planning and Operative Considerations in Transplant Candidates Bridged With Durable Mechanical Circulatory Support	91
4.4.	Complications of Durable Mechanical Circulatory Support and Their Implications for Candidacy	91
4.4.1.	General Considerations	91
4.4.2.	Gastrointestinal Bleeding	92
4.4.3.	Pump Thrombosis	93
4.4.4.	Right Heart Failure	93
4.4.5.	Infection	94
4.4.6.	Neurological Complications	95

4.4.7. Ventricular Arrhythmias	95
4.4.8. End-Organ Dysfunction	96
4.4.9. Complications of DMCS and Their Implications for Candidacy in the Pediatric Population	96
4.5. Considerations for Patients With Temporary Mechanical Circulatory Support.	97
EVIDENCE GAPS AND FUTURE RESEARCH DIRECTIONS	99
REFERENCES	100.e1

TOP 10 TAKE-HOME MESSAGES

1. In the assessment of heart transplant candidacy, the document focuses on an individualized approach rather than absolute thresholds contraindicating eligibility, specifically for parameters including age and obesity as well as conditions such as cancer, vascular disease, kidney disease, liver disease, and connective tissue diseases (CTD).
2. With the changing landscape of candidates' characteristics, particular attention is devoted to assessment of candidacy in patients with amyloidosis and congenital heart disease (CHD), as well as to issues of re-transplantation. Systematic candidate evaluation should assess the severity and natural history of extra-cardiac involvement with a particular focus on the downstream effects of malnutrition and frailty. Retransplantation for cardiac allograft vasculopathy (CAV), or in highly sensitized patients with end-organ damage, requires careful planning and emphasis on shared decision-making with patients and their families.
3. History of malignancy is common in patients undergoing evaluation for heart transplantation (HT) and confers a higher risk for post-transplant malignancies. The incidence of de novo malignancy post-transplant in the recent era is also increasing. The document provides extensive recommendations regarding the timing of HT in patients with a history or presence of malignancy (skin cancer, hematological, and solid organ malignancies) based on tumor grade and stage at diagnosis, the time from treatment, and cancer screening surveillance.
4. The psychosocial evaluation of heart transplant candidates is a key component of the multifaceted pre-transplant screening process, aimed at identifying those candidates at increased risk for poor post-transplant outcomes due to inadequate support, substance use, adherence, or optimal mental health. In particular, the evaluation of pediatric candidates warrants careful assessment of cultural considerations, the impact of intellectual and developmental disabilities, and parental refusal of vaccination.
5. Given the complexity of the medical and psychosocial issues faced by heart transplant candidates, a multidisciplinary approach is paramount, including but not limited to a heart failure (HF) cardiologist, cardiac surgeon, transplant nurse coordinator, transplant infectious diseases specialist, transplant pharmacist, immunologist, mental health expert, social worker, registered dietician, physical and occupational therapist, and palliative care specialist, with other specialists included based on the patient's specific needs. For pediatric heart transplant candidates, additional specialists may be required, including those with expertise in assessing capacity to assent; child-life specialists to optimize education and participation of the pediatric patient and family in the transplant process; and mental health experts with specific expertise in pediatric mental health.
6. Maximally tolerated doses of guideline-directed medical therapy (GDMT) should be maintained while patients await HT. For patients on anticoagulant and/or antiplatelet therapy, a plan for perioperative management should be established at the time of heart transplant listing. For those with worsening HF, optimal support with inotropes and mechanical circulatory support (MCS) should be considered before the onset of significant end-organ dysfunction. It is also important to consider percutaneous interventional procedures and devices for monitoring [e.g., pulmonary artery (PA) pressure monitor] and management [e.g., implantable cardioverter

defibrillator (ICD), cardiac resynchronization therapy (CRT), transcatheter edge-to-edge repair, transcatheter valve replacement, arrhythmia ablation] in patients meeting appropriate indications.

7. For patients who are awaiting HT, it is recommended to continue, at appropriate intervals, evaluation including noninvasive testing [cardiopulmonary exercise test (CPET), renal and liver function, panel-reactive antibody (PRA) and ABO titers, biomarker assessment, imaging for malignancy surveillance], invasive testing (hemodynamic assessment), nutritional/frailty and psychosocial evaluation and malignancy screening. Also, it is important to provide appropriate recommended vaccinations during the waitlist period. For patients who are improving, discussion around removal from the list to continue medical therapy, and for those who are worsening, discussions around care escalation (inotropic support/MCS) or de-escalation should be taken.
8. The heart transplant team should establish a preoperative plan focusing on pharmacological therapy adjustment at the time of transplant—that is, when to stop select HF medications to avoid vasoplegia, to reverse anticoagulation, to initiate antibiotic treatment for methicillin-resistant *Staphylococcus aureus* (MRSA) colonization, ventricular assist device (VAD) infections, and antiviral treatment for possible exposure to hepatitis B virus (HBV), hepatitis C virus (HCV), coronavirus disease 2019 (COVID-19).
9. Durable mechanical circulatory support (DMCS) is a useful bridging strategy for transplant-eligible patients refractory to optimal medical therapy (OMT), avoiding further end-organ injury, improving quality of life (QOL), and prolonging survival. Given the availability of reliable and lower-risk left ventricular assist devices (LVADs) for clinical use, it is essential to revisit the indications for bridge-to-transplantation LVAD therapy and the optimal timing for MCS support. In patients with DMCS, candidacy for HT must be assessed longitudinally during follow-up regardless of the intended initial strategy. Preoperative planning is vital to ensure successful HT in this population.
10. In transplant candidates supported with a DMCS, the occurrence of a life-threatening complication, device-related, or patient-related adverse events refractory to conventional medical or surgical treatment warrants evaluation for urgent HT. Patients with severe sepsis secondary to a device-related or device-specific infection should not be transplanted until end-organ functions recover and the sepsis is controlled. The presence of an irreversible clinical condition that might impair post-transplantation survival (e.g., disabling stroke) in patients with DMCS should preclude HT. For patients in cardiogenic shock refractory to medical therapy, support with temporary MCS (tMCS) is a viable bridging strategy for urgent HT.

1. INTRODUCTION

1.1. Rationale

There have been significant practice-changing developments in the evaluation and care of heart transplant recipients since the publications of the previous guidelines and updates (Table 1). The changes pertain to 3 aspects of HT: (1) patient selection criteria, (2) care of selected patient populations, and (3) durable mechanical support. The areas that have evolved dramatically in recent decades include recipient age, frailty assessment, pulmonary hypertension (PH) evaluation, substance use, combined heart and other solid organ transplantation (SOT), adult CHD, cardiac amyloidosis, high sensitization and management of antibodies to human leukocyte antigen (HLA), infections and antiviral therapies (i.e., HCV, HIV, etc.), and the long-term noncardiac care. Notably, the introduction of MCS devices has changed the characteristics of patients and the landscape for patients with severe HF, necessitating adaptations in heart allocation policy.

1.2. Purpose and Structure of the Document

Evaluation for heart transplant candidacy is a multidisciplinary endeavor, integrating medical, psychosocial, environmental, and genetic parameters. The purpose of the document is to provide tools that will help integrate the various variables involved in evaluating patients for transplantation, with an emphasis on updating the collaborative treatment while waiting for a transplant. To address these issues, 3 task forces were assembled. Each task force was cochaired by an adult and a pediatric heart transplant physician with the specific mandate to highlight issues unique to the pediatric heart transplant population and to ensure their adequate representation.

Table 1 Associated Guidelines and Statements		
Guidelines (Title)	Organization	Publication Year
Rationale and Process: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidates—2006	ISHLT	2006 ¹
Optimal Pharmacologic and Non-pharmacologic Management of Cardiac Transplant Candidates: Approaches to be Considered Prior to Transplant Evaluation: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidates—2006	ISHLT	2006 ²
Listing Criteria for Heart Transplantation: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidates—2006	ISHLT	2006 ³
Heart Rhythm Considerations in Heart Transplant Candidates and Considerations for Ventricular Assist Devices: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidates—2006	ISHLT	2006 ⁴
The 2016 International Society for Heart Lung Transplantation Listing Criteria for Heart Transplantation: A 10-year Update	ISHLT	2015 ⁵
The 2018 ISHLT/APM/AST/ICCAC/STSW recommendations for the Psychosocial Evaluation of Adult Cardiothoracic Transplant Candidates and Candidates for long-term mechanical circulatory support	ISHLT; APM; AST; ICCAC; STSW	2018 ⁶
ISHLT Consensus Statement on Donor Organ Acceptability and Management in Pediatric Heart Transplantation	ISHLT	2020 ⁷
Donor Heart Selection: Evidence-Based Guidelines for Providers	ISHLT	2022 ⁸
The ISHLT Guidelines for the Care of Heart Transplant Recipients	ISHLT	2022 ⁹
The ISHLT/HFSA Guideline on Acute Mechanical Circulatory Support	ISHLT; HFSA	2023 ¹⁰
The 2023 International Society for Heart and Lung Transplantation Guidelines for Mechanical Circulatory Support: A 10-year Update	ISHLT	2023 ¹¹
Dual-Organ Transplantation: Indications, Evaluation, and Outcomes for Heart-Kidney and Heart-Liver Transplantation: A Scientific Statement From the American Heart Association	AHA (endorsed by ISHLT)	2023 ¹²
Assessing and Managing Frailty in Advanced Heart Failure: An International Society for Heart and Lung Transplantation Consensus Statement	ISHLT	2023 ¹³
Abbreviations: AHA, American Heart Association; APM, Academy of Psychosomatic Medicine; AST, American Society of Transplantation; ICCAC, International Consortium of Circulatory Assist Clinicians; ISHLT, International Society for Heart and Lung Transplantation; STSW, Society for Transplant Social Workers; HFSA, Heart Failure Society of America.		

1.3. Task Forces

1.3.1. Task Force I: Evaluation for Heart Transplant Candidacy. Cochairs: Michelle Kittleson and Neha Bansal (Pediatric)

This Task Force aims to identify the patients with the greatest need and the highest potential for favorable outcomes of HT. The document will aid in integrating multiple factors, including indicators for poor prognosis without transplant and potential contraindications that may cause suboptimal outcomes post-transplant (subsection 1; Listing criteria for HT, led by Maryjane Farr). Following rigorous medical and psychosocial evaluation, the listing decision is made by a multidisciplinary team (subsection 2; Psychosocial evaluation of candidates for HT, led by Fabienne Dobbels). Task Force I will define the multidisciplinary team's composition and the division of roles and responsibilities (subsection 3; Multidisciplinary team, led by Brian Clarke).

1.3.2. Task Force II: Optimization of the Medical Surveillance of Patients on the Waitlist. Cochairs: Josef Stehlik and Shahnawaz Amdani (Pediatric)

The general aim is to maintain or even improve the level of function at listing until transplantation, that is, essentially to make sure that each patient remains an optimal candidate and is appropriately risk-stratified (subsection 1; Optimal pharmacologic management, led by Lazaros A. Nikolaidis). Advancements in nonpharmacologic management continue to improve outcomes. Percutaneous interventions may substantially alter HF trajectory and should complement aggressive attempts to maximize GDMT (subsection 2; Nonpharmacologic management of cardiac transplant candidates, led by JoAnn Lindenfeld). Patients should be frequently evaluated while on the waitlist to determine if they have developed potential contraindications to transplantation or have become too well to merit transplantation; this evaluation will focus on serial evaluation and repeat testing on the waitlist of HF symptoms, hemodynamic stability (including PH), exercise capacity, renal function, and multiorgan involvement. A notable proportion of waitlist patients is "sensitized"; thus, attention should be paid to considerations for desensitization therapy or waitlist prioritization consideration (subsection 3; Surveillance and management of decompensation/deterioration, led by Jignesh Patel). Preoperative preparation of the patient for transplantation incorporates standard and specialized considerations to maximize the chance of a favorable outcome (subsection 4; Preoperative preparation of the patient for transplantation, led by Richard Cheng).

1.3.3. Task Force III: Considerations for Mechanical Circulatory Support Systems. Chair: Diyar Saeed

The concept of MCS has developed concomitantly with the field of HT. Task Force III comprises a short section relating to the 2023 International Society for Heart and Lung Transplantation Guidelines for Mechanical Circulatory Support.¹¹ Patients selection, complications of DMCS and their implications for HT candidacy, and bridging to transplant with tMCS will be discussed.

1.4. Document Format: Modular Knowledge Chunk

The American College of Cardiology (ACC)/American Heart Association (AHA) formatting guidelines were adopted using the modular knowledge chunk.¹⁴ This format allows guideline information to be grouped into discrete packages (or modules) of information on a disease-specific topic or management issue. The focus of the guideline is on the recommendations themselves, presented in the modular knowledge chunk format, consisting of

1. a table of related recommendations;
2. a brief synopsis, which may include important background information overarching management or treatment concepts;
3. more detailed recommendation-specific supportive text for each recommendation;
4. a flow diagram or additional information table(s) (when appropriate).

1.5. Grading the Evidence

In applying the ACC/AHA Class of Recommendation (COR) and Level of Evidence (LOE) to Clinical Strategies, Interventions, Treatments, or Diagnostic Testing in Patient Care, the COR indicates the strength of recommendation, encompassing the estimated magnitude and certainty of benefit in proportion to risk. The LOE rates the quality of scientific evidence supporting the intervention or other clinical activity on the basis of the type, quantity, and consistency of data from clinical trials and other sources (Table 2).¹⁵

Table 2 Applying ACC/AHA Class of Recommendation and Level of Evidence

CLASS (STRENGTH) OF RECOMMENDATION	
CLASS 1 (STRONG)	Benefit >>> Risk
CLASS 2a (MODERATE)	Benefit >> Risk
CLASS 2b (WEAK)	Benefit > Risk
CLASS 3: No Benefit (MODERATE)	Benefit = Risk
CLASS 3: Harm (STRONG)	Risk > Benefit
LEVEL (QUALITY) OF EVIDENCE	
LEVEL A	
High-quality evidence from more than 1 randomized controlled trial	
Meta-analyses of high-quality randomized controlled trials	
One or more randomized controlled trials corroborated by high-quality registry studies	
LEVEL B-R (Randomized)	
Moderate-quality evidence from 1 or more randomized controlled trials	
Meta-analyses of moderate-quality randomized controlled trials	
LEVEL B-NR (Nonrandomized)	
Moderate-quality evidence from 1 or more well-designed, well-executed nonrandomized studies, observational studies, or registry studies	
Meta-analyses of such studies	
LEVEL C-LD (Limited Data)	
Randomized or nonrandomized observational or registry studies with limitations of design or execution	
Meta-analyses of such studies	
Physiological or mechanistic studies in human subjects	
LEVEL C-EO (Expert Opinion)	
Consensus of expert opinion based on clinical experience	
Adapted from. ¹⁵	

1.6. Abbreviations

ACC, American College of Cardiology; ACEi, angiotensin-converting enzyme inhibitors; AdvHF, advanced heart failure; AF, atrial fibrillation; AHA, American Heart Association; AKI, acute kidney injury; AL-CM, amyloid monoclonal immunoglobulin light chain cardiomyopathy; ARB, angiotensin II receptor blocker; ARNi, angiotensin receptor-neprilysin inhibitor; ATTR-CM, amyloid transthyretin cardiomyopathy; ATTRv, variant transthyretin amyloid; ATTRwt, wild-type transthyretin amyloid; AUDIT, alcohol use disorder identification test; BHS, behavioral health specialists; BiV, biventricular; BiVAD, biventricular assist device; BMI, body mass index; BNP, B-type natriuretic peptide; BTC, bridge to candidacy; BTT, bridge to transplantation; BTR, bridge to recovery; CAV, cardiac allograft vasculopathy; CF, continuous flow; CHD, congenital heart disease; CKD, chronic kidney disease; CO, cardiac output; COR, class of recommendation; COVID-19, coronavirus disease 2019; CpcPH, combined post- and pre-capillary pulmonary hypertension; CPET, cardiopulmonary exercise test; CrCl, creatinine clearance; CRS, cardio-renal syndrome; CRT, cardiac resynchronization therapy; CT, computed tomography; CTD, connective tissue disease; CVP, central venous pressure; DAAs, direct-acting antivirals; DAPT, dual antiplatelet therapy; dFLC, difference between involved and uninvolved free light chain; DLCO, diffusing capacity of the lung for carbon monoxide; DMCS, durable mechanical circulatory support; DOAC, direct oral-anticoagulants; DRHR, donor-to-recipient height ratio; DRWR, donor-to-recipient weight ratio; DT, destination therapy; EF, ejection fraction; eGFR, estimated glomerular filtration rate; ELISA, enzyme-linked immunosorbent assay; ESCAPE, Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness; ETV, entecavir; EUROMACS, European Registry for Patients with Mechanical Circulatory Support; FALD, Fontan-associated liver disease; FEV1, forced expiratory volume in 1 second; FP, frailty phenotype; FVC, forced vital capacity; GDMT, guideline-directed medical therapy; GIB, gastrointestinal bleeding; GFR, glomerular filtration rate; GWTH-HF, Get With The Guidelines-Heart Failure; HbA1c, hemoglobin A1c; HBV, hepatitis B virus; HCM, hypertrophic cardiomyopathy; HCV, hepatitis C virus; HIT, heparin-induced thrombocytopenia; HIV, human immunodeficiency virus; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced

ejection fraction; HFSS, Heart Failure Survival Score; HLA, human leukocyte antigen; HLHS, hypoplastic heart syndrome; HT, heart transplantation; ICD, implantable cardioverter defibrillator; IDD, intellectual and developmental disabilities; IFA, immunofluorescent antibody assay; IGRA, interferon- γ release assay; INR, international normalized ratio; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; IVIG, intravenous immunoglobulin; ISHLT, International Society for Heart and Lung Transplantation; ISOs, isohemagglutinins; VAD, ventricular assist device; LV, left ventricular; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction; LOE, level of evidence; MAGGIC, Meta-Analysis Global Group in Chronic Heart Failure; MCS, mechanical circulatory support; MECKI, Metabolic Exercise Test Data combined with Cardiac and Kidney Indexes; MNA, Mini Nutritional Assessment; MNA-SF, MNA-short form; MR, mitral regurgitation; MRAs, mineralocorticoid receptor antagonists; MRI, magnetic resonance imaging; MRSA, methicillin-resistant *Staphylococcus aureus*; NAT, nucleic acid tests; NYHA, New York Heart Association; NOAC, new oral anticoagulants; NP, natriuretic peptides; NT-proBNP, N-terminal pro-brain natriuretic peptide; OMT, optimal medical therapy; OPTIMIZE-HF, Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure; PA, pulmonary artery; PB, plastic bronchitis; PACT, Psychosocial Assessment of Candidates for Transplantation; PASP, pulmonary artery systolic pressure; PAP, pulmonary artery pressure; PAPI, pulmonary artery pressure index; PCWP, pulmonary capillary wedge pressure; PH, pulmonary hypertension; PDE5, phosphodiesterase 5; PGD, primary graft dysfunction; PLE, protein-losing enteropathy; QOL, quality of life; peak VO₂, maximal oxygen consumption; pHM, predicted heart mass; PI, protease inhibitor; PRA, panel-reactive antibody; PSA, prostate-specific antigen; PVR, pulmonary vascular resistance; PVRI, PVR indexed to body surface area; RA, right atrial; RAASi, renin-angiotensin-aldosterone system inhibitors; RCM, restrictive cardiomyopathy; RHC, right heart catheterization; RHF, right heart failure; RV, right ventricular; RV-FAC, right ventricular fractional area change; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SGLT2i, sodium-glucose cotransporter-2 inhibitors; SHFM, Seattle Heart Failure Model; SHKT, simultaneous heart-kidney transplantation; SIPAT, Stanford Integrated Psychosocial Assessment for Transplant; SOT, solid organ transplant; TAH, total artificial heart; TB, tuberculosis; TDF, tenofovir disoproxil fumarate; TERS, Transplant Evaluation Rating Scale; tMCS, temporary mechanical circulatory support; TPG, transpulmonary gradient; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation; TST, tuberculin skin test; TTR, transthyretin; UNOS, United Network for Organ Sharing (United States); VAD, ventricular assist device; VTA, ventricular tachyarrhythmia.

2. TASK FORCE I: EVALUATION FOR HEART TRANSPLANT CANDIDACY

2.1. Listing Criteria for Heart Transplantation

2.1.1. Indications for Heart Transplantation

Recommendations for Indications for Heart Transplantation		
COR	LOE	RECOMMENDATIONS
1	B-NR	1. In patients with HF, when consistent with the patient's goals of care, the presence of clinical indicators of advanced HF (AdvHF) should trigger evaluation for AdvHF therapies, including HT.
1	B-NR	2. In ambulatory adult HF patients referred for transplant evaluation (and pediatric patients when age-appropriate), CPET should routinely be performed to quantify exertional intolerance, inform HF prognosis, and guide transplant listing.
1	C-LD	3. In adult HF patients evaluated for transplantation, right heart catheterization (RHC) should be performed prior to listing to assess for potentially prohibitive PH and for cardiogenic shock requiring inotropic support and/or temporary MCS.
2b	C-EO	4. In pediatric HT candidates, RHC may be performed prior to listing.
2a	C-LD	5. In adult HT candidates, HF prognosis scores can be considered in the context of other data collected during transplant evaluation to guide listing decisions.

Synopsis

A subset of patients with chronic HF will progress to advanced disease despite maximally tolerated guideline-directed medical and device therapies. The most common indications for HT are highly symptomatic HF, cardiogenic

shock, or uncontrolled ventricular arrhythmias. Other less common etiologies encompass restrictive cardiomyopathies (RCMs), including hypertrophic cardiomyopathy (HCM) and complex CHD after surgical palliation has failed. The first essential step in evaluation is to determine if the patient's clinical situation is limited enough to warrant transplant consideration, which requires confirmation that all attempts to optimize cardiac function—using OMT and interventions, such as CRT and transcatheter mitral valve repair, as indicated—have been exhausted. Measures to identify AdvHF include clinical indicators, CPET, right heart catheterization (RHC), and HF prognosis scores.

Recommendation-Specific Supportive Text

1. Because the presence of one or more clinical signs or symptoms of AdvHF is associated with a worse prognosis, recognition of these clinical indicators should prompt timely referral and evaluation for HT (Table 3). Encompassed by the mnemonic “I NEED HELP” are clinical clues to AdvHF. The components of this mnemonic are all risk factors that have been proven to increase all-cause mortality in HF patients.^{16–30} Other similar definitions and indicators of AdvHF have been described.^{31–34} Importantly, even patients with preserved left ventricular ejection fraction (LVEF) may have AdvHF in the setting of restrictive or valvular cardiomyopathy, isolated right ventricular (RV) failure, or congenital cardiac abnormalities when other clinical indicators are present.^{35–37} Early recognition of these clinical clues and events is essential to ensure time-appropriate transplant evaluation, as late recognition risks patients being considered too unwell to undergo transplantation.
2. Parameters derived during CPET are strongly prognostic in ambulatory HF patients being considered for HT. In HFrEF, Guazzi et al showed that the prognostic value of maximal oxygen consumption (peak VO_2) and the minute ventilation/carbon dioxide production (VE/VCO_2) slope are comparable for both men and women, with a greater discriminative power of the VE/VCO_2 slope over peak VO_2 in female patients,³⁸ which has been confirmed recently.³⁹ A summary of CPET parameters supporting transplant listing in different populations is shown in Table 4. In ambulatory patients, the results of CPET should be evaluated in the context of other data collected during transplant evaluation rather than used as the sole criterion for listing. In patients limited enough to require urgent or semiurgent inpatient evaluation, there is no clear role for CPET except in select cases where sufficient clinical improvement occurs and allows hospital discharge to be considered. The use of CPET is challenging in pediatric HF patients due to wide variations in protocols and patients' ages, sizes, and muscle mass.⁴⁰ In addition, patients with single-ventricle physiology have poor exercise performance with peak VO_2 often less than 65% predicted. Thus, a peak VO_2 less than 50% predicted is often considered supportive of transplant listing in this population.⁴¹
3. Invasive hemodynamics obtained during RHC at initial listing inform the severity of HF, predict waitlist outcomes, guide medical optimization, and assess for the presence of PH that might contribute to post-transplant right heart failure (RHF) and survival.^{42–44} Although elevations in pulmonary artery systolic pressure (PASP), transpulmonary gradient (TPG), and pulmonary vascular resistance (PVR) above certain thresholds have been proposed as contraindications to listing, the risk associated with each parameter is continuous from low to high values and absolute cutoffs do not exist.^{45,46} This is discussed in detail in [Pulmonary Hypertension](#).
4. Accurate assessment of PVR before transplantation and the related decision-making present specific challenges in the pediatric HF population. Limited data exist on the acceptable hemodynamics for HT listing in pediatrics and associated post-transplant outcomes. Assessment of PVR may be extremely difficult in patients with single-ventricle palliation, those with complex CHD, and those with long-standing dilated cardiomyopathy and either very poor function or mechanical assistance, and at times accurate determination may be impossible.⁴⁷ An elevated PVR was reported to be an independent risk factor for early and late post-transplant death and RV failure, with older patients experiencing greater PVR-related mortality after HT.⁴⁸ Thus, it might be reasonable to perform RHC in all pediatric patients when feasible.^{49,50}
5. Multiple prognosis scores have been developed to risk stratify patients with HF.^{51,52} The Heart Failure Survival Score (HFSS), Seattle Heart Failure Model (SHFM), Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) score, and Metabolic Exercise Test Data combined with Cardiac and Kidney Indexes (MECKI) score were developed for patients with chronic HF,^{53–55} while other scores such as the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF), Get With The Guidelines-Heart Failure (GWTG-HF), and Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) score were developed for patients with acute HF.^{56–60} In circumstances where there is ambiguity regarding appropriateness for listing based on other data, scores that suggest an estimated 1-year survival < 85% may help guide decision-making. Importantly, because all scores have inherent limitations, few have been developed or validated in a contemporary cohort, and most perform poorly when applied to individuals (as opposed to populations). Thus, their values should not be used as the sole criteria for listing.^{61,62}

Table 3 Markers of Advanced Heart Failure

	Parameter	Description
<i>I</i>	Inotropes	Previous or ongoing requirement for dobutamine, milrinone, dopamine, or levosimendan
<i>N</i>	NYHA class/Natriuretic peptides	Persisting NYHA class III or IV and/or persistently high BNP or NT-pro-BNP
<i>E</i>	End-organ dysfunction	Worsening renal or liver dysfunction in the setting of heart failure
<i>E</i>	Ejection fraction	Very low LVEF < 20%
<i>D</i>	Defibrillator shocks	Recurrent appropriate defibrillator shocks
<i>H</i>	Hospitalizations	More than 1 hospitalization with HF in the last 12 months
<i>E</i>	Edema/Escalating diuretics	Persisting fluid overload and/or increasing diuretic requirement
<i>L</i>	Low blood pressure	Consistently low blood pressure with systolic < 90-100 mm Hg
<i>P</i>	Prognostic medication	Inability to up-titrate (or need to decrease/cease) GDMF

Abbreviations: BNP, B-type natriuretic peptide; HF, heart failure; LVEF, left ventricular ejection fraction; NT-ProBNP, N-terminal pro-b-type natriuretic peptide; NYHA, New York Heart Association.

Adapted from.¹⁶

Table 4 Summary of CPET Parameters Supporting Transplant Listing in Different Populations

Patient population	Parameter supporting transplant listing
On beta-blocker ⁶³⁻⁶⁷	Lower peak VO ₂ cutoff is supportive of transplant listing, generally ≤12 ml/kg/min
Off beta-blocker ^{67,68}	Higher peak VO ₂ may be considered supportive of transplant listing, generally ≤14 ml/kg/min
Patients with obesity (BMI ≥ 30 kg/m ²) ⁶⁹	Peak VO ₂ adjusted for lean body mass ≤19 ml/kg/min
All, especially if submaximal CPET ⁷⁰⁻⁷⁵	VE/VCO ₂ slope > 35
Women or patients ≤50 or ≥70 years ⁷⁶⁻⁷⁸	Peak VO ₂ ≤ 50% predicted

Abbreviations: BMI, body mass index; CPET, cardiopulmonary exercise test; VE/VCO₂, the minute ventilation/carbon dioxide production. Maximal CPET: respiratory exchange ratio (RER) > 1.05 and reaching anaerobic threshold.⁷⁹

2.1.2. Comorbidities and Potential Contraindications to Heart Transplantation

Synopsis

Eligibility for and timing of HT evaluation requires a comprehensive survey of all comorbidities that may impact surgical risk, post-transplant QOL, and survival. ISHLT registry data indicates that over the last decade, heart transplant recipients have a higher body mass index (BMI), a greater burden of hypertension, diabetes, prior malignancy, prior cardiac surgery, and pre-transplant need for dialysis. Heart transplant recipients are becoming more complex, with a greater proportion of patients with allosensitization, older age, complex CHD, and need for dual-organ transplantation with kidney, liver, or lung transplantation.^{80,81} In addition, allocation schemes prioritize the sickest patients, including those in hospital settings, on tMCS, and with prior infections, increasing medical complexity and thus creating a greater need for careful and expeditious assessment of comorbidities.

A general theme when considering extracardiac contraindications to HT is to consider whether the extracardiac condition will (1) confer mortality risk such that patients will not garner the expected improvement in survival after transplantation; (2) impact post-transplant QOL and impair rehabilitation efforts; and (3) worsen in the context of immunosuppression. One approach to improve the HT evaluation process, especially for those unstable patients requiring urgent expedited inpatient evaluations, is to consider all patients with AdvHF to be potential HT candidates and to prioritize guideline-directed health care maintenance (including age-appropriate screening with Pap smears, mammograms, and colonoscopies, for example), vaccinations, and control of comorbidities. In this manner, AdvHF patients, even those perhaps considered too well for transplant consideration, could preserve their potential for future HT eligibility.

2.1.2.1. Age

Recommendations for Comorbidities and Potential Contraindications to Heart Transplantation: Age		
COR	LOE	RECOMMENDATIONS
1	B-NR	1. In patients with AdvHF aged ≤ 70 years, evaluation for HT is recommended.
2b	B-NR	2. In patients with AdvHF who are over 70 years of age, evaluation for HT may be considered in carefully selected patients depending on their functional status and control of comorbidities, taking into account the need for specialized post-transplant care for older patients, including the need for tailored immunosuppression.

Recommendation-Specific Supportive Text

- As life expectancy continues to increase, traditional age limits for HT may be expanded in select cases.^{80,81} Older age does confer more risk of certain post-transplant complications; compared to recipients under the age of 60 years, older transplant recipients have more infections, renal dysfunction, and malignancy but less rejection.^{82,83} Increasing recipient age is associated with an increase in post-transplant mortality, particularly in patients aged > 70 years at the time of transplant, with the incidence of specific causes of post-transplant mortality varying widely with recipient age.^{82,83} Although survival in patients ≥ 60 years of age is lower compared with younger recipients, the 5-year survival is acceptable.⁸³ The difference in outcomes between older and younger transplant recipients underscores the need for tailored immunosuppression.^{82,83} However, for patients aged ≤ 70 years, eligibility for HT should be based on the assessment of comorbidities without specific attention to age.
- While some studies indicate that heart transplant recipients over 70 years of age have comparable survival, after adjusting for comorbidities, to younger transplant recipients,^{84,85} this population is highly selected with careful attention to control and management of comorbidities. While older donors may be considered for older heart transplant candidates, this practice is of uncertain value given the observation that older donors are associated with worse post-transplant survival both in young and old recipients.⁸⁶ This issue raises the ethical question of using the scarce resource of young donor hearts for older recipients, with the question being further exacerbated by the potential need for dual-organ transplantation.⁸⁷ Strategies to mitigate these ethical dilemmas include limitations on dual-organ transplantation for patients over a given age, with program-specific thresholds based on consensus on clinical outcomes, and allocation systems that prioritize the listing of younger transplant candidates.⁸⁸ In summary, chronologic age alone should not constitute a contraindication for HT. However, careful patient selection criteria must be applied to identify those candidates most likely to derive acceptable QOL and survival.

2.1.2.2. Obesity

Recommendations for Comorbidities and Potential Contraindications to Heart Transplantation: Obesity		
COR	LOE	RECOMMENDATIONS
2a	B-NR	1. In adult heart transplant candidates with a pre-transplant BMI ≥ 35 kg/m ² , weight loss to achieve a BMI of < 35 kg/m ² is reasonable before listing for HT to improve post-transplant outcomes.
2b	C-LD	2. In pediatric heart transplant candidates, the use of a BMI threshold in assessing transplant candidacy is not well established.

Recommendation-Specific Supportive Text

- Increasing rates of obesity are observed in the heart transplant population, with a significant increase in BMI over time.⁸⁹ Obesity with BMI ≥ 35 kg/m² is associated with increased waitlist time, increased waitlist mortality,^{90,91} and increased post-transplant mortality.⁹¹ There is a graded relationship between increased BMI and worse post-transplant survival in multiple registry and meta-analyses,^{92–94} with the best survival being observed in those patients with normal BMI but acceptable survival in those patients with BMI 30 to 35 kg/m².⁹⁵ Considering that obesity is a potentially modifiable risk factor, achieving a BMI under 35 kg/m² is preferred to optimize waitlist time and survival, and post-transplant QOL and survival. For some patients, options including bariatric surgery may be considered, depending on center expertise, resources, and patient stability.^{96–98}

2. The role of a BMI threshold in transplant candidacy has not been established in pediatric heart transplant candidates.⁹⁹ Outcome data for obese pediatric heart transplant recipients are limited and conflicting: while some studies have demonstrated worse transplant outcomes for obese pediatric recipients, other studies have shown minimal or no difference in outcome.⁹⁹ There are insufficient data to support using any BMI cutoff as an absolute contraindication for HT in children. As childhood obesity is increasing and is unequally distributed by race and socioeconomic status,¹⁰⁰ exclusion of pediatric heart transplant candidates on the basis of obesity alone may be considered as contributing to health care disparities.

2.1.2.3. Cancer

Recommendations for Comorbidities and Potential Contraindications to Heart Transplantation: Cancer		
COR	LOE	RECOMMENDATIONS
2a	B-R	1. All HT candidates should be screened for solid organ tumors as recommended for the general population. ¹⁰¹ A. Colorectal cancer: patients aged 45–49-year (Class 2a) or aged 50–75 years (Class 1) with an average risk of colorectal cancer should undergo regular screening with either a high-sensitivity stool-based test (fecal immunochemical, high-sensitivity, guaiac-based fecal occult blood test, multitarget stool DNA high sensitivity) or a structural (visual) examination (colonoscopy, computed tomography (CT) colonoscopy, flexible sigmoidoscopy), depending on patient preference and test availability. As a part of the screening process, all positive results of non-colonoscopy screening tests should be followed up with a timely colonoscopy. ^{102,103} B. Screening for prostate cancer is recommended with prostate-specific antigen (PSA) with or without digital rectal examination for patients beginning at age 50 years, for patients at higher risk (African American and men who have a first-degree relative diagnosis with prostate cancer before age 65 years) beginning at age 45 years, for patients at appreciably higher risk (multiple family members diagnosed with prostate cancer before age 65 years) beginning at age 40 years (Class 1). ^{101,104} C. Breast cancer: women aged 45 to 54 years should have annual screening mammogram. Women aged 55 years and older should have a screening mammogram every 2 years but can continue annually if the patient prefers (Class 1). ¹⁰⁵ D. Cervical cancer: women aged 25 to 65 years should have a primary HPV test every 5 years (Class 1). If HPV testing is unavailable, screening may be done with either a co-test that combines an HPV test with a Papanicolaou (Pap) test every 5 years or a Pap test alone every 3 years. ¹⁰⁶ E. Lung cancer: patients aged 50–80 years with 20 pack-year smoking history who have quit smoking within the last 15 years should have annual low-dose chest CT. Screening should be discontinued once a patient reaches 15 years of smoking cessation. ¹⁰⁷ CT chest done in all heart transplant candidates should be evaluated for the early detection of lung cancer.
1		
2a	B-NR	2. Skin cancer screening by a full-body skin examination completed by a dermatologist for all heart transplant candidates can be useful to reduce skin cancer morbidity and mortality.
1	C-LD	3. In heart transplant candidates with a history of malignancy, collaboration with oncology specialists is recommended for individualized risk stratification to assess malignancy-related survival and risk of recurrence in the context of immunosuppression.
1	C-LD	4. In heart transplant candidates with a history of malignancy, HT is recommended when malignancy-related survival will not impact post-transplant survival and the risk of recurrence is low based on tumor type, response to therapy, and negative metastatic evaluation.
2a	B-NR	5. New technologies (i.e., circulating tumor DNA) can detect and measure microscopic residual disease in patients who have undergone definitive treatment, provide information on the status of a patient's cancer, and offer unique advantages in certain settings.

Recommendation-Specific Supportive Text

1. Malignancy after HT remains a significant cause of morbidity and mortality in adult and pediatric recipients. All HT candidates should be screened for solid organ tumors as recommended for the general population, as there are little data to support malignancy screening recommendations specific to the heart transplant recipient.¹⁰¹ Cancer screening guidelines from relevant expert societies may change over time, and the corresponding recommendations for heart transplant candidates should be updated accordingly.^{102–107} The role of screening with positron emission tomography for occult solid organ neoplasia in otherwise asymptomatic individuals with no other evidence of potential neoplasia from standard screening tests is not clear. This strategy cannot be universally recommended in the absence of data indicating benefit, especially given the potential risks of subsequent invasive testing resulting from incidental findings of unclear significance (See also [Frequency of Malignancy Screening, Table 19](#)).
2. The development of skin cancer post-transplantation portends tremendous morbidity, adversely affecting QOL for many transplant recipients. Pre-transplantation skin cancer is a major risk factor toward the development of skin cancer post-transplantation.¹⁰⁸ Skin cancer screening by a full-body skin examination completed by a dermatologist for all heart transplant candidates can be useful to reduce skin cancer morbidity and mortality. Heart transplant recipients with a history of skin cancer should continue standard skin cancer surveillance as recommended by their dermatologists.¹⁰⁹ Recommended wait times pre-transplantation for patients with a history of skin cancer before transplantation are presented in [Table 5](#).
3. Pre-existing neoplasms are diverse, and many are treatable with excision, radiotherapy, chemotherapy, or immunotherapy to induce cure or remission. An aging population, side effects from radiation and chemotherapy, and improved cancer survivorship have increased the number of patients undergoing evaluation for cardiac transplantation with a history of pre-transplant malignancy.^{110,111} The presence of pre-transplant malignancy is strongly associated with the development of post-transplant malignancies and decreased post-transplant survival (both cancer related and noncancer related), especially if the pre-transplant malignancy is hematologic, high-risk, or present ≤ 1 year before transplant.^{111–114} Collaboration with an oncologist is essential for an individualized approach to risk stratification.
4. Those candidates with low-risk pre-transplant malignancy, including early-stage cancers with complete resection and/or low-risk features, including prostate adenocarcinoma, renal cell carcinoma, cervical cancer, and bladder cancer, may undergo HT with minimal or no pre-transplant observation and plans for post-transplant intervention, after a comprehensive evaluation and shared decision with treating oncologists.¹¹⁵ While a period of observation before transplant listing may be recommended, this will be unique and specific to the given patient's cancer history. These patients might have significant multiorgan dysfunction, and this might also preclude or at least complicate further HT candidacy needing combined transplants. An individualized approach with multidisciplinary collaboration is essential, as arbitrary time intervals for observation may result in unnecessary delays in transplant listing. Further guidance is available in consensus statements from the American Society of Transplantation with granular recommendations on transplant candidacy for patients with a history of skin cancer ([Table 5](#)), hematological malignancies ([Tables 6 and 7](#)), and solid organ malignancies based on tumor-grade and stage ([Table 8](#)).^{115,116}
5. With recent advances in cancer treatment, the prognosis for many cancers continues to improve, highlighting the potential need for new methods of risk stratification. The precision immune-oncology approach that seeks to better understand the immune system, the complexity of the tumor microenvironment, and the tumor signaling pathways that affect the individualized response to therapy provides a framework for evaluation of highly active anticancer therapies in the neoadjuvant context, wherein patients would potentially be spared from chemoradiotherapy and surgery while their tumor is treated when it is most likely to respond—namely, before exposure to other agents that might select for cells with a resistant phenotype.¹¹⁷ The dynamic monitoring of the whole cancer journey, from detection to interception to monitoring of resistance in metastatic cancer, using new technologies is evolving.^{118,119} Ultrasensitive technologies can detect and measure microscopic residual disease in patients who have undergone definitive treatment, allowing to apply interception strategies to eradicate cancer in those high-risk patients.

Table 5 Recommended Wait Times Pre-transplantation for Patients With a History of Skin Cancer Before Transplantation

Skin malignancy	Wait time before transplantation after treatment
Cutaneous squamous cell carcinoma (cSCC)	
No history of SCC but at risk for development of SCC	No delay necessary
Low risk	No delay necessary
High-risk SCC (not including perineural invasion)	2 years
High-risk SCC with perineural invasion or 2 risk factors	2-3 years
High risk with local nodal metastatic disease	5 years
Distant metastasis	Not eligible for transplantation
Merkel cell carcinoma	
Local with negative sentinel lymph node biopsy	2 years
Local with nodal metastasis	3-5 years
Distant metastasis	Not eligible for transplantation
Malignant melanoma	
In situ melanoma	No wait necessary, follow-up post transplantation 3 months
Stage IA melanoma	1 year
Stage IB melanoma	1 year
Stage IIA melanoma	1 year
Stage IIB melanoma	2-4 years
Stage IIC melanoma	2-4 years
Stage IIIA melanoma	1-2 years
Stage IIIB melanoma	2-4 years
Stage IIIC melanoma	At least 5 years
Stage IIID melanoma	At least 5 years
Stage IV melanoma	At least 5 years
Modified from Recommendations for Solid Organ Transplantation for Transplant Candidates with a Pre-transplant Diagnosis of Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma and Melanoma: A Consensus Opinion From the International Transplant Skin Cancer Collaborative. ¹⁰⁸	
Abbreviation: SCC, squamous cell carcinoma.	

Table 6 Recommended Wait Times Pre-transplantation for Patients With a History of Hematological Malignancies Before Transplantation

Histology	Wait time before transplantation after treatment
Diffuse large B cell lymphoma	2 years
Follicular lymphoma	2 years
Peripheral T-cell lymphoma	2 years
Burkitt lymphoma	2 years
Hodgkin lymphoma	2 years PET scan negative patients after initial treatment have a low rate of relapse
Monoclonal B cell lymphocytosis	No wait time
Chronic lymphocytic leukemia	2-3 years after treatment
Modified from pre-existing melanoma and hematological malignancies consensus expert opinion statement. ¹¹⁶	
Abbreviation: PET, positron emission tomography.	

Table 7 Criteria for Safe Transplant Candidacy for Candidates With a Prior History of Myeloma^a

Criteria

Stringent complete response
 No monoclonal protein in serum or urine by immunofixation
 Normal free light chain ratio
 Bone marrow plasma cells < 1% by flow or immunohistochemistry

Performance status 0 or 1

FISH at diagnosis fail to demonstrate deletion (17p), t(4; 14), t(14; 16)

Hematologic remission > 6 months

Modified from pre-existing melanoma and hematological malignancies consensus expert opinion statement.¹¹⁶

Abbreviation: FISH, fluorescence in situ hybridization.

^aData are extrapolated from kidney transplant data.

Table 8 Recommended Wait Times Pre-transplantation for Patients With a History of Solid Organ Malignancy Before Transplantation

Risk/stage of solid organ malignancy	Wait time before transplantation after treatment ^a
History of breast cancer	
Ductal carcinoma in situ Stage I	No additional waiting time after the completion of all standard treatments
Stage II	1-2 years with no evidence of disease
Stage III	3-5 years with no evidence of disease
Stage IV	Not eligible for transplantation
History of colon cancer	
Stage I (T1 or T2, N0, M0)	1 year
Stage II (T3, N0, M0)	2 years, consider longer if high-risk features present ^b
Stage II (T4, N0, M0)	3 years5 years if high-risk features present ^b
Stage III (any T, N+, M0)	3 years5 years if high-risk features present ^b
Stage IV (any T, any N, M+)	5 years with no evidence of disease
History of prostate cancer	
PSA < 10 ng/ml; 3 or fewer cores of Gleason 6 with no greater than 50% of individual core; T1c-T2a	No wait time ^c
PSA < 10 ng/ml, Gleason 6 not meeting very low-risk criteria; T1c-T2a	No wait time ^c
PSA > 10 ng/ml; Gleason 7; T2b	Surveillance or treatment are optional treatments ^c If surveillance, no wait time If treatment initiated, and nomogram (www.nomogramrams.org) predicts cancer-specific death over the next 15 years < 10%, no wait time necessary
PSA > 20 ng/ml or high-volume Gleason 7 or any Gleason 8-10; T3	If treatment initiated, and nomogram predicts cancer-specific death over the next 15 years < 10%, no wait time
Metastatic castration-sensitive	If stable disease for 2 years with prolonged estimated life expectancy, may consider transplant
Metastatic castration-resistant	Not eligible for transplantation
History of renal cell carcinoma ^d	
T1a (≤4 cm), N0, M0	No wait time ^a

Continued

Table 8 Recommended Wait Times Pre-transplantation for Patients With a History of Solid Organ Malignancy Before Transplantation

Risk/stage of solid organ malignancy	Wait time before transplantation after treatment ^a
T1b (> 4 cm ≤ 7 cm), N0, M0	Fuhrman grade 1-2: no wait time ^a Fuhrman grade 3-4: 1-2 years ^a
T2 (7-10 cm), N0, M0	2 years ^a
T3, N0, M0	Minimum of 2 years, then reassess ^a
T4, N0, M0	Minimum of 2 years, then reassess ^a
Any T, node positive, metastatic disease	Not a candidate (if solitary metastasis + resected, tumor board discussion on candidacy)
Any T with sarcomatoid and/or rhabdoid histologic features	Not eligible for transplantation
Collecting duct or medullary RCC	Not eligible for transplantation
History of lung cancer	
Stage I	
T1aN0	≥3 years ^a
T1bN0	≥3 years ^a
T1cN0	3-5 years ^a
Stage IB	
T2aN0	5 years ^a
Stage IIA	
T2bN0	5 years ^a
Stage IIB	
T3 N0	5 years ^a
Stage IIIA	5 years ^a (special caution with N2 disease)
Stage IIIB	Not eligible for transplantation
Stage IIIC	Not eligible for transplantation
Stage IVA	Not eligible for transplantation
Stage IVA	Not eligible for transplantation

Abbreviation: PSA, prostate-specific antigen; RCC, renal cell carcinoma.

Modified from Consensus Expert Opinion Statement for Pre-transplant Solid Organ Malignancy and Organ Transplant Candidacy.¹¹⁵

^aAfter the completion of all standard oncologic treatments.

^bHigh-risk features of colon cancer include lymphovascular or perineural invasion, mucinous or signet histology, poorly differentiated histology, bowel obstruction, tumor perforation, < 12 lymph nodes examined.

^cImmunosuppression does not increase the risks of a clinically meaningful prostate cancer, recurrence following previous treatment, or 5-year cancer-specific mortality (< 1%) after a post-transplant diagnosis of prostate cancer. Population-based data suggest that surveillance in men with prostate cancer who are being considered for transplant has become more common, without any apparent long-term adverse cancer-specific consequences.¹²⁰⁻¹²⁵

^dNephrectomy remains the standard approach for small renal mass treatment for patients on a transplant waiting list. For the general nontransplant population, active surveillance of small renal mass is a safe, standard-of-care option. Nonetheless, long-term safety data of surveillance in patients being considered for transplant are lacking and nephrectomy (radical/partial) remains the most popular treatment before transplantation.¹²⁶⁻¹²⁸

2.1.2.4. Diabetes

Recommendations for Comorbidities and Potential Contraindications to Heart Transplantation: Diabetes		
COR	LOE	RECOMMENDATIONS
2a	C-LD	1. In heart transplant candidates with diabetes with end-organ damage or poor glycemic control (glycosylated hemoglobin [HbA1c] > 7.5%), delay in HT evaluation and listing is reasonable until diabetic control is improved.
2a	B-NR	2. In heart transplant candidates, ophthalmologic consultation to determine the presence of retinopathy can be beneficial as a surrogate for duration of diabetes and degree of diabetic control and vascular/kidney involvement.

Recommendation-Specific Supportive Text

- Approximately 30% of patients with AdvHF and 20% of heart transplant recipients have pre-existing diabetes.^{129,130} The presence of uncomplicated post-transplant diabetes is not associated with worse post-transplant survival.¹³⁰ However, those heart transplant candidates with diabetes-related complications, including obesity, kidney dysfunction, cerebrovascular disease, or peripheral vascular disease, have worse post-transplant survival as well as an increased risk of post-transplant infections and kidney failure in one registry analysis¹³⁰ and additional risks of late graft failure and mortality in other cohorts.^{131–136} Therefore, diabetes per se is not considered a contraindication for HT, but careful assessment of diabetic control and end-organ damage (atherosclerotic vascular disease, nephropathy, proliferative retinopathy) is necessary. Post-transplant use of calcineurin inhibitors and corticosteroids will worsen glycemic control,¹³⁷ so pre-transplant optimal control to achieve glycosylated hemoglobin (HbA1c) $\leq 7.5\%$ ¹³⁸ is highly encouraged. On a program-specific basis, centers may identify an HbA1c level that is considered a relative contraindication to transplantation. This level portends worse post-transplant outcomes, and may also, in some cases, be an additional indicator of suboptimal medical adherence.
- Patients with complicated diabetes have significantly worse survival.¹³⁰ Diabetic retinopathy is a highly specific vascular complication of both type 1 and type 2 diabetes, with prevalence strongly related to both the duration of diabetes and the level of glycemic control. Thus, ophthalmologic consultation to determine the presence of retinopathy can be useful in patients with diabetes to assess the post-transplant risk associated with diabetes.¹³⁹ However, it is unclear how the presence of diabetic retinopathy, once identified, should affect transplant candidacy.

2.1.2.5. Cerebral and Peripheral Vascular Disease

Recommendations for Comorbidities and Potential Contraindications to Heart Transplantation: Cerebral and Peripheral Vascular Disease		
COR	LOE	RECOMMENDATIONS
1	C-EO	1. In heart transplant candidates with a history of stroke or neurologic signs or symptoms suggestive of cerebrovascular disease, screening for cerebrovascular disease with carotid ultrasonography is recommended.
2b	B-NR	2. In heart transplant candidates with clinically severe symptomatic cerebrovascular disease not amenable to revascularization (as determined by a neurologist), the benefit of HT is uncertain due to the risks of perioperative stroke and impact on post-transplant rehabilitation efforts and QOL.
1	C-EO	3. In heart transplant candidates with symptoms of peripheral arterial disease, diminished peripheral pulses, atherosclerotic disease, or the presence of risk factors, screening for peripheral vascular disease with ankle-brachial indices is recommended.
2b	C-LD	4. In heart transplant candidates with clinically severe symptomatic peripheral vascular disease, especially associated with nonhealing ischemic ulcers (as determined by a vascular specialist), the benefit of HT is uncertain due to the risks of perioperative limb ischemia and impact on post-transplant rehabilitation efforts and QOL.

Recommendation-Specific Supportive Text

1. Postoperative stroke after HT is associated with reduced functional capacity,¹⁴⁰ dialysis,¹⁴¹ and reduced survival.¹⁴² While heart transplant recipients are at a lower risk for stroke compared with HF patients on the waitlist,¹⁴³ there are indications that the risk of stroke might be increasing after implementation of revised United Network for Organ Sharing (UNOS) allocation system in the United States in 2018.¹⁴¹ Thus, efforts to reduce the risk of post-transplant stroke are paramount to the evaluation process. Heart transplant recipients with a history of transient ischemic attack or stroke are at increased risk of stroke after transplantation.¹⁴⁰ Screening for asymptomatic carotid artery stenosis in the general population has no benefit and may be harmful,¹⁴⁴ and for individuals requiring cardiopulmonary bypass, data on the management of asymptomatic carotid stenosis are limited.¹⁴⁵ Based on this, screening for carotid artery stenosis is recommended for all heart transplant candidates with a history of stroke or neurologic signs or symptoms concerning for cerebrovascular disease.¹⁴¹ Several modalities are proposed for screening for carotid artery stenosis, including carotid duplex ultrasonography, magnetic resonance angiography, and CT, with carotid duplex ultrasonography having a 90% sensitivity and 94% specificity for detecting $\geq 70\%$ stenosis.¹⁴⁴ Further testing with imaging of the brain and cranial vessels may be required, as dictated by neurologic consultation.
2. The benefit of carotid revascularization at the time of cardiac surgery is not well established.^{146,147} Similarly, there is no evidence regarding the impact of revascularization of carotid disease in heart transplant candidates on post-transplant risk, and for asymptomatic carotid artery stenosis, there are no externally validated, reliable methods to determine who is at increased risk of stroke and at what degree of stenosis.¹⁴⁴ Carotid disease warranting revascularization independent of transplant evaluation should be addressed. Consultation with a neurologist and/or vascular surgeon can be useful in this assessment. Another potential contraindication to transplant listing would be deficits from prior cerebrovascular accidents that impair rehabilitation efforts or increase risk of aspiration and pulmonary infection. These decisions are necessarily individualized based on the patient's overall risk.
3. The diagnosis of peripheral arterial disease cannot rely solely on symptoms, as only a minority of patients with peripheral arterial disease present with intermittent claudication.¹⁴⁸ However, the presence of peripheral arterial disease portends worse survival in patients with HF^{149–151} as well as in patients after HT.¹⁵² Thus, evaluation for peripheral arterial disease with ankle brachial indices is recommended for all candidates with claudication, diminished peripheral pulses, atherosclerotic disease, or risk factors associated with peripheral arterial disease. Further testing with arterial ultrasound, CT angiography, or invasive angiography may be required, as dictated by results of initial testing and vascular surgery consultation.¹⁵³
4. The impact of peripheral arterial disease revascularization on post-transplant outcomes is not established. However, certain characteristics of peripheral arterial disease would impact post-transplant outcomes and QOL and, therefore, could be considered contraindications. First, if a patient has disabling claudication not amenable to revascularization, transplantation would not offer an improvement in QOL, and the claudication would impair rehabilitation efforts. Second, if a patient has nonhealing ischemic ulcers, immunosuppression offers a prohibitive risk of infection and delayed wound healing.

2.1.2.6. Pulmonary Disease

Recommendations for Comorbidities and Potential Contraindications to Heart Transplantation: Pulmonary Disease		
COR	LOE	RECOMMENDATIONS
1	C-EO	1. In heart transplant candidates, pulmonary evaluation with pulmonary function testing (spirometry, lung volume assessment, and diffusion capacity) and chest CT is recommended, ideally once optimized from a volume perspective.
2b	C-LD	2. In heart transplant candidates with severe parenchymal lung disease, as evidenced by chronic hypoxia from a pulmonary source or significant abnormalities in pulmonary function tests (as determined by a pulmonologist), the benefit of HT is uncertain due to the increased risk of post-transplant mortality.
2b	C-EO	3. In heart transplant candidates deemed ineligible for transplantation due to severe irreversible end-stage parenchymal lung disease, evaluation for combined heart and lung transplantation may be considered.

Recommendation-Specific Supportive Text

- Up to one-third of unselected patients with HF have concurrent chronic obstructive pulmonary disease, largely attributed to the shared risk factor of smoking.¹⁵⁴ HF also commonly coexists with other lung diseases, including interstitial lung disease.¹⁵⁵ For some patients, distinguishing between pulmonary vs cardiac sources of dyspnea may be challenging and is beyond the scope of this guideline. However, patients with HF and lung disease are at increased risk for worse QOL, increased hospitalizations, and increased mortality,^{156–159} and also increased risk for post-transplant longer hospital stay and increased mortality.^{160,161} Thus, it is essential to screen heart transplant candidates for pulmonary parenchymal disease with pulmonary function testing, including spirometry, volume assessment, and diffusion capacity, as well as chest imaging, most commonly noncontrast CT, to assess for parenchymal disease. As pulmonary congestion may interfere with interpreting of these tests,^{162,163} optimization of volume status with diuretic therapy should occur before pulmonary evaluation. Further testing may be required as dictated by a pulmonary specialist.
- Few studies have analyzed pulmonary function testing and specific parameters that may be used to predict risk after HT, but the data are conflicting.^{160,164} Patients with severe obstructive ventilatory defects or severely reduced diffusion capacity for carbon monoxide (DLCO) represent a high-pulmonary risk group. However, guidance on specific thresholds cannot be provided for patient selection; rather, the findings of pulmonary function testing can assist in the decision for listing.¹⁶⁴ The usefulness of spirometry to diagnose and grade pulmonary function abnormalities in transplant candidates may be further limited by the association of AdvHF with impaired spirometric values. There is a well-established association between clinically defined pre-existing pulmonary disease and worse outcomes after cardiac surgery; thus, the benefit of HT for severe parenchymal lung disease is uncertain due to the increased risk of post-transplant mortality.^{164,165}
- The primary indication for heart-lung transplant is PH, either secondary to idiopathic PH or CHD.¹⁶⁶ Severe pulmonary parenchymal disease, such as chronic obstructive pulmonary disease, in conjunction with AdvHF is not often an indication for heart-lung transplantation as the older age of such patients may contraindicate consideration of heart-lung transplantation. However, the decision about whether to list a patient for heart-lung transplant remains difficult,¹⁶⁷ as survival after heart-lung transplantation is inferior to that after HT alone,^{89,166} and some patients may thrive after isolated lung transplantation.^{168–171}

2.1.2.7. Pulmonary Hypertension

Recommendations for Comorbidities and Potential Contraindications to Heart Transplantation: Pulmonary Hypertension		
COR	LOE	RECOMMENDATIONS
1	C-LD	1. In adult heart transplant candidates with pulmonary artery systolic pressure (PASP) ≥ 50 mmHg and either a TPG ≥ 15 mmHg or PVR ≥ 3 Wood units while maintaining a systolic arterial blood pressure > 85 mmHg, the following stepwise evaluation is recommended to assess transplant candidacy: 1) an acute vasodilator challenge to assess for reversibility of PH (Class 1); 2) hospitalization with continuous hemodynamic monitoring as often the PVR will decline after 24 to 48 hours of treatment consisting of diuretics, inotropic support, and vasodilators (Class I); and 3) temporary or durable MCS for unloading of the left ventricle (Class 2a).
2a		
2a	B-NR	2. In pediatric heart transplant candidates, HT is reasonable if PVR indexed to body surface area (PVRI) is less than 9 Wood units $\cdot m^2$ on initial assessment or after treatment with diuretics, inotropic support, vasodilator therapy, or MCS.
2b	C-EO	3. In heart transplant candidates deemed ineligible for transplantation due to severe irreversible PH, evaluation for combined heart and lung transplantation may be considered in carefully selected patients.
3 No Benefit	B-NR	4. In heart transplant candidates with severe PH not reversible with measures including diuretic therapy, inotropic support, vasodilators, and temporary or durable MCS as indicated, HT alone is not recommended.


Recommendation-Specific Supportive Text

- PH (mean PA pressure > 20 mmHg), most commonly group 2 due to left heart disease [pulmonary capillary wedge pressure (PCWP) > 15 mmHg],^{172–174} is common in patients with HF,^{175,176} and an elevated PVR ≥ 2.5

- Wood units is associated with increased early post-transplant mortality.¹⁷⁷ Although elevations in PASP, TPG, and PVR above certain thresholds have been proposed as contraindications to HT listing, the risk associated with each parameter is continuous from low to high values and absolute cutoffs do not exist.^{45,46} Even so, in patients with PASP ≥ 50 mm Hg and either TPG ≥ 15 mm Hg or PVR ≥ 3 Wood units, an acute vasodilator challenge should be administered during RHC to document acute reduction in the PVR to acceptable levels, while maintaining a systolic arterial pressure > 85 mm Hg.¹⁷⁸ An appropriate response to the vasodilator challenge would be if the TPG can be reduced to ≤ 12 to 15 mm Hg and the PVR to ≤ 2.5 to 3 Wood units. If the PVR is reversible but systolic blood pressure falls to < 85 mm Hg with pharmacologic maneuvers, the risk of RHF remains high.^{178,179} When response to the acute vasodilator challenge is not acceptable, hospitalization with continuous vasoactive therapies and hemodynamic monitoring would be the next step in management,¹⁸⁰ followed by implantation of tMCS or a durable LVAD in eligible candidates (Figure 1).^{181–187}
- In pediatric heart transplant candidates, there is no association between elevated PVR indexed to body surface area (PVRI) on mortality at 30 days and up to 5 years post-transplant,¹⁸⁸ with increased mortality observed only in those pediatric heart transplant recipients with pre-transplant PVRI over 9 Wood units $\cdot m^2$. This holds true for those pediatric heart transplant candidates with both CHD¹⁸⁹ and cardiomyopathy.¹⁹⁰ In pediatric heart transplant candidates with PVRI over 9 Wood units $\cdot m^2$, unloading with diuresis and vasodilation (with vasoactive agents or MCS as needed) may be used to achieve acceptable PVRI. Patients with Fontan circulation present unique challenges; one cannot assume that PVR is low enough to tolerate HT based on the presence of passive circulation. Furthermore, estimating PVR in patients with Fontan failure can be difficult due to low cardiac output (CO) and systemic-to-pulmonary collaterals with possible unequal blood flow in the left and right lungs.¹⁹¹
 - The primary indication for a heart-lung transplant is PH, either secondary to idiopathic PH or CHD.¹⁶⁶ However, the decision about whether to list a patient for heart-lung transplant remains difficult¹⁶⁷ as survival after heart-lung transplantation is inferior to HT alone^{89,166} and some patients with PH may do well after isolated lung transplantation.^{168–171}
 - If a stepwise approach to achieving acceptable PA pressures is not successful, including an acute vasodilator challenge, diuretic therapy, inotropic support, vasodilators, and temporary and/or durable MCS, then the candidate would be deemed to have irreversible PH. This would be a contraindication to HT alone, as improved outcomes are evidence in patients who can achieve acceptable reversibility of PA pressures.^{178, 179, 192–194}

Figure 1

Management of pulmonary hypertension in the adult heart transplant candidate. PASP, pulmonary artery systolic pressure; SBP, systolic blood pressure; TPG, transpulmonary gradient.



2.1.2.8. Kidney Disease

Recommendations for Comorbidities and Potential Contraindications to Heart Transplantation: Kidney Disease		
COR	LOE	RECOMMENDATIONS
1	B-NR	1. In heart transplant candidates, a comprehensive assessment of kidney function is recommended, including: 1) historical trends in kidney function; 2) kidney function as measured by estimated glomerular filtration rate (GFR) and 24-hour creatinine clearance (CrCl) when hemodynamically optimized; and 3) comorbidities known to impact kidney function. If there is abnormal kidney function, further investigation is recommended, including nephrology consultation, renal ultrasonography, and estimation of proteinuria for assessment of intrinsic renal disease.
1	B-NR	2. In heart transplant candidates with established GFR < 30 ml/min/1.73 m ² , evaluation for simultaneous heart-kidney transplantation (SHKT) is recommended.
2a	B-NR	3. In heart transplant candidates with established GFR of 30–44 ml/min/1.73 m ² and evidence of chronic kidney disease (CKD), such as small kidney size or persistent proteinuria >0.5 g/day in the presence of stable hemodynamics, evaluation for SHKT is reasonable.


Recommendation-Specific Supportive Text

1. The goal of the pre-transplant evaluation of kidney function is to differentiate CKD that will not improve post-HT from acute kidney injury (AKI) or CKD that may reverse with the hemodynamic optimization afforded by HT. This evaluation should take into account (1) historical trends in kidney function during the months to years before cardiac decompensation, (2) current trends in kidney function when the patient is hemodynamically optimized, ideally over a few weeks' duration, (3) comorbidities (e.g., diabetes, lupus) known to be associated with irreversible kidney damage, and (4) other findings such as the presence of proteinuria.^{12,195} Transplant candidates should have 2 independent measurements for GFR at least 2 weeks apart using serum creatinine measurements and race-free equations for eGFR.^{196–198} The confirmatory GFR measurement should be a measured GFR, such as 24-hour creatinine clearance.¹⁹⁹ According to international nephrology societies, the CKD-EPIKrea formula should preferably be used to estimate the GFR (estimated GFR); in the case of borderline findings (estimated GFR 45–59 ml/min/1.73 m²), there is the option of determining cystatin C as an additional filtration marker (estimation of the GFR using the CKD-EPIKrea-Cys formula).²⁰⁰ The results of ancillary testing may be used to assess the presence, severity, and chronicity of intrinsic renal disease, including the presence of cortical scarring on renal ultrasound or proteinuria. A kidney biopsy is rarely required.
2. While worse renal function pre-HT^{201,202} and post-HT²⁰³ portends worse outcomes post-HT, data demonstrating improved survival with SHKT vs HT when pre-transplant GFR is below a specific threshold are limited.^{204–207} A UNOS registry analysis of over 26,000 recipients transplanted in 2000–2010 determined that transplant recipients derived increased survival for SHKT vs HT if they had eGFR < 37 ml/min/1.73 m², although the absolute difference in median post-transplant survival was small, 7.7 years for the SHKT cohort vs 7.1 years for the HT cohort.²⁰⁵ Another challenge is marked changes in kidney function in a HT candidate while on the waitlist. In situations where there is inadequate time to assess for AKI recovery, both heart and kidney specialists should weigh all factors (i.e., perceived kidney reserve and recovery potential, risk or presence of CKD) in order to decide SHKT vs HT candidacy. Nonetheless, if eGFR < 30 ml/min/m² and patients are deemed ineligible for kidney transplantation, HT alone should generally not be pursued, given worse outcomes in recipients of HT alone compared with SHKT when eGFR < 30 ml/min/m².²⁰⁸
3. A key concern in SHKT eligibility is whether and how much an individual will benefit more from a SHKT. SHKT is associated with increased survival in dialysis-dependent patients (median survival SHKT: 12.6 vs HT: 7.1 years $p < 0.0001$) but not with nondialysis patients (median survival SHKT: 12.5 vs HT 12.3, $p = 0.24$).²⁰⁹ Evaluation for CKD pre-transplant offers prognostic information on kidney function after HT but cannot fully predict the trajectory of kidney function post-HT, as it is also dependent on donor characteristics and the perioperative and post-transplant course. Moreover, prognosis is distinct from causation: pre-transplant CKD may predict worse kidney function and lower survival after HT, but whether these disadvantages are mitigated

by a SHKT is not established. Thus, collaboration with nephrologists is essential for optimal donor stewardship (Figure 2). Importantly, in the setting of organ scarcity, SHKT must balance the benefit to the individual with that of other candidates awaiting a single kidney transplant. Thus, efforts to explore other strategies (i.e., delayed multi-organ transplant) will optimize a fair allocation of the scarce resource of donor organs. In the United States, a Safety Net approach has been implemented to theoretically allow better prioritization of donor organs. In this policy, heart transplant recipients would qualify for the Safety Net kidney donor if they were (1) registered on the kidney waiting list before the 1-year anniversary of their HT and (2) were on chronic dialysis or had a measured or estimated creatinine clearance or $GFR \leq 20 \text{ ml/min/1.73m}^2$ between day 60 to day 365 post-transplant.²¹⁰ Some critically ill heart transplant recipients face a high rate of renal allograft dysfunction due to perioperative hemodynamic instability and may benefit from this option, assuming a living donor is not available.

Figure 2

Assessment for heart-kidney transplantation (Adapted from Kittleson et al, AHA Scientific Statement 2023)¹². CrCl, creatinine clearance; eGFR, estimated glomerular filtration rate; GFR, glomerular filtration rate.



2.1.2.9. Liver Disease

Recommendations for Comorbidities and Potential Contraindications to Heart Transplantation: Liver Disease		
COR	LOE	RECOMMENDATIONS
1	B-NR	1. In heart transplant candidates, a comprehensive assessment of liver function is recommended, including: 1) liver function tests (albumin, bilirubin, INR); 2) biochemical assays (AST, ALT, GGT), 3) MELD-XI score; and 4) abdominal imaging with ultrasound or CT and/or magnetic resonance imaging (MRI). If there is abnormal initial liver evaluation, further investigation is recommended, including hepatology consultation and liver biopsy.
2a	B-NR	2. In patients with biopsy-proven cirrhosis and/or severe liver fibrosis with evidence of portal hypertension, evaluation for heart-liver transplantation is reasonable.


Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; INR, international normalized ratio; MELD-XI, model for end-stage liver disease excluding INR.

Recommendation-Specific Supportive Text

- Acute HF can lead to liver injury through either ischemia and/or congestion.²¹¹ In chronic HF, ischemia and congestion also contribute to chronic liver disease, often related to RV failure, advanced biventricular (BiV) failure, severe tricuspid regurgitation, restrictive/constrictive cardiomyopathy, and CHD, particularly in single-ventricle physiology palliated with a Fontan operation [Fontan-associated liver disease (FALD) which is addressed in [Congenital Heart Disease](#)].^{211,212} The evaluation of patients with AdvHF being considered for transplantation with concomitant liver disease focuses on whether the liver disease (1) may reverse with optimization of cardiac function and (2) is advanced enough to impact perioperative risk and/or require dual-organ transplantation. A modification of the MELD score (MELD-XI) that excludes INR, offers prognostic information in HT candidates.^{213,214} Liver ultrasound, abdominal CT, and liver MRI comprise the most common imaging techniques. However, the diagnosis of cirrhosis in HT candidates should never rest on imaging findings alone, as imaging can neither accurately characterize the degree of hepatic fibrosis, nor distinguish cirrhosis from nodular regenerative hyperplasia²¹⁵ or noncirrhotic portal hypertension.²¹⁶ Hepatic elastography allows for noninvasive assessment of hepatic fibrosis. Liver biopsy remains the only accurate and reliable method of assessing hepatic histology in the process of assessing HT candidacy,²¹⁷ though also prone to sampling error due to the heterogeneity of liver fibrosis.²¹⁸ In FALD, the presence of bridging fibrosis or cirrhosis portends a worse survival and the degree of fibrosis correlates with temporal changes in platelet count and MELD-XI.^{219,220} In pediatric heart transplant candidates, increases in MELD-XI score and total bilirubin, as well as abnormal serum albumin,^{43,221} are associated with worse post-transplant survival.^{213,222}
- Advanced liver disease and cirrhosis are considered contraindications to isolated HT because patients with cirrhosis who undergo isolated HT have short-term mortality as high as 50%.^{223–227} Transvenous liver biopsy is preferred as it allows for assessment of wedged and free hepatic vein pressure measurements. A normal (5 mm Hg or less) gradient between hepatic wedge pressure and free hepatic vein pressure excludes significant portal hypertension, providing important information regarding the presence of chronic liver disease, which may impact HT candidacy.²²⁸ Collaboration with hepatologists is essential to determine if simultaneous heart-liver transplantation is warranted ([Figure 3](#)) and to ensure there are no liver-transplant-specific contraindications.¹²

Figure 3

Assessment for heart-liver transplantation (Adapted from Kittleson et al, AHA Scientific Statement 2023)¹². ALT, alanine aminotransferase; AST, aspartate aminotransferase; CT, computed tomography; INR, international normalized ratio; MELD-XI, model for end-stage liver disease excluding INR.



2.1.2.10. Connective Tissue Diseases and Sarcoidosis

Recommendations for Comorbidities and Potential Contraindications to Heart Transplantation: Connective Tissue Diseases and Sarcoidosis		
COR	LOE	RECOMMENDATIONS
1	B-NR	1. In heart transplant candidates with connective tissue disease (CTD) or sarcoidosis, focused multidisciplinary collaboration is recommended to determine 1) the impact of the CTD on post-transplant survival, rehabilitation efforts, and QOL; 2) the impact of immunosuppression on the progression of the CTD; 3) the risk of cardiac recurrence; and 4) CTD-specific extracardiac manifestations such as PH, pulmonary parenchymal disease, aspiration risk, and/or arthritis.
3: No Benefit	B-NR	2. In heart transplant candidates with CTD that is expected to shorten post-transplant survival, that is associated with severe non-cardiac disease, or that is not controlled with pre-transplant immunosuppression, HT is not recommended.

Recommendation-Specific Supportive Text

- The most common connective tissue diseases (CTD) with associated cardiomyopathies include systemic lupus erythematosus, systemic sclerosis, and rheumatoid arthritis.²²⁹ While sarcoidosis is not a CTD, it is considered here, as it also treated with immunosuppression, may progress to require heart transplant consideration, and may have associated extracardiac manifestations that impact transplant candidacy. The largest heart transplant experience exists for cardiac sarcoidosis, where survival is generally comparable to that of heart transplant recipients without sarcoidosis.^{230–232} In other conditions, heart transplant experience is limited to case reports or case series,^{233–235} and while outcomes appear favorable, it is important to note that these heart transplant candidates are highly selected. There are case reports of recurrent sarcoidosis after HT, and collaboration with a specialist for CTD or sarcoidosis is essential to confirm that the planned post-HT immunosuppression regimen will be adequate to also control the CTD.
- Multidisciplinary collaboration is required to determine that the CTD will not impact post-HT survival, QOL, or rehabilitation efforts. Specific attention to organ involvement is important in different CTDs. In sarcoidosis, evaluation of lung disease is paramount. For lupus, consideration of kidney disease, arthritis, and thromboembolism is warranted. For systemic sclerosis, attention must be paid to esophageal dysmotility, arthritis, PH, and kidney disease. If there is severe or uncontrolled extracardiac disease, HT should not be pursued, though in selected cases, multiorgan transplantation may be considered, including heart-lung transplantation for systemic sclerosis with cardiomyopathy and PH.²³⁶

2.1.2.11. Infections and Vaccinations

Recommendations for Comorbidities and Potential Contraindications to Heart Transplantation: Infections and Vaccinations		
LOE	COR	RECOMMENDATIONS
1	C-EO	1. In heart transplant candidates, screening for chronic or latent diseases that have the risk for post-transplant reactivation and may warrant pre-transplant treatment or post-transplant surveillance is recommended, including but not limited to human immunodeficiency viral (HIV) infection, Chagas disease, tuberculosis (TB), HBV and HCV infections (Table 9); surveillance for geographically restricted specific pathogens may be warranted.
3: No Benefit	C-EO	2. In heart transplant candidates with certain infections, HT is not recommended; these include 1) active infections requiring ongoing antibiotic treatment (except for infected durable LVADs); and 2) HIV with opportunistic infections or related malignancy, lack of stable antiretroviral regimen, detectable viral load, and/or low CD4 count.
1	B-NR	3. In heart transplant candidates, vaccine history and assessment of seroprotection (as appropriate) should be reviewed, and age-appropriate vaccinations administered ideally at least 2 weeks prior to transplantation are recommended (Table 10); live-attenuated vaccines should be avoided unless transplant can be deferred for 4 weeks after receipt due to concern for ongoing viral replication.

Recommendation-Specific Supportive Text

1. Heart transplant candidates should be screened for chronic or latent infection during the evaluation process with the aim of resolving or suppressing active infection before transplant and developing a post-transplant prophylaxis plan. A focused summary of screening most likely to impact pre-transplant management is shown in [Table 9](#). Screening of heart transplant candidates should also include *Cytomegalovirus* IgG, *Epstein-Barr virus* (EBV) antibody (EBV VCA IgG, IgM), *Toxoplasma* IgG antibody, *Strongyloides* IgG and *Strongyloides* stool culture (if from endemic areas), *Coccidioides* serology (if from endemic areas), *trypanosomiasis* serology (if from endemic areas) and syphilis.²³⁷
2. Since there are no specific infections that would contraindicate HT, the goal is appropriate risk stratification and management of infections in the pre-transplant phase, as well as a plan for post-transplant prophylaxis if indicated. In most instances, active infection should be a reason to defer transplant. The exception is DMCS infection, as explantation of all MCS components at the time of transplantation is often the definitive cure for the device-associated infection.²³⁸ While highly selected candidates with HIV can be successfully transplanted,²³⁹ specific criteria should be met,²⁴⁰ as outlined in [Table 9](#). Consideration of HT in patients with active and refractory infective endocarditis is controversial. Apart from demonstrated success in sporadic case reports, there is currently a lack of any other robust body of evidence to endorse HT for infective endocarditis.²⁴¹ HT may be carefully considered in extreme cases where repeated operative procedures have failed to eradicate persistent or recurrent infective endocarditis.²⁴²
3. There are limited data specifically addressing vaccination of adults and children with AdvHF in the pre-transplant setting.^{243,244} Nonetheless, vaccinations are part of health care maintenance, and as such, initiating or updating life-saving vaccines is best practice in contemporary transplant medicine.²⁴³ Pre-transplant vaccination is essential, as the candidate is generally not immunosuppressed and is thus expected to mount a more robust immune response than after transplantation; this has been observed most dramatically with vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).^{245–248} Ideally, vaccination should be completed at least 2 weeks before transplantation to optimize immune response. Refusal to accept guideline-recommended vaccinations may be considered a contraindication to transplantation. If live-attenuated vaccines are utilized, the transplant should be deferred for 4 weeks to reduce the risk of active viral replication at the time of transplant.²⁴³ [Table 10](#) summarizes recommended pre-transplant vaccinations for adult candidates. Detailed vaccination schedules are also publicly available and regularly updated by organizations, such as the United States Advisory Committee on Immunization Practices.²⁴⁹

Table 9 Screening for Latent Disease Requiring Pre-transplant Treatment and/or With the Potential for Post-Transplant Reactivation

Infection	Who to check	What to check	Pre-transplant management	Contraindications to HT
HIV ²⁴⁰	All candidates	HIV RNA CD4 count	Consultation with HIV specialist to ensure stable anti-retroviral regimen that is safe post-HT	<ul style="list-style-type: none"> • Opportunistic infections or related malignancy (Kaposi sarcoma, lymphoma) • Chronic wasting or severe malnutrition • Lack of stable antiretroviral regimen • Detectable HIV RNA • CD4 count < 200 cells/microliter during the 3 months before transplantation
Chagas disease ^{250,251}	Born in Latin America (Central and South America or Mexico) or have spent significant time in Latin America, those with a Latin American mother, or received unscreened blood products	<ul style="list-style-type: none"> • Chronic Chagas disease diagnosed by serologic methods to detect IgG antibodies to <i>T. cruzi</i>, most commonly enzyme-linked immunosorbent assay (ELISA) and immunofluorescent antibody assay (IFA). • A positive result by a single assay does not constitute a confirmed diagnosis; 2 serologic tests based on different antigens (e.g., whole-parasite lysate and recombinant antigens) and/or techniques (e.g., ELISA and IFA) are used in parallel to increase the accuracy of the diagnosis. 	Benefit of prophylactic therapy is not established.	None
TB ²⁵²	All candidates	Tuberculin skin test (TST) and/or interferon- γ release assay (IGRA) where available	<ul style="list-style-type: none"> • Candidates with a positive IGRA or TST ≥ 5-mm induration should be treated pre-transplant with isoniazid and pyridoxine, if tolerated. • Candidates from a TB-endemic area with a positive IGRA or TST ≥ 5-mm induration should have at least 1 other risk factor (evidence of a recent seroconversion, evidence of old TB lung disease, history of untreated or inadequately treated TB, close contact with a person with TB) before commencing isoniazid prophylaxis. 	Treatment for latent TB infection should be for 6-9 months and should not interfere with the timing of transplantation
HBV ²⁵³	All candidates	HBV surface antigen, HBV core antibody, HBV surface antibody	Resolved or prior HBV infection (HBcAb+ and/or HBsAb+ but HBsAg-): serology and DNA viral load testing at 3-month intervals while listed. Complete viral HBV evaluation before HT should also include HBV nucleic acid test, HBe antigen, HBe antibody, hepatitis delta virus (HDV) antigen, HDV antibody, serum alfa-fetoprotein	Presence of cirrhosis on liver biopsy; heart-liver transplantation may be offered in select patients
HCV ²⁵³	All candidates	HCV antibody and nucleic acid test	Chronic HCV: direct-acting antiviral therapy, choice based on genotype and other medications to achieve sustained virologic response	Presence of cirrhosis on liver biopsy; heart-liver transplantation may be offered in select patients

Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; HT, heart transplantation; HIV, human immunodeficiency virus; HBcAb+, hepatitis B core antibody positive; HBsAb+, hepatitis B surface antibody positive; HBsAg-, hepatitis B surface antigen negative; HBe, Hepatitis B e.

Table 10 Pre-transplant Vaccinations for Adult Heart Transplant Candidates

Vaccine	Pre-transplant serology	Pre-transplant vaccination	Confirm response pre-transplant	Special circumstances
Hepatitis A	Yes	Yes	Yes	Recommended for those with increased risk; travel or residence in high-risk areas; occupational or lifestyle exposure risk
Hepatitis B	Yes	Yes	Yes	
Pneumococcus	Consider	Yes	Consider	PCV20 single dose or PCV15 followed by PPSV23
Tetanus (dT)	Yes	Yes	No	Administer Tdap to all who have not previously received Tdap
Pertussis (Tdap)	No	Yes	No	Administer Tdap to all who have not previously received Tdap
Influenza	No	Yes	No	Seasonally, vaccination is also recommended for close contacts
SARS-CoV-2	No	Yes	No	Vaccination is also recommended for close contacts; up-to-date booster vaccination is recommended.
Meningococcus	No	Yes	No	Recommended for those at increased risk, including asplenia/polysplenia, high-risk travel, terminal complement deficit, including before eculizumab
Rabies	No	No	No	Consider those with a risk of significant post-transplant exposure
Human papilloma virus	No	Yes	No	Approved age 9-26 years
<i>Live viral vaccines</i>				
Varicella	Yes	Yes	Yes	Not needed if seropositive
Herpes zoster		Yes		The recombinant subunit zoster vaccine is preferred over the live-attenuated vaccine for transplant candidates and should be given in accordance with local vaccination guidelines ²⁵⁴
Mumps, measles, rubella	Yes	Yes	Yes	Not needed if born before 1957

Abbreviation: SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

2.1.2.12. Frailty

Recommendations for Comorbidities and Potential Contraindications to Heart Transplantation: Frailty		
LOE	COR	RECOMMENDATIONS
2a	B-NR	1. In heart transplant candidates, assessment of frailty can be beneficial to identify actionable targets for improvement in conditioning and perform risk assessment of transplant candidacy.
1	C-LD	2. In heart transplant candidates, regular exercise as tolerated is recommended, ideally in a structured program if available, to prevent or improve frailty.
3 No benefit	C-EO	3. In heart transplant candidates with severe frailty that will preclude adequate post-transplant rehabilitation efforts and is not expected to improve with restoration of cardiac function, HT is not recommended.

Recommendation-Specific Supportive Text

- Frailty is a syndrome of reduced physiological reserve resulting in a reduced capacity for an individual to tolerate minor or major stressors^{255,256} and can be observed in association with various chronic disease states and at any age. There is no universally accepted definition of frailty, and the lack of standardization makes using frailty as a definitive criterion for listing difficult. A commonly used frailty assessment instrument in patients with HF is the phenotype model, or frailty phenotype (FP). The phenotype, focusing on the physical aspects of frailty, is composed of 5 physical domains—slowness, weakness, weight loss, reduced activity, and exhaustion (Table 11).^{255,257,258} The impracticability of performing some of the physical measures in unstable clinical settings

and the complicated cut points (dependent on sex, height, and BMI) led to multiple modifications of the FP. The unintended weight loss criterion was replaced with loss of appetite over the 3 months before assessment because weight loss could be masked by fluid retention. Chair stands replacing grip strength measurements are easily reproducible in clinical settings. Frailty, as measured by the FP, is common in HF, occurring in up to 50% of patients^{257,259} and is an independent predictor of mortality, including those who were actively listed for HT.^{259–261}

Frail heart transplant candidates are also at increased risk for post-transplant mortality.²⁶² In patients with CHD, frailty is prevalent and can be measured using standardized tools adapted to this younger population.^{263,264} Frailty can be partially reversible after LVAD implantation^{265,266} and HT.²⁶⁶ However, whether those patients who reverse frailty while awaiting transplantation have better outcomes after transplantation remains unclear.

- Consensus-based guidelines for preventing and improving frailty recommend physical activity,^{267–270} adequate protein intake, and targeting any contributing underlying disease processes.²⁶⁹ In transplant candidates, exercise may take the form of “prehabilitation,” a program to enhance the patient’s functional capacity before transplantation to improve postoperative outcomes. Prehabilitation can improve frailty scores and exercise performance in candidates for SOT,^{271–273} but it remains to be seen if such measures improve post-transplant outcomes.
- An assessment of frailty can be useful as part of advanced care planning, incorporating both a patient’s current functional status and future goal of care into the shared decision-making process.²⁷⁴ The potential for successful post-transplant recovery should be considered when weighing the impact of a candidate’s frailty; the ability to ambulate and quadriceps muscle strength may offer insight into recovery potential.²⁷⁵ Therefore, there is no evidence of benefit for HT in frail patients with poor potential for recovery despite post-transplant rehabilitation.

Table 11 Physical Frailty Assessment

	Frailty phenotype criteria ²⁵⁵		Modified frailty phenotype criteria ¹³
Elements	Measurement		Measurement
Physical exhaustion	Self-reported. “In the last week, did you feel, on <i>at least 3 days</i> , that everything you did was an effort or you could not get going?” (No = 0; Yes = 1)		Self-reported. “In the last week, did you feel, on <i>at least 3 days</i> , that everything you did was an effort?” (No = 0; Yes = 1)
Weakness	Hand grip strength measured using handheld dynamometer (Yes = 1):		Rising from and sitting down on a chair 5 times without using arms/hands:
	Men	BMI ≤24 ≤29 kg BMI 24.1–28 ≤30 kg BMI >28 ≤32 kg	≤15 seconds (No = 0) > 15 seconds or unable to complete (Yes = 1)
	Women	BMI ≤23 ≤17 kg BMI 23.1–26 ≤17.3 kg BMI 26.1–29 ≤18 kg BMI >29 ≤21 kg	
Weight loss	Self-reported unintentional weight loss > 10 pounds or > 5% in the last year (No = 0; Yes = 1)		Self-reported. “Have you been eating the same/more than usual?” (Yes = 0) “or less than usual?” (Yes = 1)
Slowness	Time to walk 15 feet (Yes = 1):		Time to walk 5 meter:
	Men	Height ≤173 cm ≥7 seconds Height > 173 cm ≥6 seconds	≤6 seconds (No = 0) > 6 seconds or unable to complete (Yes = 1)
	Women	Height ≤159 cm ≥7 seconds Height > 159 cm ≥6 seconds	
Low physical activity	Self-reported kilocalories expended per week ^a (Yes = 1): Males < 383 Kcals/week Females < 270 Kcals/week		Self-reported. “How often do you engage in activities that require a low or moderate level of energy (gardening, cleaning the car, or doing a walk)?” ≥once/week (No = 0) < once/week (Yes = 1)

Total scoring:

0 criteria met = not frail; 1–2 criteria met = prefrail; 3–5 criteria met = frail

Abbreviation: BMI, body mass index.

^aKcals per week expended are calculated using a standardized algorithm (short version of the Minnesota Leisure Time Activity questionnaire).

2.1.2.13. Surgical Risk

Recommendations for Comorbidities and Potential Contraindications to Heart Transplantation: Surgical Risk		
COR	LOE	RECOMMENDATIONS
1	B-NR	1. In HT candidates with prior cardiac surgery, this additional risk should be factored into the comprehensive assessment of transplant eligibility.
2b	C-LD	2. In heart transplant candidates with circular aortic calcification ("porcelain" aorta), the benefit of HT is uncertain due to the high risk of perioperative mortality and stroke.

Recommendation-Specific Supportive Text

1. Prior cardiac surgery increases the surgical risk and early morbidity and mortality of HT.^{276–279} Nonetheless, despite the increased postoperative risk conferred by prior cardiac surgery, this history should not be considered an absolute contraindication to transplantation. Instead, this additional risk factor should be considered in the context of the clinical picture, including the urgency for transplantation and the extent of other comorbidities, including age and center-specific surgical experience.
2. Porcelain aorta is extensive calcification of the ascending aorta or aortic arch that can be completely or near completely circumferential and reflects an underlying atherosclerotic process or the consequence of mediastinal radiation. The presence of a porcelain aorta is important to assess because it precludes safe cross-clamping or entry to the ascending aorta. During aortic valve surgery, the presence of a porcelain aorta increases the risk of perioperative mortality and stroke^{280,281} and this risk is extrapolated to HT. Although there are reports of surgical techniques adapted to reduce neuro-embolic risk and to achieve safe aortic insertion and closure, these are highly selected cases and not likely widely applicable.²⁸² Mediastinal radiation therapy for cancer can contribute to the formation of a porcelain aorta and result in perioperative complications.²⁸³

2.1.2.14. Bone Disease

Recommendations for Comorbidities and Potential Contraindications to Heart Transplantation: Bone Disease		
COR	LOE	RECOMMENDATION
1	B-NR	1. Heart transplant candidates should be assessed for osteoporosis and fracture risk.

Recommendation-Specific Supportive Text

1. Both pre-transplantation bone disease and immunosuppressive regimens result in rapid bone loss and increased fracture rates. Given existing ample data confirming the high frequency of bone disease in patients awaiting SOT, osteoporosis and fracture risk should be assessed. A comprehensive evaluation would include a fracture history, a routine bone densitometry of the lumbar spine and femoral neck measured by dual X-ray absorptiometry and spine radiographs or vertebral fracture assessment to diagnose prevalent fractures. Patients with osteoporosis should be treated before and after transplantation.²⁸⁴

2.1.3. Assessment of Transplant Eligibility in Special Populations

2.1.3.1. Cardiac Amyloidosis

Recommendations for Assessment of Transplant Eligibility in Special Populations: Cardiac Amyloidosis		
COR	LOE	RECOMMENDATIONS
2a	B-NR	1. In heart transplant candidates with cardiac amyloidosis from immunoglobulin light chain deposition (AL-CM) or transthyretin deposition (ATTR-CM) with evidence of AdvHF as indicated by amyloid-specific staging systems (Table 12) and traditional risk factors (Table 13), heart transplant evaluation is reasonable, including multidisciplinary collaboration to evaluate the extent and control of extracardiac disease.
3 Harm	B-NR	2. In patients with AL-CM and high-grade albuminuria, significant hepatic infiltration, significant gastrointestinal involvement with malnutrition, pulmonary amyloidosis with refractory effusions, significant peripheral neuropathy with autonomic dysfunction, and/or projected reduced survival despite plasma cell-directed therapies as determined in collaboration with hematologists and other relevant specialists, HT is not recommended.
3 No Benefit	B-NR	3. In patients with ATTR-CM with significant gastrointestinal involvement with malnutrition, significant peripheral neuropathy with autonomic dysfunction, and/or advanced age, HT is not recommended.
2b	B-NR	4. In patients with ATTRv-CM, the role of heart-liver transplantation is not well established given the advent of TTR silencer therapy, which reduces the progression of amyloid neuropathy.
2b	B-NR	5. In patients with AL-CM or ATTR-CM, the role of durable LVAD support is not well established, given the small left ventricular (LV) cavity size and biventricular involvement.

Synopsis

Cardiac amyloidosis results in RCM caused by extracellular deposition of proteins in the myocardium, most commonly a monoclonal immunoglobulin light chains (AL) from an abnormal clonal proliferation of plasma cells, or transthyretin (ATTR), a liver-synthesized protein which can be variant (ATTRv) or wild-type (ATTRwt) gene. Clinical recognition and diagnosis of cardiac amyloidosis at an early stage of the disease is critical, as important advances in the treatment of both ATTR-CM and AL-CM, will allow prompt implementation of therapeutic interventions that may improve survival, physical function, and/or QOL. However, for carefully selected patients with advanced symptoms and limited extracardiac involvement, HT may improve QOL and survival.

Recommendation-Specific Supportive Text

- Cardiac involvement is the most important prognostic indicator in patients with amyloidosis with both AL-CM or ATTR-CM.^{285–288} For both AL-CM and ATTR-CM, troponin and NT-proBNP are powerful indicators of disease burden and prognosis.^{289,290} Multiple staging systems have been developed that rely predominantly on these biomarkers (Table 12).^{291–294} There are additional biomarkers uniquely prognostic to the type of amyloidosis as well: free light chains (dFLC) and kidney function for AL-CM and ATTR-CM, respectively.^{293,295} However, traditional markers of poor prognosis in HF (as outlined in Task Force 1 [Listing Criteria for Heart Transplantation](#)) are also useful to best identify those candidates who are limited enough from a cardiac standpoint to warrant consideration of AdvHF therapies. The ideal timing of HT in AL-CM is challenging, as contemporary therapies may result in improved cardiac function, though patients with HF were excluded from key trials.²⁹⁶ In ATTR, while tafamidis slows disease progression, it does not reverse disease and is less effective in patients with more advanced symptoms.²⁸⁵ Thus, transplant evaluation should not be delayed in highly symptomatic patients to assess the response to tafamidis.

2. As multiorgan amyloid infiltration is common, the contraindications to HT in patients with cardiac amyloidosis center around the degree of extracardiac involvement and the impact of this involvement on post-transplant morbidity and mortality (Table 13). In AL-CM, it is critical to screen for the presence of significant extracardiac organ involvement, including high-grade albuminuria, significant hepatic infiltration, significant gastrointestinal involvement with malnutrition, pulmonary amyloidosis with exudative effusions,^{297,298} and significant peripheral neuropathy with autonomic dysfunction. The presence of multiple myeloma in the setting of AL amyloidosis and response to administered plasma-cell-directed therapies will also impact transplant candidacy.^{299,300} All patients undergoing consideration for HT should also be assessed by an experienced team for eligibility for stem cell transplantation, though this may not always be necessary in the current era of effective plasma cell-directed therapies.²⁹⁶
3. For ATTR-CM, potentially contraindicating extracardiac involvement includes gastrointestinal involvement and autonomic neuropathy (Table 13). Gastrointestinal involvement can result in malnutrition with risk for infection and poor wound healing. Disabling neuropathy will not improve after HT and may significantly impair rehabilitation efforts and QOL.
4. For ATTRv-CM, heart-liver transplantation has traditionally been considered in patients at risk for neuropathy, as neuropathy may progress with HT alone. However, the criteria for HT alone vs heart-liver transplantation are not well defined,⁵ especially with the advent of transthyretin (TTR) silencer therapy that may have a role after HT.^{301,302} TTR-specific therapy, including tafamidis or silencing agent (in patients with ATTRv-CM), should be prescribed following HT if coexistent neuropathy attributable to amyloidosis is present.³⁰³
5. Barriers to the successful use of DMCS devices include the small LV cavity and BiV involvement.^{304,305} A second challenge arises from the fact that patients with cardiac amyloidosis typically have evidence of BiV dysfunction, resulting in the risk of RV failure when LVADs are placed. In this situation, a durable BiV assist device, such as the total artificial heart (TAH), may be placed.³⁰⁶ Another concern for the use of DMCS in patients with amyloidosis is the risk of infection in those patients with AL amyloidosis upon receiving plasma-cell-directed therapies.³⁰⁰ Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) registry data indicate worse survival in all patients with cardiac amyloidosis and MCS compared to those with dilated cardiomyopathy and nonamyloid RCM regardless of whether LVAD or BiV MCS was employed.³⁰⁷

Table 12 Staging Systems for Cardiac Amyloidosis

Variable	Mayo staging system ²⁹⁴	UK staging System ²⁹⁵	Mayo 2004 ²⁹¹	Mayo 2004 with European modification ³⁰⁸	Mayo 2012 ²⁹³	Boston University ³⁰⁹
Population	ATTRwt-CM	ATTRwt-CM and ATTRv-CM	AL-CM	AL-CM	AL-CM	AL-CM
Parameters and thresholds	<ul style="list-style-type: none"> • Troponin T ≤ 0.05 ng/ml • NT-proBNP $\leq 3,000$ pg/ml 	<ul style="list-style-type: none"> • NT-proBNP $\leq 3,000$ pg/ml • eGFR ≥ 45 ml/min 	<ul style="list-style-type: none"> • Troponin: - TnT ≥ 0.035 mcg/liter or - TnI ≥ 0.1 mcg/liter or - High-sensitivity TnT ≥ 50 ng/liter • BNP: - NT-proBNP ≥ 332 ng/liter 	<ul style="list-style-type: none"> • Troponin: - TnT ≥ 0.035 mcg/liter or - TnI ≥ 0.1 mcg/liter or - High-sensitivity troponin T ≥ 40 ng/liter • BNP: - NT-proBNP ≥ 1800 ng/liter or - BNP ≥ 400 ng/dl or - dFLC ≥ 18 mg/dl 	<ul style="list-style-type: none"> • Troponin T ≥ 0.025 mcg/liter or - High-sensitivity troponin T ≥ 40 ng/liter • BNP: - NT-proBNP ≥ 1800 ng/liter or - BNP ≥ 400 ng/dl or - dFLC ≥ 18 mg/dl 	<ul style="list-style-type: none"> • BNP > 81 pg/ml • TnI > 0.1 ng/ml
<i>Median survival</i>						
Stage I: no parameters above threshold	66 months	69.2 months	26.4-27.2 months	Median survival not reached; 60% survival at 10 years	94.1 months	Median survival not reached; > 12 years
Stage II: 1 parameter above threshold	40 months	46.7 months	10.5-11.1 months	49 months	40.3 months	113 months
Stage III: 2 parameters above threshold	20 months	24.1 months	3.5-4.1 months	14 months	14 months	52 months
Stage IIIA: 2 parameters above threshold and NT-proBNP $< 8,500$ ng/ml	n/a	n/a	n/a	14 months	n/a	
Stage IIIB: 2 parameters above threshold and NT-proBNP $\geq 8,500$ ng/ml	n/a	n/a	n/a	5 months	n/a	12 months (if BNP > 700 mg/ml)
Stage IV: 3 parameters above threshold	n/a	n/a	n/a	n/a	5.8 months	n/a

Abbreviations: AL-CM, amyloid monoclonalimmunoglobulin light chain cardiomyopathy; ATTRwt-CM, wild-type transthyretin amyloid cardiomyopathy; ATTRv-CM, transthyretin variant amyloid cardiomyopathy; BNP, B-type natriuretic peptide; dFLC, difference between involved and uninvolved free light chain; eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal pro-brain natriuretic peptide; TnT, Troponin T.

Table 13 Extracardiac Complications of Amyloidosis

System involvement	AL vs ATTR	Common presentation	Tools for assessment	Considerations in the heart transplant candidate
Renal ³¹⁰	• AL	<ul style="list-style-type: none"> • Proteinuria • Nephrotic syndrome 	<ul style="list-style-type: none"> • Urine protein • Serum creatinine 	<ul style="list-style-type: none"> • Consider dual heart/kidney transplant in eGFR < 50 ml/min/1.73 m² and albuminuria > 0.5 g/day • Discussion with nephrology regarding reversibility post-transplant
Hepatic ³¹¹	• AL	<ul style="list-style-type: none"> • Elevated alkaline phosphatase • Hepatomegaly • Splenomegaly 	<ul style="list-style-type: none"> • Liver function tests • Biopsy 	<ul style="list-style-type: none"> • Consider need for dual heart-liver transplant
Gastrointestinal ³¹²	• AL	<ul style="list-style-type: none"> • Gastrointestinal bleeding • Weight loss • Refractory dyspepsia 	<ul style="list-style-type: none"> • Whole-body¹²³I-labeled serum amyloid P scintigraphy • Biopsy 	<ul style="list-style-type: none"> • Malnutrition • Impact on medication absorption
Autonomic nervous system ³¹³	• ATTR	<ul style="list-style-type: none"> • Carpal tunnel • Sensorimotor polyneuropathy • Orthostasis/autonomic dysfunction 	<ul style="list-style-type: none"> • Physical exam • Electromyography 	<ul style="list-style-type: none"> • Impact on frailty and ambulation
Pulmonary ³¹⁴	• AL	<ul style="list-style-type: none"> • Rarely symptomatic • Pleural effusions 	<ul style="list-style-type: none"> • CT-chest • Biopsy of effusions for light chains 	<ul style="list-style-type: none"> • Functional limitations post-transplant • Possible PH, contribute to cardiopulmonary disease
Coagulation ³¹⁵	• AL	<ul style="list-style-type: none"> • Bleeding 	<ul style="list-style-type: none"> • Factor X levels • Coagulation labs 	<ul style="list-style-type: none"> • Surgical impact of bleeding

Abbreviations: AL, amyloid monoclonal immunoglobulin light chain; ATTR, amyloid transthyretin; CT, computed tomography; eGFR, estimated glomerular filtration rate; PH, pulmonary hypertension.

2.1.3.2. Restrictive and Hypertrophic Cardiomyopathy

Synopsis

Cardiomyopathy is the cause of several clinical presentations (e.g., HF and arrhythmia); it is characterized by a dynamic evolution of disease phenotypes across the life course, from childhood to adulthood. Etiological complexity with multiple disease processes (genetic and nongenetic) contributes to the various phenotypes. It is vital to recognize that different cardiomyopathy phenotypes may coexist in the same family, and that disease progression in an individual patient can include evolution from one cardiomyopathy phenotype to another. Morphological traits, at the time of presentation of the disease, are used to define the cardiomyopathy phenotype. Coupling cardiomyopathy phenotype at presentation with the underlying etiology has prognostic significance, with the emergence of novel etiology-focused therapies. The HCM phenotype is characterized by increased LV wall thickness or mass, which is not solely explained by abnormal loading conditions (i.e., hypertension, valvular, or congenial disease). The RCM phenotype is defined as restrictive left and/or RV pathophysiology in the presence of normal or reduced diastolic volumes (of one or both ventricles), normal or reduced systolic volumes, and normal ventricular wall thickness, and commonly present as biatrial enlargement.³¹⁶

2.1.3.2.1. Restrictive Cardiomyopathy

Recommendations for Assessment of Transplant Eligibility in Special Populations: Restrictive Cardiomyopathy		
COR	LOE	RECOMMENDATIONS
1	B-NR	1. In patients with restrictive cardiomyopathy (RCM) and severe HF symptoms (NYHA Class III–IV), HT evaluation is recommended.
1	C-LD	2. In patients with RCM being evaluated for HT, a diagnostic evaluation to exclude treatable or reversible causes is recommended.
2b	C-LD	3. In patients with RCM, the role of DMCS is not well established.

Recommendation-Specific Supportive Text

1. RCM is characterized by the predominance of increased ventricular stiffness associated with markedly increased filling pressure and either normal or mildly reduced ejection fraction (EF).³¹⁶ Both adults and children with RCM have higher waitlist mortality compared to those with dilated cardiomyopathy,^{317–321} likely related to the limited available therapies. Therefore, regardless of systolic function, the indications for HT listing in patients with RCM should be carefully assessed and include a hemodynamic evaluation with RHC to identify high-risk features for decompensation, namely, PH (Section [Pulmonary Hypertension](#)).^{317,322} Owing to long-standing RHF, patients with RCM are at increased risk for advanced hepatic fibrosis and cirrhosis and liver biopsy may be required (Section [Liver Disease](#)).
2. Patients with restrictive physiology require evaluation to exclude constrictive pericarditis and elucidate underlying myocardial disease and its extracardiac involvement. RCM and constrictive pericarditis may sometimes coexist, for example, in radiation-induced cardiac disease, subacute or chronic myocarditis, or drug-induced cardiomyopathy. For these patients, treatment for constrictive pericarditis should precede assessment of the necessity/eligibility for HT listing. RCM may be idiopathic/genetic, toxic, infiltrative, inflammatory, or caused by other disorders. The endomyocardial biopsy can be valuable, although it often demonstrates nonspecific findings in idiopathic RCM. The functional and morphologic pattern of RCM can be associated with a large spectrum of underlying nonmyocardial pathologies, including hypertension, coronary artery disease, and pericardial disease, all of which should be excluded during the diagnostic workup before considering these patients for HT. RCM patients secondary to idiopathic, genetic, infiltrative, inflammatory, or storage diseases should be carefully assessed. Some conditions that may at times present with restrictive physiology are discussed in other sections, including sarcoidosis (Section [Connective Tissue Diseases and Sarcoidosis](#)) and amyloidosis (Section [Cardiac Amyloidosis](#)). Other rarer causes of RCM are hemochromatosis, glycogen storage diseases, and genetic deficiencies, such as Fabry disease. As disease-directed therapy may obviate the need for transplantation, a thorough assessment for a potentially treatable underlying cause is essential.³²³
3. Given that patients with RCM often have smaller LV cavities and BiV involvement, durable LVAD support may be less well tolerated. Compared to patients with dilated cardiomyopathy, patients with RCM are more likely to require BiV support, although post-transplant outcomes were comparable to patients without RCM who underwent DMCS as bridge to transplantation (BTT).^{307,324,325}

2.1.3.2.2. Hypertrophic Cardiomyopathy

Recommendations for Assessment of Transplant Eligibility in Special Populations: Hypertrophic Cardiomyopathy		
COR	LOE	RECOMMENDATIONS
1	B-NR	1. In patients with nonobstructive hypertrophic cardiomyopathy (HCM) and AdvHF (NYHA Class III-IV despite GDMT) or with life-threatening ventricular arrhythmias refractory to maximal GDMT, evaluation for HT is indicated.
2a	B-NR	2. In patients with nonobstructive HCM and persistent or progressive HF symptoms (NYHA Class III-IV) despite GDMT who are otherwise suitable for HT, continuous-flow LVAD therapy is reasonable as a bridge to HT, in those with suitable anatomy.

Recommendation-Specific Supportive Text

1. AdvHF, commonly associated with but not limited to those with a reduced EF, arises in a small subset (3%-5%) of patients with nonobstructive HCM.^{326–328} Although observational studies of patients with HCM and EF < 50% indicate that survival is worse than that of patients with HCM and preserved EF,^{329–331} transplant referral does not absolutely require reduced EF, as patients with preserved EF may also develop AdvHF with restrictive physiology.^{332,333} Patients with HCM, particularly those with LV outflow tract obstruction, whose symptoms respond to medical, interventional, surgical, or device therapy as indicated should not be referred for transplantation. Post-transplant survival in patients with HCM is comparable, and in some studies superior, to that of patients with other forms of heart disease in both adult and pediatric heart transplant recipients.^{334–338} Children with HCM should also be considered for transplantation if they are not responsive to or appropriate candidates for other therapeutic interventions.³²⁰
2. Patients with HCM have traditionally been ineligible for LVAD support due to small LV cavities and relatively preserved EF. However, a number of case series have demonstrated that support with continuous flow (CF) LVADs is feasible in patients with HCM, with better increased post-LVAD survival in HCM patients with larger LV cavities (> 46–50 mm).^{305, 339–341} There are little data on the role of BiV assist devices in patients with HCM. Data on the role of MCS in children with HCM are similarly limited.³⁴²

2.1.3.3. Congenital Heart Disease

Recommendations for Assessment of Transplant Eligibility in Special Populations: Congenital Heart Disease		
COR	LOE	RECOMMENDATIONS
1	B-NR	1. In heart transplant candidates with CHD, care at centers with established medical and surgical experience in both pediatric and adult CHD and transplantation is recommended to confirm that transplant evaluation is appropriate and that all non-transplant medical, interventional, and surgical therapies have been exhausted prior to evaluation.
1	C-LD	2. In heart transplant candidates with CHD, detailed assessment is recommended, including: <ol style="list-style-type: none"> The position and anatomy of the abnormalities within the chest (via cardiac MRI and/or chest CT) to guide the surgical strategy; Evaluation of PH, and all potential sources of pulmonary flow; Patency of major veins and arteries and venous collaterals across the chest wall; Disease in organ systems that can affect post-transplant care and/or cannot be reversed with transplantation (including but not limited to lung, liver, gastrointestinal, and kidney disease); Anti-human leucocyte antigen (HLA) antibody sensitization; Psychosocial evaluation of the patient, family, and caregiver support.
1	B-NR	3. In patients with single ventricle CHD and a Fontan circulation (total cavopulmonary anastomosis), HT evaluation is recommended to improve QOL and survival in the following situations: <ol style="list-style-type: none"> Symptomatic HF and reduced systolic function (Class 1); Symptomatic HF, preserved systolic function, and abnormal systemic ventricular filling pressures (Class 1); Lymphatic abnormalities including plastic bronchitis and protein-losing enteropathy refractory to lymphatic interventions and medical management (Class 2a); Cirrhosis or CKD attributed to chronically elevated central venous pressures (Class 2a).
2a		
1	B-NR	4. In patients with single ventricle CHD, HT evaluation is recommended to improve QOL and survival in the following situations: <ol style="list-style-type: none"> Palliation to a shunted circulation or a superior cavo-pulmonary anastomosis (first procedure of a staged Fontan) and prohibitive risk for further single ventricle palliation; Cyanotic heart disease with severe atrio-ventricular valve regurgitation and prohibitive risk for operative repair; Pulmonary atresia with an intact ventricular septum, right ventricular dependent coronary circulation, and atresia of at least one aorto-coronary ostium; Neonatal hypoplastic left heart syndrome with high-risk features including HF symptoms, ventricular dysfunction, left ventricular-coronary artery fistulae.
1	B-NR	5. In patients with CHD, HT evaluation is recommended to improve QOL and survival in the following situations: <ol style="list-style-type: none"> HF symptoms or ventricular arrhythmias refractory to medical, interventional, and device therapies (Class 1). Reactive PH and a potential risk of developing fixed, irreversible elevation of PVR that could preclude HT in the future (Class 1) Neonatal cyanotic CHD with high-risk features as determined by an experienced pediatric CHD and cardiac surgery center (Class 2a).
2a		

Continued

2b	B-NR	6. The benefit of HT for CHD is not well established and may be considered as significant risk in the following CHD-specific situations: a. Increased surgical risk including multiple prior cardiac surgeries, aortopulmonary collaterals not amenable to catheter-based or surgical interventions; and/or prior mediastinitis b. Congenital absence, or near-total venous thromboembolism, of major systemic venous connections.
2b	B-NR	7. In patients with Fontan-associated liver disease and cirrhosis, the specific indications for heart alone versus heart-liver transplantation are not well-established and include: a. HT alone in patients with no stigmata of liver disease based on Child-Pugh Class A function and no portal hypertension; b. Heart-liver transplantation in patients with stigmata of liver disease based on Child-Pugh Class B/C function and/or portal hypertension (varices, ascites, splenomegaly, and/or thrombocytopenia). For patients with FALD score ≥ 2 combined heart-liver transplants may confer a survival advantage vs. isolated HT.


Synopsis

Due to advances in the medical, interventional, and surgical management of congenital heart defects, up to 90% of children born with CHD now survive to adulthood.³⁴³ However, despite successful interventions to repair cardiac anatomy, many with CHD experience long-term morbidity and reduced survival relative to the general population, with HF being the leading cause of death.^{344–349} One important consideration is preparing young patients and their families for the expectation of ultimate transplant, and the reassessment of the transplant option when patients require serial palliations over the years. The thresholds for multiorgan transplantation remain center-specific, although growing consensus supports heart-liver transplantation for failed Fontan physiology and FALD if associated with cirrhosis and/or severe fibrosis with evidence of portal hypertension.²²⁰ For many patients with complex CHD, sensitization—from prior transfusions or from existing homografts—adds risk and complexity to the transplant operation and long-term management.

Recommendation-Specific Supportive Text

1. There are many causes of HF symptoms in patients with CHD that may be reversible, including valve dysfunction, shunts, arrhythmias, venous obstruction, and systolic and/or diastolic ventricular dysfunction, which require evaluation and treatment when possible. Unlike acquired HF, and despite the clinical importance of HF in adults with CHD, there is limited evidence of benefit of traditional GDMT for HF.³⁵⁰ When patients with CHD develop refractory AdvHF, they may be evaluated for HT. However, patients may be denied due to a perceived higher risk based on prior cardiac surgeries, which increases surgical complexity and antibody sensitization from perioperative blood transfusions and the presence of homografts.^{351,352} These factors result in longer waitlist times with increased waitlist mortality, less use of MCS, and an increase in perioperative and short-term post-transplant mortality.^{41,353,354} Nonetheless, patients with CHD who undergo HT have equal or even superior long-term survival^{41, 349, 353–357} and increased transplant center volume and CHD expertise are associated with improved post-transplant short-term outcomes.^{358,359} Thus, heart transplant candidates with CHD should be cared for at centers with established medical and surgical experience in both pediatric and adult CHD and transplantation to confirm that nontransplant therapies have been exhausted and to ensure timely referral for transplantation when appropriate.
2. Indications for HT in patients with CHD are typically based on the physiological classification of the lesion and include mainly those patients with complex CHD,³⁶⁰ although data on proper timing of transplantation are limited, particularly for individual lesions (Figure 4). Repaired 2-ventricle CHD will generally fit traditional indications for HT. Patients with 2-ventricle CHD (repaired dextro-transposition of the great arteries (D-TGA, also known as classic TGA), unrepaired levo-transposition of the great arteries (L-TGA, also known as congenitally corrected TGA), or double-outlet right ventricle), may present with HF later in life than patients with single-ventricle physiology (double inlet left ventricle, tricuspid atresia, hypoplastic left heart, any other anatomic abnormality with a functionally single ventricle) with “failed Fontan physiology.”^{361,362} While all patients with CHD require routine transplant evaluation as outlined throughout the document, CHD-specific evaluation comprises additional assessment of cardiac anatomy, end-organ function, and antibody sensitization.

3. Patients with single ventricle CHD who have undergone Fontan palliation surgery (total cavopulmonary anastomosis) may exhibit “failed Fontan physiology,” which can manifest as (1) reduced systolic function; (2) preserved systolic function and abnormal filling pressures; (3) abnormal lymphatics manifesting as plastic bronchitis (PB) and/or protein-losing enteropathy (PLE); and (4) liver or kidney disease related to chronic congestion.³⁶³ HT can improve QOL and survival in patients with a Fontan circulation and symptomatic HF.^{41, 364–368} Patients with PB and PLE have improved QOL and survival after HT,^{367, 369–371} although frailty needs to be carefully assessed.²⁶⁴
4. HT should be considered in patients with cyanotic CHD (shunted or bidirectional Glenn (cavopulmonary anastomosis)) who are not candidates for completion of Fontan palliation or repair of severe atrioventricular valve regurgitation.^{372,373} Waitlist mortality is higher in patients listed for HT within 6 months of Fontan surgery compared to patients listed > 6 months after Fontan surgery. Such time-related mortality was not observed in patients listed after bidirectional Glenn, indicating a role for early listing in patients who do poorly after the first stage of palliation.²⁷ Although most patients with pulmonary atresia with intact ventricular septum and right ventricular dependent coronary circulation can be palliated via a single ventricle pathway, while those with aorto-coronary ostial atresia represent a high risk subtype where HT is indicated.^{374–377} Because hypoplastic heart syndrome (HLHS) with standard risk features has good intermediate outcomes with current surgical approaches and because of the limited availability of donor organs, HT is not indicated in neonates with HLHS and acceptable surgical risk for staged reconstruction.^{378–380} Rather, listing for HT should be reserved for those patients with high-risk features, including HF symptoms, ventricular dysfunction, and left ventricular-coronary artery fistulae.^{381,382}
5. Other indications for HT in patients with CHD include those common to all heart transplant candidates, namely, HF symptoms or ventricular arrhythmias refractory to medical, interventional, and device therapy. Reactive PH is a poor prognostic sign in CHD^{383–385} and should prompt transplant consideration, including possible heart-lung transplantation.^{166,168,170} Neonatal cyanotic CHD with high-risk features as determined by an experienced pediatric CHD and cardiac surgery center may be also warrant transplant evaluation.
6. Patients with CHD should be assessed for the standard contraindications to transplantation outlined throughout this document. However, there are CHD-specific contraindications to consider. Patients with repaired CHD commonly have anti-HLA antibody sensitization due to exposure to blood products and homograft material,^{386–388} although the latter may be mitigated by pretreating homograft material with glutaraldehyde^{389,390} or using decellularized homografts.³⁹¹ Prior cardiac surgeries increase the perioperative transplant risk due to scar formation resulting in increased bleeding risk and need for blood products; technical difficulties with vascular reconstruction; and the presence of aortopulmonary collaterals.^{392,393} Venous thromboembolism is common in patients with CHD,^{394,395} related to use of central venous lines and the low-flow Fontan state.^{394,396} The presence of near-total or total occlusion of systemic veins can represent a contraindication to HT depending upon their severity and location.
7. Patients with CHD, particularly those with Fontan physiology and chronic systemic venous congestion, are at high risk for the development of liver fibrosis and cirrhosis. FALD is related to time from Fontan,³⁹⁷ with near-universal evidence of liver disease by 20 years post-Fontan³⁹⁸ and cirrhosis present in nearly half by 30 years post Fontan.³⁹⁹ However, FALD is frequently associated with mild-to-moderate fibrosis³⁹⁷ and liver biopsies may be subject to sampling error,^{400,401} making the decision to proceed with heart alone vs heart-liver transplant challenging, especially given the lack of prospective studies with standardized criteria for heart vs heart-liver transplantation. Single-center reports demonstrate that heart transplant recipients with high Child-Pugh or MELD-XI scores have increased post-transplant mortality.^{402,403} Nonetheless, advanced liver fibrosis alone can regress after HT, suggesting that assessment of hepatic function (rather than histology alone) would be preferable in determining need for heart-liver transplant,⁴⁰⁴ especially as other single-center reports indicate that patients with hepatic fibrosis on biopsy and Child-Pugh Class A may have acceptable outcomes after HT alone.^{191,404,405} A retrospective multicenter study of adult Fontan patients undergoing HT or combined heart-liver transplantation demonstrated that higher pre-transplant FALD scores (calculated 1 point for each of the 4 elements: (1) cirrhosis; (2) varices; (3) splenomegaly; or (4) ≥ 2 paracenteses) were associated with worse outcomes overall. Survival postcombined heart-liver transplantation may have been superior in patients with a FALD score ≥ 2 when performed at experienced centers.^{406,407}

Figure 4 Transplantation in congenital heart disease. CHD, congenital heart disease; CKD, chronic kidney disease.

2.1.3.4. Retransplantation

Recommendation for Assessment of Transplant Eligibility in Special Populations: Retransplantation		
COR	LOE	RECOMMENDATIONS
2a	B-NR	1. In heart transplant recipients with ISHLT Grade 3 CAV, evaluation for retransplantation is reasonable.
2b	C-LD	2. In heart transplant recipients with the following, the benefit of retransplantation is not well established: <ol style="list-style-type: none"> Graft failure due to active rejection Advanced age Need for DMCS as a bridge to retransplantation.

Recommendation-Specific Supportive Text

- The number of patients who are candidates for heart retransplantation is rising and comprises about 3% of adult heart transplant recipients, increasing to 7% of recipients between 18 and 39 years.²⁰³ The most common indication for retransplantation is CAV. Treatment options with limited demonstrated efficacy include management of atherosclerotic risk factors,⁴⁰⁸ use of proliferation signal inhibitors sirolimus⁴⁰⁹ or everolimus,⁴¹⁰ and percutaneous intervention^{411,412}; thus, retransplantation is often pursued. Grade 3 CAV is defined as (1) angiographic left main stenosis $\geq 50\%$; (2) 2 or more primary vessels $\geq 70\%$ stenosis; isolated branch stenosis $\geq 70\%$ in all 3 systems; (3) ISHLT CAV1 or CAV2 with allograft dysfunction (defined as LVEF $\leq 45\%$ usually in the presence of regional wall motion abnormalities); or (4) evidence of significant restrictive physiology based on symptoms, echocardiogram, and/or RHC.⁴¹³ Grade 3 CAV is associated with worse outcomes,⁴¹⁴ up to 75% mortality at 5 years⁴¹² and thus consideration of retransplantation is reasonable in this cohort. Registry analyses indicate worse survival in patients undergoing retransplantation compared with those undergoing primary transplant in adults^{203,415} and children.⁴¹⁶ However, after matching for comorbidities, late retransplantation in the adult population is not associated with an increase in all-cause mortality, emphasizing the importance of assessing indication acuity and comorbid conditions when considering retransplant candidacy.⁴¹⁷ As heart transplant recipients often have kidney dysfunction from long-term calcineurin inhibitor use, SHKT may be considered.⁴¹⁸
- Candidate selection for retransplantation should follow the same recommendations established for primary transplants. There are conditions for which retransplantation portends worse outcomes, including transplantation for active rejection,^{417,419} transplantation within the first 2 years after transplantation,^{417,420} and need for DMCS as a bridge to retransplantation. Advanced age is potential barrier to retransplantation, with data showing increased 5- and 10-year post-transplant mortality after age 60.⁴²¹ Heart transplant recipients who require DMCS as a bridge to retransplantation are at high risk of death⁴²² and this may be considered a contraindication to transplantation. Given the ethical concerns of donor stewardship in retransplantation,^{423,424} careful patient selection is paramount.

2.1.4. Special Considerations Regarding Transplant Eligibility in Pediatric Patients

Recommendations for Special Considerations Regarding Transplant Eligibility in Pediatric Patients		
COR	LOE	RECOMMENDATIONS
1	B-NR	1. In pediatric heart transplant candidates with extracardiac conditions that would increase the risk of post-transplant morbidity or mortality, including but not limited to neuromuscular disease or chromosomal abnormalities, individualized assessment is recommended to assess transplant eligibility.
1	B-NR	2. In pediatric heart transplant candidates under the age of 2 years, ABO-incompatible HT is recommended to increase the donor pool.
3 No Benefit	C-LD	3. In pediatric heart transplant candidates with severe hypoplasia of the central branch pulmonary arteries or pulmonary veins, HT is not recommended due to increased surgical risk.

Synopsis

Where pertinent, the special pediatric-specific considerations for heart transplant candidacy are discussed in the relevant sections above. However, there are some conditions that are unique to pediatric heart transplant candidacy discussed here, including neuromuscular disease and chromosomal abnormalities, ABO-incompatible HT, and surgical considerations.

Recommendation-Specific Supportive Text

- Any condition that limits post-transplant survival and QOL or would impact successful adherence to the complex post-transplant regimen should be considered a relative contraindication to transplantation. These are discussed in detail in other sections, but those unique to pediatric HT include conditions with concomitant cardiac and extracardiac disease, including neuromuscular disease such as Duchenne muscular dystrophy⁴²⁵ or chromosomal abnormalities with significant developmental delay.^{426,427} For pediatric transplant candidates with neuromuscular disease, specific attention should be paid to respiratory muscle strength, aspiration risk, and potential for rehabilitation.⁴²⁵ Of note, exclusion of children from transplantation based solely on intellectual and developmental disabilities (IDD) from transplantation is not justified.^{426–430} Children with IDD can experience improved QOL after transplantation,^{431–435} and survival comparable to other pediatric transplant recipients.^{426, 427, 436–440} However, the potential for medical nonadherence due to IDD with lack of adequate caregiver support would be concerning, as nonadherence occurs in a significant number of children after HT and is associated with a substantial risk of death.^{40,441} Thus, children with neuromuscular disease or extracardiac disease require an individualized assessment to determine candidacy.^{40,442,443}
- Waitlist mortality of pediatric heart transplant candidates ranges between 15% and 30%.^{7,444,445} The immaturity and malleability of the infant immune system have allowed for the evolution of ABO-incompatible HT; antibodies against the non-self blood group antigens, which are ubiquitous in adults and older children, are absent in infants and slowly evolve starting around 18 months of age. ABO-incompatible HT has evolved to close this gap between waitlist candidates and donor supply and in children under 2 years of age, ABO-incompatible HT offers comparable outcomes to ABO-compatible transplantation.^{7,446–450} The UNOS is extending ABO-incompatible HT eligibility to all patients under 18 years of age who have low titers to non-self blood group antigens,⁴⁵¹ although there are paucity of data on outcomes in those recipients of ABO-incompatible transplants over 2 years of age.
- Severe hypoplasia of the central branch pulmonary arteries or pulmonary veins is considered an absolute contraindication to HT due to concern for surgical risk.⁴⁵² Such patients may, however, be considered for heart-lung transplantation or lung transplantation with the repair of cardiac abnormalities.⁴⁵³

2.2. Psychosocial Evaluation

2.2.1. Evaluation of Substance Use

Recommendations for Psychosocial Evaluation: Evaluation of Substance Use		
COR	LOE	RECOMMENDATIONS
1	C-EO	1. In heart transplant candidates with a history of active illicit drug use, at least 6 months of abstinence is recommended prior to transplant listing.
2a	B-NR	2. In heart transplant candidates with a history of active cannabis use, recommendation for abstinence prior to evaluation and listing is reasonable due to reported infectious risk and potential drug-drug interaction post-transplant.
1	B-NR	3. In heart transplant candidates with a history of active alcohol use disorder, at least 6 months of abstinence is recommended prior to transplant listing.
1	B-NR	4. In heart transplant candidates with a history of active tobacco smoking, at least 6 months of abstinence is recommended prior to transplant listing.

Synopsis

Illicit drug use, alcohol use, and tobacco smoking before HT can increase the candidate's risk for poor postsurgical outcomes and mortality.^{6, 454–456} A thorough evaluation of the heart transplant candidate's substance use history should be performed and should include assessment of any past or current illicit drug use, alcohol use, and tobacco use. Such an evaluation should examine frequency, amount, duration of use, and length of abstinence as well as the level of impairment that affects the candidate's health, job, and relationships. Any current treatment for substance abuse and the patient's willingness to seek treatment should also be assessed. The presence of substance abuse should be assessed by patient reporting, questionnaires, and biochemical testing. Referrals to addiction services should be made for patients with active substance use disorders (Figure 5).


Recommendation-Specific Supportive Text

1. Use of opiates is associated with increased mortality after kidney⁴⁵⁷ and liver transplantation, and these findings have been extrapolated to other illicit substances and other organ transplants.^{6, 454–457} Given the risk of relapse, the transplant candidate should have a period of abstinence of at least 6 months, demonstrated by negative biochemical drug screening. Rehabilitation programs and counseling should be encouraged in patients with a history of illicit drug abuse.
2. The common modes of cannabis use include inhalation (smoking or vaporizing) and oral ingestion (common forms include edibles and beverages). Inhaled cannabis (the most common method of use) is characterized by rapid absorption and can be detected in the blood within 1 minute of circulation; it has a fast onset with a strong effects peak and a rapid decline. By-products of smoked cannabis include carcinogens, which increase the risk of bronchitis, and pulmonary infections, including tuberculosis. Vaporized cannabis contains propylene glycol and vitamin E acetate, which cause acute lung injury and severe pneumonitis. Edible cannabis has a long latency period, delayed effect onset, and peak serum concentration. Edible cannabis does not appear to have adverse pulmonary manifestations, but psychiatric and cardiovascular complications are common with edible cannabis.⁴⁵⁸ Inhaled cannabis use post-transplant has been linked to increased infection risks and fungal lung infections.⁴⁵⁹ In addition, cannabis may alter the metabolism of immunosuppressive medications.⁴⁵⁹ Cannabis interacts with other medications commonly used in HT, such as antifungals (azoles), diltiazem for hypertension, warfarin, sulfamethoxazole-trimethoprim and dapsone (*Pneumocystis jirovecii* prophylaxis) and increased statin exposure. Thus, programs will likely continue to make their own center-specific decisions regarding cannabis use and transplant candidacy, although it would be safest to emphasize avoidance of cannabis, regardless of legalization. Exceptions for approved cannabis substances prescribed legally by medical care provider, may be made under certain conditions, to qualify for HT listing.
3. Excessive alcohol use is associated with poor medication adherence and adverse outcomes post-transplant,^{454,460} including increased mortality, and is an absolute contraindication for HT. Large international variation exists on acceptable alcohol intake; hence, the national recommendations and standards may be useful in defining excessive alcohol use. Methods of evaluation for alcohol use disorder (both dependency and abuse) should include self-reporting by the candidate and biochemical testing. The alcohol use disorder identification test is a reliable tool used to detect harmful drinking patterns in candidates and can be considered in the candidate's evaluation.^{460–462} A structured rehabilitative program may be considered for patients with a recent history of alcohol abuse if transplantation is being considered. Because of the association of shorter time periods of abstinence with relapse

post-transplant, the recommended period for abstinence from alcohol is at least 6 months.⁴⁶³ Abstinence can be monitored using phosphatidylethanol, an abnormal phospholipid produced only in the presence of ethanol and can be measured in the serum.⁴⁶⁴ A patient with an alcohol use disorder can demonstrate candidacy after abstaining from alcohol use for 6 months or more, as proven by frequent biochemical testing.

4. Active tobacco smoking is a contraindication to HT due to the significant increase in malignancy, CAV, renal dysfunction, and death associated with tobacco use in heart transplant recipients.^{465–467} A patient should demonstrate candidacy for transplant by abstaining from tobacco use for at least 6 months. Abstinence from tobacco can be monitored using serum or urine cotinine levels.⁴⁶⁸ The candidate should be educated on reducing environmental and secondhand exposure to tobacco smoking. The use of other tobacco products has not been well studied. As the prevalence of e-cigarette use increases, research will be required to determine if this is detrimental to the transplant population. Given the lack of information currently, avoidance of all nicotine products is preferred.

Figure 5 Summary of substance use disorder assessment.



2.2.2. Evaluation of Support, Adherence, and Mental Health

Recommendations for Psychosocial Evaluation: Evaluation of Support, Adherence and Mental Health		
COR	LOE	RECOMMENDATIONS
1	B-NR	1. In heart transplant candidates, confirmation of social support is recommended, including caregivers who: 1) understand the severity of patient's illness and their role as caregiver toward a potential transplant recipient; 2) can support both the patient's emotional and physical needs; 3) are dedicated to providing dependable care.
1	B-NR	2. Heart transplant candidates should exhibit adherence to medical recommendations, medications, and healthy lifestyle behaviors including optimal diet and physical activity as well as an understanding of expectations regarding the post-transplant regimen of medications and follow-up.
1	B-NR	3. In heart transplant candidates, assessment of adequate control of mental health problems is recommended with screening by a healthcare professional with expertise in mental health for 1) past and current mood disorders (including suicidal ideation or other self-injurious behavior), anxiety disorders, and other mental health problems (e.g., psychosis, personality disorders); 2) willingness, response, and adherence to treatment for past or current mental health problems; and 3) mental health issues in their social support network.
2a	B-NR	4. In candidates for HT, the use of psychosocial screening tools (e.g., PACT, SIPAT, TERS) can be useful as part of a comprehensive and multifaceted psychosocial evaluation to highlight risk factors for which further supportive interventions pre- and post-transplant are needed.

Synopsis

Psychosocial assessment is routinely performed at the time of initial HT evaluation and involves behavioral health specialists, such as psychiatrists, psychologists, or social workers. HT requires significant engagement from patients and their caregivers, as post-transplant care is typically complex and necessitates regular clinic visits and testing, strict adherence to medications, and adoption of healthy lifestyle measures. The psychosocial evaluation is a key component of the multifaceted pre-transplant screening process, aimed at identifying those candidates at increased risk of poor post-transplant outcomes due to inadequate support, adherence, or optimal mental health; deficits in these factors are associated with poor post-transplant outcomes. The 2018 ISHLT/APM/AST/ICCAC/STSW recommendations for the psychosocial evaluation of adult cardiothoracic transplant candidates offer a detailed assessment aligned with the recommendations here. The psychosocial evaluation should identify any evidence that cognitive status may compromise patients' ability to make decisions, give informed consent, and assess patients' personal, social, and environmental resources and circumstances; these issues are detailed in the 2018 ISHLT Consensus.

Recommendation-Specific Supportive Text

1. The social support network refers to the emotional, physical, practical, informational, and relational support offered by the patient's social contacts.^{469,470} Important characteristics of caregivers that have been shown to improve

Table 14 The Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT)⁵⁰²

Item	Questions	Score
Patient's readiness level and illness management		
Item 1	Knowledge and understanding of medical illness process (that caused specific organ failure)	0–4
Item 2	Knowledge and understanding of the process of transplantation	0–4
Item 3	Willingness/desire for treatment (transplant)	0–4
Item 4	History of treatment adherence/compliance (pertinent to medical issues)	0–8
Item 5	Lifestyle factors (including diet, exercise, fluid restrictions, and habits, according to organ system)	0–4
		(0–24)
Social support system level of readiness		
Item 6	Availability of social support system	0–8
Item 7	Functionality of social support system	0–8
Item 8	Appropriateness of physical living space and environment	0–4
		(0–20)
Psychological stability and psychopathology		
Item 9	Presence of psychopathology (other than personality disorders and organic psychopathology)	0–8
Item 10	History of organic psychopathology or neurocognitive impairment (i.e., illness or medication induced psychopathology)	0–5
Item 11	Influence of personality traits vs disorder	0–4
Item 12	Effect of truthfulness vs deceptive behavior	0–8
Item 13	Overall risk for psychopathology	0–4
		(0–37)
Lifestyle and effect of substance use		
Item 14	Alcohol use, abuse, and dependence	0–8
Item 15	Alcohol abuse—risk for recidivism	0–4
Item 16	Illicit substance abuse and dependence	0–8
Item 17	Illicit substance abuse—risk for recidivism	0–4
Item 18	Nicotine use, abuse, and dependence	0–5
		(0–29)
Total score *		0–110

*0–6 = excellent candidate; 7–20 = good candidate; 21–39 = minimally acceptable candidate; 40–68 = high risk candidate; and > 69 = poor candidate.

survival include understanding the severity of patient's illness and available treatment options, identifying a backup system, and providing logistical support.^{471,472} Better social support is associated with less substance use relapse,⁴⁵⁴ although there is variable impact on adherence.^{473,474} Nonetheless, caregivers play an important practical role through assistance with medications, transportation to appointments, and emotional support.^{475–477} Adequate caregiver support may also be helpful in mitigating the impact of other psychosocial barriers to successful transplant outcomes, including mental health problems such as depression.^{478–480} The absence of stable and appropriate caregiver support should therefore be considered a contraindication to HT. In addition, mental health problems in caregivers should be evaluated in the assessment of transplant candidacy.⁴⁸¹

2. Assessment of adherence is an essential component of the evaluation process. Adherence to a strict medication regimen and to a healthy lifestyle after transplantation prevents rejection, infection, and other poor outcomes.^{478,482,483} Pre-transplant medication nonadherence is a predictor of post-transplant medication nonadherence; notably, adherence-enhancing intervention can improve medication adherence in the transplant population.^{484–487} Serious and sustained nonadherence together with poor collaboration with adherence supportive initiatives should be considered a contraindication for HT.
3. Depression and anxiety are common in heart transplant candidates,⁴⁸⁸ pre-transplant depression is a risk factor for post-transplant depression,⁴⁸⁹ and post-transplant depression, in turn, increases the risk of post-transplant nonadherence and mortality.^{489–493} The impact of other mental health problems, such as anxiety, psychosis, or personality disorders, on post-transplant outcomes is not well studied, but careful assessment is essential to identify factors that would negatively impact post-transplant adherence, abstinence from substance use, or adequate social support. The presence of mental health problems is not necessarily a contraindication to HT, as many may be effectively managed in conjunction with therapists, psychologists, or psychiatrists. However, inadequately controlled mental health problems with associated nonadherence, substance use, or a lack of social support are contraindications to transplantation. Mental health problems in caregivers should also be considered in the assessment of transplant candidacy.^{6, 481, 494–501}
4. As the content of the psychosocial evaluation focuses on substance use, caregiver support, adherence, and mental health history, mental health professionals and social workers would be best qualified to execute this multifaceted assessment.⁶ The psychosocial evaluation is inherently subjective, relying not only on extraction of information from the patient, but also on individualized interpretation from the evaluator. The use of standardized psychosocial screening tools (e.g., Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT),⁵⁰² Transplant Evaluation Rating Scale (TERS),⁵⁰³ and Psychosocial Assessment of Candidates for Transplantation (PACT)⁵⁰⁴;

Table 15 Psychosocial Assessment of Candidates for Transplantation (PACT)⁵⁰⁴

Domain	Subscale	Score
Social support	Family or support system stability	1-5
	Family or support system availability	1-5
		(2-10)
Psychological health	Psychopathology, stable personality factors	1-5
	Risk for psychopathology	1-5
		(2-10)
Lifestyle factors	Healthy lifestyle, ability to sustain change in lifestyle	1-5
	Drug and alcohol use	1-5
	Adherence/compliance with medications and medical advice	1-5
		(3-15)
Understanding of transplant and follow-up	Relevant knowledge and receptiveness to education	1-5
		(1-5)
Total score ^a		8-40
Final rating ^b		0-4

Bold values represent the minimal and maximal scores possible for each category.

^aOf note, as opposed to other assessments, higher scores are associated with lower psychosocial risk.

^bSubjective global impression: 0 = poor candidate; 1 = borderline, acceptable under certain conditions; 2 = acceptable with some reservations; 3 = good candidate; and 4 = excellent candidate.

Table 16 Transplant Evaluation Rating Scale (TERS)⁵⁰³

Psychosocial characteristics and weight	Level 1	Level 2	Level 3	Weight Score ^a
Prior psychiatric history: axis I	None	Current adjustment disorder, due to health; previous axis I disorder, treated and now resolved; current significant symptoms of axis I disorder	Current axis I diagnosis (not adjustment disorder due to health); continuing symptoms of chronic axis I disorder	4 4-12
Prior psychiatric history: axis II	No diagnosis; subdiagnostic symptoms of cluster C disorder	Cluster C axis II diagnosis; subdiagnostic symptoms of cluster A or B disorder	Cluster A or B axis II diagnosis	4 4-12
Substance use/abuse	No history of heavy use/abuse of alcohol or drugs; true social drinking; very limited drug experimentation	History of significant use/abuse; successful treatment or stopped before current diagnosis	History of use/abuse stopped only after significant time since current diagnosis; ongoing use/abuse	3 3-9
Compliance	Appropriately compliant throughout treatment	Only partially compliant or compliant only with difficulty throughout treatment	Noncompliant until very recently or still noncompliant	3 3-9
Health behaviors	Practiced good health behaviors (exercise, no smoking, diet, etc.) before developing illness	Changed health behaviors only after diagnosis was made	Continues to practice poor health behaviors	2.5 2.5-7.5
Quality of family/social support	Good-excellent: friends/family members present and available; willing to focus on patient's needs	Fair-good: some separation difficulties; some conflict or dependency problems	Fair-poor: enmeshed or disengaged boundaries; extreme conflicts; focused on individuals' needs at patient's expense	2.5 2.5-7.5
Prior history of coping	Good-excellent: adapts to problems and changes flexibly; has extensive repertoire of coping behaviors	Fair-good: some flexibility in coping repertoire and some variations in coping responses, with general limitations; some negativistic patterns of responding when under stress	Fair-poor: decompensations under stress; negativistic patterns; rigid style; history of self-destructive behaviors; impulsive and/or aggressive responses	2.5 2.5-7.5
Coping with disease and treatment	Resolution of feelings about diagnosis; considers treatment options with realistic balance of hope and concern for future	Denial; lack of clarity; ambivalence over treatment choice	Extreme denial; confusion over disease course; severe ambivalence about treatment	2.5 2.5-7.5
Quality of affect	Appropriate fears; some anxiety; appropriate sadness	Moderate fears and anxiety; moderate depression	Generalized anxiety; severe depression; extreme fears and anger	1.5 1.5-4.5
Mental status (past and present)	No cognitive impairment or disorder of attention; normal sleep-wake cycle; normal activity level and responsiveness	Some past or current impairment in cognitive function, attention, sleep-wake cycle, activity level, and/or responsiveness	Global disorder of cognitive functions, attention; severe disruption of sleep-wake cycles; reduced or heightened activity level and responsiveness	1 1-3
Total score ^b				26.5-79.5

^aObtained by multiplying the level by the weight.^bHigher scores are associated with higher psychosocial risk.

Tables 14-16) as part of a comprehensive and multifaceted psychosocial evaluation can be effective as a means to summarize the findings of the psychosocial evaluation and to highlight aspects of psychosocial functioning for which further interventions or follow-up are indicated.^{475,502} However, studies of these tools in transplant recipients are limited by their single-center, retrospective design, and small sample size. Thus, using these tools as sole determinants of suitability for transplantation is not recommended. The SIPAT is the most recent and comprehensive psychosocial tool with the greatest published experience in HT candidates. A worse SIPAT score has been associated with worse post-transplant adherence⁵⁰⁵ and a higher risk of rejection.⁵⁰⁶ PACT and TERS have not been explicitly studied in HT candidates.

2.2.3. Special Considerations in Pediatric Psychosocial Assessment

2.2.3.1. High-risk Psychosocial Assessment in Pediatric Heart Transplant Candidates

Pediatric-specific standards for psychosocial assessment and subsequent care for pediatric heart transplant recipients and their families do not exist,^{507,508} although, notably, approximately 40% of families of pediatric heart transplant candidates endorse psychosocial risk.⁵⁰⁸ As in adult heart transplant candidates, assessment of psychosocial function is essential in pediatric heart transplant candidates because psychosocial functioning, particularly socioeconomic status, family functioning, and quality of social support, impacts health-related outcomes, including adherence⁵⁰⁹⁻⁵¹⁹ and hospitalizations.⁵²⁰ Similar to the evaluation in adult heart transplant candidates, the psychosocial assessment of pediatric candidates should be performed by mental health professionals and/or social workers.

The unique and central challenge of the pediatric heart transplant candidate psychosocial assessment is that children are not responsible for, nor do they have control over, their environment or family functioning.^{521,522} The family-centered care of the pediatric SOT recipient begins during the pre-transplant evaluation and should continue until transition to adult health care. Specifically in pediatric heart transplant candidates, the focus of the psychosocial assessment should be on identifying strengths and opportunities for optimization rather than reasons to deny transplant.⁵²¹

2.2.3.2. Cultural Considerations in the Pediatric Heart Transplant Candidate Evaluation

2.2.3.2.1. Race/Ethnicity and Socioeconomic Status. Black children tend to have a higher risk of graft loss and death after HT, attributed to genetic and immunologic factors, such as donor-recipient HLA mismatch and more rapid metabolism of calcineurin inhibitors, as well as health care and socioeconomic disparities.⁵²³⁻⁵²⁹ The impact of low socioeconomic status on worse outcomes in heart transplant candidates and recipients is well established,⁵³⁰⁻⁵³² and Black and Hispanic children are more often socioeconomically disadvantaged, contributing to worse outcomes due in part to reduced health literacy impacting adherence.⁵³²⁻⁵³⁴

Racial and ethnic disparities also impact outcomes in transplant candidates and recipients through implicit bias. Poor patient-clinician communication can result in reduced adherence.⁵³⁵⁻⁵³⁹ Specifically among pediatric heart transplant clinicians, survey findings indicate that there is an implicit preference for individuals who are White and from higher socioeconomic status, and an explicit preference for educated people.⁵⁴⁰ These attitudes may impact the care of pediatric heart transplant candidates.

An awareness of the potential for implicit and explicit bias in the evaluation process is essential. Efforts to improve access to AdvHF therapies for children from disadvantaged communities, creating and fostering organizational and institutional commitment to a culture of inclusivity, committing to hiring a diverse and inclusive workforce, and promoting cultural competency and diversity training may mitigate barriers to equitable transplantation.

2.2.3.2.2. Religion. Religious considerations may impact how families perceive pediatric organ donation. As feasible, the multidisciplinary pediatric heart transplant evaluation team should work on a case-by-case basis toward understanding the religious factors that may impact families' perceptions and wishes regarding their child's need for HT. Although Jewish⁵⁴¹ and Islamic⁵⁴² law do not prohibit organ transplantation, this is an important consideration in Jehovah's Witnesses. Jehovah's Witnesses refuse blood component transfusion (red blood cells, plasma, and platelets) and regard nonconsensual transfusion as a physical violation. Nonetheless, transplantation may be feasible in highly selected transplant candidates.⁵⁴³

2.2.3.3. Impact of Intellectual and Developmental Disabilities on Pediatric Heart Transplant Candidacy

A major challenge in pediatric HT is the inconsistency with which IDD are defined and the threshold for which transplantation is considered contraindicated.^{428,429,544} Exclusion of children with IDD from transplantation is not justified.^{428,429,544} In fact, children with IDD can experience improved QOL after transplantation,⁴³⁰⁻⁴³⁴ and survival comparable to other pediatric transplant recipients.^{426, 435-440}

Cognitive testing alone is inadequate to characterize an individual's level of disability. It is more important during the transplant evaluation process to assess an individual's level of adaptive functioning. Adaptive functioning refers to impairments in conceptual, practical, and social skills needed for communication, self-care, self-direction, home living, and use of community resources and better describes the skills with which individuals live in their environment.^{545,546}

Thus, the evaluation of a pediatric heart transplant candidate with IDD should comprise an assessment of adaptive functioning as well as social and caregiver support to ensure optimal adherence. Transplant programs also have a responsibility to educate families about the risks and benefits for heart transplant in the context of a potential transplant recipient's IDD, and the psychosocial evaluation should include the functioning of the family unit rather than only that of the child with IDD.⁴²⁸

2.2.3.4. Parental Refusal of Vaccination

Although vaccine hesitancy may occur in families of pediatric heart transplant candidates, few pediatric transplant programs have a written policy regarding their approach to candidates who decline recommended vaccinations.⁵⁴⁷

There are multiple medical concerns regarding vaccine refusal. Pediatric transplant recipients have an increased risk of acquiring and experiencing morbidity and mortality from vaccine-preventable illnesses compared to the general pediatric population. This risk is not confined to the unvaccinated pediatric transplant recipient but can impact other vulnerable individuals through the possible increased risk of transmission. There is also a concern that parents who refuse vaccination may refuse other medical recommendations that will impact post-transplant care, although evidence for this association is lacking.⁵⁴⁸

Transplant centers should prioritize all vaccinations for both pre- and post-transplant care for which all candidates and their families are eligible. However, denying transplantation to a child who is unvaccinated based on parental beliefs and wishes is ethically problematic. At this time, the most reasonable approach would be individualized consideration based on other medical and psychosocial factors impacting transplant candidacy.

2.3. Multidisciplinary Team Approach

Recommendations for Multidisciplinary Team Approach		
COR	LOE	RECOMMENDATIONS
1	B-NR	1. Heart transplant candidates should be cared for by a multidisciplinary collaborative team comprising HF cardiologist, cardiac surgeon, transplant nurse coordinator, experts in transplant infectious diseases, transplant pharmacist, immunologist, mental health expert, social worker, registered dietitian, physical and occupational therapist, and palliative care specialist, with other specialists included based on the patient's specific needs.
1	C-EO	2. The responsibilities of the multidisciplinary heart transplant team should include 1) coordination of care unique to their area of expertise; and 2) participation in heart transplant selection committee meetings, held on a regular basis, to assess heart transplant candidacy.
1	C-EO	3. Pediatric heart transplant candidates should be cared for, in addition to the multidisciplinary specialists assembled for the care of adult heart transplant candidates, by specialists with expertise in assessing capacity to assent; child-life specialists to optimize education and participation of the pediatric patient and family in the transplant process; and mental health experts with specific expertise in pediatric mental health.

Synopsis

Optimal medical and psychosocial evaluation of a patient for transplantation necessitates the collaborative efforts of a multidisciplinary team (Table 17). Integration of input from multidisciplinary team members is essential during the assessment for candidacy. The multidisciplinary team of the heart transplant evaluation process incorporates health care professionals with unique expertise to deliver comprehensive and collaborative care that adequately addresses medical, behavioral, and psychosocial needs (Table 18).

Recommendation-Specific Supportive Text

- 1. The optimal composition of the multidisciplinary team for heart transplant evaluations is outlined in Table 17. The multidisciplinary team approach enhances the management of chronic illnesses and improves post-

transplant outcome.^{549–551} As patient complexity increases, it is often necessary to collaborate with other specialists, including but not limited to those with expertise in pulmonology, nephrology, gastroenterology, hepatology, neurology, oncology, adult CHD, or other SOT fields.

2. The value of multidisciplinary collaboration lies in the division and coordination of tasks comprising the optimal medical and psychosocial assessment of the heart transplant candidate. The benefit of specific team members has been demonstrated; for example, the presence of an HF pharmacist as part of the care team is associated with better survival⁵⁵² and reduced hospitalization,⁵⁵³ and cardiology societies support the inclusion of a pharmacist as part of an HF multidisciplinary team.⁵⁵⁴ Physical activity is a benefit in patients with HF,⁵⁵⁵ and these observations can be extrapolated to heart transplant candidates.^{556,557} Palliative care, aimed at improving QOL, is associated with increased patient satisfaction at the end of life.⁵⁵⁸ Formal meetings to assess transplant candidacy should occur on a regular and recurring basis and include the core members of the multidisciplinary team with additional specialists as dictated by the patient's clinical situation. The outcome of the meeting would include decisions regarding (1) transplant eligibility (accepted, declined, deferred pending additional evaluation as specified); (2) transplant urgency; and (3) candidacy for temporary or durable MCS if needed.
3. The multidisciplinary care of the pediatric heart transplant recipient includes unique challenges as outlined in Section [Psychosocial Evaluation](#). Pediatric heart transplant recipients benefit from a team approach, including comparable expertise to the adult heart transplant team. However, the unique challenges of pediatric transplantation also warrant additional support from pediatric specialists with expertise in the assent process and support patients and families, such as the child life team, pediatric social workers, and pediatric-trained mental health experts, such as psychologists and psychiatrists.

Table 17 Roles and Responsibilities of the Multidisciplinary Heart Failure Team

Team member	Roles and responsibilities
Heart failure cardiologist	<ul style="list-style-type: none"> • Medical assessment and optimization of heart transplant candidates • Evaluate alternative/complementary options for the HF patient • Integrate pre-transplant evaluation testing to determine relative/absolute contraindications • Lead multidisciplinary team in decision-making on candidacy for HT
Cardiothoracic surgeon	<ul style="list-style-type: none"> • Evaluate candidates to determine if patients are adequate surgical candidates for HT • Identify surgical-specific considerations and risks for HT • Communicate risks, benefits, and potential surgical complications directly to the patient
Transplant coordinator/nurse	<ul style="list-style-type: none"> • Provide education to the patient regarding transplant evaluation process, surgery, postsurgical recovery process, and life post-transplant • Review medical evaluation of the patient and assist in determining medical candidacy for transplantation
Experts in transplant infectious diseases	<ul style="list-style-type: none"> • Promote education in the prevention of infection complications pre- and post-transplant • Prevention strategies to reduce post-transplant infectious complications (i.e., vaccinations, etc.) • Diagnosis and treatment of infections • Management of infectious etiologies
Clinical pharmacist	<ul style="list-style-type: none"> • Optimize medication therapy and participate in complex medication management/drugs interaction for the heart transplant candidate. • Assess medication compliance and develop plan for post-transplant medication regimen based on the patient's medical history
HLA specialist/immunology	<ul style="list-style-type: none"> • Assist in determining immunologic risk and considerations for donor/recipient matching
Social worker	<ul style="list-style-type: none"> • Complete psychosocial evaluation assessing for presence of social support and adherence to current medical therapies.
Psychologist/psychiatrist	<ul style="list-style-type: none"> • Complete psychosocial evaluation for heart transplant candidate • Develop, recommend, and implement individualized treatment/support plan
Registered dietitian	<ul style="list-style-type: none"> • Nutritional assessment and recommendations for optimization preheart transplant
Physiotherapy	<ul style="list-style-type: none"> • Physical assessment preheart transplant and rehabilitation plan • Rehabilitation post-LVAD/transplant • Participate in frailty assessment
Palliative care specialist	<ul style="list-style-type: none"> • Palliative care is aimed at improving QOL by the prevention and relief of suffering for patients with AdvHF

Abbreviations: AdvHF, advanced heart failure; HF heart failure; HT, heart transplantation; LVAD, left ventricular assist device; QOL, quality of life.

Table 18 Summary of Heart Transplant Evaluation

Test (COR)	Baseline	While listed	Comments
<i>Assessment of HF severity</i>			
CPET (Class 1, Baseline; Class 2b Waitlist)	x	x	Table 4 Should not be used as the sole determinant of need/ listing status for HT
RHC (Class 1)	x	x	For patients with potentially prohibitive PH, a vasodilator challenge should be administered to document reversibility to acceptable levels
HF prognosis scores (Class 2a)	x	x	Should not be used as the sole determinant of need for HT
<i>Evaluation of organ function and comorbidities</i>			
Frailty assessment (Class 2a)	x	x	Table 11
Nutritional status (Class 1)	x	x	Table 20
BMI ≥ 35 kg/m ² is a potential contraindication (Class 2a)	x	x	
Routine laboratories (comprehensive metabolic profile, complete blood count, PT/INR)	x	x	
Natriuretic peptides (Class 1, Baseline; Class 2a Waitlist)	x	x	
HbA1c $> 7.5\%$ is a potential contraindication (Class 2a)	x	x	
Ophthalmologic examination (if diabetic) (Class 2a)	x	x	
Urinalysis	x	x	
Serum creatinine, eGFR (Class 1)	x	x	Use race-free equation for eGFR
24-hour urine for creatinine clearance (Class 1)	x	x	If there is abnormal kidney function, further investigation with nephrology consultation, renal ultrasonography, and estimation of proteinuria for assessment of intrinsic renal disease
Liver function tests (albumin, bilirubin, INR); biochemical assays (AST, ALT, GGT); MELD-XI score (Class 1)	x	x	Further investigation should be considered when worsening liver function is suspected
Abdominal ultrasound or CT (Class 1)	x	x	If there is abnormal liver function further investigation with hepatology consultation and liver biopsy
Pulmonary function testing (spirometry, lung volume assessment, and diffusion capacity; Class 1)	x	x	
Chest CT (Class 1)	x		Pulmonary evaluation, risk assessment (presence of circular aortic calcification, porcelain aorta)
Carotid ultrasound in select patients (Class 1)	x	x	For patients with history of stroke or neurologic signs or symptoms concerning for cerebrovascular disease
Ankle brachial indices in select patients (Class 1)	x		If symptoms of peripheral arterial disease, known atherosclerotic disease, risk factors for atherosclerotic disease

Continued

Table 18 Summary of Heart Transplant Evaluation

Test (COR)	Baseline	While listed	Comments
Infectious serologies (Class 1): CMV IgG, EBV (EBV VCA IgG, IgM), Toxoplasma IgG, Syphilis, HAV serology Tetanus serology Varicella serology (IgG) HSV IgG Mumps serology Measles serology Rubella serology <i>Strongyloides</i> IgG, <i>Strongyloides</i> stool culture (if from endemic areas) <i>Coccidioides</i> serology (if from endemic areas) Trypanosomiasis serology (if from endemic areas)	x	x	Table 9 Repeat screening waitlist for > 1 year or relevant infectious disease exposure
Screen for latent infection (Class 1): HIV serology and/or viral load IgG antibodies to <i>T. cruzi</i> , TST/IGRA HBVsAg, HBVcAb, HBVsAb, HBV nucleic acid test HCV antibody and nucleic acid test	x	x	Table 9
Vaccination (Class 1)	x	x	Table 10
Dual X-ray absorptiometry (DEXA scan) (Class 1)	x		
<i>Immunocompatibility</i>			
ABO HLA tissue typing PRA and flow cytometry	x x x	x	HLA antibody every 3-6 months/3 weeks after sensitizing event
<i>Age-appropriate routine health maintenance</i>			
Dental evaluation	x	x	
Skin cancer screening (Class 2a)	x	x	Section Cancer , Table 19
Colorectal cancer screening (Class 1-2a)	x	x	Section Cancer , Table 19
Mammogram (Class 1)	x	x	Section Cancer , Table 19
HPV/Pap smear (Class 1)	x	x	Section Cancer , Table 19
Prostate-specific antigen with/without digital rectal exam (Class 1)	x	x	Section Cancer , Table 19
<i>Consultations</i>			
Psychosocial evaluation (Class 1)	x	x	Evaluation of substance use, support, adherence and mental health; Figure 5 , Tables 14-16

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CMV IgG, Cytomegalovirus Immunoglobulin G; CPET cardiopulmonary exercise test; CT, computed tomography; EBV, Epstein-Barr virus; eGFR, estimated glomerular filtration rate; GGT, gamma-glutamyl transferase; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HF, heart failure; HLA, human leukocyte antigen; HPV, human papillomavirus; HT, heart transplantation; INR, international normalized ratio; IGRA, interferon- γ release assay; LVAD, left ventricular assist device; MELD-XI, model for end-stage liver disease excluding INR; PH, pulmonary hypertension; PRA, panel-reactive antibody; PT, prothrombin time; QOL, quality of life; RHC right heart catheterization; TST, tuberculin skin test.

3. TASK FORCE II: OPTIMIZATION OF THE MEDICAL SURVEILLANCE OF PATIENTS ON THE WAITLIST

3.1. Optimal Pharmacologic Management of Heart Transplant Candidates

3.1.1. Standard Heart Failure Guideline-Directed Medical Therapies

Recommendations for Optimal Pharmacologic Management of Heart Transplant Candidates: Standard Heart Failure Guideline-Directed Medical Therapies		
COR	LOE	RECOMMENDATIONS
1	A	1. Standard maximally tolerated GDMT for HF should be continued in heart transplant candidates with reduced ejection fraction (HFrEF).
2a	B-NR	2. Standard maximally tolerated HF GDMT can be beneficial for patients with durable LVAD listed for HT.
1	C-LD	3. Dose reduction or discontinuation of some drugs that are part of standard GDMT is recommended when patients exhibit drug intolerance, such as persistent symptomatic hypotension (not due to over-diuresis), secondary organ dysfunction (renal or liver failure), or cardiogenic shock.
2a	C-LD	4. In patients with non-dilated phenotype of cardiomyopathies (HCM, RCM, infiltrative cardiomyopathy such as cardiac amyloidosis) who develop LV systolic dysfunction, HF GDMT is beneficial; however, tolerance can be limited.

Synopsis

Most HF patients evaluated for HT receive standard GDMT for HF with HFrEF. While on the waitlist, efforts should be made to continue and further optimize GDMT to avoid further clinical and hemodynamic decline. This approach is extrapolated from evidence from broader HF trials, acknowledging that data are limited in this subgroup of AdvHF patients since patients listed for HT and those supported by MCS are frequently excluded or under-represented in randomized HF clinical trials.

Recommendation-Specific Supportive Text

- Standard maximally tolerated GDMT should be continued in patients with HFrEF listed for HT. The main pillars of GDMT are angiotensin receptor-neprilysin inhibitors (ARNi) or renin-angiotensin-aldosterone system inhibitors (RAASi) [angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB)], beta-blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors (SGLT2i).³⁵⁰ Additional therapies for specific patient populations include hydralazine-nitrate combination, ivabradine, vericiguat, and digoxin.^{19,31,350,559,560}
- Existing evidence supports the continuation of GDMT in patients supported with durable LVAD in general.⁵⁶¹ Data specific to LVAD-supported patients listed as heart transplant candidates are limited. Specific clinical circumstances that may prompt certain LVAD-supported patients to be listed for HT may limit the application of certain classes of GDMT medications; for example, RV failure may limit beta-blocker use.^{562–564} Conversely, LVAD implant may present an opportunity to optimize GDMT in previously intolerant patients.
- Dose reduction or discontinuation of standard GDMT is recommended when patients exhibit drug intolerance, such as persistent hypotension, secondary organ dysfunction (renal or liver failure), or cardiogenic shock. Cardiogenic shock can manifest acutely, often following acute coronary syndrome, cardiac surgery or due to acute myocarditis, or in the setting of acute decompensation of chronic HF.⁵⁶⁵
- Patients with a nondilated phenotype of cardiomyopathies who develop LV systolic dysfunction can have limited tolerance to GDMT. This is especially true for cardiac amyloidosis.^{566,567}

3.1.2. Diuretics and Volume Management

Recommendations for Optimal Pharmacologic Management of Heart Transplant Candidates:: Diuretics and Volume Management		
COR	LOE	RECOMMENDATIONS
1	B-NR	1. Diuretics should be used in HT candidates at the minimal dose necessary to accomplish decongestion.
1	B-NR	2. In refractory congestion not responding to intravenous administration and escalation of loop diuretic dose, addition of a thiazide (e.g., metolazone) or a carbonic anhydrase inhibitor (e.g. acetazolamide) to treatment with a loop diuretic should be considered.
2b	B-R	3. For those unresponsive to diuretics, utilization of mechanical unloading via ultrafiltration therapies in HT candidates may be considered.

Synopsis

Diuretics are the mainstay of decongestive therapy in HF patients, including those listed for HT. In advanced stages of HF, diuretic therapy may provide inadequate relief of congestion underscoring the importance of alternative decongestive strategies to manage volume overload. Among these is the removal of volume by ultrafiltration.

Recommendation-Specific Supportive Text

- 1-2. Loop diuretics, oral or parenteral, are recommended for decongestion, with proper electrolytes and renal function monitoring. Diuretics should be maintained at the lowest dose necessary to avoid congestion and minimize the possible adverse metabolic effects. In refractory congestion not responding to moderate or high dose loop diuretics, addition of a thiazide or thiazide-like diuretic (e.g., metolazone) to treatment with loop diuretic enhances natriuresis.^{568–570} The addition of acetazolamide, a carbonic anhydrase inhibitor that reduces proximal tubular sodium reabsorption, to loop diuretic therapy in patients with acute decompensated HF resulted in a greater incidence of successful decongestion.⁵⁷¹
3. Data regarding the benefits of ultrafiltration in the decompensated HF population resistant to diuretic therapy are mixed, with some data suggesting greater fluid loss and decrease in rehospitalizations compared to diuretics without systematic escalation. However, any possible ultrafiltration benefits need to be weighed against concerns of intravenous catheters associated adverse events.^{572–574} Ultrafiltration may be considered in patients who are listed for HT where hemodynamic optimization and diuretics are insufficient to achieve decongestion.

3.1.3. Antianginal Therapy

Recommendations for Optimal Pharmacologic Management of Heart Transplant Candidates: Anti-Anginal Therapy		
COR	LOE	RECOMMENDATION
2a	C-LD	1. In patients with ischemic heart disease and angina listed for HT, anti-anginal therapies can be continued for symptom relief.

Synopsis

Angina is a prevalent and morbid condition, impairing functional capacity and QOL. Despite the aggressive use of medical therapies and myocardial revascularization procedures, angina remains prevalent.

Recommendation-Specific Supportive Text

1. Antianginal therapies have not been specifically studied in patients listed for HT. In addition to beta-blockers, antianginal therapies include oral nitrates, calcium channel blockers, ranolazine, ivabradine, and trimetazidine.^{575–577} The potential systemic effects of these medicines (hypotension, vasoplegia, etc.) need to be considered in patients on the waitlist.

3.1.4. Pulmonary Hypertension Therapy

Recommendations for Optimal Pharmacologic Management of Heart Transplant Candidates: Pulmonary Hypertension Therapy		
COR	LOE	RECOMMENDATIONS
3: Harm	B-R	1. The use of endothelin receptor antagonists and prostanoids in HT candidates with Group 2 PH associated with left heart disease is not recommended.
2b	C-LD	2. The use of phosphodiesterase 5 (PDE5) inhibitors to improve hemodynamics and exercise capacity in PH and HFrEF, and in patients with heart failure with preserved ejection fraction (HFpEF) -associated combined post- and pre-capillary PH (CpcPH) may be reasonable.
3: No Benefit	C-LD	3. The use of PDE5 inhibitors in patients with HFpEF and isolated post-capillary PH is not recommended.

Synopsis

PH, in which reversal cannot be demonstrated, is considered a contraindication to HT (Section [Pulmonary Hypertension](#), [Figure 1](#)). Elevation of pulmonary pressures and PVR in patients evaluated for HT typically results from left-sided heart disease (Group 2, PH associated with left heart disease). The primary strategy in managing PH-left heart disease is optimizing the treatment of the underlying cardiac disease. Diuretics remain the cornerstone of medical therapy in the presence of fluid retention due to PH-left heart disease. There is limited and conflicting evidence for the use of drugs approved for PH in patients with group 2 PH. Some medications may have variable and potentially detrimental effects in such patients and are therefore not indicated in PH-left heart disease.

Recommendation-Specific Supportive Text

1. The use of pulmonary arterial hypertension-specific therapies, such as endothelin antagonists and prostacyclin derivatives in HT candidates with group 2 PH, to reduce PVR before transplant is not recommended as they might increase filling pressures and lead to HF decompensation.^{172, 578–580} Bosentan was assessed in a multicenter randomized study of patients with pulmonary arterial hypertension associated with HFrEF, showing no efficacy but an increase in adverse events compared with placebo, predominantly related to fluid retention.⁵⁸¹
2. Phosphodiesterase 5 (PDE5) inhibitors, mostly sildenafil, have been used in an attempt to reduce PVR in patients in whom acute reversal with short-acting agents was not demonstrated. Whether this approach, in patients with or without LVAD support, leads to reduced post-transplant risk of RHF is unknown.^{582–587} Small studies have suggested that sildenafil may improve hemodynamics and exercise capacity in PH and HFrEF, but randomized clinical trials are lacking.^{172, 588–590} In patients with HFpEF with a predominantly combined post- and pre-capillary PH (CpcPH) profile, sildenafil improved hemodynamics, RV function and QOL at 6 and 12 months vs placebo,^{172,591} and retrospective analyses and registry data suggest improvement in exercise capacity with PDE5 inhibitors therapy in patients with HFpEF-associated CpcPH and with a severe pre-capillary component.^{172,592,593}
3. In patients with HFpEF with a predominantly isolated postcapillary PH, sildenafil had no effect on mean pulmonary artery pressure (PAP) or other hemodynamic and clinical measures vs placebo.⁵⁹⁴

3.1.5. Anticoagulant and Antiplatelet Therapy

Recommendations for Optimal Pharmacologic Management of Heart Transplant Candidates: Anticoagulant and Antiplatelet Therapy		
COR	LOE	RECOMMENDATIONS
1	C-EO	1. In patients with indications for anticoagulation or dual antiplatelet therapy (DAPT), a plan for perioperative management should be established at the time of listing for HT.
1	C-EO	2. In patients with indications for chronic anticoagulation listed for HT, vitamin K antagonists or heparin-based agents are more established.
1	B-NR	3. Agents available for reversal of vitamin K antagonists include a. vitamin K b. fresh frozen plasma c. prothrombin complex concentrate.
1	B-NR	
2a	C-LD	
2a	C-LD	4. When direct oral-anticoagulants (DOAC) need to be continued prior to HT, on-site availability of reversal agents can be useful.
2a	B-NR	5. Anti-platelet therapy with P2Y12 receptor antagonists should be interrupted pre-operatively if possible, to decrease the risk of bleeding.
1	B-NR	6. Heparin should be avoided in patients with heparin-induced thrombocytopenia (HIT) listed for transplant. Patients with HIT should be managed with warfarin, DOACs, argatroban, bivalirudin, or fondaparinux, depending on the clinical scenario.

Synopsis

Patients listed for HT often require systemic anticoagulation. Because of the lack of predictability of the timing of HT, the ability to reverse anticoagulation rapidly and safely to reduce the risk of intraoperative bleeding is paramount. The widespread use of the direct oral-anticoagulants (DOAC) is challenging because the data and clinical experience of their reversal in this setting are limited. Antiplatelet therapy, including P2Y12 receptor antagonists, ideally should be interrupted perioperatively to decrease the risk of bleeding. However, this may not be always feasible due to the half-life of the drugs and the indications for antiplatelet therapy.

Recommendations-Specific Supportive Text

- Decisions regarding anticoagulation and dual antiplatelet therapy (DAPT) including plans for anticoagulation reversal should be established by the multidisciplinary team, considering the anticoagulation and DAPT indications, urgency of HT, inpatient vs outpatient status, and other logistical factors.
- Although specific DOAC reversal agents have been approved, various factors complicate the use of these agents in clinical practice, particularly in the setting of a need for an urgent unplanned procedure (i.e., HT). These factors include availability, risk of thrombosis, cost, preparation, and a lack of data on the comparative effectiveness of different reversal strategies. Moreover, reversal agents are not indicated for use with all DOACs.⁵⁹⁵ Patients receiving DOAC-based therapy at the time of listing should be considered to transition to vitamin K antagonists (outpatients) or heparin-based agents (inpatients).
- Of the several agents available for the reversal of vitamin K antagonists, it is suggested to start with vitamin K. Due to the delayed effects of vitamin K, fresh frozen plasma should be administered when there is a need for rapid reversal. Prothrombin complex concentrate containing vitamin-K-dependent clotting factors can also be beneficial. The cost and availability of prothrombin complex concentrate should also be weighed vs the potential advantage of reducing transfusion requirements and the risk of sensitization and future rejection in this setting.^{596,597}
- The risks and benefits of continuing DOAC with a plan to reverse at transplant can be considered over the more conventional practice of transitioning to heparin or warfarin anticoagulation in every HT candidate. Specific reversal agents for DOAC exist; however, they may be costly or not universally available. While there may be slightly more available evidence regarding dabigatran reversal with idarucizumab in the setting of HT, oral factor Xa inhibitors, such as apixaban or rivaroxaban, may be reversed with andexanet.^{597–604}
- Antiplatelet therapy with P2Y12 receptor antagonists is associated with increased risk of bleeding and higher mortality (as extrapolated from non-HT cardiac surgery).⁶⁰⁵ The risk of waiting for DAPT termination (i.e., in the setting of a recent percutaneous intervention) before listing the patient for HT must be weighed against the risk of HF mortality if listing is delayed. Platelet transfusion is unlikely to reverse platelet inhibition with P2Y12 receptor antagonists.⁶⁰⁶ Antibody-based agents for P2Y12 receptor antagonist reversal are currently under

development and testing.⁶⁰⁷ Case reports describe the feasibility of conversion to a prolonged cangrelor (short-acting continuous-infusion P2Y12 inhibitor with a half-life of 3-6 minutes) infusion, without complication as a bridge to successful heart/liver transplantation.^{608,609}

6. Heparin should be avoided in patients with heparin-induced thrombocytopenia (HIT) listed for transplant. Depending on the clinical scenario and anticipated proximity of the transplant, patients with HIT should be managed with warfarin, DOACs, argatroban, bivalirudin, or fondaparinux. Rechallenge with heparin at the time of HT may be considered; however, the evidence is limited. In patients with ongoing thrombocytopenia and/or HIT syndrome with thrombotic complications, the use of intraoperative plasmapheresis has been utilized.⁶¹⁰⁻⁶¹⁵ A plan for anticoagulation at the time of HT should be established ahead of time with the multidisciplinary team. Decisions on addressing anticoagulation in HT candidates who develop HIT should be individualized involving a multidisciplinary team.

3.1.6. Systemic Disease Modifying Therapies

Recommendations for Optimal Pharmacologic Management of Heart Transplant Candidates: Systemic Disease Modifying Therapies		
COR	LOE	RECOMMENDATIONS
1	C-EO	1. Disease-modifying drugs for systemic conditions with immune suppressive effects should be continued during the period of listing for HT.
1	C-EO	2. A plan should be established for the use of disease-modifying drugs for systemic conditions perioperatively and after transplant.

Synopsis

Patients on the waitlist may have systemic conditions related or unrelated to their heart disease, including sarcoidosis, amyloidosis, connective tissue disorders, etc. A clear plan should be established for modifying this therapy while awaiting HT, perioperatively and after transplant to avoid complications.

Recommendation-Specific Supportive Text

1. Disease-modifying drugs used for systemic conditions may have immune suppressive effects. Typically, these medications should be effectively continued during the period of listing for HT.^{89, 616-618}
2. A customized plan for use of these therapies in the perioperative period and following HT should be established in consultation with the appropriate specialists—rheumatologists, pulmonologists, hematologists, etc. There may be interactions or potentiation of the immunosuppressive effect when disease-modifying therapies for systemic conditions and immunosuppressive for heart transplant are combined. The aim is to avoid over-suppression of the immune system, reduce the risk of infection, and minimize other potential drug-related side effects.^{285, 287, 301, 619-621}

3.1.7. Special Considerations for Combined Organ Transplant Candidates

Recommendations for Optimal Pharmacologic Management of Heart Transplant Candidates: Special Considerations for Combined Organ Transplant Candidates		
COR	LOE	RECOMMENDATIONS
3	C-EO	1. In candidates for SHKT with low eGFR, SGLT-2i should not be used.
2b	C-EO	2. Mineralocorticoid receptor antagonists (MRAs) and RAASi may be used with caution in patients listed for SHKT but are contraindicated in those on dialysis. Potassium-binding agents (patiromer or sodium zirconium cyclosilicate) might be considered to favor the tolerability of these agents.
2b	C-EO	3. In candidates for combined heart-lung transplantation, oral, inhaled or parenteral pulmonary vasodilator therapies may be useful to slow the progression of the disease according to standard PH guidelines.

Synopsis

Limited data exist as to the optimal pharmacotherapy of HF in patients listed for combined organ transplantation. There may be specific considerations regarding medication interactions and contraindications in patients with multiorgan failure awaiting combined heart transplantation.

Recommendation-Specific Supportive Text

1. In the randomized clinical trials demonstrating the benefit of SGLT2i on outcomes in patients with HF, patients with eGFR < 20 or eGFR < 30 ml/min/1.73 m² were excluded. Most patients listed for SHKT will not be candidates for SGLT2i therapy due to low eGFR.^{622,623}
2. Mineralocorticoid receptor antagonists (MRAs) and RAASi may be used with caution in patients listed for SHKT, especially in those with residual renal function. These patients may be at risk of hyperkalemia and further worsening of eGFR. Potassium-binding agents (patiomer or sodium zirconium cyclosilicate) might be considered to treat hyperkalemia and favor the tolerability of these agents in patients not on hemodialysis (MRAs, RAASi, and SGLT2i are contraindicated in this cohort).^{624–629}
3. Patients listed for combined heart-lung transplantation with group 1 PH can have conventional indications for pulmonary vasodilator therapies to slow the progression of the disease, according to American College of Clinical Pharmacy (ACCP) guidelines.^{167,172} These therapies are otherwise not indicated in most patients with HFrEF listed for HT, the majority of which have group 2 PH, because they may result in increased PCWP, increased risk of pulmonary edema and worse clinical outcomes.^{630,631}

3.1.8. Special Considerations for Pediatric Heart Failure Patients

Recommendations for Optimal Pharmacologic Management of Heart Transplant Candidates: Special Considerations for Pediatric Heart Failure Patients		
COR	LOE	RECOMMENDATIONS
2b	C-EO	1. Pediatric patients with AdvHF listed for HT may be treated with triple therapy consisting of ACEi or ARB, beta-blockers, and MRA, as long as these therapies are well tolerated and not otherwise contraindicated.
2b	C-EO	2. Evidence regarding ARNi and SGLT2i among pediatric patients with AdvHF awaiting HT remains limited.
2a	B-NR	3. Digoxin added to standard HF therapy can be beneficial in pediatric heart transplant patients with interstage single ventricle physiology.
2b	C-EO	4. The use of continuous inotropes may be considered in pediatric patients with acute decompensated HF, including those listed for HT, with or without MCS.

Synopsis

Medical therapy for pediatric patients with HF is not as well established as in adults. Pediatric patients with cardiomyopathies have better waitlist outcomes compared to patients with CHD. Overall mortality for children waiting for HT is higher compared to other solid organs.

Recommendation-Specific Supportive Text

1. Although there is less evidence regarding optimal therapy for pediatric HF patients listed for HT compared to adults, pediatric patients with AdvHF may be treated with triple therapy: ACEi or ARB, beta-blockers, and MRA, unless contraindicated. Diuretics can be used to achieve euvolemia.^{632–636}
2. There is limited evidence regarding the utility of ARNi in children with HF. Preliminary results from the Panorama-HF study showed NT-proBNP reduction with ARNi after 12 weeks of therapy in children who were > 1-year old.^{636–638} Limited data suggest dapagliflozin use in pediatric HF, when added to GMDT, is well tolerated.⁶³⁹
3. Digoxin is often used as a second-line agent.⁶⁴⁰ Several observational studies reported higher interstage transplant-free survival in infants treated with digoxin after Norwood procedure, but prospective controlled data are unavailable.^{641–644}
4. Intravenous inotropes are routinely utilized for children presenting with acute decompensated HF and those with AdvHF listed for HT.^{325,353,526,645} For patients with evidence of hemodynamic decompensation on continuous intravenous inotropic support, the use of VAD should be considered early before evidence of end-organ dysfunction as that portends poor outcomes.^{325,353,526,646,647}

3.2. Nonpharmacologic Management of Cardiac Transplant Candidates: Approaches to Be Considered

3.2.1. Percutaneous Interventional Procedures in Heart Transplant Candidates

Recommendations for Non-pharmacologic Management of Cardiac Transplant Candidates: Percutaneous Interventional Procedures in Heart Transplant Candidates		
COR	LOE	RECOMMENDATIONS
1	C-EO	1. Patients with AdvHF and structural heart disease should be evaluated by a multidisciplinary heart team if intervention is considered.
1	C-EO	2. GDMT should be optimized by an HF cardiologist, and CRT implanted if appropriate prior to percutaneous mitral valve intervention for moderately-severe and severe secondary mitral regurgitation (MR) and AdvHF.
2a	B-R	3. In patients with chronic severe secondary MR with LVEF 20-50% who have NYHA II-IV symptoms and an LV end-systolic dimension <7 cm despite GDMT and CRT, if appropriate, mitral transcatheter edge-to-edge repair is reasonable.
1	C-EO	4. In patients with right-sided HF and edema and/or ascites attributable to severe secondary tricuspid regurgitation (TR) diuretics are indicated.
2a	C-EO	5. In patients with right-sided HF attributable to severe secondary TR, therapies to treat the underlying causes (PH, RV failure, and HFrEF) can be effective prior to transcatheter valvular consideration.
2b	B-R	6. In patients with RHF attributable to severe TR despite optimization of therapy who are deemed high surgical risk, transcatheter edge-to-edge repair may be reasonable.
2a	B-R	7. In patients with symptomatic HF, remote monitoring of PAP with an implanted PAP sensor to reduce risk of hospitalizations and improve QOL is reasonable.

Synopsis

Patients with AdvHF may have concomitant valvular, coronary, or other structural abnormalities. Adequate coronary revascularization and treatment of primary valvular diseases by percutaneous or surgical methods according to established guidelines should be performed. In a proportion of patients with AdvHF, structural or valvular abnormalities are secondary to atrial and/or ventricular enlargement and/or volume overload. Transcatheter approaches to the management of these abnormalities may substantially alter HF trajectory. In the current era, transcatheter edge-to-edge repair for moderately-severe and severe functional mitral regurgitation (Mitraclip) has therapeutic benefits in patients with HF who meet the criteria. Transcatheter tricuspid valve repair has an emerging role in patients with RHF and severe TR. Other device platforms for transcatheter valvular repair or replacement, percutaneous mitral and tricuspid annuloplasty, interatrial shunts, cardiac contractility modulation, and autonomic nerve modulation are under evaluation and may change the landscape of AdvHF management in the future, but insufficient data are currently available to provide guideline recommendations.

Recommendation-Specific Supportive Text

- Given the complexity of decision-making, patients with AdvHF and structural heart disease for whom structural intervention is considered should be evaluated by a multidisciplinary heart team.¹ It is important to emphasize that percutaneous interventions should complement and not replace aggressive attempts to maximize GDMT, and complex decision-making is best performed in a multidisciplinary manner.
- GDMT and CRT therapy should be optimized, and the severity of valvular disease should be reassessed after a sufficient period to ascertain whether the patient is likely to benefit from percutaneous mitral valve intervention.^{648–651}
- The 2 randomized trials of Mitraclip in functional MR, COAPT, and Mitra-FR had divergent results. COAPT showed a significant reduction in HF hospitalization (HR 0.53) and all-cause mortality at 24 months (HR 0.62) in the Mitraclip arm, whereas Mitra-FR showed no difference in hospitalization or all-cause mortality between the device and medical therapy groups.^{650,651} Multiple factors may explain these findings: GDMT was better optimized in the COAPT group; COAPT had more severe MR (ERO 0.41 cm² vs 0.31 cm² in Mitra-HF) and

smaller LV size (Left ventricular end-diastolic diameter 62 mm vs 69 mm in Mitra-HF); patients in the COAPT group were more likely to receive more than 1 clip, and residual MR was less in COAPT (5% vs 17% in Mitra-HF).^{652,653} These results underscore the need to maximize medical therapy and optimize procedural techniques for successful functional MR management. In the MitraBridge registry of 119 patients in 17 centers undergoing Mitraclip implantation, freedom from the composite endpoint of death, urgent transplant/LVAD, or first rehospitalization for HF was 64% at 1 year. Significant clinical improvement led to the removal of patients from transplant listing in 23.5%.⁶⁵⁴ However, the specific demographics of the patients removed from the list were not reported, nor was the use of GDMT, including sacubitril/valsartan and SGLT2i, making the results less generalizable.

- 4-6. In patients with right-sided HF and edema and/or ascites attributable to severe secondary TR, the severity of TR should be reassessed after full decongestion with diuretics.⁶⁴⁹ The severity of secondary TR may be dynamic, depending on RV function and PH, thus management entails focusing on underlying causes, such as PH, RV failure, and HFrEF.² The TRILUMINATE single-arm study enrolled 85 patients with high surgical risk, predominantly functional severe TR and NYHA III-IV symptoms at baseline in 75% of patients. Transcatheter tricuspid edge-to-edge repair (TEER) with the Triclip device resulted in a sustained reduction in TR, improved functional class with 83% NYHA I/II, and improved right heart size and function at 1-year follow-up.⁶⁵⁵ In a prospective randomized trial of percutaneous TEER for symptomatic severe TR enrolling 350 patients, Tricuspid TEER was safe, reduced the severity of tricuspid regurgitation, and was associated with an improvement in QOL but with a trend for a higher hospitalization rate, no change in diuretic dose and no effect on mortality.⁶⁵⁶
7. In patients with symptomatic HF and NYHA Class III symptoms with a previous HF hospitalization, the CHAMPION trial demonstrated that remote PAP monitoring with an implanted PAP sensor (CardioMEMS) led to a reduction in HF hospitalizations at 6 months (hazard ratio 0.70, 95% CI 0.60-0.84, $p < 0.0001$).⁶⁵⁷ GUIDE-HF enrolled NYHA Class II to IV patients with either a previous HF hospitalization or elevated NPs to hemodynamic monitoring or control. The overall primary end-point was not significant, but a prespecified analysis to account for the effects of COVID-19 was significant for a reduction in HF hospitalizations. Therefore, the Food and Drug Administration expanded the indication for the device to NYHA Class II and III patients with either a previous hospitalization or elevated NPs.⁶⁵⁸ The randomized trial MONITOR-HF demonstrated that PAP monitoring (CardioMEMS-HF system) vs standard care in a European health system cohort substantially improved QOL and reduced HF hospitalizations in patients with moderate-to-severe HF.⁶⁵⁹

3.2.2. Heart Rhythm Considerations in Heart Transplant Candidates

Recommendations for Non-pharmacologic Management of Cardiac Transplant Candidates: Heart Rhythm Considerations in Heart Transplant Candidates		
COR	LOE	RECOMMENDATIONS
2a	B-NR	1. ICD is reasonable in NYHA IV patients who are candidates for HT.
1	B-R	2. CRT is indicated in patients with LVEF $\leq 35\%$, sinus rhythm, left bundle branch block (LBBB) with QRS duration ≥ 150 ms, and ambulatory NYHA IV symptoms who are being considered for HT.
2a	B-NR	3. CRT can be beneficial in patients with LVEF $\leq 35\%$, sinus rhythm, LBBB with QRS duration 120-149 ms and ambulatory NYHA IV symptoms who are being considered for HT.
2b	B-R	4. Catheter ablation may be considered for selected patients with symptomatic atrial fibrillation and HFrEF.
2b	B-NR	5. AV nodal ablation and CRT may be considered in medically refractory AF and HF.
2b	C-LD	6. Catheter ablation may be considered for heart transplant candidates with NYHA IV symptoms and recurrent ventricular tachycardia.
2a	B-NR	7. Amiodarone dose reduction or discontinuation can be considered on an individualized basis in patients listed for HT.

Synopsis

Arrhythmias can cause hemodynamic decompensation, significant morbidity and mortality in AdvHF patients, and may lead to waitlist mortality. Many patients with chronic HF already have implantable cardioverter defibrillator (ICDs), but those with new-onset or rapidly progressive cardiomyopathy may need to be evaluated for ICD or wearable defibrillators during transplant evaluation, particularly if they will not be hospitalized until transplantation or are discharged on inotropes which increase arrhythmic risk. CRT should be considered in transplant candidates with appropriate electrocardiographic criteria to improve symptoms and delay or even prevent the need for a transplant. Antiarrhythmic choices are limited in AdvHF, and the risk-benefit ratio of catheter ablation for atrial and ventricular arrhythmias remains uncertain.

Recommendation-Specific Supportive Text

1. ICDs are not generally recommended for refractory NYHA IV patients with less than 1-year survival, but heart transplant candidates represent a subset of NYHA IV patients who may benefit from this therapy. In a multicenter analysis of 32,599 patients listed for HT, having an ICD was associated with decreased mortality in patients with or without LVADs (HR 0.81 and 0.87, respectively).⁶⁶⁰ In a meta-analysis including 36,112 patients awaiting heart transplant, those with ICDs had decreased total mortality (Relative Risk 0.6) and decreased sudden cardiac death risk (Relative Risk 0.27).⁶⁶¹ The wearable cardioverter defibrillator can be a reasonable noninvasive alternative approach, though data on its use in patients awaiting HT are limited.^{662–664}
- 2-3. CRT is indicated in patients with LVEF $\leq 35\%$, sinus rhythm, left bundle branch block with QRS duration ≥ 150 ms, and ambulatory NYHA IV symptoms who are being considered for HT as CRT decreased time to death or hospitalization (HR 0.64) in ambulatory NYHA IV patients in the COMPANION trial.⁶⁶⁵ CRT-D implant in patients with sinus rhythm, QRS duration 120 to 149 ms is reasonable.⁶⁶⁵
- 4-5. Several randomized clinical trials of AF ablation in HF patients showed improvements in hospitalization and mortality but primarily enrolled NYHA II and III patients.^{666,667} The AMICA trial enrolled mostly NYHA III and IV patients, and a subgroup analysis of the CASTLE-HF trial of NYHA III and IV patients did not show a difference between ablation and medical therapy.^{668–670} In the randomized CASTLE-HTx single-center trial involving AdvHF patients with symptomatic AF referred for HT evaluation, the combination of catheter ablation and GDMT was associated with a lower likelihood of a composite of death from any cause, implantation of an LVAD, or urgent HT than medical therapy alone.⁶⁷¹ Atrioventricular nodal ablation and CRT may be considered in medically refractory AF and HF as an alternative to AF ablation.^{672–674}
6. Catheter ablation with substrate modification may effectively suppress ventricular arrhythmias in patients with AdvHF, including those with LVADs. In high-risk cases, based on presentation and hemodynamic conditions, tMCS may be beneficial. In patients on the waitlist who have recurrent ventricular tachycardias, catheter ablation may be considered.^{675,676}
7. Amiodarone is effective against ventricular and atrial arrhythmias in AdvHF but can have substantial adverse effects. A multi-institutional analysis of 14,944 patients revealed higher adjusted mortality 1 year after transplant (HR 1.15) in those with pre-transplant amiodarone use compared to those without difference in early graft failure rate.⁶⁷⁷ A meta-analysis of 9 studies did not find an association of pre-transplant amiodarone use with post-transplant mortality.⁶⁷⁸ A single-center study of 269 patients showed an association of amiodarone with primary graft dysfunction (PGD) in a dose-dependent manner⁶⁷⁹ and a subsequent report from the same group reported lower incidence of PGD if amiodarone was discontinued 74 days [interquartile range, 38–137] before transplantation.⁶⁸⁰ A SRTR analysis of 25,394 adults revealed association of amiodarone use with higher graft dysfunction (OR 1.30), higher 30-day (HR 1.25), and 1 year (1.13) but not 5 or 10-year mortality (OR 0.81).⁶⁸¹ It seems prudent to assess the continued need for amiodarone in patients on the transplant waiting list and consider discontinuation when possible.

3.2.3. Nonpharmacologic Management of Pediatric Transplant Candidates

Recommendations for Non-Pharmacologic Management of Pediatric Transplant Candidates		
COR	LOE	RECOMMENDATIONS
2b	C-EO	1. ICD implantation may be considered in pediatric patients with CHD.
2b	C-EO	2. ICD implantation may be considered in pediatric patients with non-ischemic dilated cardiomyopathy.
3: No Benefit	C-EO	3. ICD implantation is not recommended in pediatric patients with AdvHF who will remain hospitalized until transplantation.
2b	C-EO	4. CRT may be considered in CHD patients with symptomatic HF and electrical dyssynchrony.

Synopsis

The role of ICD while listed for HT in the pediatric age group is to mitigate the risk of sudden death while waiting. Nonetheless, there are limited clinical data regarding ICD benefits in pediatric patients. There is also an extensive range of patient age, size, disease pathogenesis, and potentially complicating anatomic factors. ICD implantation requires case-by-case analysis and a shared decision-making approach.

Recommendation-Specific Supportive Text

1. In pediatric patients with CHD, case-based clinical judgment with a shared decision-making approach is warranted for ICD implantation.⁶⁸² There are limited clinical data, and consideration, including patient age, size, and disease pathogenesis, is warranted. ICD implantation in waitlisted CHD patients is generally considered in the setting of documented ventricular tachycardia with syncope and additional risk factors, including ventricular dysfunction or severe aortic valve insufficiency. In addition, the underlying anatomy, which can consist of intracardiac shunts and irregular vascular, may influence decisions.^{683–685}
2. Convincing evidence for ICD implantation for primary prevention in pediatric patients with nonischemic dilated cardiomyopathy and no additional risk factors is lacking.⁶⁸² ICD implantation may be considered in those with LVEF < 35%, and additional clinical factors include the etiology and the clinical phenotype of cardiomyopathy, for example, the degree of ventricular dysfunction, the presence of cardiac arrhythmias, and overall estimated cumulative risk of sudden cardiac death.⁶⁸⁶
3. ICD implantation is not recommended in pediatric patients with AdvHF who will remain hospitalized until transplantation.⁶⁸²
4. While earlier studies on CRT use in pediatric patients with CHD have been conflicting, more recent data suggest that in CHD patients with symptomatic HF and electrical dyssynchrony, CRT may provide benefit.^{687–689}

3.3. Surveillance and Management on the Waitlist

3.3.1. Serial Evaluation (Guidelines for Repeat Testing on the Waitlist)

3.3.1.1. Cardiac Catheterization to Assess Hemodynamic Stability

Recommendations for Repeat Testing on the Waitlist: Cardiac Catheterization to Assess Hemodynamic Stability		
COR	LOE	RECOMMENDATIONS
1	C-LD	1. RHC should be performed on all adult candidates periodically after listing until transplantation. For patients with potentially prohibitive PH, a vasodilator challenge should be administered to document reversibility to acceptable levels.
2b	C-EO	2. In pediatric heart transplant candidates, RHC may be performed periodically while waitlisted to evaluate PVRI, reaffirm heart-only transplant suitability, indicate a potential need for MCS, and address aortopulmonary collaterals particularly in those with CHD.
2a	C-LD	3. If medical therapy fails to achieve acceptable hemodynamics and if the left ventricle cannot be effectively unloaded with mechanical adjuncts, including an intra-aortic balloon pump and/or LVAD, it is reasonable to conclude that the PH is irreversible. Reevaluation of hemodynamics can be done 3 to 6 months after LVAD to ascertain reversibility of PH.

Synopsis

Patients listed for HT should continue to receive OMT. Given the progressive nature of patients with AdvHF of diverse etiologies, hemodynamics is essential to optimize their management. Some patients are urgently listed for HT in the setting of cardiogenic shock and are intolerant to standard GDMT. In some of these patients, GDMT may be started if hemodynamic status improves. A unique aspect pertains to the unplanned nature of HT surgery.

Recommendation-Specific Supportive Text

- 1. RHC hemodynamic is a significant predictor for survival on the waitlist.^{42–44, 690} Serial RHCs in HT candidates are beneficial to optimize medical therapy, define candidacy urgency, assess end-organ injury, and as a guide for temporary and durable MCS implantation.^{690,691} The optimal timing of RHCs, while waitlisted, has not been ascertained and should be at the discretion of the transplant team guided by clinical stability, echocardiographic findings suggestive of PH (i.e., systolic pulmonary arterial pressure, signs of RV overload and/or dysfunction), and the degree of PH on initial testing. It is reasonable to do surveillance RHC every 3 to 6 months while awaiting HT or more frequently as clinically indicated. A vasodilator challenge should be administered to assess reversibility to acceptable levels for a potentially prohibitive PH, as detailed in Section [Pulmonary Hypertension](#).
- 2. Serial evaluation of PVR may be helpful to ensure patients remain heart-only transplant candidates, optimize vasodilator therapy, and indicate a potential need for MCS.¹⁸⁵ Fontan circulatory failure requires special considerations especially when driven by relatively high PVR and chronic diastolic dysfunction.³⁶³
- 3. Temporary or durable MCS should be considered for PH if medical therapy fails to achieve acceptable hemodynamics. Although durable LVADs improve hemodynamics⁶⁹² and enable patients to survive longer while awaiting transplantation,⁶⁹³ hemodynamic variability upon serial reassessment can occur even among patients with PVR < 3 Wood units increasing the risk of RV failure post-HT.⁶⁹⁴ Durable LVADs have been shown to unload the LV and reverse PH over time.^{692–696} When comparing LVAD candidates with persistent PH to those who improved PH over time, there is an increased risk of post-transplant mortality with persistent PH.¹³ Therefore, if medical therapy and MCS fail to achieve acceptable hemodynamics after effectively unloading the LV for 3 to 6 months, it is reasonable to conclude that the PH is irreversible.

3.3.1.2. Exercise Capacity: Frequency of Assessment

Recommendations for Repeat Testing on the Waitlist: Exercise Capacity: Frequency of Assessment		
COR	LOE	RECOMMENDATIONS
2b	C-EO	1. Serial CPET testing after initial listing for HT may be considered in patients with change in clinical status or in patients who remain on a waitlist for >1 year.
3: No Benefit	C-EO	2. Changing patient listing status solely on the criterion of a peak VO ₂ measurement should not be done.

Synopsis

CPET is a useful tool to assess the pathophysiologic mechanisms of exercise intolerance. It provides important prognostic information in HF and is used as one of the clinical parameters to guide listing for transplant.

Recommendation-Specific Supportive Text

- 1. The utility of serial CPET in listed patients has not been determined, therefore, the utility of repeat testing in the absence of change in patient symptoms or management is unclear. However, repeat CPET testing may be helpful to reclassify the severity of illness and reassess prognosis when HF symptoms and/or signs change—either worsen or improve. For instance, peak VO₂ and risk of mortality can change with exercise training, GDMT, and device therapy. In the HF-ACTION trial, patients randomized to exercise training had improved peak VO₂ by 0.6 [–0.7 to 2.3] ml/kg/min in 3 months compared to control with a change of 0.2 [–1.2 to 1.4] ml/kg/min, *p* < 0.001. There was also a 5% lower risk of mortality or hospitalization for every 6% increase in peak VO₂.⁶⁹⁷ CRT has also been shown to have improvement in peak VO₂ and survival.⁶⁹⁸ In patients who remain on the waitlist for an extended period, repeat CPET testing may be considered, for example, annually, even without an overt change in symptoms to confirm the accuracy of the initial prognostic assessment.
- 2. Decisions regarding listing changes should not be based solely on the criterion of a peak VO₂ measurement and should include additional CPET variables and other clinical factors that may affect the overall prognosis,

including the risk of waitlist mortality. The predictive value of CPET variables is additive, such as the incorporation of VE/VCO₂ slope and percentage of predicted peak VO₂ in the MECKI risk model.⁶⁹⁹

3.3.1.3. Assessment of Extracardiac Organ Function (Renal and Liver Function)

Recommendations for Repeat Testing on the Waitlist: Assessment of Extracardiac Organ Function		
COR	LOE	RECOMMENDATIONS
1	B-NR	1. Serial assessment of serum creatinine and estimated GFR is recommended for patients on the waitlist. The frequency of monitoring of kidney function is dictated by the clinical status of the patient.
1	B-NR	2. Serial assessment of liver function is recommended, with serum liver function tests (serum albumin, bilirubin, INR), biochemical assays (AST, ALT, GGT) and MELD-XI score. Further investigation should be considered when worsening liver function is suspected, including consideration of repeat abdominal imaging, hepatology consultation and liver biopsy.

Synopsis

Extracardiac organ function is carefully considered when determining HT candidacy and risk of postheart transplant mortality. AdvHF can lead to dynamic changes in noncardiac organ function, such as renal and liver failure. Systemic diseases, such as diabetes and hypertension can also cause or contribute to noncardiac organ dysfunction. Therefore, serial assessment of renal and liver function is recommended, and its frequency is guided by the clinical condition of the patient. Indications for dual organ transplant are discussed in Sections [Kidney Disease](#) and [Liver Disease](#).

Recommendation-Specific Supportive Text

- Renal dysfunction at the time of listing and time of transplant is one of the most powerful predictors of waitlist mortality and post-transplant survival.^{42,43,201,221,700,701} An eGFR < 30 ml/min/1.73 m² has an adjusted HR 1.5, 95% CI (1.4-1.7), $p < 0.001$ compared to eGFR 45-59 ml/min/1.73 m². Although the best method to calculate eGFR and the frequency of renal function assessment on the waitlist remain controversial, serum creatinine and calculated eGFR are the most practical tests and strong predictors of pre- and post-transplant survival.^{43,201,221,701} Dynamic changes in renal function can substantially alter estimated mortality on the waitlist.⁷⁰² The frequency of monitoring of renal function is dictated by the clinical status of the patient, ranging from daily monitoring in critically ill intensive care unit (ICU) patients to monitoring approximately every 3 months in stable outpatients. Worsening renal function should trigger an assessment by a multiprofessional team that includes a nephrologist to determine the etiology and appropriate treatment plan to stabilize renal function and the need for SHKT if kidney function recovery is unlikely.¹⁹⁵
- Liver disease in AdvHF is assessed with biochemical assays, MELD-XI score,⁴⁰² abdominal imaging, and liver histopathology as needed. Abnormal serum albumin at time of listing and time of transplant is also an important mortality risk factor pre- and post-HT.^{43,222,703} Serial assessment of liver function is recommended for patients on the waitlist, especially in patients with history of liver function abnormalities or those at risk of liver fibrosis and cirrhosis, for example, patients with CHD and patients with RHF or RCM. The frequency of monitoring of liver function is dictated by the clinical status of the patient. Worsening liver function should trigger further investigation, including repeat abdominal imaging, hepatology consultation, and liver biopsy.

3.3.1.4. Updating Vaccinations and Screening for Infections on the Waitlist

Recommendations for Repeat Testing on the Waitlist: Updating Vaccination and Screening for Infections on the Waitlist		
COR	LOE	RECOMMENDATION
1	B-NR	1. Should the patient remain on the waitlist for >1 year, annual influenza vaccine is recommended prior to the influenza season, and COVID-19 vaccination per regional recommendations.
2b	C-EO	2. Repeat screening of patients may be considered in patients who remain on the waitlist for >1 year.
1	C-EO	3. Repeat screening of patients on the waitlist should be done after a known relevant infectious disease exposure.

Synopsis

Vaccine-preventable diseases continue to be a considerable cause of morbidity and mortality in SOT candidates and recipients. Vaccination should be completed before transplantation (Table 10).

Recommendation-Specific Supportive Text

1. Should the patient remain on the waitlist for more than 1 year, an annual influenza vaccine and potentially other immunizations are recommended based on the current epidemiological situation.²⁴³ COVID-19 vaccination recommendations vary according to the emergence of new variants, epidemiological situation, new variant-updated vaccines; these recommendations are regularly updated.⁷⁰⁴
2. Screening of transplant candidates and donors is a crucial component of pre-transplant assessment,^{237,243} given the potential risk for reactivation. Screening allows the determination of the candidate's immunity, identifies latent infections that may be reactivated in the immunosuppression setting and helps guide immunization counseling and preventive strategies to reduce the risk of infectious complications after transplantation. Repeat screening of patients may be considered in patients who remain on the waitlist for > 1 year.
3. Repeat screening should also be done after an exposure to a known relevant infectious disease. At the time of transplantation, particular attention should be paid to donor-recipient match in previous exposure to specific infections and assessment of subsequent risk of reactivation of latent infection and risk of donor-transmitted infection.^{237,243,704}

3.3.1.5. Frequency of Malignancy Screening

Recommendations for Repeat Testing on the Waitlist: Frequency of Malignancy Screening		
COR	LOE	RECOMMENDATION
1	A	1. Patients on the waitlist should undergo age-appropriate cancer screening per current clinical guidelines for the general population (Table 19).

Synopsis

SOT recipients incur an increased risk of malignancy when compared with the general population. Cancer is the second leading cause of death; its incidence increases significantly over time and with recipient age and depends on cancer type and site (Table 19).

Recommendation-Specific Supportive Text

1. Currently, there is no evidence that more extensive cancer screening of transplant candidates vs the general population translates into reduced post-transplant risk of malignancy.^{3,5,167} While close surveillance for EBV seroconversion could be important in pediatric SOT recipients, guidelines do not support cancer screening in pediatric waitlisted patients. Surveillance guidelines specifically for transplant candidates with a prior history of malignancy are not available; thus, screening decisions should incorporate shared decision-making. The incidence of colorectal cancer in heart and kidney candidates is similar to the general population.⁷⁰⁵ The incidence of prostate cancer is similar in SOT candidates and the general population.⁷⁰⁶ KDIGO Kidney Transplant Candidate Work Group proposed pre-transplant cancer screening consistent with the general population guidelines for breast, colorectal, cervical, liver, prostate, and lung cancers.^{707,708} Recommendations of the American Cancer Society and the USA Preventive Services Task Force outline age-appropriate screening and surveillance for breast, lung in at-risk groups, colorectal, and cervical malignancies.^{102–107} Dermatologic follow-up for skin cancer screening pre-transplantation and education regarding sun protection are imperative, especially for those at high risk for skin cancer, as an increased risk of developing subsequent skin cancer in SOT recipients has been demonstrated.^{108,709} Predictive index scores that may help to provide a comprehensive and cost-effective, targeted surveillance of skin cancer are reported^{710–713} and can be helpful in prioritizing and providing better screening and surveillance for HT candidates. Suggested cancer screening on the waitlist, based on the appropriate cancer screen per current clinical guidelines, is presented in Table 19.⁷¹³

Table 19 | Suggested Cancer Screening on the Waitlist: for the Early Detection of Cancer in Average-Risk, Asymptomatic Adults

Cancer site and population	Screening modality and frequency
<i>Colorectal cancer screening</i> ^{102,103}	
Screen all adults aged 45-75 years at average risk of colorectal cancer	<p>Either a stool-based test or a visual examination, depending on patient preference and test availability. All positive results of noncolonoscopy screening tests should be followed up with a timely colonoscopy</p> <p>Stool tests FIT every year HSgFOBT every year sDNA-FIT every 1-3 years (as stated by the manufacturer)</p> <p>Direct visualization tests Colonoscopy every 10 years CT colonography every 5 years Flexible SIG every 5 years Flexible SIG every 10 years plus FIT every year</p>
<i>Prostate cancer screening</i> ¹⁰⁴	
a) Men aged 50 years at average risk of prostate cancer.	PSA \geq 2.5 ng/ml, screening should be conducted yearly
b) Men aged 45 years with increased risk of developing prostate cancer (African American men or men with first-degree relative diagnosed with prostate cancer younger than age 65)	PSA < 2.5 ng/ml, screening intervals can be extended to every 2 years
c) Men aged 40 years at highest risk (those with more than one first-degree relative who had prostate cancer at an early age)	PSA \geq 4 ng/ml, referral for further evaluation or biopsy
<i>Breast cancer screening</i> ¹⁰⁵	
Women aged 45-54 years	Mammogram annually
Women > 55 years	Mammogram every 2 years
<i>Cervical cancer screening</i> ¹⁰⁶	
Women aged 25-65 years	<p>Primary HPV (alone) test every 5 years (preferred).</p> <p>HPV test + Pap test every 5 years (a cotest)</p> <p>Pap test alone every 3 years</p>
<i>Lung cancer</i> ¹⁰⁷	
Patients aged 50-80 years with 20 pack-year smoking history who have quit smoking within the last 15 years	Annual low-dose chest CT
<i>Skin cancer</i> ^{108,709}	
All HT candidates	<p>Specialist exam annually</p> <p>Patients at high risk owing to susceptible skin type, history of high sun exposure, or history of skin health concerns undergo physician screening more frequently than yearly</p>
Abbreviations: CT, computed tomography; FIT, fecal immunochemical test; HPV, human papillomavirus; HSgFOBT, high-sensitivity guaiac fecal occult blood test; HT, heart transplantation; Pap, papanicolaou; PSA, prostate-specific antigen; sDNA, stool DNA; SIG, sigmoidoscopy.	

3.3.1.6. Dynamic Psychosocial Evaluation

Recommendations for Repeat Testing on the Waitlist: Dynamic Psychosocial Evaluation		
COR	LOE	RECOMMENDATIONS
1	C-EO	1. HT candidates should undergo periodic assessments of psychosocial status while on the waitlist.
1	C-EO	2. HT candidates undergoing therapy or treatment for a mental health disorder should be monitored and reassessed at agreed-upon time periods.
1	C-EO	3. HT candidates with abstinence from smoking, alcohol, or substance use should be monitored and reassessed at agreed-upon time periods.
1	C-EO	4. HT candidates with a history of medical regimen nonadherence should be monitored and reassessed at agreed-upon time periods.
1	C-EO	5. Pediatric HT candidates transitioning to an adult program while on the waitlist should have a structured transition plan and be monitored closely during the transition.

Synopsis

The goals of psychosocial interventions recommended during the initial HT evaluation and the strategies outlined to assess the progress should be dynamically monitored and reassessed. Exact timepoints for psychosocial re-evaluation of transplant candidates while on the waitlist are not well determined. Psychosocial evaluation in children is complex and multifactorial, also involving parents and families. The assessment of children tends to focus more on potential modifiable risk factors aimed at improving post-transplant outcomes.

Recommendation-Specific Supportive Text

- Dynamic psychosocial evaluation includes a review of a candidate's adherence to a medical regimen, mental health status, cognitive function, substance misuse, and level of social support.^{5,6,714} Exact timepoints for psychosocial re-evaluation of transplant candidates while on the waitlist are not well determined.
- Mental health disorders and depression have been linked to post-transplant mortality in HT recipients.⁵ Patients experiencing depressive or anxious symptoms or other mental health disorders should be referred for treatment with medication or psychotherapy and may require reassessment while on the waitlist.^{5,6,493,714}
- Patients with a recent history of alcohol abuse (within 24 months) may benefit from a structured rehabilitation program. Adherence to smoking cessation and abstinence from substance abuse should be monitored while on the transplant waitlist. Behavioral health specialists may use substance abstinence or behavioral contracts to outline expectations before HT.^{6,714}
- History of medical regimen nonadherence is a risk factor for worse post-transplant outcomes.⁷¹⁵ Adherence to a medical regimen while on the transplant waitlist should be monitored and reassessed at agreed-upon periods.
- Evaluation of neurocognitive function, age, and developmental level is important in pediatric psychosocial assessment.^{511,517,716,717} Numerous studies report nonadherence in adolescents compared to younger children, associated worse outcomes. Determining modifiable risk factors remains challenging and understanding barriers to adherence in pediatric transplant candidates/caregivers can aid in development of strategies to overcome these obstacles.^{511,517,716,717} For pediatric HT candidates transitioning to an adult program while on the waitlist, a structured transition plan is recommended,^{718,719} as adolescence may be a critical period for self-care and acquisition of healthy lifestyle habits, including compliance with medical therapies with psychosocial, social and financial contributions to nonadherence.^{720–722}

3.3.1.7. Evaluation of Malnutrition and Frailty on the Waitlist

Recommendations for Repeat Testing on the Waitlist: Evaluation of Malnutrition and Frailty on the Waitlist		
COR	LOE	RECOMMENDATIONS
1	B-NR	1. Nutritional status should be established in all listed patients and reassessed regularly.
1	B-NR	2. Goals of nutritional therapy should be established in those with suboptimal nutrition.
2a	C-LD	3. In listed heart transplant candidates, periodic reassessment of frailty is reasonable to identify actionable targets for improvement in conditioning and perform risk assessment of transplant candidacy.

Synopsis

Malnutrition is a common comorbidity in patients with HF associated with poor prognosis. Cachexia is a complex metabolic wasting syndrome characterized by unintentional edema-free weight loss (muscle mass loss, with or without fat mass loss), anorexia and systemic inflammation biochemistry. Malnourished patients are at higher risk of postsurgical complications and mortality after HT.

Frailty is common in AdvHF patients who are awaiting HT and affects mortality on the waitlist and in the post-transplant period (Section [Frailty](#) and [Table 11](#)).

Recommendation-Specific Supportive Text

- Malnourished patients are at higher risk of morbidity and mortality after HT, and malnutrition may worsen while patients await transplantation. Preoperative weight loss $\geq 10\%$ is associated with reduced survival in patients listed for HT.⁷²³ Nutritional status should be assessed at the time of transplant evaluation and on a regular basis, more frequently in hospitalized patients ([Table 20](#)). Parameters typically included in the assessment are anthropometrics (height, weight, % unintentional weight loss, BMI), nutritional screening and serum markers (prealbumin [albumin in ambulatory patients], C-reactive protein, sodium, potassium, magnesium, phosphorus).⁷²⁴ Commonly used tools that have shown an association with mortality in HF include Mini Nutritional Assessment (MNA), MNA-short form (MNA-SF), Nutritional risk index,^{725,726} and Geriatric Nutritional Risk Index.^{727–729}
- Patients with nutritional deficits should receive nutritional supplements. Assessment, supplementation if needed, and follow-up from the nutrition service is recommended in patients with more severe forms of malnutrition ([Table 20](#)).⁷²⁴
- Reassessment of frailty can be beneficial to identify actionable targets of transplant candidacy, especially if on tMCS and for high urgency status awaiting HT in the hospital. Patients with an acceptable level of frailty, when listed as outpatients, may no longer be suitable for transplantation after prolonged bed rest.^{262, 730–732}

Table 20 Suggested Nutritional Assessment in Patients on the Waitlist Awaiting Transplantation: Frequency of Nutritional Assessment and Recommended Intervention

MNA-SF score ^a	Frequency of nutritional assessment and recommended intervention
<i>Ambulatory patients</i>	
MNA-SF score 12-14	Repeat every visit (or at least every 3 months)
MNA-SF score 8-11	Re-evaluate every 1-2 months; if no improvement, refer to nutrition service
MNA-SF score 0-7	Start nutritional support; refer to nutrition service
<i>Hospitalized patients</i>	
MNA-SF score 12-14	Repeat weekly
MNA-SF score 8-11	Repeat weekly or more often; if no improvement, referral to nutrition service
MNA-SF score 0-7	Start nutritional support; refer to nutrition service

Abbreviation: BMI, body mass index.

^aThe Mini Nutritional Assessment-Short Form (MNA-SF; scored 0-14)⁷²⁴ consists of 6 questions that assess food intake, weight loss, mobility, acute events, neuropsychological problems, and BMI. Subjects with an MNA-SF score of 12-14 have normal nutritional status, and those with an MNA-SF score of 8-11 and ≤ 7 have mild and \geq moderate malnutrition, respectively. Subjects with an MNA-SF score ≤ 11 are classified as malnourished.

3.3.1.8. Monitoring of HLA and ABO Sensitization while Awaiting Transplantation

Recommendations for Repeat Testing on the Waitlist: Monitoring of HLA- and ABO Sensitization while Awaiting Transplantation		
COR	LOE	RECOMMENDATIONS
1	B-NR	1. Screening for HLA antibody is recommended every 3-6 months for all actively listed patients.
1	B-NR	2. Screening for HLA antibody is recommended approximately 3 weeks after a potentially sensitizing event.
2a	C-EO	3. Screening for HLA antibody can be considered as soon as 7 days after potentially sensitizing event in patients with previous sensitization/expected memory response.
1	B-NR	4. Screening for isohemagglutinin (ISO) antibodies against the non-self blood group(s) is recommended for all children listed for ABO-incompatible transplantation every 4 weeks, or 1-3 weeks after sensitizing events.
2a	B-NR	5. In patients awaiting transplantation, it is reasonable to reduce the risk of <i>de novo</i> sensitization by minimizing exposure to HLA antigens using leukodepleted blood products, single donor or matched thrombocytes and decellularized homografts when possible.

Synopsis

Sensitization toward HLA antigens in all patients awaiting HT and toward blood group antigens (isohemagglutinins, ISOs) in children listed for ABO-incompatible transplantation is a dynamic process. This may include new or reactivated sensitization, alteration of sensitization in response to therapies, or natural decline and disappearance of antibodies, especially if passively acquired. For ISOs, changes are also result of natural maturation. Accordingly, assessment of plasma levels of HLA antibodies and ISOs is recommended in regular time intervals for all listed patients as appropriate, and after events associated with sensitization.

Recommendation-Specific Supportive Text

1. HLA antibody screening is performed for every patient before listing and while listed for transplantation every 3 to 6 months by most centers following the technical and interpretation guidance of the STAR working group recommendations.^{733,734} Donor hearts are not selected on the basis of HLAs because of time restrictions related to cardiac preservation; therefore, tissue type should be determined for retrospective analysis and may assist with determination of donor-specific antibodies. Flow cytometry is an immunofluorescence method for identifying cell surface antigens by detecting conjugated antibody. Results from flow cytometry allow for assessment regarding the risk of a positive crossmatch at the time of transplant. Patients at risk for suboptimal outcome post-transplant are defined as having a PRA > 10% or donor-specific antibodies at the time of transplantation. Decisions can be made with more confidence regarding the need for a prospective vs retrospective crossmatch, as well as giving providers more insight into the likelihood of antibody-mediated rejection after transplantation.
2. Antibody production is a dynamic process, and changes in HLA antibody levels can happen even in the absence of a clear sensitizing event.⁷³⁵ A recent antibody screen while actively listed minimizes the chance of an unexpected positive crossmatch result at the time of transplant. Production of *de novo* or reactivated production of previously known antibodies can be triggered by certain sensitizing events. Potentially sensitizing events include pregnancy, transfusion of blood products, especially thrombocytes which express HLA antigens,⁷³⁵ surgical procedures with use of human tissues (e.g., vascular grafts),^{736,737} MCS devices,^{737,738} or renal replacement therapy.⁷³⁹ *De novo* sensitization via T-mediated B-cell activation takes approximately 21 days until peak response.⁷⁴⁰ Use of single donor or HLA-matched blood products⁷⁴¹ and decellularized tissue-grafts³⁹⁰ can prevent *de novo* sensitization.
3. Reactivation of immune memory occurs within 5 to 7 days of a sensitizing event and can therefore be detected earlier than in *de novo* antibody production.⁷⁴⁰ HLA antibody screening is recommended after potentially sensitizing events, such as blood product transfusions, and infections which can sensitize through cross-reactivity between bacterial or viral epitopes and HLA antigens.⁷³³
4. Children naturally develop adult titers of ISOs between 6 and 24 months of age.⁷⁴² Therefore, in children listed for ABO-incompatible transplantation, screening for ISO antibodies against the non-self blood group(s) is

- recommended every 4 weeks, or 1 to 3 weeks after sensitizing events to confirm eligibility for ABO incompatible organs.⁷⁴³
- For all patients on the transplant list, if possible, potentially sensitizing events should be avoided or minimized.⁷³⁵ Transfusion of blood products should be done only for clear indications. Current common practice of leukodepleting red cell products decreases HLA exposure with transfusion. Platelet transfusions pose a risk of exposure to a wide range of HLA antigens.⁷³³ Use of single donor or matched thrombocytes may be preferred over pooled platelet products when possible.⁷⁴⁴ Use of decellularized homografts also reduces the risk of sensitization.³⁹⁰ Desensitization strategies have been advocated in patients who are highly sensitized.⁷³⁴

3.3.1.9. Role of Biomarkers

Recommendations for Repeat Testing on the Waitlist: Cardiac Biomarker Assessment		
COR	LOE	RECOMMENDATIONS
1	B-R	1. Natriuretic peptides (NP) should be determined at the time of initial evaluation of a patient with AdvHF (Class 1). Periodic assessment of NP in a patient on the waitlist can be useful for early detection of clinical deterioration (Class 2a).
2a		
2a	C-LD	2. Progressive significant reduction of NP levels, accompanied by meaningful clinical improvement, and in the absence of other poor prognostic features, can help identify patients on the waitlist whose disease has improved on GDMT to the point where removal from the waitlist can be considered.
1	C-LD	3. In patients with cardiogenic shock, or with suspected cardiogenic shock, monitoring of blood lactate levels allows for stratification of severity and can be used to guide treatment escalation.

Synopsis

The natriuretic peptides (NP), BNP, and NT-proBNP are secreted by cardiomyocytes in response to increased atrial or ventricular wall tension. They promote myocardial relaxation, natriuresis, and vasodilation and reduce the activity of the sympathetic nervous system and the renin-angiotensin system.⁷⁴⁵ Elevated NP levels are supportive of the diagnosis of HF with, but with less utility in certain situations, including decreased sensitivity with obesity and HF with mildly reduced or preserved EF. Although there is no specific marker for diagnosing cardiogenic shock, serum lactate is a biomarker that supports the cardiac mechanism of hemodynamic decompensation and hypoperfusion of organs. Lactate provides important information regarding the condition of a shock patient at presentation and prognostic information. However, end-organ hypoperfusion may be present with normal lactate and lactate elevation due to local tissue ischemia from noncardiac conditions that may occur in the absence of cardiogenic shock.

Recommendation-Specific Supportive Text

- Serum NP levels are part of the routine pre-transplant evaluation, and serial testing helps identify early deterioration of the patients on the waitlist.^{746,747} Serum levels of NT-proBNP or BNP are used in the initial diagnosis of HF and are useful for prognostication. Persistent elevation despite optimal treatment is a poor prognostic factor in identifying patients that may need a referral to an advanced HF center.^{16,748} Increased NT-proBNP in patients on the waitlist has been associated with adverse events.^{746,747} However, the usefulness of NT-proBNP in assessing the prognosis of patients on the waitlist is limited as it must also take into account fluctuation resulting from organ congestion and hepatic and renal dysfunction,⁷⁴⁹ and decreased specificity in the setting of sepsis.
- A progressive significant reduction of NP levels, in the absence of other poor prognostic features, can identify patients on the waitlist who have significant improvement of their clinical condition, either as a result to favorable response to GDMT or resolution of certain reversible factors that lead to their HF.⁵⁵⁹
- Serum lactate is a helpful marker that reflects tissue hypoperfusion. In patients in cardiogenic shock, monitoring of serum lactate levels can stratify the severity of hemodynamic derangement and help in planning for escalation of therapies such as initiation or increase in vasoactive medications or initiation of MCS. Lactate is used to distinguish between SCAI SHOCK stage B—hemodynamic instability without hypoperfusion, and stage C—hypoperfusion with or without overt hemodynamic instability. A lactate level of > 2 mol/liter is consistent with at least SCAI SHOCK Stage C.^{559,750} However, there may be other manifestations of end-organ

hypoperfusion with normal lactate, as well as other causes of lactate elevation, for example, local tissue ischemia from noncardiac conditions, that need to be taken into consideration.⁷⁵⁰

3.3.1.10. Improvement and Removal from the Waitlist

Recommendations for Improvement and Removal from the Waitlist		
COR	LOE	RECOMMENDATIONS
1	C-LD	1. Ambulatory patients on GDMT should be re-evaluated at 3–6-month intervals for maximal pharmacologic and device therapy. If they have improved significantly, they should be considered for delisting.
2b	B-NR	2. Patients on LVAD therapy with myocardial recovery resulting in device explant may be delisted.
1	B-NR	3. After delisting, follow-up every 3-6 months by HF specialists is recommended to identify deterioration.

Synopsis

A subset of patients on the waitlist will respond favorably to ongoing HF management to the point where the benefit of HT may need to be reassessed and patients are considered for delisting.⁵ These will include patients with higher recovery potential, such as those with potentially reversible HF etiologies, for example, acute myocarditis, acute cardiogenic shock after myocardial infarction, etc., but also patients with a more chronic course of HF responding to the expanding GDMT.^{751,752}

Recommendation-Specific Supportive Text

- Listed patients who are ambulatory and not requiring inotropes should be continually evaluated for maximal pharmacologic and device therapy. Response to GDMT should be re-evaluated at 3- to 6-month intervals. If patients significantly improve over time and no longer have survival benefit from transplantation, they should be considered for delisting.^{5,751,752} Approximately 6%-8% of candidates removed from the waitlist are due to medical improvement.^{752,753} Indications for delisting for medical improvement include objective improvement in symptoms, NYHA Class, maximal VO_2 , and biomarkers. Importantly, outcomes are improved with attentive follow-up care provided within a HF disease management program.⁷⁵¹
- LVAD patients who have achieved myocardial recovery resulting in device explant, with stable cardiac function and symptoms on maximally tolerated GDMT, should also be delisted for improvement.^{754–756} After delisting, close follow-up by HF specialists every 3 to 6 months is recommended to identify possible deterioration.
- Approximately 30% of patients delisted for improvement eventually present again with worsening HF, including reaching AdvHF with an increased risk of death.² Patients delisted for HF improvement should continue to be followed by AdvHF teams and assessed serially for evidence of decompensation. Numerous studies have shown improved outcomes in those under the care of an HF team and ongoing GDMT.^{751,757} Further studies are required to better risk-stratify patients delisted after improvement with medical therapies or with LVAD unloading.

3.3.2. Acute Decompensation on the Waitlist

3.3.2.1. Considerations for Status Upgrade on the Waitlist

Recommendations for Acute Decompensation on the Waitlist: Considerations for Status Upgrade		
COR	LOE	RECOMMENDATIONS
1	C-EO	1. Listing urgency status should be assessed at regular intervals and at the time of change of clinical status.
2a	C-LD	2. Listing status adjustment based on corresponding allocation rules is reasonable when acute hemodynamic decompensation does not improve despite appropriate treatment.
3: No Benefit	C-LD	3. Status upgrade is not indicated for candidates whose symptoms and end-organ dysfunction resolve with adjustment of baseline therapies such as oral anti-congestive therapies, successful treatment of arrhythmias, and device optimization.

Recommendation-Specific Supportive Text

1. Waitlist management should include regular assessment of urgency status and determination whether changes in the level of urgency are needed to provide equal access to scarce organs to those with the highest waitlist mortality while maintaining transplant survival benefit.⁷⁵⁸
2. Mortality risk has been shown to increase in ambulatory HF patients after each episode of HF hospitalization; thus, acute HF decompensation is an important clinical event for waitlisted candidates.⁷⁵⁹ Many mortality risk factors are accounted for in current allocation schema. However, acute decompensated HF is marked by other clinical factors associated with increasing risk for death in HF and worse waitlist outcomes. Strong predictors of mortality in adults with HF include higher blood urea nitrogen and NP, lower hemoglobin, and cardiac cachexia.^{760,761} Predictors of waitlist mortality include lower renal function, lower albumin, new neurologic events, initiation of dialysis, cumulative respiratory complications, rising bilirubin, rising creatinine, and RHF.^{43,702,762} Status upgrade based on corresponding local allocation rules can be considered in candidates with acute decompensation where hemodynamic derangement does not improve despite appropriate treatment.
3. If after acute hemodynamic decompensation or other clinical worsening on the waiting list (e.g., arrhythmias) therapies are optimized and the candidate returns to baseline clinical condition, then status upgrade is not indicated.

3.3.2.2. Inotropic and Vasoactive Therapy

Recommendations for Acute Decompensation on the Waitlist: Inotropic and Vasoactive Therapy		
COR	LOE	RECOMMENDATIONS
2a	B-NR	1. Continuous administration of intravenous inotropic drugs (dobutamine and/or milrinone) can be considered in heart transplant candidates with cardiogenic shock, low cardiac output and/or secondary organ dysfunction.
2a	B-R	2. Periodic administration of levosimendan, as a continuous infusion for 24-48 hours or intermittently over a shorter time, in patients with advHF with evidence of organ hypoperfusion awaiting HT, can improve the hemodynamic status, congestion, and QOL, enable the optimization of GDMT, and reduce symptoms and hospitalizations.
2a	C-EO	3. Initiation and titration of IV inotropes in heart transplant candidates is recommended following hemodynamic profiling using a PA catheter. Implantable PA monitoring can be effective for hemodynamic-guided therapy in HT candidates.
2b	C-LD	4. The effectiveness of long-term use of inotropes as an alternative bridging strategy to the use of DMCS may lead to further deterioration.
2a	B-NR	5. Additional intravenous vasoactive drugs with vasoconstrictive or vasodilating properties can be effective in individual patients listed for HT according to their specific hemodynamic profile.
3: No Benefit	C-EO	6. Routine use of oral vasoconstrictor medications (midodrine or droxidopa) to increase blood pressure or avoid the need for inotropic therapy in HF patients listed for HT is not recommended.
2b	C-EO	7. Oral vasoconstrictor medications (midodrine or droxidopa) may be beneficial for specific subgroups of HT candidates, such as those with cardiac amyloidosis or to maintain blood pressure in patients requiring renal replacement therapy.
2b	B-R	8. Vericiguat may be considered in high-risk patients with HFrEF to reduce the incidence of a composite of an HF event or cardiovascular death.

Synopsis

The advanced nature of HF may present hemodynamic scenarios where inotropic drugs can be effective while patients await HT under close clinical and hemodynamic monitoring. The effective use of vasoactive drugs is founded on accurately assessing the etiology of decompensation and the specific patient's hemodynamic profile. When congestion and hypertension predominate, vasodilators and diuretics are preferred to unload the heart and mobilize fluid. Inotropic therapy and, possibly, vasopressors are indicated for "wet and cold" patients. The intermittent use of the calcium sensitizer levosimendan is safe and well tolerated and represents a viable therapeutic option as a "bridge to transplant" strategy.

Recommendation-Specific Supportive Text

1. Intravenous inotropes improve hemodynamics in the short-term but may be associated with increased risk of long-term mortality in HF.^{350,763,764} The use of intravenous inotropes is a reasonable option in a bridge-to-HT strategy in patients with cardiogenic shock, low cardiac output, and/or secondary organ dysfunction if needed in conjunction with temporary or durable MCS. Outpatient inotrope use for adult waitlisted patients has been shown to be safe and effective in selected patients with an ICD but increases the risk of catheter-related infections.^{765,766} Outpatient inotrope therapy can also be considered in the pediatric population awaiting transplant.⁷⁶⁷ The most commonly used agents include the beta-1 agonist dobutamine and the phosphodiesterase-3 inhibitor milrinone, administered as a continuous intravenous infusion. Limited studies have compared the 2 drugs directly, without a clear advantage of one vs the other. Each drug needs to be tailored to systemic and pulmonary hemodynamics, renal function, and other relevant clinical characteristics.^{768,769}
2. Periodic levosimendan infusion can be effective in patients with AdvHF with evidence of organ hypoperfusion awaiting HT. Levosimendan, administered intermittently, can improve congestion, QOL, and hemodynamic status, reduce symptoms and hospitalizations, and enable the optimization of GDMT.^{770,771} Nonetheless, the optimal administration strategy has not yet been identified.⁷⁷²⁻⁷⁸⁰ Consideration for the first administration of levosimendan to be performed in an inpatient setting and in 24-hour infusion at a dose of 0.1 to 0.2 µg/kg/min according to blood pressure to verify both safety (particularly in terms of the appearance of symptomatic hypotension and ventricular tachycardias) and efficacy. The response to levosimendan infusion can be assessed as an objective improvement of BiV systolic function and reduction of pulmonary pressure or by RHC. Subsequent dosing can be given in either an infusion of 12.5 mg of levosimendan at the dose of 0.1 µg/kg/min every 4 weeks or an infusion of 6.25 mg at a dose of 0.2 µg/kg/min every 2 weeks [for SPB > 100 mm Hg, eGFR ≥ 45 ml/min/1.73 m², and absence of a history of ventricular tachyarrhythmia (VTA)].
3. Initiation and titration of intravenous inotropes in HT candidates is recommended following hemodynamic profiling using a PA catheter. In patients with moderate to severe HF, hemodynamic monitoring (CardioMEMSHF system, Abbott Laboratories, Abbott Park, IL) substantially improved QOL and reduced HF hospitalizations.⁶⁵⁹ Although implantable PA monitoring systems can be effective for hemodynamic-guided therapy in HT candidates, listed HT candidates on inotropes were excluded from the pivotal clinical trials of this device.^{659,781}
4. The effectiveness of the long-term use of inotropes as an alternative bridging strategy to the use of DMCS may lead to further deterioration, especially if the patient is expected to spend significant amount of time on the waitlist.⁷⁸²⁻⁷⁸⁵
5. Additional intravenous vasoactive drugs with vasoconstrictive properties (norepinephrine, epinephrine, vasopressin, dopamine) for refractory hypotension or vasodilating properties (nitroglycerin, nitroprusside) to decrease systemic or pulmonary afterload can be effective in individual patients listed for HT according to their specific hemodynamic profile. Continuous vasoactive drugs are often given in combination with inotropes and diuretics.⁷⁸⁶
6. There is no evidence of benefit of oral vasoconstrictors, such as midodrine or droxidopa, in most HT candidates with HFrEF. There is a concern for possible harm with vasoconstriction and afterload increase, especially in those with ischemic cardiomyopathy.^{787,788}
7. Oral vasoconstrictor medications (midodrine or droxidopa) may be beneficial for treatment of hypotension in cardiac amyloidosis patients with concomitant autonomic dysfunction and in patients with end-stage renal disease requiring renal replacement therapy (who may be candidates for combined heart-kidney transplantation).⁷⁸⁹
8. The novel oral vasodilator, vericiguat, a soluble guanylate cyclase stimulator, may be considered in high-risk patients with HFrEF and recent worsening of HF already on GDMT to reduce HF hospitalization or cardiovascular death.⁷⁹⁰ Vericiguat significantly reduced NT-proBNP levels in patients with deteriorating HFrEF compared to the placebo⁷⁹¹, but the QOL with the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score did not significantly improve.⁷⁹² However, limited data are available regarding its use in HT

candidates, as they were excluded from the major clinical trial that established the benefit of this drug.⁷⁹⁰ Because of its potent vasodilatory properties, it is reasonable to discontinue vericiguat (such as other vasodilators) once the HT surgery is confirmed.

3.3.2.3. Cardio-Renal Syndrome

Recommendations for Acute Decompensation on the Waitlist: Cardio-Renal Syndrome		
COR	LOE	RECOMMENDATIONS
1	B-NR	1. Patients listed for HT who develop cardio-renal syndrome (CRS) should be managed as per published best practices for CRS in HF.
2a	C-LD	2. It is reasonable to consider PA catheter placement in selected patients with worsening renal function not responsive to diuresis or with hemodynamic compromise requiring parenteral vasoactive agents.
1	B-NR	3. Patients with CRS secondary to cardiogenic shock refractory to initial stabilization attempts should be managed with parenteral vasoactive agents, with early consideration for MCS.
2a	B-NR	4. It is reasonable to re-evaluate the appropriateness of heart-only transplant listing in patients with progressive renal deterioration.

Recommendation-Specific Supportive Text

1. Patients on the waitlist who develop CRS should be treated based on published guidelines addressing CRS in HF patients.^{1,2} The general management of CRS is explored elsewhere, including stepped pharmacological therapy and screening for intra-abdominal hypertension, although data on specific targeted interventions are lacking.^{574,793–795}
2. It is reasonable to consider hemodynamic profiling using a PA catheter in patients listed for HT who experience decompensation with CRS, especially if refractory to diuresis or hemodynamically unstable (in cardiogenic shock).⁷⁹⁶ Furthermore, PA catheter may help gauge the contribution of RHF in CRS, which is often under-recognized,⁷⁹⁷ impacting tailored management, including decisions around MCS.
3. The limited data on either temporary or durable MCS in CRS suggest poor outcomes in patients with severe renal dysfunction.⁷⁹⁸ However, MCS undertaken before significant deterioration of renal function may lead to acceptable outcomes as bridge to recovery, decision, HT alone, or even for SHKT.⁷⁹⁹
4. In patients with progressive renal deterioration, re-evaluation of heart-only transplant listing is reasonable for the early identification of irreversible renal dysfunction and eligibility for SHKT.^{12,195} (refer to Section [Kidney Disease](#)). If the patient is deemed no longer eligible for advanced therapies, referral to palliative care should be undertaken.⁸⁰⁰

3.3.2.4. End-of-Life Care and Removal from the Waitlist

Recommendations for Acute Decompensation on the Waitlist: End-of-Life Care and Removal from the Waitlist		
COR	LOE	RECOMMENDATIONS
1	C-EO	1. Advanced care planning with a multidisciplinary team should be done with focus on symptom management and emotional support.
1	C-EO	2. Shared decisions should be pursued with emphasis on improving or maintaining an acceptable QOL for the patient and caregivers/family.

Synopsis

End-of-life care and removal from the waitlist raises ethical challenges. The search for course-modifying therapies for AdvHF must be balanced and integrated into a multidisciplinary palliative approach. Patients maintain optimism for prolonged life, value QOL, and hope through drug and surgical interventions. Discussions about possible removal from the transplant list should be with patients and caregivers in consultation with palliative care during the initial phase of the evaluation for transplant.

Recommendation-Specific Supportive Text

1. Palliative and end-of-life care of patients with HF is an integral part of international guidelines^{350,559,801,802} with consensus about important key areas in the end-of-life care. Cultural differences related to beliefs and expectations for positive results of surgical strategies, such as HT and MCS, must be considered.⁸⁰³ A multidisciplinary team should be involved with a focus on symptom management and emotional support.
2. Shared decision-making is crucial and should emphasize improving or maintaining acceptable QOL in both the patient and the caregivers.⁸⁰⁴ Symptoms should be assessed frequently with the primary goal of providing therapeutic relief. Advanced care planning in cooperation with the multidisciplinary team, patient, and caregivers should include a discussion of:
 - The effects of medications on symptom relief and QOL and when to stop medications in the absence of the desired effects.
 - Desired use of life-sustaining interventions and resuscitation attempts.
 - Timing of deactivation of ICD.
 - Timing of discontinuation of temporary or durable MCS or removal from the heart transplant waitlist.
 - Psychosocial or spiritual support to the patient, family, and caregivers.

3.3.3. Managing Special Populations on the Waitlist

3.3.3.1. Retransplant and Multiorgan Transplant

Recommendations for Managing Special Populations on the Waitlist: Retransplant and Multi-Organ Transplant		
COR	LOE	RECOMMENDATIONS
1	C-EO	1. Patients listed for heart retransplantation should undergo serial evaluation as recommended for all transplant candidates and be closely followed by the transplant team.
2a	C-EO	2. It is reasonable to avoid mTOR inhibitors in patients awaiting retransplantation to prevent delayed surgical wound healing and a higher incidence of pleural and pericardial effusions after transplant.
1	C-EO	3. Multidisciplinary management of patients awaiting multi-organ transplant is recommended to optimize waitlist and post-transplant survival.
1	C-EO	4. A plan should be established for perioperative and post-transplant management, including immunosuppression protocol, in patients awaiting multi-organ transplant.

Synopsis

Retransplant candidates tend to be younger, more sensitized, and more critically ill, with an increased likelihood of hospitalization or being supported with renal replacement therapy, mechanical ventilation, inotropes, or extracorporeal membrane oxygenation compared to primary heart recipients. Multiorgan heart transplant accounts for 4% to 7% of all heart transplants, with the majority (> 85%) being heart-kidney transplants.

Recommendation-Specific Supportive Text

1. Patients awaiting retransplantation are receiving immunosuppression and are likely to have a higher comorbidity burden than primary HT candidates.⁸⁰⁵ The most common indication for a heart retransplant is CAV, followed by chronic graft dysfunction.^{5,195,356,805–807} Since both short- and long-term survival after retransplantation is lower than in primary transplantation, careful follow-up of retransplant candidates by the transplant team is recommended.^{415,417,808,809}
2. Patients awaiting retransplantation are already receiving maintenance immunosuppressive therapy. It is reasonable to avoid mammalian target of rapamycin inhibitors in patients awaiting retransplantation to prevent delayed surgical wound healing and a higher risk of pleural and pericardial effusions after transplant.⁸¹⁰

3. Multiorgan transplantation is appropriate in selected patients with multiple organ failure according to established transplant candidacy guidelines for each respective organ or when multiple organ transplantation confers a significant benefit to the patient with primary organ failure.^{12,195,356,811,812} Multidisciplinary management of patients awaiting multiorgan transplant is recommended in order to optimize management on the waitlist and optimize post-transplant survival.
4. Plan for perioperative and post-transplant management, including an immunosuppression regimen agreed upon by the respective transplant teams, should be established ahead of time in patients awaiting multiorgan transplantation.¹²

3.3.3.2. Pediatric and Congenital Heart Disease Considerations

Recommendations for Managing Special Populations on the Waitlist: Pediatric and Congenital Heart Disease Considerations		
COR	LOE	RECOMMENDATIONS
1	B-NR	1. Recurrent detailed monitoring of HLA antibodies is recommended, especially for failed Fontan physiology and other single ventricle patients, to guide antibody removal strategies and post-transplant immunosuppression therapy.
2b	B-NR	2. Desensitization treatment may be considered for allosensitized pediatric waitlisted patients to shorten waitlist time.
1	B-NR	3. Vascular occlusions should be assessed at time of evaluation and periodically while waitlisted and interventions to prevent or treat venous and arterial thromboses are recommended.
1	B-NR	4. Due to neurocognitive and mental health risk in pediatric patients awaiting transplant, mental health assessment and support for children and caregivers are recommended.
1	C-EO	5. Multidisciplinary management of patients with failing Fontan physiology is recommended to optimize waitlist and post-transplant survival.
1	C-EO	6. Failing Fontan patients should receive ongoing surveillance for FALD while awaiting transplantation.
1	C-LD	7. EBV and CMV IgM and IgG should be retested periodically in a patient awaiting transplant to reflect changes in infection status.

Synopsis

Infants and children have special considerations while waitlisted due to increased prevalence of CHD, prior cardiac surgery, and greater likelihood of allosensitization increasing waitlist time. A multidisciplinary approach is paramount to address the unique challenges of pediatric transplantation while awaiting HT. Immunological risk with sensitization to HLA and ABO requires monitoring and management. CHD remains a risk factor for waitlist mortality; periodic imaging and hemodynamic assessment (refer to Section [Cardiac Catheterization to Assess Hemodynamic Stability](#)) to evaluate the need for MCS are essential in the management of CHD patients on the waitlist, especially in patients with failed Fontan physiology and risk of FALD.

Recommendation-Specific Supportive Text

- 1-2. There are high rates of HLA sensitization and risk of immune memory reactivation due to previous use of human tissue grafts. HLA and ABO sensitization may be underestimated in the setting of protein-losing enteropathy.^{185,736,813} Over half of the children listed for HT have CHD, and the majority of these have had cardiac surgery before—or while awaiting HT,⁸¹⁴ increasing the likelihood of allosensitization that can increase waitlist time.^{386,815} Desensitization treatment may be considered for allosensitized pediatric waitlist patients to shorten waitlist time and increase the likelihood of a negative crossmatch.⁸¹⁶ However, it may not be beneficial to require a prospective, negative crossmatch in pediatric candidates when waitlist mortality and 1-year HT survival are considered.⁸¹⁷

3. Venous thrombosis and thromboembolism are common in critically ill children. Major infection or inflammatory state, infancy, central venous lines, immobility, CHD, and extended hospitalization are independent risk factors.^{818,819} Vascular occlusions should be assessed at time of evaluation and periodically while waitlisted, and interventions to prevent or treat venous and arterial thromboses are recommended.
4. Waitlisted candidates with CHD and those with significant pre-transplant illness and morbidity have worse neurocognitive outcomes⁸²⁰ and QOL after transplant.⁸²¹ Interventions while on the waitlist, where feasible, are recommended, including mental health support for children and caregivers to improve transplant outcomes.^{822,823}
5. Problems of Fontan circulatory failure can include collateral blood vessel development, lymphatic abnormalities, nutritional insufficiency, renal dysfunction, and hepatopathy.⁸²⁴ A multidisciplinary team is needed to optimize patients for successful transplant. The composition of team members and the division of roles and responsibilities are discussed in Section [Multidisciplinary Team Approach](#).
6. New literature and guidelines regarding FALD are rapidly evolving, with ongoing surveillance necessary to rule out development of malignancy or irreversible cirrhosis which would prompt consideration for heart-liver transplantation.^{825,826}
7. Changes in CMV and EBV status and adjustment of false positive serologies⁸²⁷ should be monitored while awaiting transplant.

3.4. Preoperative Preparation of the Patient for Transplantation

3.4.1. Standard and Specialized Preoperative Measures

Recommendations for Pre-Operative Preparation of the Patient for Transplantation: Standard and Specialized Pre-Operative Measures		
COR	LOE	RECOMMENDATIONS
1	C-EO	1. Standard pre-operative considerations for preparation of the recipient should include identification of changes in clinical status to confirm the patient continues to be a good candidate for transplantation.
2a	C-LD	2. SGLT2i and vasodilators may be associated with postoperative complications, and it is reasonable that these drugs are discontinued before HT.
1	C-EO	3. Patients on systemic anticoagulation should undergo anticoagulation reversal.
1	C-EO	4. Standard pre-operative pacemaker and ICD reprogramming should be done.
2a	B-NR	5. In patients with cPRA>50%, desensitization is reasonable to improve access to donor hearts.
1	B-NR	6. In sensitized patients, donor organ consideration should proceed according to the plan established along with the histocompatibility and immunogenetics team.
2a	C-EO	7. In allosensitized patients, induction therapy can be considered to reduce the risk of rejection.
1	C-LD	8. Perioperative antibiotics should be administered to reduce the risk of infection after cardiac surgery. The recommended prophylaxis includes a single pre-incision dose of first- or second-generation cephalosporin.
1	C-EO	9. Vancomycin or clindamycin is an acceptable alternative in patients with a documented beta-lactam allergy for perioperative antibiotics.
1	C-EO	10. Vancomycin for perioperative prophylaxis should be considered for patients with known MRSA colonization or infection.

Synopsis

The preoperative preparation of a patient for HT incorporates multiple considerations to maximize the chance of a favorable outcome. When a potential donor is identified, the patient is admitted and prepared for the transplant surgery. It should be determined whether there are any relevant changes to the patient's clinical status

since the last follow-up and whether the patient continues to be a good candidate for transplantation. It should also be confirmed that serial evaluation of the patient has confirmed any outlying concerns have been addressed before transplant. Standard preoperative considerations for preparation of the recipient for surgery relate to specific medications that might be associated with postoperative complications, particularly SGLT2i and vasodilators, assessment of PA pressures, management of allosensitization, reversal of anticoagulation, and ICD device reprogramming. Infectious disease considerations include the use of perioperative antibiotic prophylaxis as well as additional antimicrobial therapy in patients with ongoing infection (e.g., in patients with a history of LVAD infection).

Recommendation-Specific Supportive Text

1. Standard preparation of the recipient for transplant surgery involves clinical review directed at assessing changes in health status that might impact the decision to proceed with transplantation. Clinical events that may impact the risk of surgery or postoperative survival include acute infection, worsening end-organ function, such as renal and liver dysfunction, active bleeding, recent sensitizing event, or other conditions of significance that have developed since the last patient follow-up.
2. Most oral medications are discontinued once a potential donor is identified, with particular attention on timely discontinuation of SGLT2i to lessen the risk of ketoacidosis after surgery,⁸²⁸ and discontinuation of vasodilators, particularly ACEi/ARB/ARNi, to avoid postoperative vasoplegia.⁸²⁹ In patients in high urgency status where HT is anticipated within days, avoidance of SGLT2i and of longer-acting oral vasodilators is reasonable.
3. For additional details regarding anticoagulation and reversal before HT, please refer to Section [Anticoagulant and Antiplatelet Therapy](#).
4. Patients with pacemakers require device reprogramming to asynchronous pacing mode (e.g., DOO, VOO). Patients with ICDs require antitachycardia pacing and shock therapies turned off.
5. Sensitization decreases access to donors, prolongs wait times, and increases risk of removal from the waitlist and risk of rejection and death after transplant.^{830,831} Candidates with CPRA > 50% have a significantly lower likelihood of transplantation and a higher risk of waitlist removal/death, with CPRA > 80% having the most negative impact.⁸³⁰ Despite limited data, desensitization strategies may shorten wait times without compromising outcomes.^{832,833} The general approach to desensitization is mechanical removal of antibodies (plasmapheresis or plasma exchange) or suppression of antibodies [intravenous immunoglobulin (IVIG), rituximab, bortezomib]. Both plasmapheresis and IVIG can effectively reduce HLA antibodies; however, they are associated with rebound.⁸³⁴ IVIG may be more effective and have a better safety profile than plasmapheresis.⁸³⁵ Adjuvant therapies are commonly added to plasmapheresis and IVIG and may prevent rebound. In kidney transplant candidates, IVIG with rituximab significantly decreased PRA and was associated with shorter duration to transplant.⁸³⁶ Compared to IVIG alone, rituximab and IVIG appear to have less rebound and less antibody-mediated rejection.⁸³³ In HT candidates unresponsive to IVIG and rituximab, bortezomib and plasmapheresis reduced HLA from 62% to 35%.⁸³⁷ Bortezomib has demonstrated greater efficacy against HLA Class I than HLA Class II.^{838,839} Other emerging and promising therapies exist and have been investigated in small studies.
6. In sensitized patients, a specific plan for acceptable donor organs should be established by the transplant team ahead of time. At the time the prospective organ donor is identified, the clinical team should work along with the histocompatibility and immunogenetics team to confirm the donor will represent an acceptable immunologic match. This process may include virtual crossmatch with avoidance of donors with specific alloantigens, prospective direct crossmatch, and alteration of standard perioperative immune suppression.^{840,841} It is also important to identify potential sensitizing events that may have taken place since the last patient follow-up. If these exist, repeat assessment of HLA antibodies should be considered.

7. In allosensitized patients, particularly those with a positive crossmatch, induction with antithymocyte globulin or basiliximab can be considered.⁸⁴² There are also limited data on the use of intraoperative plasmapheresis in those with a positive crossmatch to decrease the risk of early rejection.^{843,844}
- 8-10. Surgical site infections occur in 4% to 19% of heart transplant recipients and can present as soft tissue infections or sternal infections and mediastinitis. The most common organisms involved are Gram-positive (*Staphylococcus* species including MRSA, *Enterococcus* species), lactose fermenting, and non-fermenting Gram-negative (*Enterobacteriales*, *Pseudomonas aeruginosa*, *Stenotrophomonas*). The choice of antimicrobial agent must take into consideration beta-lactam allergy and colonization with multidrug-resistant organisms. First-generation cephalosporin (i.e., cefazolin) for 24 to 48 hours is recommended as primary prophylaxis for HT, with an alternative regimen of vancomycin plus cefazolin for MRSA colonization. For patients with beta-lactam allergy, vancomycin or clindamycin is acceptable alternatives. For a patient with an active infection at the time of transplant, the antibiotic regimen should target the specific pathogen(s).⁸⁴⁵⁻⁸⁴⁸

3.4.2. Infectious Disease Considerations

3.4.2.1. Hepatitis B and C Viral Infections

Recommendations for Pre-Operative Preparation of the Patient for Transplantation: Infectious Disease Considerations: HBV and HCV		
COR	LOE	RECOMMENDATIONS
1	C-EO	1. Screening for HBV to include serum anti-HBs, anti-HBc and HBs Ag tests should be done prior to HT.
1	C-EO	2. Non-HBV immune candidates should be vaccinated against HBV.
1	C-EO	3. Candidates with chronic HBV (HBs Ag positive, anti-HBc positive) infection should be referred to a hepatitis specialist to guide management.
2a	C-LD	4. It is reasonable for candidates with past HBV infection (anti-HBc positive, anti-HBs positive, HBs Ag negative) to undergo HBsAg and HBV DNA monitoring every 3-6 months for the first year after transplantation and be referred to a hepatitis specialist should HBsAg or HBV DNA become detectable.
2b	C-EO	5. Utilization of a donor with active HBV infection (HBsAg positive) may be considered but is associated with a risk of infection transmission. A consultation with an infectious disease specialist is recommended.
2b	C-EO	6. Utilization of a donor with isolated anti-HBc may be considered as it is associated with a very low risk of seroconversion (0.28%). Ideally, all candidates should be immunized prior to transplantation. Non-immune recipients (anti-HBs negative) receiving an organ from anti-HBc positive donor should receive antiviral prophylaxis with lamivudine for the first 12 months after transplantation. Non-immune recipients should undergo routine monitoring of liver enzymes, HBsAg, anti-HBs, anti-HBc and HBV DNA every 3 months for the first 12 months after transplantation.
1	C-EO	7. Screening for HCV should be performed in all heart transplant candidates.
1	C-EO	8. Candidates with active HCV infection should be referred to a transplant infectious disease specialist to guide management.
2a	C-LD	9. Organs from HCV viremic donors can be considered for HCV-negative patients. Due to the high rate of HCV transmission to the recipient, a plan for post-transplant treatment with direct-acting antivirals should be in place prior to transplant.
1	C-EO	10. Recipients of increased-risk donors should be monitored for HBV, HCV and HIV at 1, 3 and 12 months after transplantation.

Synopsis

Hepatitis B and hepatitis C status of the recipients and the donors need to be considered in HT. Transplant candidates should be tested and vaccinated for hepatitis B before heart transplant as appropriate (Table 10). Organs from donors with isolated positive anti-HBc should be considered as the risk of HBV infection in an immunized recipient is negligible. Transplant candidates should also be tested for hepatitis C; if confirmed to have active infection, they should be referred to a specialist for genotyping and liver assessment, as well as establishing a treatment plan preferably before transplant. Due to organ scarcity as a limited resource and to reduce wait-list time, a growing number of programs are utilizing HCV viremic donors. While the risk of HCV transmission from HCV viremic donors is high, treatment with direct-acting antivirals (DAAs) yields a very high cure rate even in the setting of immunosuppression and survival is similar to recipients of HCV-negative donors. Caution must be exerted in increased-risk donors, where recipients should be monitored for HBV, HCV, and HIV at 1, 3, and 12 months after transplantation.

Recommendation-Specific Supportive Text

- HBV screening should be done before transplantation and should include HBsAg, anti-HBs, and anti-HBc.²⁵³
- Non-HBV immune** candidates should be vaccinated before transplant to decrease the risk of developing active HBV infection after transplant.²⁵³
- In candidates with **chronic HBV infection** (HBsAg positive), additional testing including HBeAg, anti-HBe, quantitative HBV DNA, liver enzymes, and abdominal ultrasound should be done. Hepatic fibrosis assessment by liver biopsy or noninvasive methods is recommended. If treatment is indicated, preferred treatment options include entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide due to their efficacy and high barrier to resistance; therapy should be continued indefinitely pre- and post-transplantation.^{849,850} Patients with chronic HBV who did not receive treatment before transplantation are at risk of disease progression after transplantation and should be started on therapy after transplantation and continue treatment indefinitely.
- Candidates with **past HBV infection** (HBsAg negative, anti-HBc positive \pm anti-HBs positive) have a low risk of reactivation (around 5%) and do not require routine antiviral therapy. Monitoring of HBsAg and HBV DNA should be performed every 3 to 6 months for at least the first years after transplantation and therapy should be initiated if HBsAg or HBV DNA become detectable.^{253,851}
- The use of organs from **donors testing positive for HBV** may be considered to expand the donor pool. If the donor **is HBsAg positive**, there is a risk of HBV transmission to the recipient.^{852,853} Indefinite antiviral prophylaxis with ETV or TDF is recommended. HBIG for the first 6 to 12 months after transplantation may be considered if the recipient's anti-HBs titers are below 100 IU/ml.⁸⁵¹
- Utilization of **donor with isolated positive anti-HBc** in HT carries a risk of infection transmission of 2% to 5%.^{854,855} If the recipient is immunized against HBV (anti-HBs titer > 10 IU/ml), the risk of transmission is negligible, and no treatment is required.⁸⁵⁶ If the recipient is not adequately immunized against HBV, antiviral prophylaxis (with ETV, TDF, or lamivudine) is recommended for the first 12 months.^{253,851,857}
- Screening for antibodies to HCV should be done at the time of transplant assessment, with HCV RNA used to confirm active infection.^{253,858,859}
- In candidates with active HCV infection, genotyping and hepatic fibrosis assessment by liver biopsy or by noninvasive methods is recommended. Patients with chronic HCV should be referred to a hepatitis C specialist.^{860,861} Optimal timing (before or after transplant) of therapy remains controversial and must be individualized, considering access to therapy, severity of liver disease, expected wait time, and willingness to consider organs from HCV donors.^{860,861} Sofosbuvir-containing DAA regimens may be associated with symptomatic bradycardia in patients taking amiodarone. Certain DAAs significantly increase the concentration of statins and the combination should be used with caution.
- The high potency of the DAAs combined with organ shortage has led to expanding utilization of HCV donors for organ transplantation. **Organs from HCV Ab-positive/RNA-negative donors** should be considered routinely for waitlisted candidates.²⁵³ **Organs from HCV viremic donors** may be transplanted to HCV-negative recipients. Informed consent and a clear plan for post-transplant treatment should be established. The risk of HCV transmission from HCV viremic donors is nearly 100%. Treatment with DAA in recipients that seroconvert demonstrates excellent short-term outcome (cure rates ~100%), but there are limited long-term data.^{253,862,863} Optimal management and timing of DAA remains unknown but either a prophylaxis or a pre-

- emptive strategy have been proposed^{864,865} (Table 21). For transplant recipients treated with DAA, it is important to monitor for drug interactions with immunosuppression (refer to Table 22).^{860,861,864}
10. Recipients of increased-risk donors (donors who have behaviors, such as active intravenous drug use, that are at higher risk of HIV, HBV, and HCV, may yield negative viral test at the time of organ donation (eclipse period) but may harbor the infection) should be monitored for HBV, HCV, and HIV at 1, 3, and 12 months after transplantation, as they are at risk for seroconversion after transplant.^{253,858}

Table 21 Summary of Strategies for HCV Viremic Donor Management

Parameter	Prophylaxis	Pre-emptive
Objectives of strategy	DAA is initiated immediately (within a few hours) after transplantation to prevent transmission from donor to recipient	DAA is initiated when HCV infection transmission to the recipient has occurred, diagnosed by HCV RNA detection; this strategy's goal is a sustained virologic response at 12 weeks
DAA regimen	Sofosbuvir/velpatasvir (4 week) or Glecaprevir/pibrentasvir (8 wk)	Sofosbuvir/velpatasvir (12 week) or Glecaprevir/pibrentasvir (8-12 week) <i>Alternatives:</i> Ledipasvir/sofosbuvir (12 week) or Elbasvir/grazoprevir (12 week)
Advantages	Shorter duration of DAA Prevention of the onset of HCV latency Prevention of HCV-related adverse events	Knowledge of genotype Improved hemodynamic stability Less variability in drug absorption/kidney function
Disadvantages	Difficulty of administration in critically ill patients, variability in drug exposure due to early shock, renal failure, ECMO, dialysis support, upfront access to drug may be a barrier.	Adverse events related to HCV infection, extrahepatic manifestation, unknown long-term effect on allograft

Abbreviations: DAA, direct-acting antivirals; HCV, hepatitis C virus; RNA, Ribonucleic acid.

Table 22 Drug Interactions Between Immunosuppressive and Direct-Acting Antiviral (DAA) Agents

DAA agents	Interaction with tacrolimus	Interaction with cyclosporine	Interaction with mTOR inhibitor
Ledipasvir/sofosbuvir	No significant interaction	No significant interaction	Not reported
Daclatasvir	No significant interaction	No significant interaction	Not reported
Elbasvir/grazoprevir	Grazoprevir ↑ tacrolimus concentration	Cyclosporine ↑ grazoprevir concentration	↑ mTOR concentration
Sofosbuvir/velpatasvir	No significant interaction	No significant interaction	Not reported
Sofosbuvir/velpatasvir/voxilaprevir	No significant interaction	Cyclosporine ↑ voxilaprevir—not recommended	Not reported
Glecaprevir/pibrentasvir	No significant interaction	Cyclosporine ↑ glecaprevir; Cyclosporine ↑ pibrentasvir; Doses of cyclosporine > 100 mg/day are not recommended	May ↑ mTOR

Adapted from Aslam et al ISHLT expert consensus statement; mTOR, mammalian target of rapamycin.⁸⁶⁴

3.4.2.2. Coronavirus Disease 2019

Recommendations for Pre-Operative Preparation of the Patient for Transplantation: Infectious Disease Considerations: COVID-19		
COR	LOE	RECOMMENDATIONS
1	C-LD	1. Heart transplant candidates should be fully vaccinated for COVID-19 prior to transplantation.
1	C-LD	2. All potential donors should undergo universal screening by nucleic acid tests (NAT) for SARS-CoV-2. NAT should be performed within 72 hours of donation, but ideally be as close to procurement as possible. NAT results should be available at the time of organ offer.
2b	C-LD	3. The use of organs from a deceased donor with positive NAT may be used for non-lung transplantation provided the donor's death is not related to COVID-19 complication (including myocarditis or pericarditis) and there is no evidence of hypercoagulability or COVID-19 induced hyperinflammatory state.
2a	C-EO	4. The risk of SARS-CoV-2 transmission from deceased donors who test negative for SARS-CoV-2 but who have had a household contact who tested positive for COVID-19 in the last 10 days is unknown.
1	C-EO	5. Healthcare workers should adhere to local infection control guidance to minimize the risk of SARS-CoV-2 transmission during organ recovery and transplantation.
2b	C-LD	6. There is no recommendation regarding optimal peri-transplant therapies (antivirals, monoclonal antibodies) to minimize the risk of transmission to recipients of organs from donors with positive SARS-CoV2-NAT.
1	C-EO	7. All transplant candidates should undergo COVID-19 screening with SARS-CoV-2 NAT and an epidemiological questionnaire about history of disease or exposure.
3: No Benefit	C-LD	8. For candidates with new onset active COVID-19 infection, transplantation should be deferred.
2b	C-LD	9. The candidate may be reactivated on the list once the three conditions are met: 1) complete resolution of symptoms; 2) no COVID-19-related end-organ damage, and 3) >14-28 days from the onset of symptoms, considering the risk of the candidate's waitlist mortality.

Synopsis

The COVID pandemic caused by the SARS-CoV-2 virus emerged in 2019 and has dramatically impacted the landscape of organ donation and transplantation. The epidemiology of SARS-CoV-2 continues to evolve, and our knowledge base is rapidly expanding.

Recommendation-Specific Supportive Text

1. All heart transplant candidates should be fully vaccinated against COVID-19 to decrease the risk for acquiring active COVID infection while on the transplant waiting list and after transplant.⁸⁶⁶
2. All donors should be screened for known contacts with COVID-19 and for a history of known or suspected COVID-19 infection. Universal screening with nucleic acid tests (NAT) for SARS-CoV-2 is indicated for all potential donors. NAT should be performed within 72 hours of donation, but ideally be as close to procurement as possible. Upper respiratory tract sample is acceptable for nonlung donors while lower respiratory tract sample is recommended for potential lung donors. NAT results should be available at the time of organ offer.
3. Data on the utilization of extrapulmonary organs from **donors with positive SARS-CoV-2 NAT** have reported a low risk of transmission and good post-transplant outcomes.^{867–875} Donors with positive SARS-CoV-2 NAT can be found in the following scenarios:
 - a) Past resolved infection with symptom onset between 11 and 90 days prior;
 - b) Recent active infection with symptom onset between 1 and 10 days prior;
 - c) No history of infection with asymptomatic positive SARS-CoV-2 NAT.


Donors with past infection with symptom onset between 11 and 90 days previously likely have resolved infection with persistent noninfectious viral shedding and the organ can be safely used. Donors with active infection with symptom onset within 10 days are considered to have active COVID-19 infection. Similarly, donors with no history of infection who are otherwise asymptomatic with a positive SARS-CoV-2 NAT are considered to have active infection. To date, there have been 3 cases of SARS-CoV-2 transmission to lung transplant recipients from donors with negative upper

respiratory tract NAT testing but who were subsequently found to have positive NAT in a sample from the lower respiratory tract.⁸⁷⁶ On the other hand, there are no known transmissions to nonlung recipients of organs recovered from donors with positive upper respiratory or lower respiratory SARS-CoV-2 NAT results. Recipients of nonlung organs from SARS-CoV-2 polymerase chain reaction-positive donors have short-term patient and graft survival similar to those who received organs from SARS-CoV-2 polymerase chain reaction-negative donors. As such, organs from SARS-CoV-2 NAT-positive donors may be used for nonlung transplantation provided there is no evidence of hypercoagulability or COVID-19 induced hyperinflammatory state during terminal hospitalization. While the long-term allograft outcomes from donors with COVID-19 remain unknown, the decision to recover organs from donors with positive SARS-CoV-2 NAT testing should take into account the recipient's risk for mortality while remaining on the waiting list and donor factors, including severity of illness, time from symptom onset, and organ quality.⁸⁷⁷ Any transplant candidates in whom COVID-19 positive donors are being considered should undergo informed consent before transplantation.

4. The risk of SARS-CoV-2 transmission from a deceased donor who tests negative for SARS-CoV-2 but who has had close contact with a person with active COVID-19 in the last 10 days is unknown. To date, there have been no reported case of transmission from a donor in this scenario.
5. Donors with active infection are contagious and may transmit infection during an aerosol generation procedure. As such, health care workers should adhere to local infection control guidance to minimize the risk of SARS-CoV-2 transmission during organ recovery and transplantation. Eye protection and use of an N95 or equivalent respirator are recommended for aerosol-generating procedures and surgical procedures that may pose a higher risk for transmission if the patient was to have COVID-19. Additionally, all health care workers should be vaccinated against COVID-19.⁸⁷⁶
6. Currently, there is no recommendation regarding optimal peritransplant therapies (antivirals, monoclonal antibodies) to minimize the risk of transmission to recipients of organs from donors with positive SARS-CoV-2 NAT. The recommendations are subject to change based upon emerging data.
7. All transplant candidates should undergo COVID-19 screening with SARS-CoV-2 NAT and an epidemiological questionnaire about history of disease or exposure.
- 8-9. For a candidate with a recent history of COVID-19 infection or with a positive screening SARS-CoV-2 NAT, the optimal timing of transplantation remains unclear. For candidates with new onset active COVID infection, transplantation should be deferred. The candidate may be relisted once the 3 conditions are met: (1) complete resolution of symptoms; (2) no COVID-19-related end-organ damage, and (3) > 14 to 28 days from the onset of symptoms, considering the risk of the candidate's waitlist mortality.^{866,878} Transplantation within 4 weeks of COVID-19 infection is not recommended unless the risk of deferring transplantation outweighs the risk of postoperative morbidity and mortality associated with COVID-19 (Figure 6).^{879,880}

Figure 6

Heart transplantation after COVID-19. COVID-19, coronavirus disease 2019; NAT, nucleic acid tests; SARS-Cov-2, severe acute respiratory syndrome coronavirus 2.



3.4.2.3. Human Immunodeficiency Viral Infection

Recommendations for Pre-Operative Preparation of the Patient for Transplantation: Infectious Disease Considerations: HIV		
COR	LOE	RECOMMENDATIONS
1	C-EO	1. All heart transplant candidates should be screened for human immunodeficiency virus (HIV) infection at the time of listing and after possible infectious exposures.
1	C-EO	2. HIV-infected individuals with undetectable viral load and CD4 count of >200 cells/mL on a well-tolerated antiretroviral regimen should be considered for HT.
1	C-EO	3. HIV-infected candidates should be closely followed by an HIV-experienced provider for management of antiretroviral therapy and screening for HIV-associated malignancies, opportunistic infections, and the appropriate prophylaxis and treatment.
3	C-EO	4. The use of HIV+ organs for transplantation outside of research protocols is not recommended.

Synopsis

HIV-infected individuals with undetectable viral load and CD4 count > 200 cells/ml on a well-tolerated antiretroviral regimen should be evaluated for heart transplantation. If deemed appropriate transplant candidates, they should be managed by a provider experienced in the care of HIV patients. Favorable survival after transplant has been reported in carefully selected HIV-infected patients. The use of HIV+ organs for transplantation outside of research protocols is not recommended.

Recommendation-Specific Supportive Text

1. All heart transplant candidates should be screened for HIV infection using serology and/or viral load testing. Testing should be repeated after possible infectious exposures while on the waiting list.
2. Carefully selected HIV-infected individuals should be evaluated for HT. Such candidates should have well-controlled HIV with undetectable viral load and CD4 > 200 cells/ml in the 4 to 6 months before listing. There is now significant experience with favorable outcomes in the abdominal transplant setting and data demonstrate that immunosuppression regimens should be followed as per center policy and do not need to be altered based on the HIV diagnosis alone.^{881,882} Experience for cardiothoracic transplant is increasing as well showing overall comparable survival as HIV-negative patients undergoing heart transplant.^{883,884}
3. HIV-infected candidates should be closely followed by an HIV-experienced provider for specialized disease management.⁸⁸⁵ The antiretroviral regimen should ideally consist of a nonprotease inhibitor (PI) based regimen as PI have significant drug interactions with some immunosuppressives. If the candidate is on a PI-based regimen at listing, switch to a non-PI regimen should be considered if possible. If a PI-based regimen is needed based on genotypic/phenotypic resistance data, dose adjustment and close monitoring of the immunosuppressives will be needed. The HIV-infected candidate should also be assessed for prior or current opportunistic infections and HIV-related malignancies, including cryptococcal meningitis, other invasive fungal infections, disseminated atypical mycobacterial infection, tuberculosis, cytomegalovirus disease (retinitis), wasting syndrome, anal metaplasia, Kaposi's sarcoma, and lymphoproliferative disease, among others. Resolution of opportunistic infections and HIV-related malignancies needs to be documented and appropriate prophylaxis regimens implemented.
4. The use of HIV+ organs for heart transplant remains experimental, and the use of HIV+ organs for transplantation outside of research protocols is not recommended.⁸⁸⁶⁻⁸⁸⁸

3.4.3. Donor-Recipient Matching Considerations

Recommendations for Pre-Operative Preparation of the Patient for Transplantation: Donor-Recipients Matching Considerations		
COR	LOE	RECOMMENDATIONS
2a	B-NR	1. Donor-recipient height, weight, and predicted heart mass (pHM) ratio can be useful to improve donor-recipient matching.
2a	B-NR	2. For pediatric candidates, weight- and height-based matching can be effectively utilized for donor-recipient matching. It is reasonable that acceptable donor weight and height range be periodically reassessed to account for somatic growth of the pediatric candidate on the waitlist.
2b	C-LD	3. For pediatric candidates, total cardiac volume or virtual 3D fit assessment may help to safely increase the donor pool.

Synopsis

Different metrics have been used to determine appropriate matching of donors and recipients, including weight, height, predicted heart mass (pHM), and predicted lean body mass. In adults, size matching using pHM is widely accepted. In pediatrics, weight- and height-based matching are commonly utilized.

Recommendation-Specific Supportive Text

1. An accepted rule has been to advise against matching donors with body weight < 70% of recipient's weight⁸⁸⁹ due to increased 30-day and cumulative mortality.⁸⁹⁰ The adverse consequences of under-sizing have also been shown using pHM in adults, both in single-center⁸⁹¹ and multi-center database studies.^{203, 892–894} The pHM ratio, which is derived from the right and left ventricular mass equations from the Multi-Ethnic Study of Atherosclerosis, has been proposed as the optimal size parameter for donor-recipient size matching. Recipients with PH with undersized grafts by pHM are at increased risk compared to those with size matched or oversized donor hearts.^{5,6} Avoidance of undersizing might be sufficient to avoid this, as no survival benefit has been demonstrated for oversizing donors in recipients with moderate PH (PVR 2.5–5.0 Wood units or TPG 10–18 mm Hg) at either 90 days or 1 year; similarly, there was no advantage shown to oversizing female donors for male recipients with moderate PH.⁸⁹⁴ An increase in post-transplant mortality has been reported with a donor-recipient pHM ratio < 0.86. The ISHLT 2022 donor heart selection guidelines indicate donor pHM within 20% to 30% of the donor is acceptable.^{8,895,896} Sex matching may be relevant particularly in the context of donor size and/or the presence of PH in the recipient. Male recipients of female allografts have been reported to have increased 1-year and cumulative mortality compared to male recipients of male allografts.^{890,895,896} Sex mismatch may predominantly influence short-term outcomes, with no survival differences reported beyond 1 year.⁸⁹⁶ Some of the risks associated with sex mismatch can be explained by differences in heart mass in males and females of the same height and weight. Therefore, the use of pHM can be especially advantageous when a transplant with donor-recipient sex mismatch is being considered.^{8,890,893}
2. In children, donor-to-recipient weight (DRWR) and height ratio (DRHR) are commonly used to identify suitable donors. However, consideration must be given to the differences in heart size due to complex CHD vs cardiomyopathy.^{897–899} Extending the DRWR upward to 3.0 has been reported with equivalent short-term outcomes.^{8, 897–899} Caution should be exercised when accepting donors who are undersized by weight relative to the pediatric candidate, given the association with increased post-heart transplant mortality. DRHR of 0.7 to 1.2 does not increase post-transplant mortality, while DRHR > 1.2 is associated with increased 5-year post-heart transplant mortality.⁸⁹⁹ Caution should be exercised when accepting donors oversized by height for pediatric candidates. Acceptable donor weight and height ranges should be periodically reassessed to account for somatic growth of the pediatric candidate on the waiting list.
3. In children, newer imaging techniques, such as echo-derived total cardiac volume⁹⁰⁰ or virtual 3D volumetric fit assessment,^{901–903} may provide more granular detail to safely widen the donor pool for pediatric candidates.

3.4.4. Recommendations for Preoperative Preparation of Pediatric Patients for Transplantation

Recommendations for Pre-Operative Preparation of Pediatric Patients for Transplantation		
COR	LOE	RECOMMENDATIONS
1	C-EO	1. Pediatric patients with complex CHD should have optimal (typically cross-sectional) imaging to allow planning for safe re-sternotomy, cannulation and implantation strategy, and to identify unique donor organ retrieval needs.
1	C-EO	2. For pediatric patients listed for ABO-incompatible HT, isohemagglutinin titers should be closely monitored perioperatively to guide need for antibody removal and immunosuppression strategy.

Synopsis

Pediatric patients have unique preoperative considerations to optimize them for HT. Detailed knowledge of the anatomy of patients with CHD is necessary when preparing for donor organ retrieval. Patients with multiple past surgeries (e.g., complex congenital, VAD) may require earlier admission to the operative room before donor heart arrival to facilitate extensive dissection and minimize cold ischemic time.

Recommendation-Specific Supportive Text

1. Cross-sectional imaging facilitates safe sternal re-entry, surgical cannulation (e.g., need for femoral bypass), implantation strategies, and donor organ retrieval to support vessel reconstruction (e.g., aorta, PA, venous return) at transplant.^{813, 904–906}
2. For young children listed for ABO-incompatible HT, ISO titers should be sent upon acceptance of the donor organ and should be rechecked before cross-clamp removal to facilitate perioperative decision-making regarding need for ISO antibody removal strategy (e.g., need for plasma or whole blood exchange pre-/intraoperatively, type and timing of vascular access, immunosuppression strategy, need for plasma exchange postoperatively).^{446,450} Tailoring of blood products utilized is required to facilitate ABO-incompatible transplants.⁹⁰⁷

3.5. Ethical Considerations

Utility, respect for patient autonomy, and a shared decision-making process are the foundational ethical principles that create the ethical framework for listing a patient for HT. Respect for patient autonomy requires that patients be fully informed about their disease and treatment options, empowering them to refuse or consent to proposed interventions. Donor heart is a scarce resource and is a gift made to the community of patients in need, heightening the responsibility of the transplant team in the shared decision-making process and requiring the team to adhere to a higher standard to assure the heart is allocated in a way that is likely to result in significant benefit to the recipient (representing the principle of utility).^{908–910} Thus, the transplant team uses its professional expertise to set screening protocols and requirements for potential recipients to promote behaviors that increase the likelihood of successful long-term transplant outcomes. Other considerations include the physician's obligation to avoid harming the patient (the principle of "primum non nocere") and, when that is not possible, to take appropriate steps to alleviate that harm; also, consideration of a "support team" maintaining certain qualifications that correlate with successful outcomes. Heart transplant recipients are "harmed" by the physician subjecting them to immunosuppression to prevent graft rejection. Being immunocompromised places the HT recipient at increased risk of cancer and infections, many of the latter are avoidable through vaccination. Therefore, a basic requirement is that the candidate be "up to date" on range of vaccinations that are proven to be efficacious against infections that would significantly jeopardize the benefit of organ transplantation.⁹⁰⁹ The eligibility of the patient for listing is dependent on candidates' respect for and agreement to the integrity of the shared decision-making process to increase successful outcomes. The ethical framework should be adopted to clarify controversies. Thus, assessment of whether an apparent "controversial" requirement is consistent with the current standard of care and respects the integrity of the shared decision-making process to ensure successful outcomes. Areas of controversy may include vaccination or therapies for which the benefit is unknown; patient prioritization and urgent cases criticized and monitored to ensure no harm is done; and the use of medical cannabis, which requires further clarification of concerns of heightened predisposition to fungal infection or heavy use that impairs cognitive ability and that could lead to medication nonadherence.

4. TASK FORCE III: CONSIDERATIONS FOR MECHANICAL CIRCULATORY SUPPORT SYSTEMS

4.1. Scope of the Problem

4.1.1. Trends in Utilization of Durable Mechanical Support Devices

LVADs are an important treatment option for patients with AdvHF refractory to OMT, avoiding further end-organ injury, improving QOL, and prolonging survival. The last several years have been characterized by a shift in device type and indication. Advances in bioengineering have led to the introduction of durable CF LVADs with more favorable side-effect profiles, yielding progressive gains in short- and long-term survival.^{561, 911-914} In 2021, the newest technology, fully magnetically levitated CF HeartMate3, accounted for 92.7% of all CF-LVAD implants. Destination therapy (DT) is now the predominant indication in the USA, with 81.1% of patients in 2021 implanted as DT (vs 56.5% in 2018), whereas the number of implants for the BTT indication has now been nearly eliminated (5.3% in 2021 vs 18.9% in 2018).⁹¹¹ This change in BTT-DT ratio coincided with the modification in the USA heart allocation system (that lowered the transplant priority for patients on DMCS), approval of the HeartMate3 device for DT and the simultaneous growth of stand-alone DT programs, together with its improved survival and reduction in readmissions. In Europe, however, the indication for the vast majority of patients to undergo LVAD implantation remained BTT.^{915,916}

4.1.2. Waitlist Outcomes

The rate of HT remains significantly higher in the USA, as compared with most European countries.⁹¹⁷ For DMCS patients, the probability of receiving an HT at 1 and 3 years has declined after the 2018 UNOS allocation change (7.3% and 17.2%, respectively) and is comparable to data from the European Registry of 7.5% and 20.2% at 1 and 3 years, respectively.^{911,915,916} These findings underscore the improved overall adverse events profile of the currently implanted device and the lower listing priority status of the BTT patients with no to minimal device complications in the 2018 UNOS allocation policy. Despite LVAD patients being older and more ill, 1- and 5-year survival (83% and 51.9%, respectively) as well as the incidence of adverse events improved in the newer era (2017-2021).⁹¹¹ The > 50% 5-year survival after LVAD implantation confirms LVADs as serious competitor with HT.

4.1.3. Indications for Durable Mechanical Support Devices

Indications for Durable Mechanical Support Devices		
COR	LOE	RECOMMENDATIONS
1	A	1. Patients with low LVEF and AdvHF symptoms (NYHA Class IIIB-IV) refractory to maximal medical management or with inotrope dependence or on tMCS should be considered for DMCS as a bridge to transplant or candidacy or as DT (for patients who are ineligible for HT).
2a	B-NR	2. It is reasonable to consider DMCS as a bridge to recovery in patients with dilated cardiomyopathy, particularly of recent onset, and non-ischemic etiology refractory to maximal medical therapy. Pharmacological treatment should be with maximally tolerated neurohormonal modulation and surveillance for recovery of LV function should be undertaken.
2a	C-EO	3. It is reasonable to perform routine risk stratification at regular intervals to determine the need for and optimal timing of DMCS in patients with advanced systolic who do not fall into recommendations 1 and 2 above. This determination may be aided by risk assessment calculators and CPET.
2b	C-LD	4. Patients presenting with INTERMACS 1 and 2 status, with laboratory evidence of elevated bilirubin, INR, creatinine, and blood urea nitrogen and clinical manifestations of severe malnutrition, in conjunction with a hemodynamic profile of prohibitive RV failure, with elevated RA pressure and lower pulmonary artery pressure index (PAPi) may be considered for TAH or biventricular assist device (BiVAD), with the choice related to selection issues of patient size, flow demand, fit and related individual considerations.

Synopsis

Identifying the optimal timing for MCS and selection of the device remains a major clinical challenge in managing patients with AdvHF.⁹¹⁸⁻⁹²¹

Recommendation-Specific Supportive Text

1. DMCS should be considered in patients whose ventricular function is unlikely to recover or who are too ill to maintain normal hemodynamics and vital organ function without MCS. The use of LVAD in patients with AdvHF vs OMT resulted in a clinically meaningful survival benefit and improved QOL. The newest CF HeartMate3 has further reduced mortality with a 5-year survival of 58.4%.^{918,920,922-924} LVAD therapy allows patients and care providers to address modifiable risk factors for HT, especially organ dysfunction. The support provided by LVAD therapy improves end-organ function, nutritional status, PVR, and functional capacity.^{912,925,926}
2. A subset of patients may exhibit myocardial recovery after LVAD implantation, permitting weaning from the DMCS device. Myocardial recovery often presents within a 6- to 9-month period.^{912,917,925,927} Reverse remodeling with LVAD support and a standardized pharmacological regimen improved the rate of LVAD explantation.⁷⁵⁴ Independent predictors of myocardial recovery include younger age, nonischemic etiology, normal renal function, and a shorter duration of HF.^{754,917,927-931}
3. Prognostic stratification of patients with HF is important to identify the optimal timing for referral to a specialized center providing AdvHF therapies. Postimplantation survival is closely related to preimplantation clinical status. Prompt referral for DMCS implantation is, therefore, crucial. Unfortunately, no single marker enables the identification of patients at risk for deterioration; thus, regular assessment by a dedicated multidisciplinary AdvHF team is recommended.⁹³²⁻⁹³⁴
4. Patients classified as INTERMACS profiles 1 and 2 tend to have a high incidence of RV dysfunction and failure.⁹³⁵ Preimplant characteristics, such as elevated levels of creatinine, blood urea nitrogen, bilirubin, INR, and lower albumin, and prealbumin ratio in patients presenting with INTERMACS 1 reflect worsening organ perfusion implying a BiV support may be considered. A low cardiac index (< 2.2 liter/min/m²) or cardiac power < 0.6 W coupled with hemodynamic evidence of elevated central venous pressure (CVP) (> 16 mm Hg) or CVP/PCWP > 0.63 or PAPI < 1.85 in conjunction with the above clinical characteristics support the need for an upfront BiV support strategy.^{936,937} However, a thorough diagnostic work-up to identify reversible causes of BiV HF should be completed before considering any form of BiV DMCS.⁹³⁸ Patients who require BiV support tend to have a higher rate of perioperative complications.⁹³⁵ One-year survival in patients with biventricular assist device (BiVAD) remains below 60%.^{939,940}

4.1.4. Indications for Durable Mechanical Support Devices in Pediatric Patients

Recommendation for Indications for Durable Mechanical Support Devices in Pediatric Patients		
COR	LOE	RECOMMENDATIONS
2a	B-NR	1. DMCS as BTT or BTR can be considered in pediatric patients in the case of progressive decompensation with objective measures of congestion and/or inadequate cardiac output despite optimal medical therapy. Optimal timing should be determined by the assessment of the patient's risk profile and device type.

Synopsis

AdvHF is associated with high morbidity and mortality in the pediatric population.^{941,942} Hospitalization with HF increases the risk of mortality in children by 20-fold, with an overall in-hospital mortality rate of 7% to 10%.⁹⁴³ Utilization of VADs in the pediatric population has demonstrated robust growth in the past 2 decades, from 11% in 2005 to 24% in 2016.^{916,943} Among children with dilated cardiomyopathy, approximately 40% were bridged to transplant with some form of MCS, with most patients being supported with a VAD. Among children with CHD, the utilization of MCS was less common, especially among infants.^{944,945} Most devices are implanted as either a BTT or a bridge to candidacy (BTC), whereas DT remains uncommon.^{916,943}

Recommendation-Specific Supportive Text

1. During the last decade, a 50% reduction in waitlist mortality with a 4 times higher likelihood of surviving to transplantation was reported in the pediatric population.^{946,947} The overall mortality differs according to the patients' profile and device type, with significantly inferior outcomes in infants, in Pedimacs patient profile level 1, with paracorporeal continuous VADs, and with CHD.^{646,916,943,948} Preimplant kidney and liver dysfunction are associated with postimplant adverse events and mortality.^{949,950} Interestingly, outcomes of patients with single ventricle CHD were similar to those with BiV CHD.⁹⁴³ Notably, survival after HT in VAD-supported children does not differ

from that in medically supported patients.^{947,951,952} Moreover, despite being at an increased risk of sensitization pre-transplant (42% of device-supported patients becoming sensitized as opposed to 30% of medically supported patients), there is no increased risk of rejection in pediatric patients bridged to transplant with a VAD.^{947,953}

4.2. Candidate Selection for Durable Mechanical Circulatory Support

4.2.1. Patient Evaluation and Risk Factors

Recommendations for Candidate Selection for DMCS: Patient Evaluation and Risk Factors		
COR	LOE	RECOMMENDATIONS
1	A	1. All potential DMCS patients should be managed by an AdvHF team for optimization of therapies, risk assessment, and shared decision-making.
1	C-LD	2. All patients should be assessed for nutritional status prior to DMCS implantation.
1	B-NR	3. All patients should be screened for diabetes with HbA1c prior to DMCS. Patients with established diabetes should be assessed for the degree of end-organ damage (retinopathy, neuropathy, nephropathy, and vascular disease) and their diabetes management must be optimized before implant.
1	B-NR	4. In patients evaluated for DMCS, comprehensive assessment of liver function is recommended. In patients with abnormalities in liver function tests, a history of liver disease, chronic RHF, or Fontan physiology, screening for fibrosis or cirrhosis with ultrasonography or CT scan should be performed. For patients with suspected cirrhosis, further radiologic and tissue confirmation should be performed in conjunction with a hepatology consult.
1	C-EO	5. Patients should undergo an assessment of thoracic anatomy prior to DMCS implantation. The assessment should include transthoracic and/or transesophageal echocardiogram and CT/MRI imaging to facilitate identification of thoracic aorta calcifications and anatomical features.
1	C-EO	6. Candidates for DMCS therapy should be assessed for coagulopathies and hypercoagulable states.
1	C-EO	7. All patients should be screened for psychosocial risk factors prior to DMCS.
2a	B-NR	8. In patients undergoing evaluation for DMCS, it is reasonable to include an objective evaluation to assess the burden of frailty.
1	C-EO	9. A. The presence and severity of chronic lung disease should be assessed by evaluating patient-related risk factors and performing pulmonary imaging (Class 1).
2b	C-EO	B. Pulmonary function testing (spirometry) may be beneficial for screening patients with suspected lung disease (e.g., chronic obstructive pulmonary disease) for pre-operative optimization and peri-operative management (Class 2b).
1	C-LD	10. All patients considered for DMCS should have an invasive hemodynamic assessment of PVR.
1	C-LD	11. Invasive hemodynamic evaluation of the RV combined with multimodality imaging focused on quantitative parameters of RV function and tricuspid valve integrity should be performed prior to DMCS implantation. Pre-operative optimization of RV function with invasive hemodynamic monitoring is recommended.
1	C-EO	12. A. Kidney function after hemodynamic optimization should be performed in all patients being considered for DMCS. For patients with decompensated HF and severe kidney dysfunction, initial hemodynamic support with inotropes and/or tMCS to assess the potential of kidney recovery before implanting DMCS should be performed (Class 1).
2a	C-LD	B. Patients with severe kidney dysfunction can be carefully selected for DMCS (Class 2a).
2b	B-NR	C. DMCS as a bridge to SHKT may be considered in carefully selected patients with a plan for long-term hemodialysis in an experienced center (Class 2b).

Synopsis

A comprehensive evaluation of the patient for DMCS and preoperative optimization using a multisystem approach prepares the patient for the best outcome. Nevertheless, emergency situations may occur, precluding the ability to perform a thorough or ideal evaluation. Preoperative risk scoring systems have been used to prognosticate postoperative outcomes, but their guidance yields less help in preoperative organ optimization. Although the algorithms are helpful, they cannot replace experienced clinical judgment.^{933,954–959} Psychosocial assessment specific to patients under consideration for MCS is detailed in the 2018 ISHLT/Academy of Psychosomatic Medicine/American Society of Transplantation/International Consortium of Circulatory Assist Clinicians/society for Transplant Social Workers (ISHLT/APM/AST/ICCAC/STSW) recommendations for the psychosocial evaluation of adult cardiothoracic transplant candidates and candidates for long-term MCS.⁶

Recommendation-Specific Supportive Text

1. Potential DMCS candidates should be managed by a dedicated AdvHF team for optimization of therapy, comprehensive risk assessment, and early facilitation of shared decision-making to define goals of care as well as education regarding therapeutic options, including MCS and transplant when appropriate. Continuous assessment by a dedicated team is aimed at reducing the probability of patients' deterioration to cardiogenic shock and multiorgan failure.^{922,923,960,961}
2. Routine evaluation for candidacy for DMCS should include nutritional assessment and consultation with a nutritional support team.^{962–966} Improvements in albumin following DMCS implantation have been associated with improved outcomes, but the impact of active nutritional intervention is unknown.^{954,967}
3. Diabetes has been associated with infection and late mortality in LVAD patients.^{968–972} Poor perioperative glycemic control is predictive of high mortality^{973–975}; therefore, optimization of diabetes management before implantation of DMCS is warranted. Although preoperative HbA1c has not been specifically associated with mortality or adverse events, it may be a practical laboratory test to assess overall glycemic control before surgery.
4. Preoperative liver dysfunction is associated with worse survival and adverse events, including the onset of RV failure, acute kidney injury, and bleeding.⁹⁷⁶ The reversibility of liver injury following LVAD implantation and the precise characterization of patients with liver dysfunction who will benefit from treatment with DMCS are yet to be assessed. For example, it was suggested that liver fibrosis might not negatively affect survival following LVAD implantation, and more studies are warranted to determine the impact of liver biopsy characteristics on LVAD outcomes.⁹⁷⁷ Biochemical markers of liver disease and scores, such as MELD XI, are promising prognostic tools for risk stratification in the LVAD population. Yet, robust validation in prospective randomized studies is needed. Patients with cirrhosis or end-stage liver disease are poor candidates for DMCS.^{978,979}
5. Assessment of intrathoracic anatomy is essential. Transthoracic and/or transesophageal echocardiogram provide information regarding cardiac geometry, ventricular size, protruding apical thrombus, and concomitant valvular disease or septal defects. CT imaging allows visualization of anatomical features that affect cannulation strategy, thus optimizing surgical planning. In the setting of prior cardiothoracic surgery, special attention should be paid to the distance to heart/major vessels/sternum.⁹⁸⁰ Special efforts should be made to improve surgical techniques to preserve the native anatomy in case of re-entry for HT, myocardial recovery, or device explant.^{981,982}
6. Evaluation of factors predisposing to bleeding or thrombotic events should be performed before implantation of DMCS to optimize outcomes. Patients with a history of thrombophilia should undergo hypercoagulable assessment before DMCS. To minimize the risk of bleeding, coagulation abnormalities should be corrected. Continuing P2Y12 receptor inhibitors until the operation increases the risk of bleeding, transfusions, and re-exploration for bleeding.^{983–987} It is recommended to discontinue DOAC and thienopyridine antiplatelet agents before elective DMCS implantation.
7. All DMCS candidates should undergo a comprehensive psychosocial evaluation.^{6,988} The goals of the evaluation are to assess risk factors for poor postimplantation outcomes; collect information on factors related to patients' knowledge, understanding, and capacity to engage in decision-making about DMCS; collect information to characterize patients' personal, social, and environmental resources and circumstances, including factors that may mitigate the impact of any psychosocial risk factors on postimplantation outcomes; and evaluate patients' knowledge about and capacity to operate the device.⁹⁸⁹
8. Given its significant impact on postsurgical morbidity and mortality, assessment of frailty is gaining increasing attention as part of the patient evaluation for DMCS.^{990–992} Since frailty is partly attributed to underlying HF, it has been suggested that some of the FPs may be modifiable with implantation of an LVAD—the LVAD “responsive” patient.^{265,266}
9. In patients with suspected pulmonary disease, evaluation with CT or MRI is reasonable. The incremental additive value obtained by spirometry in patients undergoing LVAD surgery is limited. In special circumstances, such as in

planned off-pump LVAD implantation through a left lateral thoracotomy and with the need for single lung ventilation, preoperative measurements of forced expiratory volume in 1 second (FEV1) and DLCO can help in planning the operative procedure.

10. Durable LVADs have been successfully used in patients with refractory elevated PVR. Several studies have demonstrated that LVAD therapy can effectively reduce left-sided filling pressures and improve PH.^{181–184,993–997} A reduction in PVR may be seen as early as 1 month post-VAD implantation. However, it may take as long as 3 to 6 months, or even more, to achieve maximum reversibility.^{181,996} Once PVR reversal is achieved, long-term post-transplant survival in patients bridged with an LVAD is comparable to that of HT recipients without PH.^{186,998,999}
11. RV failure before LVAD implantation is associated with a 3- to 4-fold increase in mortality after LVAD implant.^{1000,1001} Post-LVAD RV dysfunction can impair LVAD performance due to decreased preload, leading to low QOL and functional status. Echocardiographic evaluation is limited by the complex geometry, preload dependence and retrosternal positioning of the RV. Standard quantitative parameters, such as TAPSE, RV-FAC, and tricuspid annular systolic velocity, are load and angle-dependent and are of limited value. New techniques, such as RV strain, 3D imaging, and deep-learning algorithms, are emerging.^{1002,1003} Cardiac MRI remains the gold-standard method for assessing function and performance and for volumetric assessment of RV function.^{1004,1005} RV hemodynamics should be evaluated via RHC within 1 to 2 weeks before surgery in elective cases or preoperatively in the ICU with a PA catheter in patients deemed euvolemic and optimized.^{1006,1007} A goal of CVP of ≤ 12 to 15 mm Hg should be achieved before LVAD implantation. Patients with refractory BiV dysfunction, despite OMT, may be considered for ECMO or planned BiVAD implantation.^{1008,1009}
12. Kidney dysfunction before LVAD implantation is associated with increased morbidity and mortality in post-operative DMCS patients, and hemodialysis before DMCS is associated with dismal outcomes.^{921, 1010–1014} Careful selection of patients with severe renal dysfunction (CKD Stage IV-V), combined with applying a comprehensive strategy that focuses on preoperative maximization of renal function (including tMCS), can result in acceptable postoperative outcomes.^{1015–1017} Patients undergoing SHKT in the modern era with pre-transplant DMCS have equivalent survival to those undergoing SHKT without DMCS.^{1018–1021}

4.2.2. Pediatric Patients

Recommendations for Candidate Selection for DMCS: Pediatric Patients		
COR	LOE	RECOMMENDATIONS
1	C-EO	1. It is recommended to have recent documentation of cardiac morphological and ventricular physiological data, including the presence of shunts, collateral vessels, and the location and course of great vessels in pediatric patients undergoing evaluation for MCS.
1	B-NR	2. Pediatric patients should undergo a pre-implant evaluation, including an assessment of end-organ function, surgical planning, and psychosocial and neurocognitive assessment. It is beneficial that MCS evaluation be performed early before the progression of end-organ dysfunction.

Synopsis

Device selection in children differs significantly from that in adults with anatomically normal hearts and varies substantially among pediatric groups, depending on age and the type of CHD of the patient.^{1022–1025}

Recommendation-Specific Supportive Text

1. The optimal surgical technique depends on the device and the patient's unique characteristics. In all pediatric MCS patients, determination of the presence of intra- and extracardiac shunts is required.^{1017,1022,1026–1028} Large-scale studies on the use of MCS in patients with a single ventricle are lacking. The feasibility of VAD support for Glenn circulation has been reported with mixed results.^{1029–1031} For patients with failing Fontan circulation, TAH might be considered.¹⁰³²
2. Pediatric patients with cardiogenic shock who undergo DMCS implantation exhibit worse outcomes.^{646,984,1025,1033} Nevertheless, recent reports from Pedimacs and Paedi-Euromacs registries reveal that 27T to 32% of pediatric patients were INTERMACS 1 or had end-organ dysfunction at the time of the implant.^{646,984} Approximately 20% of patients had eGFR < 60 ml/min/1.73 m².^{984,1025} Abnormal bilirubin was found in up to 36.5% of children at the time of VAD implantation, and elevated hepatocellular enzymes were reported in 22% to 25%.^{646,984,1025} The use of mechanical ventilatory support was reported in up to 55% of

patients, with lower incidence in a subgroup of children assisted with intracorporeal CF-VADs.^{646,984,1025} The use of tube feeding or parenteral nutrition was also common.^{1013,1014} A thorough patient and family psychosocial assessment is critically important. The goal is to identify patient and family strengths, weaknesses, and intervention needs, particularly as they relate to VAD care demands. Primary domains of the pre-VAD psychosocial evaluation should include patient and family treatment adherence, barriers to medical management, disease, VAD-related knowledge, cognitive and/or neurodevelopmental functioning, current and historic mental health, substance use, social support, family functioning, and abuse and legal history.^{1033,1034}

4.3. Surgical Planning and Operative Considerations in Transplant Candidates Bridged With Durable Mechanical Circulatory Support

Recommendation for Surgical Planning and Operative Considerations in Transplant Candidates Bridged with Durable Mechanical Circulatory Support		
COR	LOE	RECOMMENDATIONS
1	C-EO	1. HT in patients with DMCS should be performed by a dedicated and experienced transplant team.
1	C-EO	2. In transplant candidates with DMCS, a CT scan of the chest and the entire aorta is recommended to guide chest reentry. The following elements need special attention: - Position of the outflow graft - Position of the driveline - Calcifications of the ascending aorta - Alternative vascular access routes.

Synopsis

HT following DMCS explant is a longer and more technically complex procedure that necessitates redo-sternotomy and careful outflow graft, driveline, and pump excision.¹⁰³⁵

Recommendation-Specific Supportive Text

1. Preoperative planning is vital to ensure successful HT in this population. Contemporary pumps are associated with significant adhesions at the left ventricular apex site, particularly if the pump is not well covered at the time of primary implant. The growing adaption of less invasive implant techniques may significantly reduce the complexity of subsequent HT. Centers that routinely perform less invasive DMCS implantations report reduced surgical complexity and bleeding and blood product used during HT.^{1036–1039}
2. A preoperative CT scan of the chest and the aorta should be available in all patients before HT.^{1040,1041} The CT scan aids in planning resternotomy and vascular access. It reveals potential hazards, including proximity of the outflow graft or driveline to the sternum and calcifications in the ascending aorta and alternative vascular access routes.^{1042,1043}

4.4. Complications of Durable Mechanical Circulatory Support and Their Implications for Candidacy

4.4.1. General Considerations

Recommendations for Complications of Durable Mechanical Circulatory Support and Their Implications for Candidacy: General Considerations		
COR	LOE	RECOMMENDATIONS
1	C-EO	1. In patients with DMCS, candidacy for HT must be assessed longitudinally during follow-up regardless of the intended strategy (BTT, BTC, DT).
1	C-EO	2. Occurrence of a life-threatening complication in transplant candidates supported with a DMCS warrants evaluation for urgent HT.
1	C-LD	3. Occurrence of device-specific, device-related, or patient-related adverse events refractory to conventional medical or surgical treatment in transplant candidates with DMCS warrants evaluation for urgent HT.
3: Harm	C-EO	4. The presence of an irreversible clinical condition that might impair post-transplantation survival (e.g., disabling stroke) in patients with DMCS should preclude HT.

Synopsis

Over the last several years, there has been a significant decline in the early and late adverse events after the DMCS implant.⁹¹¹ The outcomes of the HeartMate3 have been superior to any previous devices, particularly regarding pump thrombosis and stroke.^{1044,1045} Nonetheless, because the duration of LVAD support increases, so will the possibility of adverse events. However, long-term follow-up data in patients supported with HeartMate3 LVAD are limited.^{912,1046} Using the UNOS database, it was suggested that bridge to HT with LVAD confers higher early mortality.¹⁰⁴⁷ These findings were recently expanded demonstrating that post-transplant survival of patients bridged with a HeartMate3 remains inferior in the postallocation era.¹⁰⁴⁶ Whether this phenomenon is related to device-related adverse events remains unknown. Certain device-associated complications may render patients at higher risk for HT. Specifically, patients with chronic RHF and device infections are at high risk for perioperative vasoplegia, excessive bleeding, postoperative multiorgan failure, and infections. As such, these higher-risk patients should be even more carefully optimized and consideration regarding the best timing for surgery. Patients with hemocompatibility-related adverse events remain good transplant candidates, except for those with disabling strokes.

Recommendation-Specific Supportive Text

- 1. Strategy designations at the time of device implant are fluid, as the patient's candidacy for transplantation may change over time. About half of patients being implanted as BTT are listed for transplantation at the time of DMCS implant, and only 30.4% are transplanted at 1 year following implant.⁹¹¹ Among patients implanted as BTC and DT, 15.9% and 4.7% are transplanted at 1 year.⁹¹¹
- 2. Life-threatening complications (e.g., intractable ventricular arrhythmias, severe RHF) in patients with DMCS refer to several clinical scenarios in which patients are at high risk of dying or have an irreversible complication. Patients remain sufficiently ill to warrant ongoing hospitalization and must continue to be deemed transplant candidates. The development of complications refractory to medical or surgical treatment warrants an evaluation for urgent HT. In several allocation systems worldwide, DCMS complications in transplant candidates qualify for prioritization for HT.
- 3. Severe adverse events (e.g., pump thrombosis, device infection, gastrointestinal bleeding (GIB)) are associated with increased mortality following DCMS implant.¹⁰⁴⁸ The only curative treatment for most device-specific and device-related adverse events is pump removal and HT. If the transplantation team is of the opinion that (1) a revision or exchange of the VAD will be too high risk, or (2) if the risk of death before HT exceeds the risk of post-transplant mortality, then an urgent transplant should be considered with or without temporary support.
- 4. Patients with DMCS and severe adverse events that could justify prioritization for HT but who have an irreversible clinical condition (e.g., disabling stroke, irreversible end-organ dysfunction) that will impair post-transplantation survival should not have their transplant prioritization changed and should be disqualified as candidates for HT.

4.4.2. Gastrointestinal Bleeding

Recommendations for Complications of Durable Mechanical Circulatory Support and Their Implications for Candidacy: Gastrointestinal Bleeding		
COR	LOE	RECOMMENDATIONS
2a	C-EO	1. For patients with DMCS and refractory gastrointestinal bleeding (GIB) who are deemed candidates for HT, when the expected wait time is short, it is reasonable to consider urgent HT to decrease the burden of blood transfusion.
2b	C-EO	2. In the setting of recurrent and refractory mucocutaneous bleeding with no identified source or a source that is not amenable to therapy, it may be reasonable to consider prioritization for HT.

Synopsis

Bleeding complications are the most frequent hemocompatibility-related adverse events in LVAD recipients, most frequently in the form of mucocutaneous bleeding events.^{11, 1048–1050} Of mucocutaneous bleeding, GIB is the most common complication, occurring in 15% to 30% of patients on LVAD support.⁵⁶¹ In patients who suffer an initial mucocutaneous bleeding event, recurrence can be encountered in 30% to 40% of patients on LVAD support. GIB in patients on CF-LVAD support is most commonly the result of nonreversible conditions leading to arteriovenous malformations developing in the gastrointestinal tract.¹⁰⁵¹

Recommendation-Specific Supportive Text

1. There are currently no robust data to support the safety or efficacy of HT in patients with refractory GIB. However, bleeding is often accompanied by the need for transfusions, which is associated with important clinical implications. First, previous cardiac surgery studies suggest that blood transfusion induces an immunosuppressive state that can contribute to the development of nosocomial infections.^{1052,1053} Second, blood transfusions have been associated with pulmonary insufficiency.¹⁰⁵⁴ Transfusion-associated lung injury is thought to be induced by passive transfusion of complement-activating antibodies. These antibodies may be particularly troublesome to DMCS recipients awaiting transplantation due to an increased risk of allosensitization and elevated PRAs. Thus, focused efforts must be devoted to minimizing GIB and the need for transfusion.
2. Before considering urgent HT for DMCS patients with recurrent GIB, the transplant team should ensure that the cause of GIB is related to the CF-LVAD support. Investigation should be undertaken to identify the source of bleeding, and all medical therapies should be exhausted in collaboration with a gastroenterologist before HT consideration.

4.4.3. Pump Thrombosis

Recommendations for Complications of Durable Mechanical Circulatory Support and Their Implications for Candidacy: Pump Thrombosis		
COR	LOE	RECOMMENDATIONS
2a	C-EO	1. In transplant candidates with confirmed device thrombosis who are hemodynamically stable and the expected wait time for a HT is short, it is reasonable to defer the pump exchange for urgent transplantation if the patient is otherwise a suitable candidate.

Synopsis

Device thrombosis refers to the progression or de novo development of a clot within the pump's flow path, including the inflow cannula, the mechanical rotor, or the outflow graft.¹¹ Pump thrombosis is associated with a high rate of morbidity (hemolysis, bleeding, ischemic, and hemorrhagic strokes) and increased mortality¹⁰⁵⁵ despite therapeutic anticoagulation.^{1056–1058} The newest generation CF-LVAD HeartMate3 has significantly lower rates of pump thrombosis than the earlier generation of heart pumps.⁹¹⁸

Recommendation-Specific Supportive Text

1. Patients for whom device exchange is deemed necessary should also be considered for HT or decommissioning (or removal), if they are hemodynamically stable and without disabling embolic phenomena. HT should receive additional consideration specifically if the expected wait time is short⁹³⁷ and ventricular recovery is unlikely. It should be noted that recurrent device thrombus rates after device exchange are higher with replacement pumps.^{1059,1060} In this regard, the initial experience with device exchange from HeartMate II or HVAD to a HeartMate 3 has been promising, with lower recurrent device thrombosis rates.¹⁰⁶¹ This decision should be individualized based on patient factors, surgical expertise, and local jurisdiction.

4.4.4. Right Heart Failure

Recommendations for Complications of Durable Mechanical Circulatory Support and Their Implications for Candidacy: Right Heart Failure		
COR	LOE	RECOMMENDATIONS
1	C-LD	1. Transplant candidates who remain dependent on a temporary RV device or inotropic support because of early moderate/severe RHF despite optimal management following DMCS implantation should be considered for urgent HT.
1	C-LD	2. In transplant candidates supported with a DMCS who present progressive late post-implant RHF despite optimal management, prioritization or urgent HT should be considered.
2b	C-EO	3. Pulmonary hypertension-specific therapies might be considered for acute therapy in patients with persistent PH who exhibit signs of RHF and have failed conventional medical therapy.

Synopsis

New or progressive RHF occurring in patients following LVAD is associated with an increased risk of GIB, renal failure, more frequent hospitalizations, lower QOL and functional capacity, and decreased survival.^{1012, 1049, 1062–1066} RHF occurring after the operative LVAD period, “**late post-implant RHF**,” can result from worsening of pre-existing pre- or postoperative RV dysfunction or can occur de novo in those with presumed normal preoperative right heart function. **Early RHF** can manifest as “**early acute**” (need for right ventricular assist device (RVAD) implant concomitant with LVAD) or “**early postimplant RHF**” (need for temporary or durable RVAD or ECMO within 30 days of LVAD implant, failure to wean off inotropes or inhaled pulmonary vasodilators within 14 days, or death due to RV failure).¹⁰⁴⁹ Management of patients with DMCS and RHF is outlined in the 2023 ISHLT guidelines for MCS.¹¹

Recommendation-Specific Supportive Text

1. The risk of complications and death is high in patients with DMCS and severe **early RHF** (dependent on RVAD support or inotropic support). The increased risk of death associated with RHF is markedly attenuated following HT, with post-transplant survival similar to that in non-RHF patients.¹⁰⁶⁷ Thus, urgent HT should be considered for persistent severe early RHF despite optimal management.
2. In transplant candidates supported with a DMCS, **late postimplant RHF** is associated with significantly higher mortality. Late RHF can develop in the setting of complications that lead to volume loading (e.g., bleeding), hypoxia (e.g., pneumonia), or stimulation of the systemic inflammatory response system (e.g., infection) with concomitant hypotension and/or renal malperfusion. De novo late postimplant RHF could be the result of pulmonary embolism, acute hypoxic respiratory failure with ARDS, or excessive LVAD speeds causing LV suction and septal shift. A thorough investigation should be undertaken to look for reversible resources for RHF.¹¹
3. PH-specific therapies, such as PDE5 inhibitors, might be considered for acute therapy in patients with persistent PH who exhibit signs of RHF and have failed conventional medical therapy, although the effectiveness of these therapies is unclear.¹⁰⁶⁸

4.4.5. Infection

Recommendations for Complications of Durable Mechanical Circulatory Support and Their Implications for Candidacy: Infection		
COR	LOE	RECOMMENDATIONS
1	C-EO	1. HT is the definitive cure for deep driveline infection (infection deeper than subcutaneous fascia) or pocket/ pump/ cannula infection.
1	C-EO	2. Patients with recalcitrant infection should be considered for transplant listing.
1	C-EO	3. At the time of transplant, it is important to remove all hardware (including defibrillators or pacemakers) and any infected tissue.
2a	C-EO	4. In the setting of any prior driveline or pump infection, administration of systemic pathogen-specific antibiotic therapy initiated preoperatively and continued for approximately four to six weeks after HT can be beneficial.
2a	C-LD	5. After transplantation and removal of infected LVAD (or total artificial heart), extensive irrigation with an antibiotic solution at the time of transplant and prolonged drainage can be useful to prevent recurring mediastinal infection.
3: Harm	C-EO	6. Patients with severe sepsis shock secondary to a device-related or specific infection should not be transplanted until end-organ functions recover and the sepsis is controlled.

Synopsis

The most common adverse event in the early and late periods after CF LVAD implant is major infection (early, 1.30; late, 0.43 events per patient-year).⁹¹¹ Infection following DMCS implant (DMCS-specific and/or DMCS-related infections)^{1049,1069} carries a high burden of morbidity and mortality, with a 3-fold risk of death compared to noninfected patients.^{1070–1075} Management of DMCS-specific and related infections is detailed in the 2023 ISHLT guidelines for MCS.¹¹

Recommendation-Specific Supportive Text

- 1-2. The only curative treatment for pump-specific infection is the removal of all device components. Patients with DMCS infections who are not transplanted have poor outcomes (55% and 34% survival at 1 and 2 years, respectively).¹⁰⁷⁶ Nonetheless, the impact of DMCS infection on HT outcomes is not well established. Studies from high-volume centers showed good outcomes following transplantation, with only a few

infections relapse.^{1047,1077,1078} Still, a meta-analysis suggested that LVAD-related infections result in a 30% increase in post-transplantation mortality.¹⁰⁷⁹ Thus, in transplant candidates with pump-specific or related infection refractory to conventional therapies, prioritization or urgent HT should be considered.

3. To reduce the risk of recurrence of infection after transplantation and during immunosuppression, it is important to remove the whole system and not leave any pump parts or pieces of graft behind at the time of device explant. All precautions to avoid any intraoperative contamination should be taken.^{1069,1080}
4. When transplanting a patient with a DMCS infection, administration of systemic pathogen-specific antibiotic therapy initiated preoperatively and continued postoperatively for 4 to 6 weeks can be an effective means to prevent any infection relapse.^{1069,1081}
5. After transplantation and removal of infected LVAD (or TAH), extensive irrigation with antibiotic solution at the time of transplant and prolonged drainage can be useful to prevent recurring mediastinal infection.⁹³⁷
6. Patients with active infections often develop a systemic inflammatory response that leads to other organ dysfunctions,¹⁰⁸² which can preclude a patient from being transplanted. Before transplanting a patient with a device-related or device-specific infection, the sepsis must be controlled, and all the end-organ functions must recover to ensure optimal outcomes following HT.¹⁰⁸³

4.4.6. Neurological Complications

Recommendations for Complications of Durable Mechanical Circulatory Support and Their Implications for Candidacy: Neurological Complications		
COR	LOE	RECOMMENDATIONS
2b	C-EO	1. In transplant candidates with DMCS and a history of non-disabling neurological complications, it might be reasonable to consider non-urgent HT.
3: Harm	C-EO	2. Patients with DMCS and a history of disabling neurological complications should not be transplanted.

Synopsis

Neurological complications are common adverse events seen in patients with DMCS and are strongly associated with disability, impaired QOL, and mortality.^{11,1048,1049,1084–1087} Stroke rates are highly dependent on the device model, with the lowest frequencies noted in those on HeartMate 3 support (10% at 2 years), and can be either ischemic or hemorrhagic in etiology.^{913,1088,1089} Other risk factors for stroke include patient age (older patients are at a greater risk of ischemic stroke; younger patients are at a greater risk of hemorrhagic stroke), female sex, prior history of cardiovascular disease, anticoagulation dysregulation, device complication (device thrombosis, infection, root thrombus), and systemic hypertension.^{1088,1090}

Recommendation-Specific Supportive Text

1. There is a sparse amount of literature and no previous specific recommendations regarding the decision to transplant a patient with neurological complications secondary to DMCS. However, the type and location of the neurological event and the clinical status of the patient often dictate management. In this setting, eligibility for HT assessed by a multidisciplinary team, including neuro specialists, might be considered.
2. HT should not be performed in DMCS patients with a history of disabling stroke and neurological complications. The risks associated with HT surgery for patients after disabling stroke and neurological complications are potentially harmful.

4.4.7. Ventricular Arrhythmias

Recommendations for Complications of Durable Mechanical Circulatory Support and Their Implications for Candidacy: Ventricular Arrhythmias		
COR	LOE	RECOMMENDATIONS
1	C-EO	1. DMCS patients with refractory ventricular arrhythmias leading to device malfunction, RHF, hemodynamic compromise, or implantable ICD shocks for electrical storm should be prioritized for HT.
2a	C-LD	2. DMCS patients with refractory, hemodynamically unstable ventricular tachyarrhythmias can be considered for ablation therapy by an experienced electrophysiologist prior to an urgent listing for HT.

Synopsis

Refractory sustained VTA that persist despite best attempts at medical suppressive therapy and electrophysiological ablation occur in 20% to 50% of DMCS recipients, and may lead to RHF and portend poor outcomes, especially in nonischemic cardiomyopathy.^{11,1091,1092}

Recommendation-Specific Supportive Text

1. Transplant candidates with DMCS and refractory VTA leading to device malfunction, RHF, hemodynamic compromise or persistent ICD shocks for electrical storm should be prioritized for urgent HT.
2. Catheter ablation for VTA can be safely and effectively performed in patients with LVAD, although LVAD-specific intricacies must be considered. Epicardial mapping and ablation after LVAD are complicated because of the presence of adhesions, and alternative strategies to target epicardial substrate should be considered. Intraoperative VTA ablation during LVAD implantation can be effective in high-risk HF patients who present with a high VTA burden before LVAD placement. Additional studies are needed to identify the optimal intraoperative mapping modalities and ablation strategies for intraoperative VTA intervention during LVAD implantation.^{1093–1095}

4.4.8. End-Organ Dysfunction

Recommendations for Complications of Durable Mechanical Circulatory Support and Their Implications for Candidacy: End-Organ Dysfunction		
COR	LOE	RECOMMENDATIONS
1	C-EO	1. Transplant candidates with DMCS and acute end-organ dysfunction before device implant should be monitored closely to assess end-organ function recovery.
1	C-EO	2. In patients with DMCS and acute end-organ dysfunction and otherwise suitable for transplantation, efforts should be made to optimize organ function recovery before listing for HT.

Synopsis

End-organ dysfunction secondary to decreased perfusion and venous congestion is frequent in AdvHF patients requiring DMCS.^{1096,1097} A benefit of LVAD therapy is the improvement in end-organ function to allow reappraisal of transplant eligibility. The positive influence of LVAD therapy in end-organ recovery appears to take place early during the postoperative course, within the first 1 to 3 months after implant, which can influence the duration of LVAD support and the timing of listing.⁹¹² In patients with chronic end-organ dysfunction, recovery following DMCS implantation is less predictable and depends on the etiology and underlying mechanism.

Recommendation-Specific Supportive Text

1. A close follow-up of all organ function is recommended in patients with DMCS, regardless of the intended implant strategy.¹¹ In transplant candidates, organ recovery might impact transplant eligibility and the timing of listing or prioritization for HT.
2. To optimize post-transplant outcomes and organ utilization, transplant candidates with DMCS and renal and/or hepatic dysfunction should have a period of hemodynamic optimization (with inotropic and/or tMCS if clinically indicated) with the goal of volume optimization, before being transplanted.^{1096,1098}

4.4.9. Complications of DMCS and Their Implications for Candidacy in the Pediatric Population

Recommendations for Complications of Durable Mechanical Circulatory Support and Their Implications for Candidacy: The Pediatric Population		
COR	LOE	RECOMMENDATIONS
1	C-LD	1. In pediatric patients with hepatic and/or renal dysfunction prior to DMCS implant, evaluation of its severity and reversibility is recommended before HT.
2b	C-EO	2. Although effectiveness is unknown, simultaneous heart-liver or SHKT transplantation might be considered in selected children with DMCS and persistent significant liver or kidney dysfunction, in high-volume centers with expertise in multi-organ transplantation.
2b	C-EO	3. Urgent transplantation may be considered in pediatric transplant candidates with DCMS and life-threatening device-related or specific complications that cannot be successfully treated medically or surgically.

Recommendation-Specific Supportive Text

- Children with underlying liver disease may face higher operative mortality and should be evaluated carefully by an experienced multidisciplinary team. The MELD-XI score has been shown to stratify the mortality risk of pediatric patients undergoing HT.^{402,1099} In an analysis of the Pedimacs registry, patients with increasing or continued high MELD-XI scores early following DMCS implant had the worst survival.⁶⁴⁷ Renal dysfunction is an independent risk factor for waiting list mortality in children, with or without MCS.¹¹⁰⁰ Although a minority of children have persistent acute kidney injury following DMCS,¹¹⁰¹ the extent and rate of recovery of renal function are difficult to predict and depend on the extent of renal damage before DCMS initiation. Improvement of renal function, usually observed within a few weeks, is associated with a better post-transplant survival.^{1100–1102} Failure to normalize renal function 30 days following DMCS implant is highly associated with CKD,¹¹⁰⁰ prolonged hospital stay,¹¹⁰³ and decreased survival after HT.¹¹⁰²
- Only very few children or adults with CHD who underwent simultaneous heart-liver transplantation had DMCS at the time of transplantation.^{227,1104} Similarly, there is limited evidence of the benefit of a SHKT in pediatric patients with DMCS.¹¹⁰⁵ More data are needed to define thresholds of liver and kidney disease that should preclude HT alone, especially in the pediatric population.
- Adverse events in children with DMCS are frequent and associated with increased morbidity and mortality.¹¹⁰⁶ Several studies showed similar post-transplant survival in DMCS and non-DMCS children,^{945,1107,1108} but the impact of each type of adverse event on HT outcomes remains unknown.

4.5. Considerations for Patients With Temporary Mechanical Circulatory Support

Recommendation for Indications and Eligibility for Heart Transplantation in Patients with Temporary Mechanical Circulatory Support		
COR	LOE	RECOMMENDATIONS
1	C-LD	<ol style="list-style-type: none"> Patients in cardiogenic shock refractory to medical therapy supported with tMCS* (right, left, or biventricular) should be considered for urgent HT: <ul style="list-style-type: none"> If there is a high likelihood that heart function will not recover If they are otherwise deemed suitable for HT If another option for DMCS or cardiac replacement is not appropriate If the anticipated waiting time is short When hemodynamic parameters are stabilized When end-organ functions recovered if initially impaired In experienced centers.
1	C-LD	<ol style="list-style-type: none"> In patients with tMCS, indication and eligibility for urgent HT should be assessed promptly by a dedicated and specialized multidisciplinary team.
1	C-EO	<ol style="list-style-type: none"> A thorough assessment of the neurological status must be performed before considering urgent HT in transplant candidates with tMCS.
3: Harm	C-EO	<ol style="list-style-type: none"> Patients with tMCS and ongoing end-organ dysfunctions should not be considered for HT alone until recovery or demonstration of the reversibility before HT.

*tMCS support refers to intra-aortic balloon pump, veno-arterial membrane oxygenation, percutaneous microaxial rotary pump, percutaneously or surgically implanted external centrifugal or pulsatile pump.

Synopsis

With the increasing use of tMCS in patients with refractory cardiogenic shock, the BTT strategy with tMCS (BTT-tMCS strategy) is expanding.⁸⁰ Depending on the country, the allocation system, and the type of device, the proportion of heart recipients with tMCS at the time of transplantation varies from almost zero to 25%.^{80,88,1109,1110} These numbers have increased with the change in the allocation system in the USA, favoring tMCS for urgent status prioritization.¹¹¹¹ This subpopulation represents the sickest patients with the highest risk of death before HT and patients for whom HT may provide a survival benefit.¹¹¹⁰ Therefore, patients with tMCS are allocated to the highest priority status in most allocation systems (Table 23). However, the optimal balance between the risk of imminent death and good outcomes after HT is difficult to define. Contemporary, retrospective observational studies analyzing the effect of tMCS on survival after HT have produced mixed results.^{1110–1118} The clinical status, comorbidities, and end-organ function recovery at the time of HT highly impact post-transplant survival rates in

this population. The success of the BTT-tMCS strategy also relies on donor availability, the local allocation system, and the center's expertise.

Recommendation-Specific Supportive Text

1. Most allocation systems across the world prioritize patients with the highest risk of early death, including patients with tMCS. However, selection criteria vary among countries and teams, and more work is needed to define appropriate candidates for BTT-tMCS. The BTT-tMCS strategy has been shown to be safe and effective in some studies,¹¹²⁴ but the appropriateness of the use of tMCS in this setting and its effect on post-transplant survival remain controversial.^{1116,1125,1126} Importantly, variability in survival following HT and BTT-tMCS has been observed, ranging from 50% to 90% at 1 year.¹¹¹³ An analysis of a large international cohort of patients BTT with MCS identified ECMO and percutaneous temporary LVADs as predictors of mortality after transplant.¹¹¹⁸ Patient selection for BTT-tMCS strategy is key to ensuring good outcomes. Individualizing the bridging decision based on clinical risk profile in patients supported tMCS may improve patient outcomes, organ utilization, as well as post-transplant outcomes.
2. Pre-transplant assessment must be performed rapidly (within a few days) when HT is considered in patients with tMCS. The risks of complications and death are associated with the duration of support.^{1125,1127} In most studies, the time between tMCS initiation and HT is less than 15 days, and the waitlist mortality varies between 0% and 28%.^{1113,1114} Other long-term strategies must be considered when the anticipated waiting time is long (e.g., highly sensitized, extreme weights).
3. Neurological complications, such as hemorrhagic or ischemic strokes, are common in patients with tMCS.¹¹²⁵ In patients sedated and mechanically ventilated, the transplant team must ensure neurological integrity to avoid futile HT and organ loss. All efforts must be made to inform the patient and seek his/her consent for HT.
4. End-organ function is frequently impaired in patients with refractory cardiogenic shock.¹¹²⁸ Acute kidney injury occurs in 13% to 28% in patients with cardiogenic shock, and 20% will require continuous renal replacement therapy.^{1129–1132} Although tMCS may restore adequate systemic perfusion and allow end-organ functions to recover, dynamic assessment of end-organ function is essential to determine transplant suitability. Liver dysfunction, mechanical ventilation, and renal insufficiency are strongly associated with early mortality following HT.^{1133–1135} Post-transplant survival decreases incrementally with the number of failing organs. Several studies suggested the utility of a scoring system for organ failure in predicting survival after HT.^{88,1134} In very selected patients, multiorgan transplantation could be considered.

Table 23 Comparison of the Highest Priority Groups and tMCS Between the Current Allocation Systems in the USA, Canada, France, Spain, Eurotransplant, Italy, and the United Kingdom

Countries	High priority listing status		
USA ^{a,1119}	Status 1 <ul style="list-style-type: none">- VA-ECMO (< 7 days)- Nondischargeable BiVAD	Status 2 <ul style="list-style-type: none">- Nondischargeable LVAD, IABP, or percutaneous MCS- MCS with malfunctioning- TAH, BiVAD, RVAD, or VAD for single ventricle	Status 3 <ul style="list-style-type: none">- MCS with complications-ECMO ≥7 days- Any other tMCS after 14 days
Canada ¹¹²⁰	Status 4—National prioritization <ul style="list-style-type: none">- Dependent on temporary BiVAD, RVAD, or LVAD (excluding IABP), unable to wean, and not a candidate for durable LVAD therapy- TAH that is nondischargeable from the hospital- Hospitalized durable LVAD patients with severe LVAD complications- Mechanically ventilated on high dose single (milrinone > 0.5 mcg/kg/min OR dobutamine > 10 mcg/kg/min) or > 2 inotropes/vasoactives and not a durable LVAD candidate	Status 3.5—Provincial prioritization <ul style="list-style-type: none">- Temporary surgical paracorporeal LVAD not meeting status 4 criteria- Temporary percutaneous LVAD excluding IABP (i.e., tandem heart, Impella) not meeting status 4 criteria- High dose single or multiple inotropes/vasoactives in patients requiring ICU/CCU admission who are NOT candidates for durable LVAD- Refractory life-threatening arrhythmias requiring continuous intravenous antiarrhythmic drug therapy and not amenable to, or failed, ventricular tachycardia ablation	
France ⁸⁸	Candidate National Risk Score (from 0-1,151 points) <ul style="list-style-type: none">- Including: VA-ECMO, natriuretic peptides, renal function, total bilirubin- HT candidate with the highest national score- Time allowed for ECMO patients bridged to HT to stay in the highest priority group < 12-16 days		
Spain ¹¹⁰⁹	Urgency status 0- Dependent on tMCS, including ECMO for at least 48 hours (without multiorgan failure)		
Eurotransplant- b,1121	High Urgent National/International <ul style="list-style-type: none">- Short-term MCS	Status 1A (only Netherlands) <ul style="list-style-type: none">- Unstable patient dependent on high dose inotropes and/or IABP with restored organ function.	
Italy ¹¹²²	Status 1 <ul style="list-style-type: none">- ECMO- IABP- Mechanical ventilation + IV inotropes + IABP		
United Kingdom ¹¹²³	Super-urgent heart allocation scheme (SUHAS) <ul style="list-style-type: none">- Short-term MCS- HT candidate<ul style="list-style-type: none">(a) on IABP support(b) at imminent risk of death or irreversible complications. Meets criteria for urgent listing		

Abbreviations: BiVAD, biventricular assist device; HT, heart transplantation; IABP, intra-aortic balloon pump; ICU, intensive care unit; MCS, mechanical circulatory support; LVAD, left ventricular assist device; TAH, total artificial heart; VAD, ventricular assist device; VA-ECMO, veno-arterial membrane oxygenation; RVAD, right ventricular assist device; CCU, critical care unit.

^aAs of October 2018.

^bCountries that are members of Eurotransplant: Austria, Belgium, Croatia, Germany, Hungary, Luxembourg, The Netherlands, and Slovenia.

EVIDENCE GAPS AND FUTURE RESEARCH DIRECTIONS

Future research is needed to address the perceived gaps in different areas to improve future guidelines for the care of HT candidates. The following issues were raised by the various coauthors of the current document; they encompass areas for which there was not enough evidence to make recommendations at the time but could be achieved by ongoing analyses of registry data worldwide and multicenter collaborative studies (Table 24).

Table 24 Evidence Gaps and Future Research Directions**Definition**

- Improving the prioritization of HT candidates for optimal clinical outcomes.
- Defining the optimal matching phenotypes between donor and recipient to maximize organ usage and outcomes.
- Defining the optimal timing and frequency of frailty assessments in AdvHF.

Screening

- Timing of listing after malignancy: a personalized approach using precision immune-oncology and new tools, such as circulating tumor DNA, may detect microscopic residual disease in patients in remission. This approach may significantly reduce the wait time before transplant consideration and listing.
- Improved delineation of the need for SHKT (or liver) vs HT alone by defining optimal biomarker thresholds for eGFR, MELD score, or other biomarkers.
- Defining cut-off values for NPs as a screening tool to assess candidacy.
- Uniformizing policy screening for HLA antibodies.

Diagnostics and monitoring

- Developing threshold/clinical milestones for listing patients with hypertrophic/restrictive cardiomyopathies.
- The impact of applying precision medicine approach tailoring HF therapies to individual patient profiles on HT candidacy.
- Integrating artificial intelligence and machine learning in HF management to enable the development of predictive models for early intervention, risk stratification, and personalized treatment recommendations.

Medical therapies and emerging technologies

Well-conducted clinical trials are needed to define the optimal medical management in different areas such as:

- Desensitization strategies.
- Anticoagulation strategies beyond warfarin, incorporating NOAC and the new reversal agents, compared to usual care.
- The advent of new specific disease-modifying therapies, such as cardiac myosin inhibitors, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and other genetic modification techniques for hypertrophic cardiomyopathy (and potentially other diseases), and their impact on post-transplant outcomes.
- Pharmacologic agents for obesity and their potential impact on transplant candidacy.
- Improved treatments for viral infection (HIV, hepatitis, etc.) and their potential impact on transplant candidacy and management.
- The effect of many drugs on the occurrence of PGD, such as antiarrhythmics (mainly amiodarone) and their combination, and SGLT2 inhibitors, in addition to those mentioned above.
- Use of induction therapies: when, for whom, which agent, and optimal dosing.
- Exploring emerging therapeutic approaches focusing on underlying mechanisms of HF rather than on alleviating symptoms, and investigating their implications for time-appropriate transplant evaluation (i.e., gene-editing techniques, such as CRISPR-Cas9, for correcting genetic mutations that contribute to HF; regenerative medicine approaches, including stem cell therapy and tissue engineering for repairing damaged cardiac tissue and restoring function).

Device management and advanced therapies

Well-conducted clinical trials are needed to define the optimal device selection and management of HT candidates in areas such as:

- Indications for and individualized selection of the optimal tMCS.
- The optimal timing for listing patients on tMCS (including ExtraCorporeal Life Support or ExtraCorporeal Membrane Oxygenation).
- The impact of integrating regenerative medicine (stem cell therapy and tissue engineering) to repair damaged cardiac tissue and restore function on DMCS explantation and delisting.

Clinical outcomes

- The long-term impact of desensitization therapies on the occurrence of antibody-mediated rejection and CAV.
- The impact of increasing use of donor organs after circulatory death on wait times, outcomes, and thresholds for transplant.
- Investigating the relationship between pre-transplant frailty and post-transplant outcomes.
- Defining the mechanism of the relationship between pre-transplant frailty and post-transplant outcomes (association vs causation). Can frailty be reversed, and if so, will outcomes improve?

Comorbidities

- The candidacy and timing of listing for patients with “rare” diseases, such as amyloidosis, sarcoidosis, systemic lupus erythematosus, etc.
- The impact of liver dysfunction (liver fibrosis vs cirrhosis on histology) on post-transplant outcomes.
- Role of heart-liver transplant in highly allosensitized individuals.
- Delineating the biological mechanisms of frailty and understanding the trajectories of frailty will help to define the timing and the aggressiveness of specific interventions.

Abbreviations: AdvHF, advanced heart failure; CAV, cardiac allograft vasculopathy; DMCS, durable mechanical circulatory support; eGFR, estimated glomerular filtration rate; HF, heart failure; HIV, human immunodeficiency virus; HLA, human leukocyte antigen; HT, heart transplantation; MELD, model for end-stage liver disease; NOAC, new oral anticoagulants; NP, natriuretic peptides; PGD, primary graft dysfunction; SGLT2, sodium-glucose cotransporter-2; SHKT simultaneous heart-kidney transplantation; tMCS, temporary mechanical circulatory support.

REFERENCES

1. Mehra MR, Jessup M, Gronda E, Costanzo MR. Rationale and process: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates–2006. *J Heart Lung Transplant* 2006;25:1001-2. <https://doi.org/10.1016/j.healun.2006.06.006>.
2. Jessup M, Banner N, Brozena S, et al. Optimal pharmacologic and non-pharmacologic management of cardiac transplant candidates: approaches to be considered prior to transplant evaluation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates–2006. *J Heart Lung Transplant* 2006;25:1003-23. <https://doi.org/10.1016/j.healun.2006.06.007>.
3. Mehra MR, Kobashigawa J, Starling R, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates–2006. *J Heart Lung Transplant* 2006;25:1024-42. <https://doi.org/10.1016/j.healun.2006.06.008>.
4. Gronda E, Bourge RC, Costanzo MR, et al. Heart rhythm considerations in heart transplant candidates and considerations for ventricular assist devices: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates–2006. *J Heart Lung Transplant* 2006;25:1043-56. <https://doi.org/10.1016/j.healun.2006.06.005>. Published correction appears in *J Heart Lung Transplant*. 2006 Oct;25:1276. O'Hara, Mary Lou [added]; Chambers, Susan [added].
5. Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. *J Heart Lung Transplant* 2016;35:1-23. <https://doi.org/10.1016/j.healun.2015.10.023>.
6. Dew MA, DiMartini AF, Dobbels F, et al. The 2018 ISHLT/APM/AST/ICCAC/STSW recommendations for the psychosocial evaluation of adult cardiothoracic transplant candidates and candidates for long-term mechanical circulatory support. *J Heart Lung Transplant* 2018;37:803-23. <https://doi.org/10.1016/j.healun.2018.03.005>.
7. Kirk R, Dipchand AI, Davies RR, et al. ISHLT consensus statement on donor organ acceptability and management in pediatric heart transplantation. *J Heart Lung Transplant* 2020;39:331-41. <https://doi.org/10.1016/j.healun.2020.01.1345>.
8. Copeland H, Knezevic I, Baran DA, et al. Donor heart selection: evidence-based guidelines for providers. *J Heart Lung Transplant* 2023;42:7-29. <https://doi.org/10.1016/j.healun.2022.08.030>.
9. Velleca A, Shullo MA, Dhital K, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. *J Heart Lung Transplant* 2023;42:e1-141. <https://doi.org/10.1016/j.healun.2022.10.015>.
10. Bernhardt AM, Copeland H, Deswal A, et al. The International Society for Heart and Lung Transplantation/Heart Failure Society of America Guideline on Acute Mechanical Circulatory Support. *J Heart Lung Transplant* 2023;42:e1-64. <https://doi.org/10.1016/j.healun.2022.10.028>. Published correction appears in *J Heart Lung Transplant*. 2023 Dec;42:1770.
11. Saeed D, Feldman D, Banayosy AE, et al. The 2023 International Society for Heart and Lung Transplantation Guidelines for Mechanical Circulatory Support: a 10-year update. *J Heart Lung Transplant* 2023;42:e1-222. <https://doi.org/10.1016/j.healun.2022.12.004>.
12. Kittleson MM, Sharma K, Brennan DC, et al. Dual-organ transplantation: indications, evaluation, and outcomes for heart-kidney and heart-liver transplantation: a scientific statement from the American Heart Association. *Circulation* 2023;148:622-36. <https://doi.org/10.1161/CIR.0000000000001155>. Published correction appears in *Circulation*. 2023 Aug 15;148:e6.
13. Denfeld QE, Jha SR, Fung E, et al. Assessing and managing frailty in advanced heart failure: an International Society for Heart and Lung Transplantation consensus statement. *J Heart Lung Transplant* 2024;43:1-27. <https://doi.org/10.1016/j.healun.2023.09.013>.
14. Levine GN, O'Gara PT, Beckman JA, et al. Recent innovations, modifications, and evolution of ACC/AHA clinical practice guidelines: an update for our constituencies: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation* 2019;139:e879-86. <https://doi.org/10.1161/CIR.0000000000000651>. published correction appears in *Circulation*. 2020 Jan 14;141(2):e34.
15. ACCF/AHA Task Force on Practice Guidelines. Available at: <https://www.acc.org/Guidelines/About-Guidelines-and-Clinical-Documents/Methodology> and https://professional.heart.org/-/media/phd-files/guidelines-and-statements/methodology_manual_and_policies_ucm_319826.pdf.
16. Baumwol J. "I Need Help"-A mnemonic to aid timely referral in advanced heart failure. *J Heart Lung Transplant* 2017;36:593-4. <https://doi.org/10.1016/j.healun.2017.02.010>.
17. Lahoz R, Fagan A, McSharry M, Proudfoot C, Corda S, Studer R. Recurrent heart failure hospitalizations are associated with increased cardiovascular mortality in patients with heart failure in Clinical Practice Research Datalink. *ESC Heart Fail* 2020;7:1688-99. <https://doi.org/10.1002/ehf2.12727>.
18. Hashim T, Sanam K, Revilla-Martinez M, et al. Clinical characteristics and outcomes of intravenous inotropic therapy in advanced heart failure. *Circ Heart Fail* 2015;8:880-6. <https://doi.org/10.1161/CIRCHEARTFAILURE.114.001778>.

19. Bhagat AA, Greene SJ, Vaduganathan M, Fonarow GC, Butler J. Initiation, continuation, switching, and withdrawal of heart failure medical therapies during hospitalization. *JACC Heart Fail* 2019;7:1-12. <https://doi.org/10.1016/j.jchf.2018.06.011>.
20. Tran RH, Aldemerdash A, Chang P, et al. Guideline-directed medical therapy and survival following hospitalization in patients with heart failure. *Pharmacotherapy* 2018;38:406-16. <https://doi.org/10.1002/phar.2091>.
21. Kittleson M, Hurwitz S, Shah MR, et al. Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality. *J Am Coll Cardiol* 2003;41:2029-35. [https://doi.org/10.1016/s0735-1097\(03\)00417-0](https://doi.org/10.1016/s0735-1097(03)00417-0).
22. Damman K, Valente MA, Voors AA, O'Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. *Eur Heart J* 2014;35:455-69. <https://doi.org/10.1093/eurheartj/ehz386>.
23. Allen LA, Felker GM, Pocock S, et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. *Eur J Heart Fail* 2009;11:170-7. <https://doi.org/10.1093/eurjhf/hfn031>.
24. Tung R, Vaseghi M, Frankel DS, et al. Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: an International VT Ablation Center Collaborative Group study. *Heart Rhythm* 2015;12:1997-2007. <https://doi.org/10.1016/j.hrthm.2015.05.036>.
25. Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. *N Engl J Med* 2008;359:1009-17. <https://doi.org/10.1056/NEJMoa071098>.
26. Qian Z, Zhang Z, Guo J, et al. Association of implantable cardioverter defibrillator therapy with all-cause mortality-a systematic review and meta-analysis. *Pacing Clin Electro* 2016;39:81-8. <https://doi.org/10.1111/pace.12766>.
27. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). *Circulation* 2003;107:1278-83. <https://doi.org/10.1161/01.cir.0000054164.99881.00>.
28. Zile MR, Desai AS, Agarwal R, et al. Prognostic value of brain natriuretic peptide vs history of heart failure hospitalization in a large real-world population. *Clin Cardiol* 2020;43:1501-10. <https://doi.org/10.1002/clc.23468>.
29. Solomon SD, Anavekar N, Skali H, et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. *Circulation* 2005;112:3738-44. <https://doi.org/10.1161/CIRCULATIONAHA.105.561423>.
30. Ghimire A, Fine N, Ezekowitz JA, Howlett J, Youngson E, McAlister FA. Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study. *Eur Heart J* 2019;40:2110-7. <https://doi.org/10.1093/eurheartj/ehz233>.
31. Crespo-Leiro MG, Metra M, Lund LH, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2018;20:1505-35. <https://doi.org/10.1002/ehf.1236>.
32. Stevenson LW, Pagani FD, Young JB, et al. INTERMACS profiles of advanced heart failure: the current picture. *J Heart Lung Transplant* 2009;28:535-41. <https://doi.org/10.1016/j.healun.2009.02.015>.
33. Kittleson MM, Shah P, Lala A, et al. INTERMACS profiles and outcomes of ambulatory advanced heart failure patients: a report from the REVIVAL Registry. *J Heart Lung Transplant* 2020;39:16-26. <https://doi.org/10.1016/j.healun.2019.08.017>.
34. Morris AA, Khazanie P, Drazner MH, et al. Guidance for timely and appropriate referral of patients with advanced heart failure: a scientific statement from the American Heart Association. *Circulation* 2021;144:e238-50. <https://doi.org/10.1161/CIR.0000000000001016>.
35. Longhi S, Satri G, Caponetti AG, Gagliardi C, Biagini E. Advanced heart failure in a special population: heart failure with preserved ejection fraction. *Heart Fail Clin* 2021;17:685-95.
36. Gorter TM, van Veldhuisen DJ, Bauersachs J, et al. Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2018;20:16-37. <https://doi.org/10.1002/ehf.1029>.
37. Greutmann M, Tobler D, Kovacs AH, et al. Increasing mortality burden among adults with complex. *Congenit Heart Dis* 2015;10:117-27. <https://doi.org/10.1111/chd.12201>.
38. Guazzi M, Arena R, Myers J. Comparison of the prognostic value of cardiopulmonary exercise testing between male and female patients with heart failure. *Int J Cardiol* 2006;113:395-400.
39. Garcia Brás P, Gonçalves AV, Reis JF, et al. Cardiopulmonary exercise testing in patients with heart failure: impact of gender in predictive value for heart transplantation listing. *Life (Basel)* 2023;13:1985. <https://doi.org/10.3390/life13101985>.
40. Canter CE, Shaddy RE, Bernstein D, et al. Indications for heart transplantation in pediatric heart disease: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young; the Councils on Clinical Cardiology, Cardiovascular

- Nursing, and Cardiovascular Surgery and Anesthesia; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. *Circulation* 2007;115:658-76. <https://doi.org/10.1161/CIRCULATIONAHA.106.180449>. Published correction appears in *Circulation*. 2007 Apr 3;115:e385. Friedman, Allen H [corrected to Friedman, Alan H].
41. Ross HJ, Law Y, Book WM, et al. Transplantation and mechanical circulatory support in congenital heart disease: a scientific statement from the American Heart Association. *Circulation* 2016;133:802-20. <https://doi.org/10.1161/CIR.0000000000000353>.
 42. Hsieh EM, Blackstone EH, Thuita L, et al. Sex differences in mortality based on United Network for Organ Sharing status while awaiting heart transplantation. *Circ Heart Fail* 2017;10:e003635. <https://doi.org/10.1161/CIRCHEARTFAILURE.116.003635>.
 43. Hsieh EM, Thuita L, McNamara DM, et al. Variables of importance in the Scientific Registry of Transplant Recipients database predictive of heart transplant waitlist mortality. *Am J Transplant* 2019;19:2067-76. <https://doi.org/10.1111/ajt.15265>.
 44. Baudry G, Coutance G, Dorent R, et al. Prognosis value of Forrester's classification in advanced heart failure patients awaiting heart transplantation. *ESC Heart Fail* 2022;9:3287-97. <https://doi.org/10.1002/ehf2.14037>.
 45. Kirklin JK, Naftel DC, Kirklin JW, Blackstone EH, White-Williams C, Bourge RC. Pulmonary vascular resistance and the risk of heart transplantation. *J Heart Transplant* 1988;7:331-6.
 46. Matkovic M, Milicevic V, Bilbija I, et al. Pulmonary artery hypertension as a risk factor for long-term survival after heart transplantation. *Heart Surg Forum* 2021;24:E544-9. <https://doi.org/10.1532/hcf.3789>.
 47. Trento A, Griffith BP, Fricker FJ, Kormos RL, Armitage J, Hardesty RL. Lessons learned in pediatric heart transplantation. *Ann Thorac Surg* 1989;48:617-23. [https://doi.org/10.1016/0003-4975\(89\)90774-1](https://doi.org/10.1016/0003-4975(89)90774-1).
 48. Bando K, Konishi H, Komatsu K, et al. Improved survival following pediatric cardiac transplantation in high-risk patients. *Circulation* 1993;88:II218-23.
 49. Yilmaz B, Zuckerman WA, Lee TM, et al. Left ventricular assist device to avoid heart-lung transplant in an adolescent with dilated cardiomyopathy and severely elevated pulmonary vascular resistance. *Pediatr Transplant* 2013;17:E113-6. <https://doi.org/10.1111/petr.12096>.
 50. Bearl DW, Dodd DA, Thurm C, et al. Practice variation, costs and outcomes associated with the use of inhaled nitric oxide in pediatric heart transplant recipients. *Pediatr Cardiol* 2019;40:650-7. <https://doi.org/10.1007/s00246-018-2042-1>.
 51. Rahimi K, Bennett D, Conrad N, et al. Risk prediction in patients with heart failure: a systematic review and analysis. *JACC Heart Fail* 2014;2:440-6. <https://doi.org/10.1016/j.jchf.2014.04.008>.
 52. Nguyen LS, Coutance G, Ouldamar S, et al. Performance of existing risk scores around heart transplantation: validation study in a 4-year cohort. *Transpl Int* 2018;31:520-30. <https://doi.org/10.1111/tri.13122>.
 53. Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. *Circulation* 1997;95:2660-7. <https://doi.org/10.1161/01.cir.95.12.2660>.
 54. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. *Circulation* 2006;113:1424-33. <https://doi.org/10.1161/CIRCULATIONAHA.105.584102>.
 55. Pocock SJ, Ariti CA, McMurray JJ, et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. *Eur Heart J* 2013;34:1404-13. <https://doi.org/10.1093/eurheartj/ehs337>.
 56. Agostoni P, Corrà U, Cattadori G, et al. Metabolic exercise test data combined with cardiac and kidney indexes, the MECKI score: a multiparametric approach to heart failure prognosis. *Int J Cardiol* 2013;167:2710-8. <https://doi.org/10.1016/j.ijcard.2012.06.113>.
 57. O'Connor CM, Abraham WT, Albert NM, et al. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). *Am Heart J* 2008;156:662-73. <https://doi.org/10.1016/j.ahj.2008.04.030>.
 58. Abraham WT, Fonarow GC, Albert NM, et al. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). *J Am Coll Cardiol* 2008;52:347-56. <https://doi.org/10.1016/j.jacc.2008.04.028>.
 59. Peterson PN, Rumsfeld JS, Liang L, et al. A validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association get with the guidelines program. *Circ Cardiovasc Qual Outcomes* 2010;3:25-32. <https://doi.org/10.1161/CIRCOUTCOMES.109.854877>.
 60. O'Connor CM, Hasselblad V, Mehta RH, et al. Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score. *J Am Coll Cardiol* 2010;55:872-8. <https://doi.org/10.1016/j.jacc.2009.08.083>.

61. Gorodeski EZ, Chu EC, Chow CH, Levy WC, Hsieh E, Starling RC. Application of the Seattle Heart Failure Model in ambulatory patients presented to an advanced heart failure therapeutics committee. *Circ Heart Fail* 2010;3:706-14. <https://doi.org/10.1161/CIRCHEARTFAILURE.110.944280>.
62. Corrà U, Magini A, Paolillo S, Frigerio M. Comparison among different multiparametric scores for risk stratification in heart failure patients with reduced ejection fraction. *Eur J Prev Cardiol* 2020;27(2_Suppl):12-8. <https://doi.org/10.1177/2047487320962990>.
63. Keteyian SJ, Patel M, Kraus WE, et al. Variables measured during cardiopulmonary exercise testing as predictors of mortality in chronic systolic heart failure. *J Am Coll Cardiol* 2016;67:780-9. <https://doi.org/10.1016/j.jacc.2015.11.050>. Published correction appears in *J Am Coll Cardiol*. 2016 Apr 26;67:1979-80.
64. Lund LH, Aaronson KD, Mancini DM. Predicting survival in ambulatory patients with severe heart failure on beta-blocker therapy. *Am J Cardiol* 2003;92:1350-4. <https://doi.org/10.1016/j.amjcard.2003.08.027>.
65. Zugck C, Haunstetter A, Krüger C, et al. Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure. *J Am Coll Cardiol* 2002;39:1615-22. [https://doi.org/10.1016/s0735-1097\(02\)01840-5](https://doi.org/10.1016/s0735-1097(02)01840-5).
66. Pohwani AL, Murali S, Mathier MM, et al. Impact of beta-blocker therapy on functional capacity criteria for heart transplant listing. *J Heart Lung Transplant* 2003;22:78-86. [https://doi.org/10.1016/s1053-2498\(02\)00480-1](https://doi.org/10.1016/s1053-2498(02)00480-1).
67. Peterson LR, Schechtman KB, Ewald GA, et al. Timing of cardiac transplantation in patients with heart failure receiving beta-adrenergic blockers. *J Heart Lung Transplant* 2003;22:1141-8. [https://doi.org/10.1016/s1053-2498\(02\)01225-1](https://doi.org/10.1016/s1053-2498(02)01225-1).
68. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds Jr LH, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. *Circulation* 1991;83:778-86. <https://doi.org/10.1161/01.cir.83.3.778>.
69. Osman AF, Mehra MR, Lavie CJ, Nunez E, Milani RV. The incremental prognostic importance of body fat adjusted peak oxygen consumption in chronic heart failure. *J Am Coll Cardiol* 2000;36:2126-31. [https://doi.org/10.1016/s0735-1097\(00\)00985-2](https://doi.org/10.1016/s0735-1097(00)00985-2).
70. Robbins M, Francis G, Pashkow FJ, et al. Ventilatory and heart rate responses to exercise: better predictors of heart failure mortality than peak oxygen consumption. *Circulation* 1999;100:2411-7. <https://doi.org/10.1161/01.cir.100.24.2411>.
71. Francis DP, Shamim W, Davies LC, et al. Cardiopulmonary exercise testing for prognosis in chronic heart failure: continuous and independent prognostic value from VE/VCO(2)slope and peak VO(2). *Eur Heart J* 2000;21:154-61. <https://doi.org/10.1053/euhj.1999.1863>.
72. Kleber FX, Vietzke G, Wernecke KD, et al. Impairment of ventilatory efficiency in heart failure: prognostic impact. *Circulation* 2000;101:2803-9. <https://doi.org/10.1161/01.cir.101.24.2803>.
73. Gitt AK, Wasserman K, Kilkowski C, et al. Exercise anaerobic threshold and ventilatory efficiency identify heart failure patients for high risk of early death. *Circulation* 2002;106:3079-84. <https://doi.org/10.1161/01.cir.0000041428.99427.06>.
74. Arena R, Humphrey R. Comparison of ventilatory expired gas parameters used to predict hospitalization in patients with heart failure. *Am Heart J* 2002;143:427-32. <https://doi.org/10.1067/mhj.2002.119607>.
75. Sarullo FM, Fazio G, Brusca I, et al. Cardiopulmonary exercise testing in patients with chronic heart failure: prognostic comparison from peak VO2 and VE/VCO2 slope. *Open Cardiovasc Med J* 2010;4:127-34. <https://doi.org/10.2174/1874192401004010127>.
76. Sciomer S, Moscucci F, Salvioni E, et al. Role of gender, age and BMI in prognosis of heart failure. *Eur J Prev Cardiol* 2020;27(2_Suppl):46-51. <https://doi.org/10.1177/2047487320961980>.
77. Salvioni E, Corrà U, Piepoli M, et al. Gender and age normalization and ventilation efficiency during exercise in heart failure with reduced ejection fraction. *ESC Heart Fail* 2020;7:371-80. <https://doi.org/10.1002/ehf2.12582>.
78. Corrà U, Agostoni PG, Anker SD, et al. Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2018;20:3-15. <https://doi.org/10.1002/ehf.979>. Published correction appears in *Eur J Heart Fail*. 2018 Oct;20(10):1501.
79. Mezzani A. Cardiopulmonary exercise testing: basics of methodology and measurements. *Ann Am Thorac Soc* 2017;14(Suppl 1):S3-11. <https://doi.org/10.1513/AnnalsATS.201612-997FR>.
80. Khush KK, Hsieh E, Potena L, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-eighth adult heart transplantation report - 2021; focus on recipient characteristics. *J Heart Lung Transplant* 2021;40:1035-49. <https://doi.org/10.1016/j.healun.2021.07.015>.
81. Akintoye E, Alvarez P, Shin D, et al. Changing demographics, temporal trends in waitlist, and post-transplant outcomes after heart transplantation in the United States: analysis of the UNOS Database 1991-2019. *Circ Heart Fail* 2021;14:e008764. <https://doi.org/10.1161/CIRCHEARTFAILURE.121.008764>.

82. Weiss ES, Nwakanma LU, Patel ND, Yuh DD. Outcomes in patients older than 60 years of age undergoing orthotopic heart transplantation: an analysis of the UNOS database. *J Heart Lung Transplant* 2008;27:184-91. <https://doi.org/10.1016/j.healun.2007.11.566>.
83. Wever-Pinzon O, Edwards LB, Taylor DO, et al. Association of recipient age and causes of heart transplant mortality: Implications for personalization of post-transplant management-an analysis of the International Society for Heart and Lung Transplantation Registry. *J Heart Lung Transplant* 2017;36:407-17. <https://doi.org/10.1016/j.healun.2016.08.008>.
84. Goldstein DJ, Bello R, Shin JJ, et al. Outcomes of cardiac transplantation in septuagenarians. *J Heart Lung Transplant* 2012;31:679-85. <https://doi.org/10.1016/j.healun.2012.03.019>. published correction appears in *J Heart Lung Transplant*. 2014 Mar;33(3):326.
85. Jaiswal A, Gadela NV, Baran D, et al. Clinical outcomes of older adults listed for heart transplantation in the United States. *J Am Geriatr Soc* 2021;69:2507-17. <https://doi.org/10.1111/jgs.17271>.
86. Jawitz OK, Raman V, Klapper J, Hartwig M, Patel CB, Milano C. Donor and recipient age matching in heart transplantation: analysis of the UNOS Registry. *Transpl Int* 2019;32:1194-202. <https://doi.org/10.1111/tri.13481>.
87. Dalal AR. Philosophy of organ donation: review of ethical facets. *World J Transplant* 2015;5:44-51. <https://doi.org/10.5500/wjt.v5.i2.44>.
88. Dorent R, Jasseron C, Audry B, et al. New French heart allocation system: comparison with Eurotransplant and US allocation systems. *Am J Transplant* 2020;20:1236-43. <https://doi.org/10.1111/ajt.15816>.
89. Hsich E, Singh TP, Cherikh WS, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-ninth adult heart transplantation report-2022; focus on transplant for restrictive heart disease. *J Heart Lung Transplant* 2022;41:1366-75. <https://doi.org/10.1016/j.healun.2022.07.018>.
90. Weiss ES, Allen JG, Russell SD, Shah AS, Conte JV. Impact of recipient body mass index on organ allocation and mortality in orthotopic heart transplantation. *J Heart Lung Transplant* 2009;28:1150-7. <https://doi.org/10.1016/j.healun.2009.06.009>.
91. Chouairi F, Milner A, Sen S, et al. Impact of obesity on heart transplantation outcomes. *J Am Heart Assoc* 2021;10:e021346. <https://doi.org/10.1161/JAHA.121.021346>.
92. Doumouras BS, Fan CS, Mueller B, et al. The effect of pre-heart transplant body mass index on post-transplant outcomes: an analysis of the ISHLT Registry Data. *Clin Transpl* 2019;33:e13621. <https://doi.org/10.1111/ctr.13621>.
93. Liu Y, Padilla FA, Graviss EA, et al. Outcomes of heart transplant recipients with class II obesity: a United Network for Organ Sharing database analysis. *J Surg Res* 2022;272:69-78. <https://doi.org/10.1016/j.jss.2021.11.005>.
94. Foroutan F, Doumouras BS, Ross H, Alba AC. Impact of pre-transplant recipient body mass index on post heart transplant mortality: a systematic review and meta-analysis. *Clin Transpl* 2018;32:e13348. <https://doi.org/10.1111/ctr.13348>.
95. Russo MJ, Hong KN, Davies RR, et al. The effect of body mass index on survival following heart transplantation: do outcomes support consensus guidelines. *Ann Surg* 2010;251:144-52. <https://doi.org/10.1097/SLA.0b013e3181b5db3c>.
96. Okoh AK, Selevany M, Heaton J, et al. Outcomes of obese patients bridged to heart transplantation with a left ventricular assist device. *ASAIO J* 2021;67:137-43. <https://doi.org/10.1097/MAT.0000000000001188>.
97. Challapalli J, Maynes EJ, O'Malley TJ, et al. Sleeve gastrectomy in patients with continuous-flow left ventricular assist devices: a systematic review and meta-analysis. *Obes Surg* 2020;30:4437-45. <https://doi.org/10.1007/s11695-020-04834-4>.
98. Choudhury RA, Foster M, Hoeltzel G, et al. Bariatric surgery for congestive heart failure patients improves access to transplantation and long-term survival. *J Gastrointest Surg* 2021;25:926-31. <https://doi.org/10.1007/s11605-020-04587-6>.
99. Berkman E, Wightman A, Friedland-Little JM, Albers EL, Diekema D, Lewis-Newby M. An ethical analysis of obesity as a determinant of pediatric heart transplant candidacy. *Pediatr Transplant* 2021;25:e13913. <https://doi.org/10.1111/petr.13913>.
100. Hemmingsson E. Early childhood obesity risk factors: socioeconomic adversity, family dysfunction, offspring distress, and junk food self-medication. *Curr Obes Rep* 2018;7:204-9. <https://doi.org/10.1007/s13679-018-0310-2>.
101. Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2018: a review of current American Cancer Society guidelines and current issues in cancer screening. *CA Cancer J Clin* 2018;68:297-316. <https://doi.org/10.3322/caac.21446>.
102. US Preventive Services Task Force, Davidson KW, Barry MJ, et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. *JAMA* 2021;325:1965-77. <https://doi.org/10.1001/jama.2021.6238>. Published correction appears in *JAMA*. 2021 Aug 24;326:773.
103. Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. *CA Cancer J Clin* 2018;68:250-81. <https://doi.org/10.3322/caac.21457>.

104. US Preventive Services Task Force, Grossman DC, Curry SJ, et al. Screening for prostate cancer: US Preventive Services Task Force Recommendation Statement. *JAMA* 2018;319:1901-13. <https://doi.org/10.1001/jama.2018.3710>. published correction appears in *JAMA*. 2018 Jun 19;319(23):2443.
105. Siu AL. U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force Recommendation Statement. *Ann Intern Med* 2016;164:279-96. <https://doi.org/10.7326/M15-2886>. published correction appears in *Ann Intern Med*. 2016 Mar 15;164(6):448.
106. Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. *CA Cancer J Clin* 2020;70:321-46. <https://doi.org/10.3322/caac.21628>.
107. Jonas DE, Reuland DS, Reddy SM, et al. Screening for lung cancer with low-dose computed tomography: updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA* 2021;325:971-87. <https://doi.org/10.1001/jama.2021.0377>.
108. Zwald F, Leitenberger J, Zeitouni N, et al. Recommendations for solid organ transplantation for transplant candidates with a pre-transplant diagnosis of cutaneous squamous cell carcinoma, merkel cell carcinoma and melanoma: a consensus opinion from the International Transplant Skin Cancer Collaborative (ITSCC). *Am J Transplant* 2016;16:407-13. <https://doi.org/10.1111/ajt.13593>.
109. Crow LD, Jambusaria-Pahlajani A, Chung CL, et al. Initial skin cancer screening for solid organ transplant recipients in the United States: Delphi method development of expert consensus guidelines. *Transpl Int* 2019;32:1268-76. <https://doi.org/10.1111/tri.13520>.
110. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. *Cancer Epidemiol Biomark Prev* 2016;25:16-27. <https://doi.org/10.1158/1055-9965.EPI-15-0578>.
111. Batra J, DeFilippis EM, Golob S, et al. Impact of pre-transplant malignancy on heart transplantation outcomes: contemporary United Network for Organ Sharing analysis amidst evolving cancer therapies. *Circ Heart Fail* 2022;15:e008968. <https://doi.org/10.1161/CIRCHEARTFAILURE.121.008968>.
112. Sigurdardottir V, Bjortuft O, Eiskjær H, et al. Long-term follow-up of lung and heart transplant recipients with pre-transplant malignancies. *J Heart Lung Transplant* 2012;31:1276-80. <https://doi.org/10.1016/j.healun.2012.09.007>.
113. Delgado JF, Alonso-Pulpón L, Mirabet S, et al. Cancer incidence in heart transplant recipients with previous neoplasia history. *Am J Transpl* 2016;16:1569-78. <https://doi.org/10.1111/ajt.13637>.
114. Acuna SA, Sutradhar R, Kim SJ, Baxter NN. Solid organ transplantation in patients with preexisting malignancies in remission: a propensity score matched cohort study. *Transplantation* 2018;102:1156-64. <https://doi.org/10.1097/TP.0000000000002178>.
115. Al-Adra DP, Hammel L, Roberts J, et al. Pre-transplant solid organ malignancy and organ transplant candidacy: a consensus expert opinion statement. *Am J Transpl* 2021;21:460-74. <https://doi.org/10.1111/ajt.16318>.
116. Al-Adra DP, Hammel L, Roberts J, et al. Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: a consensus expert opinion statement. *Am J Transpl* 2021;21:475-83. <https://doi.org/10.1111/ajt.16324>.
117. Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. *N Engl J Med* 2022;386:2363-76. <https://doi.org/10.1056/NEJMoa2201445>.
118. Tivey A, Church M, Rothwell D, Dive C, Cook N. Circulating tumour DNA - looking beyond the blood. *Nat Rev Clin Oncol* 2022;19:600-12. <https://doi.org/10.1038/s41571-022-00660-y>.
119. Liu Y. At the dawn: cell-free DNA fragmentomics and gene regulation. *Br J Cancer* 2022;126:379-90. <https://doi.org/10.1038/s41416-021-01635-z>.
120. Engels EA, Pfeiffer RM, Fraumeni Jr JF, et al. Spectrum of cancer risk among US solid organ transplant recipients. *JAMA* 2011;306:1891-901. <https://doi.org/10.1001/jama.2011.1592>.
121. Liauw SL, Ham SA, Das LC, et al. Prostate cancer outcomes following solid-organ transplantation: a SEER-Medicare analysis. *J Natl Cancer Inst* 2020;112:847-54. <https://doi.org/10.1093/nci/djz221>.
122. Stöckle M, Junker K, Fornara P. Low-risk prostate cancer prior to or after kidney transplantation. *Eur Urol Focus* 2018;4:148-52. <https://doi.org/10.1016/j.euf.2018.07.003>.
123. Boissier R, Hevia V, Bruins HM, et al. The risk of tumour recurrence in patients undergoing renal transplantation for end-stage renal disease after previous treatment for a urological cancer: a systematic review. *Eur Urol* 2018;73:94-108. <https://doi.org/10.1016/j.eururo.2017.07.017>.
124. Carvalho JA, Nunes P, Dinis PJ, et al. Prostate cancer in renal transplant recipients: diagnosis and treatment. *Transplant Proc* 2017;49:809-12. <https://doi.org/10.1016/j.transproceed.2017.03.006>.

125. Gin GE, Pereira JF, Weinberg AD, et al. Prostate-specific antigen screening and prostate cancer treatment in renal transplantation candidates: a survey of U.S. transplantation centers. *Urol Oncol* 2016;34:57.e9-57.e13. <https://doi.org/10.1016/j.urolonc.2015.08.020>.
126. Bahouth Z, Halachmi S, Meyer G, Avitan O, Moskovitz B, Nativ O. The natural history and predictors for intervention in patients with small renal mass undergoing active surveillance. *Adv Urol* 2015;2015:692014. <https://doi.org/10.1155/2015/692014>.
127. Chandrasekar T, Ahmad AE, Fadaak K, et al. Natural history of complex renal cysts: clinical evidence supporting active surveillance. *J Urol* 2018;199:633-40. <https://doi.org/10.1016/j.juro.2017.09.078>.
128. Beksac AT, Paulucci DJ, Sfakianos JP, et al. Trends in management of the small renal mass in renal transplant recipient candidates: a multi-institutional survey analysis. *Urol Oncol* 2017;35:529.e17-22. <https://doi.org/10.1016/j.urolonc.2017.03.012>.
129. Dunlay SM, Killian JM, McCoy RG, Redfield MM. Diabetes mellitus in advanced heart failure. *J Card Fail* 2022;28:503-8. <https://doi.org/10.1016/j.cardfail.2021.09.016>.
130. Russo MJ, Chen JM, Hong KN, et al. Survival after heart transplantation is not diminished among recipients with uncomplicated diabetes mellitus: an analysis of the United Network of Organ Sharing database. *Circulation* 2006;114:2280-7. <https://doi.org/10.1161/CIRCULATIONAHA.106.615708>.
131. Saraiva J, Sola E, Prieto D, Antunes MJ. Diabetes as an outcome predictor after heart transplantation. *Inter Cardiovasc Thorac Surg* 2011;13:499-504. <https://doi.org/10.1510/icvts.2010.256321>.
132. Rivinius R, Gralla C, Helmschrott M, et al. Pre-transplant type 2 diabetes mellitus is associated with higher graft failure and increased 5-year mortality after heart transplantation. *Front Cardiovasc Med* 2022;9:890359. <https://doi.org/10.3389/fcvm.2022.890359>.
133. Foroutan F, Alba AC, Guyatt G, et al. Predictors of 1-year mortality in heart transplant recipients: a systematic review and meta-analysis. *Heart* 2018;104:151-60. <https://doi.org/10.1136/heartjnl-2017-311435>.
134. López-Sainz Á, Barge-Caballero E, Barge-Caballero G, et al. Late graft failure in heart transplant recipients: incidence, risk factors and clinical outcomes. *Eur J Heart Fail* 2018;20:385-94. <https://doi.org/10.1002/ehf.886>.
135. Radovancevic B, Konuralp C, Vrtovec B, et al. Factors predicting 10-year survival after heart transplantation. *J Heart Lung Transplant* 2005;24:156-9. <https://doi.org/10.1016/j.healun.2003.11.399>.
136. Jalowiec A, Grady KL, White-Williams C. Heart transplant outcomes in patients with pre-transplant diabetes mellitus. *Am J Crit Care* 2017;26:482-90. <https://doi.org/10.4037/ajcc2017571>.
137. Newman JD, Schlendorf KH, Cox ZL, et al. Post-transplant diabetes mellitus following heart transplantation. *J Heart Lung Transplant* 2022;41:1537-46. <https://doi.org/10.1016/j.healun.2022.07.011>.
138. Qaseem A, Wilt TJ, Kansagara D, et al. Hemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus: a guidance statement update from the American College of Physicians. *Ann Intern Med* 2018;168:569-76. <https://doi.org/10.7326/M17-0939>.
139. American Diabetes Association. 11. Microvascular complications and foot care: standards of medical care in diabetes-2021. *Diabetes Care* 2021;44(Suppl 1):S151-67. <https://doi.org/10.2337/dc21-S011>. Published correction appears in *Diabetes Care*. 2021 Sep;44:2186-2187.
140. Patlolla V, Mogulla V, DeNofrio D, Konstam MA, Krishnamani R. Outcomes in patients with symptomatic cerebrovascular disease undergoing heart transplantation. *J Am Coll Cardiol* 2011;58:1036-41. <https://doi.org/10.1016/j.jacc.2011.04.038>.
141. Alvarez P, Kitai T, Okamoto T, et al. Trends, risk factors, and outcomes of post-operative stroke after heart transplantation: an analysis of the UNOS database. *ESC Heart Fail* 2021;8:4211-7. <https://doi.org/10.1002/ehf2.13562>.
142. Alnsasra H, Asleh R, Kumar N, et al. Incidence, risk factors, and outcomes of stroke following cardiac transplantation. *Stroke* 2021;52:e720-4. <https://doi.org/10.1161/STROKEAHA.121.034874>.
143. Merkler AE, Chen ML, Parikh NS, et al. Association between heart transplantation and subsequent risk of stroke among patients with heart failure. *Stroke* 2019;50:583-7. <https://doi.org/10.1161/STROKEAHA.118.023622>.
144. US Preventive Services Task Force, Krist AH, Davidson KW, et al. Screening for asymptomatic carotid artery stenosis: US Preventive Services Task Force Recommendation Statement. *JAMA* 2021;325:476-81. <https://doi.org/10.1001/jama.2020.26988>.
145. Gottesman RF. Asymptomatic carotid stenosis in cardiac surgery patients: is less more? *Stroke* 2017;48:2650-1. <https://doi.org/10.1161/STROKEAHA.117.018754>.
146. Shishehbor MH, Venkatachalam S, Sun Z, et al. A direct comparison of early and late outcomes with three approaches to carotid revascularization and open heart surgery. *J Am Coll Cardiol* 2013;62:1948-56. <https://doi.org/10.1016/j.jacc.2013.03.094>.

147. Lin JC, Kabbani LS, Peterson EL, et al. Clinical utility of carotid duplex ultrasound prior to cardiac surgery. *J Vasc Surg* 2016;63:710-4. <https://doi.org/10.1016/j.jvs.2015.10.008>.
148. Bauersachs R, Debus S, Nehler M, et al. A Targeted literature review of the disease burden in patients with symptomatic peripheral artery disease. *Angiology* 2020;71:303-14. <https://doi.org/10.1177/0003319719896477>.
149. Hebert K, Lopez B, Michael C, et al. The prevalence of peripheral arterial disease in patients with heart failure by race and ethnicity. *Congest Heart Fail* 2010;16:118-21. <https://doi.org/10.1111/j.1751-7133.2010.00140.x>.
150. Ahmed MI, Aronow WS, Criqui MH, et al. Effects of peripheral arterial disease on outcomes in advanced chronic systolic heart failure: a propensity-matched study. *Circ Heart Fail* 2010;3:118-24. <https://doi.org/10.1161/CIRCHEARTFAILURE.109.866558>.
151. Samsky MD, Hellkamp A, Hiatt WR, et al. Association of heart failure with outcomes among patients with peripheral artery disease: insights from EUCLID. *J Am Heart Assoc* 2021;10:e018684. <https://doi.org/10.1161/JAHA.120.018684>.
152. Silva Enciso J, Kato TS, Jin Z, et al. Effect of peripheral vascular disease on mortality in cardiac transplant recipients (from the United Network of Organ Sharing Database). *Am J Cardiol* 2014;114:1111-5. <https://doi.org/10.1016/j.amjcard.2014.07.027>.
153. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation* 2017;135:e686-725. <https://doi.org/10.1161/CIR.0000000000000470>. Published correction appears in *Circulation*. 2017 Mar 21;135(12):e790.
154. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. *Eur J Heart Fail* 2009;11:130-9. <https://doi.org/10.1093/eurjhf/hfn013>.
155. Carter P, Lagan J, Fortune C, et al. Association of cardiovascular disease with respiratory disease. *J Am Coll Cardiol* 2019;73:2166-77. <https://doi.org/10.1016/j.jacc.2018.11.063>.
156. Mentz RJ, Schulte PJ, Fleg JL, et al. Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: findings from Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION). *Am Heart J* 2013;165:193-9. <https://doi.org/10.1016/j.ahj.2012.10.029>.
157. Tavazzi L, Swedberg K, Komajda M, et al. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. *Int J Cardiol* 2013;170:182-8. <https://doi.org/10.1016/j.ijcard.2013.10.068>.
158. Hawkins NM, Huang Z, Pieper KS, et al. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). *Eur J Heart Fail* 2009;11:292-8. <https://doi.org/10.1093/eurjhf/hfp001>.
159. Ehteshami-Afshar S, Mooney L, Dewan P, et al. Clinical characteristics and outcomes of patients with heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: insights from PARADIGM-HF. *J Am Heart Assoc* 2021;10:e019238. <https://doi.org/10.1161/JAHA.120.019238>.
160. Lundgren SW, Lowes BD, Lyden E, et al. Pulmonary function testing pre-heart transplant predicts post-transplant survival. *Transplant Direct* 2021;7:e752. <https://doi.org/10.1097/TXD.0000000000001177>.
161. Rivinius R, Helmschrott M, Ruhparwar A, et al. COPD in patients after heart transplantation is associated with a prolonged hospital stay, early post-transplant atrial fibrillation, and impaired post-transplant survival. *Clin Epidemiol* 2018;10:1359-69. <https://doi.org/10.2147/CLEP.S171929>.
162. Huang WM, Feng JY, Cheng HM, et al. The role of pulmonary function in patients with heart failure and preserved ejection fraction: looking beyond chronic obstructive pulmonary disease. *PLoS One* 2020;15:e0235152. <https://doi.org/10.1371/journal.pone.0235152>.
163. Magnussen H, Canepa M, Zambito PE, Brusasco V, Meinertz T, Rosenkranz S. What can we learn from pulmonary function testing in heart failure? *Eur J Heart Fail* 2017;19:1222-9. <https://doi.org/10.1002/ehf.946>.
164. Tao A, Raikhelkar J, Benvenuto L, et al. Impact of preheart transplant spirometry and DCLO measurement on post-transplant pulmonary outcomes. *J Heart Lung Transplant* 2023;42:819-27. <https://doi.org/10.1016/j.healun.2023.01.008>.
165. O'Boyle F, Mediratta N, Chalmers J, et al. Long-term survival of patients with pulmonary disease undergoing coronary artery bypass surgery. *Eur J Cardiothorac Surg* 2013;43:697-703. <https://doi.org/10.1093/ejcts/ezs454>.
166. Chambers DC, Cherikh WS, Harhay MO, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult lung and heart-lung transplantation Report-2019; focus theme: donor and recipient size match. *J Heart Lung Transplant* 2019;38:1042-55. <https://doi.org/10.1016/j.healun.2019.08.001>.

167. Leard LE, Holm AM, Valapour M, et al. Consensus document for the selection of lung transplant candidates: an update from the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant* 2021;40:1349-79. <https://doi.org/10.1016/j.healun.2021.07.005>.
168. Brouckaert J, Verleden SE, Verbelen T, et al. Double-lung versus heart-lung transplantation for precapillary pulmonary arterial hypertension: a 24-year single-center retrospective study. *Transpl Int* 2019;32:717-29. <https://doi.org/10.1111/tri.13409>.
169. Hill C, Maxwell B, Boulate D, et al. Heart-lung vs. double-lung transplantation for idiopathic pulmonary arterial hypertension. *Clin Transplant* 2015;29:1067-75. <https://doi.org/10.1111/ctr.12628>.
170. de Perrot M, Granton JT, McRae K, et al. Outcome of patients with pulmonary arterial hypertension referred for lung transplantation: a 14-year single-center experience. *J Thorac Cardiovasc Surg* 2012;143:910-8. <https://doi.org/10.1016/j.jtcvs.2011.08.055>.
171. Fadel E, Mercier O, Mussot S, et al. Long-term outcome of double-lung and heart-lung transplantation for pulmonary hypertension: a comparative retrospective study of 219 patients. *Eur J Cardiothorac Surg* 2010;38:277-84. <https://doi.org/10.1016/j.ejcts.2010.02.039>.
172. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Heart J* 2022;43:3618-731. <https://doi.org/10.1093/eurheartj/ehac237>. Published correction appears in *Eur Heart J*. 2023 Apr 17;44:1312.
173. Guazzi M, Borlaug BA. Pulmonary hypertension due to left heart disease. *Circulation* 2012;126:975-90.
174. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. *Eur Respir J* 2019;53:1801913. <https://doi.org/10.1183/13993003.01913-2018>.
175. Bursi F, McNallan SM, Redfield MM, et al. Pulmonary pressures and death in heart failure: a community study. *J Am Coll Cardiol* 2012;59:222-31. <https://doi.org/10.1016/j.jacc.2011.06.076>.
176. Damy T, Goode KM, Kallvikbacka-Bennett A, et al. Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure. *Eur Heart J* 2010;31:2280-90. <https://doi.org/10.1093/eurheartj/ehq245>.
177. Vakil K, Duval S, Sharma A, et al. Impact of pre-transplant pulmonary hypertension on survival after heart transplantation: a UNOS registry analysis. *Int J Cardiol* 2014;176:595-9. <https://doi.org/10.1016/j.ijcard.2014.08.072>.
178. Costard-Jäckle A, Fowler MB. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. *J Am Coll Cardiol* 1992;19:48-54. [https://doi.org/10.1016/0735-1097\(92\)90050-w](https://doi.org/10.1016/0735-1097(92)90050-w).
179. Butler J, Stankewicz MA, Wu J, et al. Pre-transplant reversible pulmonary hypertension predicts higher risk for mortality after cardiac transplantation. *J Heart Lung Transplant* 2005;24:170-7. <https://doi.org/10.1016/j.healun.2003.09.045>.
180. Zern EK, Cheng S, Wolfson AM, et al. Angiotensin receptor-neprilysin inhibitor therapy reverses pulmonary hypertension in end-stage heart failure patients awaiting transplantation. *Circ Heart Fail* 2020;13:e006696. <https://doi.org/10.1161/CIRCHEARTFAILURE.119.006696>.
181. Kutty RS, Parameshwar J, Lewis C, et al. Use of centrifugal left ventricular assist device as a bridge to candidacy in severe heart failure with secondary pulmonary hypertension. *Eur J Cardiothorac Surg* 2013;43:1237-42. <https://doi.org/10.1093/ejcts/ezs678>.
182. Mikus E, Stepanenko A, Krabatsch T, et al. Reversibility of fixed pulmonary hypertension in left ventricular assist device support recipients. *Eur J Cardiothorac Surg* 2011;40:971-7. <https://doi.org/10.1016/j.ejcts.2011.01.019>.
183. Zimpfer D, Zrunek P, Roethy W, et al. Left ventricular assist devices decrease fixed pulmonary hypertension in cardiac transplant candidates. *J Thorac Cardiovasc Surg* 2007;133:689-95. <https://doi.org/10.1016/j.jtcvs.2006.08.104>.
184. John R, Liao K, Kamdar F, Eckman P, Boyle A, Colvin-Adams M. Effects on pre- and post-transplant pulmonary hemodynamics in patients with continuous-flow left ventricular assist devices. *J Thorac Cardiovasc Surg* 2010;140:447-52. <https://doi.org/10.1016/j.jtcvs.2010.03.006>.
185. Thangappan K, Morales DLS, Vu Q, et al. Impact of mechanical circulatory support on pediatric heart transplant candidates with elevated pulmonary vascular resistance. *Artif Organs* 2021;45:29-37. <https://doi.org/10.1111/aor.13747>.
186. Moayedifar R, Zuckermann A, Aliabadi-Zuckermann A, et al. Long-term heart transplant outcomes after lowering fixed pulmonary hypertension using left ventricular assist devices. *Eur J Cardiothorac Surg* 2018;54:1116-21. <https://doi.org/10.1093/ejcts/ezy214>.
187. de Frutos F, Díez-López C, Sánchez-Salado JC, Miralles A, Manito N, González-Costello J. Left ventricular assist devices in patients eligible for heart transplant with irreversible pulmonary hypertension. *Rev Esp Cardiol (Engl Ed)* 2020;73:583-6. <https://doi.org/10.1016/j.rec.2019.12.021>.

188. Richmond ME, Law YM, Das BB, et al. Elevated pre-transplant pulmonary vascular resistance is not associated with mortality in children without congenital heart disease: a multicenter study. *J Heart Lung Transplant* 2015;34:448-56. <https://doi.org/10.1016/j.healun.2014.04.021>.
189. Fynn-Thompson F. Heart transplantation in adults with congenital heart disease. *Methodist DeBakey Cardiovasc J* 2019;15:145-8.
190. Chiu P, Russo MJ, Davies RR, Addonizio LJ, Richmond ME, Chen JM. What is high risk? Redefining elevated pulmonary vascular resistance index in pediatric heart transplantation. *J Heart Lung Transplant* 2012;31:61-6. <https://doi.org/10.1016/j.healun.2011.08.021>.
191. Kanter KR, Mahle WT, Vincent RN, Berg AM, Kogon BE, Kirshbom PM. Heart transplantation in children with a Fontan procedure. *Ann Thorac Surg* 2011;91:823-30. <https://doi.org/10.1016/j.athoracsur.2010.11.031>.
192. Drakos SG, Kfoury AG, Gilbert EM, et al. Effect of reversible pulmonary hypertension on outcomes after heart transplantation. *J Heart Lung Transplant* 2007;26:319-23. <https://doi.org/10.1016/j.healun.2007.01.012>.
193. Goland S, Czer LS, Kass RM, et al. Pre-existing pulmonary hypertension in patients with end-stage heart failure: impact on clinical outcome and hemodynamic follow-up after orthotopic heart transplantation. *J Heart Lung Transplant* 2007;26:312-8. <https://doi.org/10.1016/j.healun.2006.12.012>.
194. Gude E, Simonsen S, Geiran OR, et al. Pulmonary hypertension in heart transplantation: discrepant prognostic impact of pre-operative compared with 1-year post-operative right heart hemodynamics. *J Heart Lung Transplant* 2010;29:216-23. <https://doi.org/10.1016/j.healun.2009.08.021>.
195. Kobashigawa J, Dadhania DM, Farr M, et al. Consensus conference on heart-kidney transplantation. *Am J Transpl* 2021;21:2459-67. <https://doi.org/10.1111/ajt.16512>.
196. Delgado C, Baweja M, Crews DC, et al. A unifying approach for GFR estimation: recommendations of the NKF-ASN Task Force on reassessing the inclusion of race in diagnosing kidney disease. *J Am Soc Nephrol* 2021;32:2994-3015. <https://doi.org/10.1681/ASN.2021070988>.
197. Panchal S, Serper M, Bittermann T, Asrani SK, Goldberg DS, Mahmud N. Impact of race-adjusted glomerular filtration rate estimation on eligibility for simultaneous liver-kidney transplantation. *Liver Transpl* 2022;28:959-68. <https://doi.org/10.1002/lt.26310>.
198. Dadhania DM, Doshi MD. Achieving equity for liver transplantation recipients with chronic kidney disease. *Liver Transpl* 2022;28:920-2. <https://doi.org/10.1002/lt.26464>.
199. Kolsrud O, Ricksten SE, Holmberg E, et al. Measured and not estimated glomerular filtration rate should be used to assess renal function in heart transplant recipients. *Nephrol Dial Transplant* 2016;31:1182-9. <https://doi.org/10.1093/ndt/gfv338>.
200. Stevens PE, Levin A. Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. *Ann Intern Med* 2013;158:825-30. <https://doi.org/10.7326/0003-4819-158-11-201306040-00007>.
201. Habib PJ, Patel PC, Hodge D, et al. Pre-orthotopic heart transplant estimated glomerular filtration rate predicts post-transplant mortality and renal outcomes: an analysis of the UNOS database. *J Heart Lung Transplant* 2016;35:1471-9. <https://doi.org/10.1016/j.healun.2016.05.028>.
202. Kolsrud O, Karason K, Holmberg E, et al. Renal function and outcome after heart transplantation. *J Thorac Cardiovasc Surg* 2018;155:1593-1604.e1. <https://doi.org/10.1016/j.jtcvs.2017.11.087>.
203. Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult heart transplantation report - 2019; focus theme: donor and recipient size match. *J Heart Lung Transplant* 2019;38:1056-66. <https://doi.org/10.1016/j.healun.2019.08.004>. Published correction appears in *J Heart Lung Transplant*. 2020 Jan;39:91.
204. Agarwal KA, Patel H, Agrawal N, Cardarelli F, Goyal N. Cardiac outcomes in isolated heart and simultaneous kidney and heart transplants in the United States. *Kidney Int Rep* 2021;6:2348-57. <https://doi.org/10.1016/j.ekir.2021.06.032>.
205. Karamlou T, Welke KF, McMullan DM, et al. Combined heart-kidney transplant improves post-transplant survival compared with isolated heart transplant in recipients with reduced glomerular filtration rate: analysis of 593 combined heart-kidney transplants from the United Network Organ Sharing Database. *J Thorac Cardiovasc Surg* 2014;147:456-461.e1. <https://doi.org/10.1016/j.jtcvs.2013.09.017>.
206. Russo MJ, Rana A, Chen JM, et al. Pre-transplantation patient characteristics and survival following combined heart and kidney transplantation: an analysis of the United Network for Organ Sharing Database. *Arch Surg* 2009;144:241-6. <https://doi.org/10.1001/archsurg.2008.559>.
207. Kilic A, Grimm JC, Whitman GJ, et al. The survival benefit of simultaneous heart-kidney transplantation extends beyond dialysis-dependent patients. *Ann Thorac Surg* 2015;99:1321-7. <https://doi.org/10.1016/j.athoracsur.2014.09.026>.

208. Itagaki S, Toyoda N, Moss N, et al. Outcomes of simultaneous heart and kidney transplantation. *J Am Coll Cardiol* 2023;81:729-40. <https://doi.org/10.1016/j.jacc.2022.11.053>.
209. Shaw BI, Samoylova ML, Sanoff S, et al. Need for improvements in simultaneous heart-kidney allocation: the limitation of pre-transplant glomerular filtration rate. *Am J Transplant* 2021;21:2468-78. <https://doi.org/10.1111/ajt.16466>.
210. OPTN. Establish eligibility criteria and safety net for heart-kidney and lung kidney allocation. Available at: <https://optn.transplant.hrsa.gov/policies-bylaws/public-comment/establish-eligibility-criteria-and-safety-net-for-heart-kidney-and-lung-kidney-allocation/>, accessed on May 4, 2024.
211. Seeto RK, Fenn B, Rockey DC. Ischemic hepatitis: clinical presentation and pathogenesis. *Am J Med* 2000;109:109-13. [https://doi.org/10.1016/s0002-9343\(00\)00461-7](https://doi.org/10.1016/s0002-9343(00)00461-7).
212. Samsky MD, Patel CB, DeWald TA, et al. Cardiohepatic interactions in heart failure: an overview and clinical implications. *J Am Coll Cardiol* 2013;61:2397-405. <https://doi.org/10.1016/j.jacc.2013.03.042>.
213. Deo SV, Al-Kindi SG, Altarabsheh SE, et al. Model for end-stage liver disease excluding international normalized ratio (MELD-XI) score predicts heart transplant outcomes: evidence from the registry of the United Network for Organ Sharing. *J Heart Lung Transplant* 2016;35:222-7. <https://doi.org/10.1016/j.healun.2015.10.008>.
214. Grimm JC, Shah AS, Magruder JT, et al. MELD-XI score predicts early mortality in patients after heart transplantation. *Ann Thorac Surg* 2015;100:1737-43. <https://doi.org/10.1016/j.athoracsur.2015.07.026>.
215. Dhall D, Kim SA, Mc Phaul C, et al. Heterogeneity of fibrosis in liver biopsies of patients with heart failure undergoing heart transplant evaluation. *Am J Surg Pathol* 2018;42:1617-24. <https://doi.org/10.1097/PAS.0000000000001163>.
216. Simpson KE, Esmaeeli A, Khanna G, et al. Liver cirrhosis in Fontan patients does not affect 1-year post-heart transplant mortality or markers of liver function. *J Heart Lung Transplant* 2014;33:170-7. <https://doi.org/10.1016/j.healun.2013.10.033>.
217. Vaikunth SS, Higgins JP, Concepcion W, et al. Does liver biopsy accurately measure fibrosis in Fontan-associated liver disease? A comparison of liver biopsy pre-combined heart and liver transplant and liver explant post-transplant. *Clin Transplant* 2020;34:e14120. <https://doi.org/10.1111/ctr.14120>.
218. Rushakoff JA, Kransdorf EP, Patel JK, Kobashigawa JA, Sundaram V, Guindi M. Heterogeneity of liver fibrosis in patients with congestive hepatopathy: a biopsy and explant comparison series. *Ann Diagn Pathol* 2022;56:151876. <https://doi.org/10.1016/j.anndiagpath.2021.151876>.
219. Emamaullee J, Khan S, Weaver C, et al. Non-invasive biomarkers of Fontan-associated liver disease. *JHEP Rep* 2021;3:100362. <https://doi.org/10.1016/j.jhepr.2021.100362>.
220. Emamaullee J, Zaidi AN, Schiano T, et al. Fontan-associated liver disease: screening, management, and transplant considerations. *Circulation* 2020;142:591-604. <https://doi.org/10.1161/CIRCULATIONAHA.120.045597>.
221. Hsieh EM, Blackstone EH, Thuita LW, et al. Heart transplantation: an in-depth survival analysis. *JACC Heart Fail* 2020;8:557-68. <https://doi.org/10.1016/j.jchf.2020.03.014>.
222. Castleberry C, White-Williams C, Naftel D, et al. Hypoalbuminemia and poor growth predict worse outcomes in pediatric heart transplant recipients. *Pediatr Transplant* 2014;18:280-7. <https://doi.org/10.1111/petr.12239>.
223. Hsu RB, Chang CI, Lin FY, et al. Heart transplantation in patients with liver cirrhosis. *Eur J Cardiothorac Surg* 2008;34:307-12. <https://doi.org/10.1016/j.ejcts.2008.05.003>.
224. Lebray P, Varnous S, Pascale A, et al. Predictive value of liver damage for severe early complications and survival after heart transplantation: a retrospective analysis. *Clin Res Hepatol Gastroenterol* 2018;42:416-26. <https://doi.org/10.1016/j.clinre.2018.03.006>.
225. Farr M, Mitchell J, Lippel M, et al. Combination of liver biopsy with MELD-XI scores for post-transplant outcome prediction in patients with advanced heart failure and suspected liver dysfunction. *J Heart Lung Transplant* 2015;34:873-82. <https://doi.org/10.1016/j.healun.2014.12.009>.
226. Atluri P, Gaffey A, Howard J, et al. Combined heart and liver transplantation can be safely performed with excellent short- and long-term results. *Ann Thorac Surg* 2014;98:858-62. <https://doi.org/10.1016/j.athoracsur.2014.04.100>.
227. Bryant 3rd R, Rizwan R, Zafar F, et al. Contemporary outcomes of combined heart-liver transplant in patients with congenital heart disease. *Transplantation* 2018;102:e67-73. <https://doi.org/10.1097/TP.0000000000001978>.
228. Borquez AA, Silva-Sepulveda J, Lee JW, et al. Transjugular liver biopsy for Fontan associated liver disease surveillance: technique, outcomes and hemodynamic correlation. *Int J Cardiol* 2021;328:83-8. <https://doi.org/10.1016/j.ijcard.2020.11.037>.

229. Bozkurt B, Colvin M, Cook J, et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. *Circulation* 2016;134:e579-646. <https://doi.org/10.1161/CIR.0000000000000455>. Published correction appears in *Circulation*. 2016 Dec 6;134:e652.
230. Zaidi AR, Zaidi A, Vaitkus PT. Outcome of heart transplantation in patients with sarcoid cardiomyopathy. *J Heart Lung Transplant* 2007;26:714-7. <https://doi.org/10.1016/j.healun.2007.05.006>.
231. Crawford TC, Okada DR, Magruder JT, et al. A contemporary analysis of heart transplantation and bridge-to-transplant mechanical circulatory support outcomes in cardiac sarcoidosis. *J Card Fail* 2018;24:384-91. <https://doi.org/10.1016/j.cardfail.2018.02.009>.
232. Akashi H, Kato TS, Takayama H, et al. Outcome of patients with cardiac sarcoidosis undergoing cardiac transplantation—single-center retrospective analysis. *J Cardiol* 2012;60:407-10. <https://doi.org/10.1016/j.jicc.2012.07.013>.
233. Turcotte-Gosselin F, Turgeon PY, Ikic A, et al. Is heart transplantation a valuable option in patients with diffuse systemic sclerosis and primary cardiac involvement? *Clin Case Rep* 2019;8:137-41. <https://doi.org/10.1002/ccr3.2600>.
234. Chapa JJ, Ilonze OJ, Guglin ME, Rao RA. Heart transplantation in systemic lupus erythematosus: a case report and meta-analysis. *Heart Lung* 2022;52:174-81. <https://doi.org/10.1016/j.hrtlng.2022.01.003>.
235. Lenaerts JC, Lenaerts JL, Westhovens R, et al. Cardiac transplantation in systemic sclerosis: single-centre experience of three cases. *Rheumatol (Oxf)* 2018;57:1120-2. <https://doi.org/10.1093/rheumatology/key048>.
236. Launay D, Savale L, Berezné A, et al. Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary working group. *Presse Med* 2014;43:e345-63. <https://doi.org/10.1016/j.lpm.2014.01.020>.
237. Malinis M, Boucher HW. AST Infectious Diseases Community of Practice. Screening of donor and candidate prior to solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. *Clin Transplant* 2019;33:e13548. <https://doi.org/10.1111/ctr.13548>.
238. Koval CE, Stosor V. AST ID Community of Practice. Ventricular assist device-related infections and solid organ transplantation-guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. *Clin Transplant* 2019;33:e13552. <https://doi.org/10.1111/ctr.13552>.
239. Madan S, Patel SR, Saeed O, et al. Outcomes of heart transplantation in patients with human immunodeficiency virus. *Am J Transplant* 2019;19:1529-35. <https://doi.org/10.1111/ajt.15257>.
240. Blumberg EA, Rogers CC. American Society of Transplantation Infectious Diseases Community of Practice. Solid organ transplantation in the HIV-infected patient: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. *Clin Transplant* 2019;33:e13499. <https://doi.org/10.1111/ctr.13499>.
241. Murphy KM, Vikram HR. Heart transplantation for infective endocarditis: viable option for a limited few? *Transpl Infect Dis* 2019;21:e13006. <https://doi.org/10.1111/tid.13006>.
242. Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). *Eur Heart J* 2015;36:3075-128. <https://doi.org/10.1093/eurheartj/ehv319>.
243. Danziger-Isakov L, Kumar D. AST ID Community of Practice. Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice. *Clin Transplant* 2019;33:e13563. <https://doi.org/10.1111/ctr.13563>. Published correction appears in *Clin Transplant*. 2020 Mar;34:e13806.
244. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. *Clin Infect Dis* 2014;58:309-18. <https://doi.org/10.1093/cid/cit816>. Published correction appears in *Clin Infect Dis*. 2014 Jul 1;59:144.
245. Aslam S, Danziger-Isakov L, Mehra MR. COVID-19 vaccination immune paresis in heart and lung transplantation. *J Heart Lung Transplant* 2021;40:763-6. <https://doi.org/10.1016/j.healun.2021.04.018>.
246. Peled Y, Ram E, Lavee J, et al. BNT162b2 vaccination in heart transplant recipients: clinical experience and antibody response. *J Heart Lung Transplant* 2021;40:759-62. <https://doi.org/10.1016/j.healun.2021.04.003>.
247. Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. *JAMA* 2021;325:2204-6. <https://doi.org/10.1001/jama.2021.7489>.
248. Wadei HM, Gonwa TA, Leoni JC, Shah SZ, Aslam N, Speicher LL. COVID-19 infection in solid organ transplant recipients after SARS-CoV-2 vaccination. *Am J Transplant* 2021;21:3496-9. <https://doi.org/10.1111/ajt.16618>.

249. CDC. Vaccine recommendations and guidelines of the ACIP: COVID-19 ACIP vaccine recommendations. Atlanta, GA: US Department of Health and Human Services, CDC; 2024. Available at: <https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html>.
250. Chin-Hong PV, Schwartz BS, Bern C, et al. Screening and treatment of chagas disease in organ transplant recipients in the United States: recommendations from the chagas in transplant working group. *Am J Transplant* 2011;11:672-80. <https://doi.org/10.1111/j.1600-6143.2011.03444.x>.
251. Pierrotti LC, Carvalho NB, Amorin JP, Pascual J, Kotton CN, López-Vélez R. Chagas disease recommendations for solid-organ transplant recipients and donors. *Transplantation* 2018;102(2S Suppl 2):S1-7. <https://doi.org/10.1097/TP.0000000000002019>.
252. Subramanian AK, Theodoropoulos NM. Infectious Diseases Community of Practice of the American Society of Transplantation. *Mycobacterium tuberculosis* infections in solid organ transplantation: guidelines from the infectious diseases community of practice of the American Society of Transplantation. *Clin Transplant* 2019;33:e13513. <https://doi.org/10.1111/ctr.13513>.
253. Te H, Doucette K. Viral hepatitis: guidelines by the American Society of Transplantation Infectious Disease Community of Practice. *Clin Transplant* 2019;33:e13514. <https://doi.org/10.1111/ctr.13514>.
254. Parikh R, Widenmaier R, Lecrenier N. A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations. *Expert Rev Vaccin* 2021;20:1065-75. <https://doi.org/10.1080/14760584.2021.1956906>.
255. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci* 2001;56:M146-56. <https://doi.org/10.1093/gerona/56.3.m146>.
256. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. *Lancet* 2013;381:752-62. [https://doi.org/10.1016/S0140-6736\(12\)62167-9](https://doi.org/10.1016/S0140-6736(12)62167-9). Published correction appears in *Lancet*. 2013 Oct 19;382:1328.
257. Denfeld QE, Winters-Stone K, Mudd JO, Gelow JM, Kurdi S, Lee CS. The prevalence of frailty in heart failure: a systematic review and meta-analysis. *Int J Cardiol* 2017;236:283-9. <https://doi.org/10.1016/j.ijcard.2017.01.153>.
258. McDonagh J, Martin L, Ferguson C, et al. Frailty assessment instruments in heart failure: a systematic review. *Eur J Cardiovasc Nurs* 2018;17:23-35. <https://doi.org/10.1177/1474515117708888>.
259. Jha SR, Hannu MK, Chang S, et al. The prevalence and prognostic significance of frailty in patients with advanced heart failure referred for heart transplantation. *Transplantation* 2016;100:429-36. <https://doi.org/10.1097/TP.0000000000000991>.
260. Jha SR, Hannu MK, Gore K, et al. Cognitive impairment improves the predictive validity of physical frailty for mortality in patients with advanced heart failure referred for heart transplantation. *J Heart Lung Transplant* 2016;35:1092-100. <https://doi.org/10.1016/j.healun.2016.04.008>.
261. Moayed Y, Duero Posada JG, Foroutan F, et al. The prognostic significance of frailty compared to peak oxygen consumption and B-type natriuretic peptide in patients with advanced heart failure. *Clin Transplant* 2018;32. <https://doi.org/10.1111/ctr.13158>.
262. Macdonald PS, Gorrie N, Brennan X, et al. The impact of frailty on mortality after heart transplantation. *J Heart Lung Transplant* 2021;40:87-94. <https://doi.org/10.1016/j.healun.2020.11.007>.
263. Panchangam C, White DA, Goudar S, et al. Translation of the frailty paradigm from older adults to children with cardiac disease. *Pediatr Cardiol* 2020;41:1031-41. <https://doi.org/10.1007/s00246-020-02354-7>.
264. Studyvin S, Birnbaum BF, Staggs VS, et al. Development and initial validation of a frailty score for pediatric patients with congenital and acquired heart disease. *Pediatr Cardiol* 2024;45:888-900. <https://doi.org/10.1007/s00246-022-03045-1>.
265. Maurer MS, Horn E, Reyentovich A, et al. Can a left ventricular assist device in individuals with advanced systolic heart failure improve or reverse frailty? *J Am Geriatr Soc* 2017;65:2383-90. <https://doi.org/10.1111/jgs.15124>.
266. Jha SR, Hannu MK, Newton PJ, et al. Reversibility of frailty after bridge-to-transplant ventricular assist device implantation or heart transplantation. *Transpl Direct* 2017;3:e167. <https://doi.org/10.1097/TXD.0000000000000690>.
267. Theou O, Stathokostas L, Roland KP, et al. The effectiveness of exercise interventions for the management of frailty: a systematic review. *J Aging Res* 2011;2011:569194. <https://doi.org/10.4061/2011/569194>.
268. Gill TM, Baker DI, Gottschalk M, Peduzzi PN, Allore H, Byers A. A program to prevent functional decline in physically frail, elderly persons who live at home. *N Engl J Med* 2002;347:1068-74. <https://doi.org/10.1056/NEJMoa020423>.
269. Dent E, Martin FC, Bergman H, Woo J, Romero-Ortuno R, Walston JD. Management of frailty: opportunities, challenges, and future directions. *Lancet* 2019;394:1376-86. [https://doi.org/10.1016/S0140-6736\(19\)31785-4](https://doi.org/10.1016/S0140-6736(19)31785-4).
270. Kobashigawa J, Dadhania D, Bhorade S, et al. Report from the American Society of Transplantation on frailty in solid organ transplantation. *Am J Transplant* 2019;19:984-94. <https://doi.org/10.1111/ajt.15198>.

271. Pesce de Souza F, Massier D, Anand Raje U, Tansey CM, Boruff J, Janaudis-Ferreira T. Exercise interventions in solid organ transplant candidates: A systematic review. *Clin Transplant* 2020;34:e13900. <https://doi.org/10.1111/ctr.13900>.
272. Singer JP, Soong A, Bruun A, et al. A mobile health technology enabled home-based intervention to treat frailty in adult lung transplant candidates: a pilot study. *Clin Transpl* 2018;32:e13274. <https://doi.org/10.1111/ctr.13274>.
273. Gimeno-Santos E, Coca-Martinez M, Arguis MJ, et al. Multimodal prehabilitation as a promising strategy for preventing physical deconditioning on the heart transplant waiting list. *Eur J Prev Cardiol* 2020;27:2367-70. <https://doi.org/10.1177/2047487319889709>.
274. Allen LA, Stevenson LW, Grady KL, et al. Decision making in advanced heart failure: a scientific statement from the American Heart Association. *Circulation* 2012;125:1928-52. <https://doi.org/10.1161/CIR.0b013e31824f2173>.
275. Walsh JR, Chambers DC, Hopkins PMA. The emerging importance of skeletal muscle function in assessing candidates for transplantation. *Transplantation* 2017;101:1967-8. <https://doi.org/10.1097/TP.0000000000001784>.
276. Kansara P, Czer L, Awad M, et al. Heart transplantation with and without prior sternotomy: analysis of the United Network for Organ Sharing database. *Transplant Proc* 2014;46:249-55. <https://doi.org/10.1016/j.transproceed.2013.09.027>.
277. Axtell AL, Fiedler AG, Lewis G, et al. Reoperative sternotomy is associated with increased early mortality after cardiac transplantation. *Eur J Cardiothorac Surg* 2019;55:1136-43. <https://doi.org/10.1093/ejcts/ezy443>.
278. Kainuma A, Ning Y, Kurlansky PA, et al. Cardiac transplantation in adult congenital heart disease with prior sternotomy. *Clin Transplant* 2021;35:e14229. <https://doi.org/10.1111/ctr.14229>.
279. George TJ, Beaty CA, Ewald GA, et al. Reoperative sternotomy is associated with increased mortality after heart transplantation. *Ann Thorac Surg* 2012;94:2025-32. <https://doi.org/10.1016/j.athoracsur.2012.07.039>.
280. Gillinov AM, Lytle BW, Hoang V, et al. The atherosclerotic aorta at aortic valve replacement: surgical strategies and results. *J Thorac Cardiovasc Surg* 2000;120:957-63. <https://doi.org/10.1067/mtc.2000.110191>.
281. Buz S, Pasic M, Unbehaun A, et al. Trans-apical aortic valve implantation in patients with severe calcification of the ascending aorta. *Eur J Cardiothorac Surg* 2011;40:463-8. <https://doi.org/10.1016/j.ejcts.2010.11.075>.
282. Sugimura Y, Mehdiani A, Katahira S, et al. Combined heart transplantation and replacement of atheromatous proximal arch. *Clin Case Rep* 2021;9:e04073. <https://doi.org/10.1002/ccr3.4073>.
283. Uriel N, Vainrib A, Jorde UP, et al. Mediastinal radiation and adverse outcomes after heart transplantation. *J Heart Lung Transplant* 2010;29:378-81. <https://doi.org/10.1016/j.healun.2009.08.011>.
284. Anastasilakis AD, Tsoouri E, Makras P, et al. Bone disease following solid organ transplantation: a narrative review and recommendations for management from The European Calcified Tissue Society. *Bone* 2019;127:401-18. <https://doi.org/10.1016/j.bone.2019.07.006>.
285. Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. *N Engl J Med* 2018;379:1007-16. <https://doi.org/10.1056/NEJMoa1805689>.
286. Barrett CD, Alexander KM, Zhao H, et al. Outcomes in patients with cardiac amyloidosis undergoing heart transplantation. *JACC Heart Fail* 2020;8:461-8. <https://doi.org/10.1016/j.jchf.2019.12.013>.
287. Kristen AV, Kreusser MM, Blum P, et al. Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era. *J Heart Lung Transplant* 2018;37:611-8. <https://doi.org/10.1016/j.healun.2017.11.015>.
288. Ohiomoba RO, Youmans QR, Ezema A, et al. Cardiac transplantation outcomes in patients with amyloid cardiomyopathy. *Am Heart J* 2021;236:13-21. <https://doi.org/10.1016/j.ahj.2021.02.016>.
289. Dispenzieri A, Kyle RA, Gertz MA, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. *Lancet* 2003;361:1787-9. [https://doi.org/10.1016/S0140-6736\(03\)13396-X](https://doi.org/10.1016/S0140-6736(03)13396-X).
290. Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. *Circulation* 2003;107:2440-5. <https://doi.org/10.1161/01.CIR.0000068314.02595.B2>.
291. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. *J Clin Oncol* 2004;22:3751-7. <https://doi.org/10.1200/JCO.2004.03.029>.
292. Wechalekar AD, Schonland SO, Kastiris E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. *Blood* 2013;121:3420-7. <https://doi.org/10.1182/blood-2012-12-473066>.
293. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. *J Clin Oncol* 2012;30:989-95. <https://doi.org/10.1200/JCO.2011.38.5724>.

294. Grogan M, Scott CG, Kyle RA, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. *J Am Coll Cardiol* 2016;68:1014-20. <https://doi.org/10.1016/j.jacc.2016.06.033>. Published correction appears in *J Am Coll Cardiol*. 2017 Jun 13;69:2882.
295. Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. *Eur Heart J* 2018;39:2799-806. <https://doi.org/10.1093/eurheartj/ehx589>.
296. Kastiris E, Palladini G, Minnema MC, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. *N Engl J Med* 2021;385:46-58. <https://doi.org/10.1056/NEJMoa2028631>.
297. Tada L, Anjum H, Linville WK, Surani S. Recurrent pleural effusions occurring in association with primary pulmonary amyloidosis. *Case Rep Pulmonol* 2015;2015:421201. <https://doi.org/10.1155/2015/421201>.
298. Berk JL. Pleural effusions in systemic amyloidosis. *Curr Opin Pulm Med* 2005;11:324-8. <https://doi.org/10.1097/01.mcp.0000162378.35928.37>.
299. Theodorakakou F, Fotiou D, Dimopoulos MA, Kastiris E. Solid organ transplantation in amyloidosis. *Acta Haematol* 2020;143:352-64. <https://doi.org/10.1159/000508262>.
300. Witteles RM. Cardiac transplantation and mechanical circulatory support in amyloidosis. *JACC CardioOncol* 2021;3:516-21. <https://doi.org/10.1016/j.jacc.2021.05.007>.
301. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. *N Engl J Med* 2018;379:11-21. <https://doi.org/10.1056/NEJMoa1716153>.
302. Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. *N Engl J Med* 2018;379:22-31. <https://doi.org/10.1056/NEJMoa1716793>.
303. Griffin JM, Baughan E, Rosenblum H, et al. Surveillance for disease progression of transthyretin amyloidosis after heart transplantation in the era of novel disease modifying therapies. *J Heart Lung Transplant* 2022;41:199-207. <https://doi.org/10.1016/j.healun.2021.10.007>.
304. Swiecicki PL, Edwards BS, Kushwaha SS, Dispenzieri A, Park SJ, Gertz MA. Left ventricular device implantation for advanced cardiac amyloidosis. *J Heart Lung Transplant* 2013;32:563-8. <https://doi.org/10.1016/j.healun.2013.01.987>.
305. Grupper A, Park SJ, Pereira NL, et al. Role of ventricular assist therapy for patients with heart failure and restrictive physiology: Improving outcomes for a lethal disease. *J Heart Lung Transplant* 2015;34:1042-9. <https://doi.org/10.1016/j.healun.2015.03.012>.
306. Kittleson MM, Cole RM, Patel J, et al. Mechanical circulatory support for cardiac amyloidosis. *Clin Transplant* 2019;33:e13663. <https://doi.org/10.1111/ctr.13663>.
307. Michelis KC, Zhong L, Tang WHW, et al. Durable mechanical circulatory support in patients with amyloid cardiomyopathy: insights from INTERMACS. *Circ Heart Fail* 2020;13:e007931. <https://doi.org/10.1161/CIRCHEARTFAILURE.120.007931>.
308. Palladini G, Sachchithanatham S, Milani P, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. *Blood* 2015;126:612-5. <https://doi.org/10.1182/blood-2015-01-620302>.
309. Lillenes B, Ruberg FL, Mussinelli R, Doros G, Sanchirawala V. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. *Blood* 2019;133:215-23. <https://doi.org/10.1182/blood-2018-06-858951>.
310. Palladini G, Hegenbart U, Milani P, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. *Blood* 2014;124:2325-32. <https://doi.org/10.1182/blood-2014-04-570010>.
311. Sonthalia N, Jain S, Pawar S, Zanwar V, Surude R, Rath PM. Primary hepatic amyloidosis: a case report and review of literature. *World J Hepatol* 2016;8:340-4. <https://doi.org/10.4254/wjh.v8.i6.340>.
312. Rowe K, Pankow J, Nehme F, Salyers W. Gastrointestinal amyloidosis: review of the literature. *Cureus* 2017;9:e1228. <https://doi.org/10.7759/cureus.1228>.
313. Shin SC, Robinson-Papp J. Amyloid neuropathies. *Mt Sinai J Med* 2012;79:733-48. <https://doi.org/10.1002/msj.21352>.
314. Milani P, Basset M, Russo F, Foli A, Palladini G, Merlini G. The lung in amyloidosis. *Eur Respir Rev* 2017;26:170046. <https://doi.org/10.1183/16000617.0046-2017>.
315. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. *Am J Hematol* 2005;79:319-28. <https://doi.org/10.1002/ajh.20381>.
316. Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC guidelines for the management of cardiomyopathies. *Eur Heart J* 2023;44:3503-626. <https://doi.org/10.1093/eurheartj/ehad194>.

317. Webber SA, Lipshultz SE, Sleeper LA, et al. Outcomes of restrictive cardiomyopathy in childhood and the influence of phenotype: a report from the Pediatric Cardiomyopathy Registry. *Circulation* 2012;126:1237-44. <https://doi.org/10.1161/CIRCULATIONAHA.112.104638>.
318. Bograd AJ, Mital S, Schwarzenberger JC, et al. Twenty-year experience with heart transplantation for infants and children with restrictive cardiomyopathy: 1986-2006. *Am J Transplant* 2008;8:201-7. <https://doi.org/10.1111/j.1600-6143.2007.02027.x>.
319. Murtuza B, Fenton M, Burch M, et al. Pediatric heart transplantation for congenital and restrictive cardiomyopathy. *Ann Thorac Surg* 2013;95:1675-84. <https://doi.org/10.1016/j.athoracsur.2013.01.014>.
320. Singh TP, Almond CS, Piercey G, Gauvreau K. Current outcomes in US children with cardiomyopathy listed for heart transplantation. *Circ Heart Fail* 2012;5:594-601. <https://doi.org/10.1161/CIRCHEARTFAILURE.112.969980>.
321. Hsich EM, Rogers JG, McNamara DM, et al. Does survival on the heart transplant waiting list depend on the underlying heart disease. *JACC Heart Fail* 2016;4:689-97. <https://doi.org/10.1016/j.jchf.2016.03.010>.
322. Ammassh NM, Seward JB, Bailey KR, Edwards WD, Tajik AJ. Clinical profile and outcome of idiopathic restrictive cardiomyopathy. *Circulation* 2000;101:2490-6. <https://doi.org/10.1161/01.cir.101.21.2490>.
323. Muchtar E, Blauwet LA, Gertz MA. Restrictive cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. *Circ Res* 2017;121:819-37. <https://doi.org/10.1161/CIRCRESAHA.117.310982>.
324. Sridharan L, Wayda B, Truby LK, et al. Mechanical circulatory support device utilization and heart transplant waitlist outcomes in patients with restrictive and hypertrophic cardiomyopathy. *Circ Heart Fail* 2018;11:e004665. <https://doi.org/10.1161/CIRCHEARTFAILURE.117.004665>.
325. Amdani S, Boyle G, Saarel EV, et al. Waitlist and post-heart transplant outcomes for children with nondilated cardiomyopathy. *Ann Thorac Surg* 2021;112:188-96. <https://doi.org/10.1016/j.athoracsur.2020.05.170>.
326. Rowin EJ, Maron MS, Chan RH, et al. Interaction of adverse disease related pathways in hypertrophic cardiomyopathy. *Am J Cardiol* 2017;120:2256-64. <https://doi.org/10.1016/j.amjcard.2017.08.048>.
327. Melacini P, Basso C, Angelini A, et al. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy. *Eur Heart J* 2010;31:2111-23. <https://doi.org/10.1093/eurheartj/ehq136>.
328. Pasqualucci D, Fornaro A, Castelli G, et al. Clinical spectrum, therapeutic options, and outcome of advanced heart failure in hypertrophic cardiomyopathy. *Circ Heart Fail* 2015;8:1014-21. <https://doi.org/10.1161/CIRCHEARTFAILURE.114.001843>.
329. Musumeci MB, Russo D, Limite LR, et al. Long-term left ventricular remodeling of patients with hypertrophic cardiomyopathy. *Am J Cardiol* 2018;122:1924-31. <https://doi.org/10.1016/j.amjcard.2018.08.041>.
330. Hebl VB, Miranda WR, Ong KC, et al. The natural history of nonobstructive hypertrophic cardiomyopathy. *Mayo Clin Proc* 2016;91:279-87. <https://doi.org/10.1016/j.mayocp.2016.01.002>.
331. Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. *Circulation* 2006;114:216-25. <https://doi.org/10.1161/CIRCULATIONAHA.105.583500>.
332. Rowin EJ, Maron BJ, Kiernan MS, et al. Advanced heart failure with preserved systolic function in nonobstructive hypertrophic cardiomyopathy: under-recognized subset of candidates for heart transplant. *Circ Heart Fail* 2014;7:967-75. <https://doi.org/10.1161/CIRCHEARTFAILURE.114.001435>.
333. Rowin EJ, Maron BJ, Abt P, et al. Impact of advanced therapies for improving survival to heart transplant in patients with hypertrophic cardiomyopathy. *Am J Cardiol* 2018;121:986-96. <https://doi.org/10.1016/j.amjcard.2017.12.044>.
334. Zuñiga Cisneros J, Stehlik J, Selzman CH, Drakos SG, McKellar SH, Wever-Pinzon O. Outcomes in patients with hypertrophic cardiomyopathy awaiting heart transplantation. *Circ Heart Fail* 2018;11:e004378. <https://doi.org/10.1161/CIRCHEARTFAILURE.117.004378>.
335. Kato TS, Takayama H, Yoshizawa S, et al. Cardiac transplantation in patients with hypertrophic cardiomyopathy. *Am J Cardiol* 2012;110:568-74.
336. Lee MS, Zimmer R, Kobashigawa J. Long-term outcomes of orthotopic heart transplantation for hypertrophic cardiomyopathy. *Transplant Proc* 2014;46:1502-5. <https://doi.org/10.1016/j.transproceed.2013.12.052>.
337. Maron MS, Kalsmith BM, Udelson JE, Li W, DeNofrio D. Survival after cardiac transplantation in patients with hypertrophic cardiomyopathy. *Circ Heart Fail* 2010;3:574-9. <https://doi.org/10.1161/CIRCHEARTFAILURE.109.922872>.
338. Cheong D, Eisenberg R, Lamour JM, Hsu DT, Choi J, Bansal N. Waitlist and post-transplant outcomes of children and young adults with hypertrophic cardiomyopathy. *Ann Thorac Surg* 2023;116:588-97. <https://doi.org/10.1016/j.athoracsur.2022.05.037>.

339. Muthiah K, Phan J, Robson D, et al. Centrifugal continuous-flow left ventricular assist device in patients with hypertrophic cardiomyopathy: a case series. *ASAIO J* 2013;59:183-7. <https://doi.org/10.1097/MAT.0b013e318286018d>.
340. Patel SR, Saeed O, Naftel D, et al. Outcomes of restrictive and hypertrophic cardiomyopathies after LVAD: an INTERMACS Analysis. *J Card Fail* 2017;23:859-67. <https://doi.org/10.1016/j.cardfail.2017.09.011>.
341. Topilsky Y, Pereira NL, Shah DK, et al. Left ventricular assist device therapy in patients with restrictive and hypertrophic cardiomyopathy. *Circ Heart Fail* 2011;4:266-75. <https://doi.org/10.1161/CIRCHEARTFAILURE.110.959288>.
342. Su JA, Mentee J. Outcomes of Berlin Heart EXCOR® pediatric ventricular assist device support in patients with restrictive and hypertrophic cardiomyopathy. *Pediatr Transplant* 2017;21. <https://doi.org/10.1111/ptr.13048>.
343. Moons P, Bovijn L, Budts W, Belmans A, Gewillig M. Temporal trends in survival to adulthood among patients born with congenital heart disease from 1970 to 1992 in Belgium. *Circulation* 2010;122:2264-72. <https://doi.org/10.1161/CIRCULATIONAHA.110.946343>.
344. Diller GP, Kempny A, Alonso-Gonzalez R, et al. Survival prospects and circumstances of death in contemporary adult congenital heart disease patients under follow-up at a large tertiary centre. *Circulation* 2015;132:2118-25. <https://doi.org/10.1161/CIRCULATIONAHA.115.017202>.
345. Zomer AC, Vaartjes I, Uiterwaal CS, et al. Circumstances of death in adult congenital heart disease. *Int J Cardiol* 2012;154:168-72. <https://doi.org/10.1016/j.ijcard.2010.09.015>.
346. Engelings CC, Helm PC, Abdul-Khalik H, et al. Cause of death in adults with congenital heart disease - an analysis of the German National Register for Congenital Heart Defects. *Int J Cardiol* 2016;211:31-6. <https://doi.org/10.1016/j.ijcard.2016.02.133>.
347. Amdani S, Marino BS, Rossano J, Lopez R, Schold JD, Tang WHW. Burden of pediatric heart failure in the United States. *J Am Coll Cardiol* 2022;79:1917-28. <https://doi.org/10.1016/j.jacc.2022.03.336>.
348. Lewis M, Rosenbaum M. When should adult congenital heart disease patients be considered for transplant and deciding which organs to transplant. *Prog Cardiovasc Dis* 2018;61:377-81. <https://doi.org/10.1016/j.pcad.2018.09.004>.
349. Stout KK, Broberg CS, Book WM, et al. Chronic heart failure in congenital heart disease: a scientific statement from the American Heart Association. *Circulation* 2016;133:770-801. <https://doi.org/10.1161/CIR.0000000000000352>.
350. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation* 2022;145:e895-1032. <https://doi.org/10.1161/CIR.0000000000001063>. Published correction appears in *Circulation*. 2022 May 3;145:e1033. Published correction appears in *Circulation*. 2022 Sep 27;146:e185. published correction appears in *Circulation*. 2023 Apr 4;147:e674.
351. Tang DG, Shah KB, Hess ML, Kasirajan V. Implantation of the syncardia total artificial heart. *J Vis Exp* 2014;50377. <https://doi.org/10.3791/50377>.
352. Merás P, Riesgo-Gil F, Rybicka J, et al. Heart transplantation at a single tertiary adult congenital heart disease centre: too little, too late? *Int J Cardiol* 2021;322:107-13. <https://doi.org/10.1016/j.ijcard.2020.08.047>.
353. Townsend M, Karamlou T, Boyle G, et al. Waitlist outcomes for children with congenital heart disease: lessons learned from over 5000 heart transplant listings in the United States. *J Card Fail* 2022;28:982-90. <https://doi.org/10.1016/j.cardfail.2022.03.004>.
354. Stewart GC, Mayer Jr. JE. Heart transplantation in adults with congenital heart disease. *Heart Fail Clin* 2014;10:207-18. <https://doi.org/10.1016/j.hfc.2013.09.007>.
355. Burchill LJ, Edwards LB, Dipchand AI, Stehlik J, Ross HJ. Impact of adult congenital heart disease on survival and mortality after heart transplantation. *J Heart Lung Transplant* 2014;33:1157-63. <https://doi.org/10.1016/j.healun.2014.05.007>.
356. Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-fifth adult heart transplantation report-2018; focus theme: multiorgan transplantation. *J Heart Lung Transplant* 2018;37:1155-68. <https://doi.org/10.1016/j.healun.2018.07.022>.
357. de la Rosa AL, Singer-Englar T, Tompkins RO, Patel JK, Kobashigawa JA, Kittleson MM. Advanced heart failure and heart transplantation in adult congenital heart disease in the current era. *Clin Transplant* 2021;35:e14451. <https://doi.org/10.1111/ctr.14451>.
358. Bhamra JK, Shulman J, Bermudez CA, et al. Heart transplantation for adults with congenital heart disease: results in the modern era. *J Heart Lung Transplant* 2013;32:499-504. <https://doi.org/10.1016/j.healun.2013.01.1047>.
359. Nguyen VP, Dolgner SJ, Dardas TF, Verrier ED, McMullan DM, Krieger EV. Improved outcomes of heart transplantation in adults with congenital heart disease receiving regionalized care. *J Am Coll Cardiol* 2019;74:2908-18. <https://doi.org/10.1016/j.jacc.2019.09.062>.
360. Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*

- 2019;139:e698-800. <https://doi.org/10.1161/CIR.0000000000000603>. Published correction appears in *Circulation*. 2019 Apr 2;139:e833-e834.
361. Zomer AC, Vaartjes I, van der Velde ET, et al. Heart failure admissions in adults with congenital heart disease; risk factors and prognosis. *Int J Cardiol* 2013;168(3):2487-93. <https://doi.org/10.1016/j.ijcard.2013.03.003>.
 362. Norozi K, Wessel A, Alpers V, et al. Incidence and risk distribution of heart failure in adolescents and adults with congenital heart disease after cardiac surgery. *Am J Cardiol* 2006;97:1238-43. <https://doi.org/10.1016/j.amjcard.2005.10.065>.
 363. Dykes JC, Rosenthal DN, Bernstein D, et al. Clinical and hemodynamic characteristics of the pediatric failing Fontan. *J Heart Lung Transplant* 2021;40:1529-39. <https://doi.org/10.1016/j.healun.2021.07.017>.
 364. Bernstein D, Naftel D, Chin C, et al. Outcome of listing for cardiac transplantation for failed Fontan: a multi-institutional study. *Circulation* 2006;114:273-80. <https://doi.org/10.1161/CIRCULATIONAHA.105.548016>.
 365. Jayakumar KA, Addonizio LJ, Kichuk-Chrisant MR, et al. Cardiac transplantation after the Fontan or Glenn procedure. *J Am Coll Cardiol* 2004;44:2065-72. <https://doi.org/10.1016/j.jacc.2004.08.031>.
 366. Kovach JR, Naftel DC, Pearce FB, et al. Comparison of risk factors and outcomes for pediatric patients listed for heart transplantation after bidirectional Glenn and after Fontan: an analysis from the Pediatric Heart Transplant Study. *J Heart Lung Transplant* 2012;31:133-9. <https://doi.org/10.1016/j.healun.2011.11.004>.
 367. McCormick AD, Schumacher KR. Transplantation of the failing Fontan. *Transl Pediatr* 2019;8:290-301. <https://doi.org/10.21037/tp.2019.06.03>.
 368. Poh CL, Cordina RL, Iyengar AJ, et al. Pre- and post-operative determinants of transplantation-free survival after Fontan. The Australia and New Zealand experience. *Int J Cardiol Heart Vasc* 2021;35:100825. <https://doi.org/10.1016/j.ijcha.2021.100825>.
 369. Schumacher KR, Gossett J, Guleserian K, et al. Fontan-associated protein-losing enteropathy and heart transplant: a Pediatric Heart Transplant Study analysis. *J Heart Lung Transplant* 2015;34:1169-76. <https://doi.org/10.1016/j.healun.2015.03.022>.
 370. Schumacher KR, Yu S, Butts R, et al. Fontan-associated protein-losing enteropathy and post-heart transplant outcomes: a multicenter study. *J Heart Lung Transplant* 2019;38:17-25. <https://doi.org/10.1016/j.healun.2018.09.024>.
 371. Gossett JG, Almond CS, Kirk R, et al. Outcomes of cardiac transplantation in single-ventricle patients with plastic bronchitis: a multicenter study. *J Am Coll Cardiol* 2013;61:985-6. <https://doi.org/10.1016/j.jacc.2012.10.042>.
 372. Carlo WF, Carberry KE, Heinle JS, et al. Interstage attrition between bidirectional Glenn and Fontan palliation in children with hypoplastic left heart syndrome. *J Thorac Cardiovasc Surg* 2011;142:511-6. <https://doi.org/10.1016/j.jtcvs.2011.01.030>.
 373. Sinha R, Altin HF, McCracken C, et al. Effect of atrioventricular valve repair on multistage palliation results of single-ventricle defects. *Ann Thorac Surg* 2021;111:662-70. <https://doi.org/10.1016/j.athoracsur.2020.03.126>.
 374. Guleserian KJ, Armsby LB, Thiagarajan RR, del Nido PJ, Mayer Jr. JE. Natural history of pulmonary atresia with intact ventricular septum and right-ventricle-dependent coronary circulation managed by the single-ventricle approach. *Ann Thorac Surg* 2006;81:2250-8. <https://doi.org/10.1016/j.athoracsur.2005.11.041>.
 375. Joong A, Zuckerman WA, Koehl D, et al. Outcomes of infants with pulmonary atresia with intact ventricular septum listed for heart transplantation: a multi-institutional study. *Pediatr Transplant* 2022;26:e14338. <https://doi.org/10.1111/ptr.14338>.
 376. Iliopoulos I, Mastropietro CW, Flores S, et al. Pulmonary atresia with intact ventricular septum: midterm outcomes from a multicenter cohort. *Pediatr Cardiol* 2024;45:847-57. <https://doi.org/10.1007/s00246-022-02954-5>.
 377. Cheung EW, Richmond ME, Turner ME, Bacha EA, Torres AJ. Pulmonary atresia/intact ventricular septum: influence of coronary anatomy on single-ventricle outcome. *Ann Thorac Surg* 2014;98:1371-7. <https://doi.org/10.1016/j.athoracsur.2014.06.039>.
 378. Chrisant MR, Naftel DC, Drummond-Webb J, et al. Fate of infants with hypoplastic left heart syndrome listed for cardiac transplantation: a multicenter study. *J Heart Lung Transplant* 2005;24:576-82. <https://doi.org/10.1016/j.healun.2004.01.019>.
 379. Morrow WR, Naftel D, Chinnock R, et al. Outcome of listing for heart transplantation in infants younger than six months: predictors of death and interval to transplantation. The Pediatric Heart Transplantation Study Group. *J Heart Lung Transplant* 1997;16:1255-66.
 380. Razzouk AJ, Chinnock RE, Gundry SR, et al. Transplantation as a primary treatment for hypoplastic left heart syndrome: intermediate-term results. *Ann Thorac Surg* 1996;62:1-8. [https://doi.org/10.1016/0003-4975\(96\)00295-0](https://doi.org/10.1016/0003-4975(96)00295-0).
 381. Mahle WT, Hu C, Trachtenberg F, et al. Heart failure after the Norwood procedure: an analysis of the Single Ventricle Reconstruction Trial. *J Heart Lung Transplant* 2018;37:879-85. <https://doi.org/10.1016/j.healun.2018.02.009>.

382. Newburger JW, Sleeper LA, Frommelt PC, et al. Transplantation-free survival and interventions at 3 years in the single ventricle re-construction trial. *Circulation* 2014;129:2013-20. <https://doi.org/10.1161/CIRCULATIONAHA.113.006191>.
383. Brida M, Gatzoulis MA. Pulmonary arterial hypertension in adult congenital heart disease. *Heart* 2018;104:1568-74. <https://doi.org/10.1136/heartjnl-2017-312106>.
384. Chiu SN, Lu CW, Lin MT, Chen CA, Wu MH, Wang JK. Pulmonary hypertension in adult congenital heart disease in asia: a distinctive feature of complex congenital heart disease. *J Am Heart Assoc* 2022;11:e022596. <https://doi.org/10.1161/JAHA.121.022596>.
385. Patel ND, Weiss ES, Allen JG, et al. Heart transplantation for adults with congenital heart disease: analysis of the United network for organ sharing database. *Ann Thorac Surg* 2009;88:814-22. <https://doi.org/10.1016/j.athoracsur.2009.04.071>.
386. Donovan DJ, Richmond ME, Bacha EA, Addonizio LJ, Zuckerman WA. Association between homograft tissue exposure and allosensitization prior to heart transplant in patients with congenital heart disease. *Pediatr Transplant* 2022;26:e14201. <https://doi.org/10.1111/ptr.14201>.
387. O'Connor MJ, Lind C, Tang X, et al. Persistence of anti-human leukocyte antibodies in congenital heart disease late after surgery using allografts and whole blood. *J Heart Lung Transplant* 2013;32:390-7. <https://doi.org/10.1016/j.healun.2012.12.009>.
388. Shaddy RE, Hunter DD, Osborn KA, et al. Prospective analysis of HLA immunogenicity of cryopreserved valved allografts used in pediatric heart surgery. *Circulation* 1996;94:1063-7. <https://doi.org/10.1161/01.cir.94.5.1063>.
389. Laing BJ, Ross DB, Meyer SR, et al. Glutaraldehyde treatment of allograft tissue decreases allosensitization after the Norwood procedure. *J Thorac Cardiovasc Surg* 2010;139:1402-8. <https://doi.org/10.1016/j.jtcvs.2009.12.034>.
390. Martin BJ, Kaestner M, Peng M, et al. Glutaraldehyde treatment of allografts and aortic outcomes post-norwood: challenging surgical decision. *Ann Thorac Surg* 2017;104:1395-401. <https://doi.org/10.1016/j.athoracsur.2017.03.008>.
391. Coti I, Wenda S, Andreeva A, et al. Donor-specific HLA antibodies after fresh decellularized vs cryopreserved native allograft implantation. *HLA* 2020;96:580-8. <https://doi.org/10.1111/tan.14077>.
392. Krishnan US, Lamour JM, Hsu DT, Kichuk MR, Donnelly CM, Addonizio LJ. Management of aortopulmonary collaterals in children following cardiac transplantation for complex congenital heart disease. *J Heart Lung Transplant* 2004;23:564-9. [https://doi.org/10.1016/S1053-2498\(03\)00305-X](https://doi.org/10.1016/S1053-2498(03)00305-X).
393. Almond CS, Gauvreau K, Canter CE, Rajagopal SK, Piercey GE, Singh TP. A risk-prediction model for in-hospital mortality after heart transplantation in US children. *Am J Transplant* 2012;12:1240-8. <https://doi.org/10.1111/j.1600-6143.2011.03932.x>.
394. Atz AM, Zak V, Mahony L, et al. Longitudinal outcomes of patients with single ventricle after the Fontan procedure. *J Am Coll Cardiol* 2017;69:2735-44. <https://doi.org/10.1016/j.jacc.2017.03.582>.
395. Law YM, Sharma S, Feingold B, Fuller B, Devine WA, Webber SA. Clinically significant thrombosis in pediatric heart transplant recipients during their waiting period. *Pediatr Cardiol* 2013;34:334-40. <https://doi.org/10.1007/s00246-012-0451-0>.
396. Silvey M, Nguyen ATH, Amankwah EK, et al. Risk factors for hospital acquired venous thromboembolism in congenital heart disease patients: a report from the children's hospital acquired thrombosis (CHAT) consortium. *Thromb Res* 2022;220:116-20. <https://doi.org/10.1016/j.thromres.2022.10.010>.
397. Goldberg DJ, Surrey LF, Glatz AC, et al. Hepatic fibrosis is universal following Fontan operation, and severity is associated with time from surgery: a liver biopsy and hemodynamic study. *J Am Heart Assoc* 2017;6:e004809. <https://doi.org/10.1161/JAHA.116.004809>.
398. Wu FM, Kogon B, Earing MG, et al. Liver health in adults with Fontan circulation: a multicenter cross-sectional study. *J Thorac Cardiovasc Surg* 2017;153:656-64. <https://doi.org/10.1016/j.jtcvs.2016.10.060>.
399. Pundi K, Pundi KN, Kamath PS, et al. Liver disease in patients after the Fontan operation. *Am J Cardiol* 2016;117:456-60. <https://doi.org/10.1016/j.amjcard.2015.11.014>.
400. Silva-Sepulveda JA, Fonseca Y, Vodkin I, et al. Evaluation of Fontan liver disease: correlation of transjugular liver biopsy with magnetic resonance and hemodynamics. *Congenit Heart Dis* 2019;14:600-8. <https://doi.org/10.1111/chd.12770>.
401. Surrey LF, Russo P, Rychik J, et al. Prevalence and characterization of fibrosis in surveillance liver biopsies of patients with Fontan circulation. *Hum Pathol* 2016;57:106-15. <https://doi.org/10.1016/j.humpath.2016.07.006>.
402. Amdani S, Simpson KE, Thrush P, et al. Hepatorenal dysfunction assessment with the Model for End-Stage Liver Disease Excluding INR score predicts worse survival after heart transplant in pediatric Fontan patients. *J Thorac Cardiovasc Surg* 2022;163:1462-1473.e12. <https://doi.org/10.1016/j.jtcvs.2021.02.014>.
403. Sganga D, Hollander SA, Vaikunth S, et al. Comparison of combined heart3liver vs heart-only transplantation in pediatric and young adult Fontan recipients. *J Heart Lung Transplant* 2021;40:298-306. <https://doi.org/10.1016/j.healun.2020.12.008>.

404. Bouchardy J, Meyer P, Yerly P, et al. Regression of advanced liver fibrosis after heart transplantation in a patient with prior Fontan surgery for complex congenital heart disease. *Circ Heart Fail* 2018;11:e003754. <https://doi.org/10.1161/CIRCHEARTFAILURE.117.003754>.
405. Kanter KR. Heart transplantation in children after a Fontan procedure: better than people think. *Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu* 2016;19:44-9. <https://doi.org/10.1053/j.pcsu.2015.11.004>.
406. Lewis MJ, Reardon LC, Aboulhosn J, et al. Morbidity and mortality in adult Fontan patients after heart or combined heart-liver transplantation. *J Am Coll Cardiol* 2023;81:2161-71. <https://doi.org/10.1016/j.jacc.2023.03.422>.
407. Lewis MJ, Reardon LC, Aboulhosn J, et al. Clinical outcomes of adult Fontan-associated liver disease and combined heart-liver transplantation. *J Am Coll Cardiol* 2023;81:2149-60. <https://doi.org/10.1016/j.jacc.2023.03.421>.
408. Wenke K, Meiser B, Thiery J, et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience. *Circulation* 2003;107:93-7. <https://doi.org/10.1161/01.cir.0000043241.32523.ee>.
409. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. *Circulation* 2004;110:2694-700. <https://doi.org/10.1161/01.CIR.0000136812.90177.94>.
410. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. *N Engl J Med* 2003;349:847-58. <https://doi.org/10.1056/NEJMoa022171>.
411. Aranda JM, Pauly DF, Kerensky RA, et al. Percutaneous coronary intervention versus medical therapy for coronary allograft vasculopathy. One center's experience. *J Heart Lung Transplant* 2002;21:860-6. [https://doi.org/10.1016/s1053-2498\(02\)00413-8](https://doi.org/10.1016/s1053-2498(02)00413-8).
412. Agarwal S, Parashar A, Kapadia SR, et al. Long-term mortality after cardiac allograft vasculopathy: implications of percutaneous intervention. *JACC Heart Fail* 2014;2:281-8. <https://doi.org/10.1016/j.jchf.2014.01.003>.
413. Mehra MR, Crespo-Leiro MG, Dipchand A, et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. *J Heart Lung Transplant* 2010;29:717-27. <https://doi.org/10.1016/j.healun.2010.05.017>. Published correction appears in *J Heart Lung Transplant*. 2011 Mar;30:360.
414. Loupy A, Coutance G, Bonnet G, et al. Identification and characterization of trajectories of cardiac allograft vasculopathy after heart transplantation: a population-based study. *Circulation* 2020;141:1954-67. <https://doi.org/10.1161/CIRCULATIONAHA.119.044924>.
415. Zhu Y, Shudo Y, Lingala B, Baiocchi M, Oyer PE, Woo YJ. Outcomes after heart retransplantation: a 50-year single-center experience. *J Thorac Cardiovasc Surg* 2022;163:712-720.e6. <https://doi.org/10.1016/j.jtcvs.2020.06.121>.
416. Conway J, Manlhiot C, Kirk R, Edwards LB, McCrindle BW, Dipchand AI. Mortality and morbidity after retransplantation after primary heart transplant in childhood: an analysis from the registry of the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant* 2014;33:241-51. <https://doi.org/10.1016/j.healun.2013.11.006>.
417. Miller RJH, Clarke BA, Howlett JG, Khush KK, Teuteberg JJ, Haddad F. Outcomes in patients undergoing cardiac retransplantation: a propensity matched cohort analysis of the UNOS Registry. *J Heart Lung Transplant* 2019;38:1067-74. <https://doi.org/10.1016/j.healun.2019.07.001>.
418. Savla J, Lin KY, Pradhan M, et al. Heart retransplant recipients have better survival with concurrent kidney transplant than with heart retransplant alone. *J Am Heart Assoc* 2015;4:e002435. <https://doi.org/10.1161/JAHA.115.002435>.
419. Radovancevic B, McGiffin DC, Kobashigawa JA, et al. Retransplantation in 7,290 primary transplant patients: a 10-year multi-institutional study. *J Heart Lung Transplant* 2003;22:862-8. [https://doi.org/10.1016/s1053-2498\(02\)00803-3](https://doi.org/10.1016/s1053-2498(02)00803-3).
420. Srivastava R, Keck BM, Bennett LE, Hosenpud JD. The results of cardiac retransplantation: an analysis of the Joint International Society for Heart and Lung Transplantation/United Network for Organ Sharing Thoracic Registry. *Transplantation* 2000;70:606-12. <https://doi.org/10.1097/00007890-200008270-00013>.
421. Chen Q, Malas J, Chan J, et al. Evaluating age-based eligibility thresholds for heart re-transplantation - an analysis of the united network for organ sharing database. *J Heart Lung Transplant* 2023;42:593-602. <https://doi.org/10.1016/j.healun.2022.11.012>.
422. Zadikany RH, Cole RM, Chang DH, et al. Total artificial heart as bridge to cardiac retransplantation. *ASAIO J* 2021;67:e77-9. <https://doi.org/10.1097/MAT.0000000000001217>.
423. Haddad H. Cardiac retransplantation: an ethical dilemma. *Curr Opin Cardiol* 2006;21:118-9. <https://doi.org/10.1097/01.hco.0000203839.72902.02>.
424. Luk A, Ross HJ. "Please Sir, I want some more?"... Charles Dickens, *Oliver Twist*. *J Heart Lung Transplant* 2014;33:231-2. <https://doi.org/10.1016/j.healun.2013.12.021>.

425. Connuck DM, Sleeper LA, Colan SD, et al. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. *Am Heart J* 2008;155:998-1005. <https://doi.org/10.1016/j.ahj.2008.01.018>.
426. Godown J, Fountain D, Bansal N, et al. Heart transplantation in children with Down syndrome. *J Am Heart Assoc* 2022;11(10):e024883. <https://doi.org/10.1161/JAHA.121.024883>.
427. Khoshbin E, Khushnood A, Reinhardt Z, Parry G, Schueler S, Hasan A. Heart transplantation in children and adults with Down syndrome: a single centre experience. *Pediatr Transplant* 2022;26:e14383. <https://doi.org/10.1111/ptr.14383>.
428. Statter MB, Noritz G. Children with intellectual and developmental disabilities as organ transplantation recipients. *Pediatrics* 2020;145:e20200625. <https://doi.org/10.1542/peds.2020-0625>.
429. Wightman A, Smith J, Diekema DS. Neurodevelopmental status as a criterion for solid organ transplant eligibility. In: Greenberg RA, Goldberg AM, Rodríguez-Arias D, editors. *Ethical Issues in Pediatric Organ Transplantation*. Cham: Springer International Publishing; 2016:215-36.
430. Chen A, Ahmad M, Flescher A, et al. Access to transplantation for persons with intellectual disability: Strategies for nondiscrimination. *Am J Transplant* 2020;20:2009-16. <https://doi.org/10.1111/ajt.15755>.
431. White-Koning M, Arnaud C, Dickinson HO, et al. Determinants of child-parent agreement in quality-of-life reports: a European study of children with cerebral palsy. *Pediatrics* 2007;120:e804-14. <https://doi.org/10.1542/peds.2006-3272>.
432. Dickinson HO, Parkinson KN, Ravens-Sieberer U, et al. Self-reported quality of life of 8-12-year-old children with cerebral palsy: a cross-sectional European study. *Lancet* 2007;369:2171-8. [https://doi.org/10.1016/S0140-6736\(07\)61013-7](https://doi.org/10.1016/S0140-6736(07)61013-7).
433. Mezgebe M, Akhtar-Danesh GG, Streiner DL, Fayed N, Rosenbaum PL, Ronen GM. Quality of life in children with epilepsy: How does it compare with the quality of life in typical children and children with cerebral palsy? *Epilepsy Behav* 2015;52:239-43. <https://doi.org/10.1016/j.yebeh.2015.09.009>.
434. Calley A, Williams S, Reid S, et al. A comparison of activity, participation and quality of life in children with and without spastic diplegia cerebral palsy. *Disabil Rehabil* 2012;34:1306-10. <https://doi.org/10.3109/09638288.2011.641662>.
435. Albrecht GL, Devlieger PJ. The disability paradox: high quality of life against all odds. *Soc Sci Med* 1999;48:977-88. [https://doi.org/10.1016/S0277-9536\(98\)00411-0](https://doi.org/10.1016/S0277-9536(98)00411-0).
436. Wightman A, Bradford MC, Hsu E, Bartlett HL, Smith JM. Prevalence and long-term outcomes of solid organ transplant in children with intellectual disability. *J Pediatr* 2021;235:10-17.e4. <https://doi.org/10.1016/j.jpeds.2021.03.056>.
437. Wightman A, Young B, Bradford M, et al. Prevalence and outcomes of renal transplantation in children with intellectual disability. *Pediatr Transplant* 2014;18:714-9. <https://doi.org/10.1111/ptr.12339>.
438. Wightman A, Hsu E, Zhao Q, Smith J. Prevalence and outcomes of liver transplantation in children with intellectual disability. *J Pediatr Gastroenterol Nutr* 2016;62:808-12.
439. Martens MA, Jones L, Reiss S. Organ transplantation, organ donation and mental retardation. *Pediatr Transplant* 2006;10:658-64. <https://doi.org/10.1111/j.1399-3046.2006.00545.x>.
440. Englund M, Berg U, Tydén G. A longitudinal study of children who received renal transplants 10-20 years ago. *Transplantation* 2003;76:311-8. <https://doi.org/10.1097/01.TP.0000076472.45979.65>.
441. Oliva M, Singh TP, Gauvreau K, Vanderpluym CJ, Bastardi HJ, Almond CS. Impact of medication non-adherence on survival after pediatric heart transplantation in the U.S.A. *J Heart Lung Transplant* 2013;32:881-8. <https://doi.org/10.1016/j.healun.2013.03.008>.
442. Ross LF. Ethics of organ transplantation in persons with intellectual disability. *J Pediatr* 2021;235:6-9.
443. Fricker FJ, Addonizio L, Bernstein D, et al. Heart transplantation in children: indications. Report of the Ad Hoc Subcommittee of the Pediatric Committee of the American Society of Transplantation (AST). *Pediatr Transplant* 1999;3:333-42. <https://doi.org/10.1034/j.1399-3046.1999.00045.x>.
444. Almond CSD, Thiagarajan RR, Piercey GE, et al. Waiting list mortality among children listed for heart transplantation in the United States. *Circulation* 2009;119:717-27. <https://doi.org/10.1161/CIRCULATIONAHA.108.815712>.
445. Shimizu M, Nishinaka T, Inai K, Nakanishi T. Outcomes in children with advanced heart failure in Japan: importance of mechanical circulatory support. *Heart Vessels* 2016;31:1162-7. <https://doi.org/10.1007/s00380-015-0722-9>.
446. West LJ, Pollock-Barziv SM, Dipchand AI, et al. ABO-incompatible heart transplantation in infants. *N Engl J Med* 2001;344:793-800. <https://doi.org/10.1056/NEJM200103153441102>.

447. Rodriguez RJ, Addonizio LJ, Lamour JM, et al. Pediatric heart transplantation across ABO blood type barriers: a case study. *Prog Transpl* 2005;15:161-5. <https://doi.org/10.1177/152692480501500209>.
448. Daebritz SH, Schmoekel M, Mair H, et al. Blood type incompatible cardiac transplantation in young infants. *Eur J Cardiothorac Surg* 2007;31:339-43. <https://doi.org/10.1016/j.ejcts.2006.11.032>.
449. Saczkowski R, Dacey C, Bernier PL. Does ABO-incompatible and ABO-compatible neonatal heart transplant have equivalent survival? *Inter Cardiovasc Thorac Surg* 2010;10:1026-33. <https://doi.org/10.1510/icvts.2009.229757>.
450. Urschel S, Larsen IM, Kirk R, et al. ABO-incompatible heart transplantation in early childhood: an international multicenter study of clinical experiences and limits. *J Heart Lung Transplant* 2013;32:285-92. <https://doi.org/10.1016/j.healun.2012.11.022>.
451. Modify Heart Policy for Intended Incompatible Blood Type (ABOi) Offers to Pediatric Candidates. Available at: <https://optn.transplant.hrsa.gov/policies-bylaws/public-comment/modify-heart-policy-for-intended-incompatible-blood-type-aboi-offers-to-pediatric-candidates/>. Accessed May 4, 2024.
452. Maeda K, Yamaki S, Kado H, Asou T, Murakami A, Takamoto S. Hypoplasia of the small pulmonary arteries in hypoplastic left heart syndrome with restrictive atrial septal defect. *Circulation* 2004;110(11 Suppl 1):II139-46. <https://doi.org/10.1161/01.CIR.0000138223.74524.4e>.
453. Cheng CC, Lin MT, Huang SC, Hsu HH. Lung transplantation with concomitant cardiac repair for congenital hypoplasia of bilateral pulmonary arteries and patent ductus arteriosus. *J Cardiothorac Surg* 2022;17:49. <https://doi.org/10.1186/s13019-022-01792-z>.
454. Dew MA, DiMartini AF, Steel J, et al. Meta-analysis of risk for relapse to substance use after transplantation of the liver or other solid organs. *Liver Transplant* 2008;14:159-72. <https://doi.org/10.1002/lt.21278>.
455. Bui QM, Allen LA, LeMond L, Brambatti M, Adler E. Psychosocial evaluation of candidates for heart transplant and ventricular assist devices: beyond the current consensus. *Circ Heart Fail* 2019;12:e006058. <https://doi.org/10.1161/CIRCHEARTFAILURE.119.006058>.
456. Owen JE, Bonds CL, Wellisch DK. Psychiatric evaluations of heart transplant candidates: predicting post-transplant hospitalizations, rejection episodes, and survival. *Psychosomatics* 2006;47:213-22. <https://doi.org/10.1176/appi.psy.47.3.213>.
457. Lentine KL, Yuan H, Tuttle-Newhall JE, et al. Quantifying prognostic impact of prescription opioid use before kidney transplantation through linked registry and pharmaceutical claims data. *Transplantation* 2015;99:187-96. <https://doi.org/10.1097/TP.0000000000000248>.
458. Ilonze OJ, Vidot DC, Breathett K, et al. Cannabis use and heart transplantation: disparities and opportunities to improve outcomes. *Circ Heart Fail* 2022;15:e009488. <https://doi.org/10.1161/CIRCHEARTFAILURE.122.009488>.
459. Thompson 3rd GR, Tuscano JM, Dennis M, et al. A microbiome assessment of medical marijuana. *Clin Microbiol Infect* 2017;23:269-70. <https://doi.org/10.1016/j.cmi.2016.12.001>.
460. Parker R, Armstrong MJ, Corbett C, Day EJ, Neuberger JM. Alcohol and substance abuse in solid-organ transplant recipients. *Transplantation* 2013;96:1015-24. <https://doi.org/10.1097/TP.0b013e31829f7579>.
461. Bush K, Kivlahan DR, McDonnell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. *Arch Intern Med* 1998;158:1789-95. <https://doi.org/10.1001/archinte.158.16.1789>.
462. Verhelle L, Van Bockstaele K, Duerinckx N, et al. How to screen for at-risk alcohol use in transplant patients? From instrument selection to implementation of the AUDIT-C. *Clin Transpl* 2021;35:e14137. <https://doi.org/10.1111/ctr.14137>.
463. Tome S, Said A, Lucey MR. Addictive behavior after solid organ transplantation: what do we know already and what do we need to know? *Liver Transplant* 2008;14:127-9. <https://doi.org/10.1002/lt.21311>.
464. Aradottir S, Asanovska G, Gjerss S, Hansson P, Alling C. PHosphatidylethanol (PEth) concentrations in blood are correlated to reported alcohol intake in alcohol-dependent patients. *Alcohol Alcohol* 2006;41:431-7. <https://doi.org/10.1093/alcac/agl027>.
465. Duerinckx N, Burkhalter H, Engberg SJ, et al. Correlates and outcomes of post-transplant smoking in solid organ transplant recipients: a systematic literature review and meta-analysis. *Transplantation* 2016;100:2252-63. <https://doi.org/10.1097/TP.0000000000001335>.
466. Roussel JC, Baron O, Périgaud C, et al. Outcome of heart transplants 15 to 20 years ago: graft survival, post-transplant morbidity, and risk factors for mortality. *J Heart Lung Transplant* 2008;27:486-93. <https://doi.org/10.1016/j.healun.2008.01.019>.
467. Botha P, Peaston R, White K, Forty J, Dark JH, Parry G. Smoking after cardiac transplantation. *Am J Transpl* 2008;8:866-71. <https://doi.org/10.1111/j.1600-6143.2007.02119.x>.
468. Kim S. Overview of cotinine cutoff values for smoking status classification. *Int J Environ Res Public Health* 2016;13:1236. <https://doi.org/10.3390/ijerph13121236>.

469. Langford CP, Bowsher J, Maloney JP, Lillis PP. Social support: a conceptual analysis. *J Adv Nurs* 1997;25:95-100. <https://doi.org/10.1046/j.1365-2648.1997.1997025095.x>.
470. Berkman LF, Glass T, Brissette I, Seeman TE. From social integration to health: Durkheim in the new millennium. *Soc Sci Med* 2000;51:843-57. [https://doi.org/10.1016/s0277-9536\(00\)00065-4](https://doi.org/10.1016/s0277-9536(00)00065-4).
471. Bruce CR, Minard CG, Wilhelms LA, et al. Caregivers of patients with left ventricular assist devices: possible impacts on patients' mortality and interagency registry for mechanically assisted circulatory support-defined morbidity events. *Circ Cardiovasc Qual Outcomes* 2017;10:e002879. <https://doi.org/10.1161/CIRCOUTCOMES.116.002879>.
472. Mollberg NM, Farjah F, Howell E, Ortiz J, Backhus L, Mulligan MS. Impact of primary caregivers on long-term outcomes after lung transplantation. *J Heart Lung Transplant* 2015;34:59-64. <https://doi.org/10.1016/j.healun.2014.09.022>.
473. Ladin K, Daniels A, Osani M, Bannuru RR. Is social support associated with post-transplant medication adherence and outcomes? A systematic review and meta-analysis. *Transpl Rev (Orlando)* 2018;32:16-28. <https://doi.org/10.1016/j.trre.2017.04.001>.
474. Tam V, Arnaoutakis GJ, George TJ, et al. Marital status improves survival after orthotopic heart transplantation. *J Heart Lung Transplant* 2011;30:1389-94. <https://doi.org/10.1016/j.healun.2011.07.020>.
475. Bui QM, Braun OO, Brambatti M, et al. The value of Stanford integrated psychosocial assessment for transplantation (SIPAT) in prediction of clinical outcomes following left ventricular assist device (LVAD) implantation. *Heart Lung* 2019;48:85-9. <https://doi.org/10.1016/j.hrtlng.2018.08.011>.
476. Conway A, Schadewaldt V, Clark R, Ski C, Thompson DR, Doering L. The psychological experiences of adult heart transplant recipients: a systematic review and meta-summary of qualitative findings. *Heart Lung* 2013;42:449-55. <https://doi.org/10.1016/j.hrtlng.2013.08.003>.
477. Ivarsson B, Ekmeahag B, Sjöberg T. Heart or lung transplanted patients' retrospective views on information and support while waiting for transplantation. *J Clin Nurs* 2013;22:1620-8.
478. Dobbels F, Vanhaecke J, Dupont L, et al. Pre-transplant predictors of post-transplant adherence and clinical outcome: an evidence base for pre-transplant psychosocial screening. *Transplantation* 2009;87:1497-504. <https://doi.org/10.1097/TP.0b013e3181a440ae>.
479. Spaderna H, Mendell NR, Zahn D, et al. Social isolation and depression predict 12-month outcomes in the "waiting for a new heart study". *J Heart Lung Transplant* 2010;29:247-54. <https://doi.org/10.1016/j.healun.2009.07.018>.
480. Maldonado JR. Why it is important to consider social support when assessing organ transplant candidates? *Am J Bioeth* 2019;19:1-8.
481. Goetzinger AM, Blumenthal JA, O'Hayer CV, et al. Stress and coping in caregivers of patients awaiting solid organ transplantation. *Clin Transplant* 2012;26:97-104. <https://doi.org/10.1111/j.1399-0012.2011.01431.x>.
482. Dew MA, Kormos RL, Roth LH, Murali S, DiMartini A, Griffith BP. Early post-transplant medical compliance and mental health predict physical morbidity and mortality one to three years after heart transplantation. *J Heart Lung Transplant* 1999;18:549-62. [https://doi.org/10.1016/s1053-2498\(98\)00044-8](https://doi.org/10.1016/s1053-2498(98)00044-8).
483. De Geest S, Burkhalter H, Bogert L, et al. Describing the evolution of medication nonadherence from pre-transplant until 3 years post-transplant and determining pre-transplant medication nonadherence as risk factor for post-transplant nonadherence to immunosuppressives: the Swiss Transplant Cohort Study. *Transpl Int* 2014;27:657-66. <https://doi.org/10.1111/tri.12312>.
484. Helmy R, Duerinckx N, De Geest S, et al. The international prevalence and variability of nonadherence to the nonpharmacologic treatment regimen after heart transplantation: Findings from the cross-sectional BRIGHT study. *Clin Transplant* 2018;32:e13280. <https://doi.org/10.1111/ctr.13280>.
485. Gronewold N, Schunn F, Ihrig A, et al. Psychosocial characteristics of patients evaluated for kidney, liver, or heart transplantation. *Psychosom Med* 2023;85:98-105. <https://doi.org/10.1097/PSY.0000000000001142>.
486. Dobbels F, De Bleser L, Berben L, et al. Efficacy of a medication adherence enhancing intervention in transplantation: the MAESTRO-Tx trial. *J Heart Lung Transplant* 2017;36:499-508. <https://doi.org/10.1016/j.healun.2017.01.007>.
487. Foster BJ, Pai ALH, Zelikovsky N, et al. A randomized trial of a multicomponent intervention to promote medication adherence: the Teen Adherence in Kidney Transplant Effectiveness of Intervention Trial (TAKE-IT). *Am J Kidney Dis* 2018;72:30-41. <https://doi.org/10.1053/ajkd.2017.12.012>. published correction appears in *Am J Kidney Dis*. 2019 Apr;73(4):578.
488. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. *J Am Coll Cardiol* 2006;48:1527-37. <https://doi.org/10.1016/j.jacc.2006.06.055>.
489. de la Rosa A, Singer-Englar T, Hamilton MA, IsHak WW, Kobashigawa JA, Kittleson MM. The impact of depression on heart transplant outcomes: a retrospective single-center cohort study. *Clin Transplant* 2021;35:e14204. <https://doi.org/10.1111/ctr.14204>.

490. Dew MA, Rosenberger EM, Myaskovsky L, et al. Depression and anxiety as risk factors for morbidity and mortality after organ transplantation: a systematic review and meta-analysis. *Transplantation* 2015;100:988-1003. <https://doi.org/10.1097/TP.0000000000000901>.
491. Delibasic M, Mohamedali B, Dobrilovic N, Raman J. Pre-transplant depression as a predictor of adherence and morbidities after orthotopic heart transplantation. *J Cardiothorac Surg* 2017;12:62.
492. Sánchez R, Baillès E, Peri JM, et al. Assessment of psychosocial factors and predictors of psychopathology in a sample of heart transplantation recipients: a prospective 12-month follow-up. *Gen Hosp Psychiatry* 2016;38:59-64. <https://doi.org/10.1016/j.genhosppsych.2015.10.006>.
493. Bailey P, Vergis N, Allison M, Riddell A, Massey E. Psychosocial evaluation of candidates for solid organ transplantation. *Transplantation* 2021;105:e292-302. <https://doi.org/10.1097/TP.0000000000003732>.
494. Dobbels F, Put C, Vanhaecke J. Personality disorders: a challenge for transplantation. *Prog Transplant* 2000;10:226-32. <https://doi.org/10.1177/152692480001000406>.
495. Coffman KL, Crone C. Rational guidelines for transplantation in patients with psychotic disorders. *Curr Opin Organ Transplant* 2002;7:385-8.
496. Shapiro PA, Kornfeld DS. Psychiatric outcome of heart transplantation. *Gen Hosp Psychiatry* 1989;11:352-7. [https://doi.org/10.1016/0163-8343\(89\)90123-0](https://doi.org/10.1016/0163-8343(89)90123-0).
497. Harris J, Heil JS. Managing depression in patients with advanced heart failure awaiting transplantation. *Am J Health Syst Pharm* 2013;70:867-73. <https://doi.org/10.2146/ajhp110738>.
498. Sambucini D, Ciacchella C, Pellicano GR, et al. Psychosocial treatment on psychological symptoms, adherence, and physiological function on transplanted patients: asystematic review and metanalysis. *J Psychosom Res* 2022;154:110717. <https://doi.org/10.1016/j.jpsychores.2022.110717>.
499. Corbett C, Armstrong MJ, Parker R, Webb K, Neuberger JM. Mental health disorders and solid-organ transplant recipients. *Transplantation* 2013;96:593-600. <https://doi.org/10.1097/TP.0b013e31829584e0>.
500. Breathett K, Yee E, Pool N, et al. Does race influence decision making for advanced heart failure therapies? *J Am Heart Assoc* 2019;8:e013592. <https://doi.org/10.1161/JAHA.119.013592>.
501. Breathett K, Yee E, Pool N, et al. Association of gender and race with allocation of advanced heart failure therapies. *JAMA Netw Open* 2020;3:e2011044. <https://doi.org/10.1001/jamanetworkopen.2020.11044>.
502. Maldonado JR, Dubois HC, David EE, et al. The Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT): a new tool for the psychosocial evaluation of pre-transplant candidates. *Psychosomatics* 2012;53:123-32. <https://doi.org/10.1016/j.psym.2011.12.012>.
503. Twillman RK, Manetto C, Wellisch DK, Wolcott DL. The Transplant Evaluation Rating Scale. A revision of the psychosocial levels system for evaluating organ transplant candidates. *Psychosomatics* 1993;34:144-53.
504. Olbrisch ME, Levenson JL, Hamer R. The PACT: a rating scale for the study of clinical decision-making in psychosocial screening of organ transplant candidates. *Clin Transplant* 1989;3:164-9.
505. Vandenbogaart E, Doering L, Chen B, et al. Evaluation of the SIPAT instrument to assess psychosocial risk in heart transplant candidates: a retrospective single center study. *Heart Lung* 2017;46:273-9. <https://doi.org/10.1016/j.hrtlng.2017.04.005>.
506. Maldonado JR, Sher Y, Lolak S, et al. The Stanford Integrated Psychosocial Assessment for Transplantation: a prospective study of medical and psychosocial outcomes. *Psychosom Med* 2015;77:1018-30. <https://doi.org/10.1097/PSY.000000000000241>.
507. Cousino MK, Rea KE, Schumacher KR, Magee JC, Fredericks EM. A systematic review of parent and family functioning in pediatric solid organ transplant populations. *Pediatr Transplant* 2017;21. <https://doi.org/10.1111/petr.12900>.
508. Cousino MK, Schumacher KR, Rea KE, et al. Psychosocial functioning in pediatric heart transplant recipients and their families. *Pediatr Transplant* 2018;22. <https://doi.org/10.1111/petr.13110>.
509. Foulkes LM, Boggs SR, Fennell RS, Skibinski K. Social support, family variables, and compliance in renal transplant children. *Pediatr Nephrol* 1993;7:185-8. <https://doi.org/10.1007/BF00864393>.
510. Gerson AC, Furth SL, Neu AM, Fivush BA. Assessing associations between medication adherence and potentially modifiable psychosocial variables in pediatric kidney transplant recipients and their families. *Pediatr Transplant* 2004;8:543-50. <https://doi.org/10.1111/j.1399-3046.2004.00215.x>.
511. Killian MO, Schuman DL, Mayersohn GS, Triplett KN. Psychosocial predictors of medication non-adherence in pediatric organ transplantation: a systematic review. *Pediatr Transplant* 2018;22:e13188. <https://doi.org/10.1111/petr.13188>.

512. Shemesh E, Duncan S, Anand R, et al. Trajectory of adherence behavior in pediatric and adolescent liver transplant recipients: the medication adherence in children who had a liver transplant cohort. *Liver Transplant* 2018;24:80-8. <https://doi.org/10.1002/lt.24837>.
513. Berquist RK, Berquist WE, Esquivel CO, Cox KL, Wayman KI, Litt IF. Adolescent non-adherence: prevalence and consequences in liver transplant recipients. *Pediatr Transplant* 2006;10:304-10. <https://doi.org/10.1111/j.1399-3046.2005.00451.x>.
514. Berquist RK, Berquist WE, Esquivel CO, Cox KL, Wayman KI, Litt IF. Non-adherence to post-transplant care: prevalence, risk factors and outcomes in adolescent liver transplant recipients. *Pediatr Transplant* 2008;12:194-200. <https://doi.org/10.1111/j.1399-3046.2007.00809.x>.
515. Serrano-Ikkos E, Lask B, Whitehead B, Eisler I. Incomplete adherence after pediatric heart and heart-lung transplantation. *J Heart Lung Transplant* 1998;17:1177-83.
516. Lurie S, Shemesh E, Sheiner PA, et al. Non-adherence in pediatric liver transplant recipients—an assessment of risk factors and natural history. *Pediatr Transplant* 2000;4:200-6. <https://doi.org/10.1034/j.1399-3046.2000.00110.x>.
517. Killian MO. Psychosocial predictors of medication adherence in pediatric heart and lung organ transplantation. *Pediatr Transplant* 2017;21. <https://doi.org/10.1111/ptr.12899>.
518. Fredericks EM, Lopez MJ, Magee JC, Shieck V, Opipari-Arrigan L. Psychological functioning, nonadherence and health outcomes after pediatric liver transplantation. *Am J Transplant* 2007;7:1974-83. <https://doi.org/10.1111/j.1600-6143.2007.01878.x>.
519. Feinstein S, Keich R, Becker-Cohen R, Rinat C, Schwartz SB, Frishberg Y. Is noncompliance among adolescent renal transplant recipients inevitable? *Pediatrics* 2005;115:969-73. <https://doi.org/10.1542/peds.2004-0211>.
520. Soliday E, Kool E, Lande MB. Family environment, child behavior, and medical indicators in children with kidney disease. *Child Psychiatry Hum Dev* 2001;31:279-95. <https://doi.org/10.1023/a:1010282305881>.
521. Ethics - Ethical Principles in the Allocation of Human Organs - OPTN. 2015. Available at: <https://optn.transplant.hrsa.gov/professionals/by-topic/ethical-considerations/ethical-principles-in-the-allocation-of-human-organs/#:~:text=We%20identify%20three%20principles%20of,calls%20%22equitable%22%20allocation%20system>. Accessed May 4, 2024.
522. Diseth TH, Tangeraas T, Reinfejl T, Bjerre A. Kidney transplantation in childhood: mental health and quality of life of children and caregivers. *Pediatr Nephrol* 2011;26:1881-92. <https://doi.org/10.1007/s00467-011-1887-9>.
523. Singh TP. Black race and outcomes in children with a heart transplant. *J Heart Lung Transplant* 2019;38:1323-4. <https://doi.org/10.1016/j.healun.2019.09.013>.
524. Singh TP, Almond CS, Taylor DO, Milliren CE, Graham DA. Racial and ethnic differences in wait-list outcomes in patients listed for heart transplantation in the United States. *Circulation* 2012;125:3022-30. <https://doi.org/10.1161/CIRCULATIONAHA.112.092643>.
525. Monnin K, Lofton AM, Naclerio C, et al. Understanding substance use policies and associated ethical concerns: a survey of pediatric transplant centers. *Pediatr Transplant* 2021;25:e13984. <https://doi.org/10.1111/ptr.13984>.
526. Amdani S, Bhimani SA, Boyle G, et al. Racial and ethnic disparities persist in the current era of pediatric heart transplantation. *J Card Fail* 2021;27:957-64. <https://doi.org/10.1016/j.cardfail.2021.05.027>.
527. Morris AA, Cole RT, Veledar E, et al. Influence of race/ethnic differences in pre-transplantation panel reactive antibody on outcomes in heart transplant recipients. *J Am Coll Cardiol* 2013;62:2308-15. <https://doi.org/10.1016/j.jacc.2013.06.054>.
528. Kilic A, Higgins RS, Whitson BA, Kilic A. Racial disparities in outcomes of adult heart transplantation. *Circulation* 2015;131:882-9. <https://doi.org/10.1161/CIRCULATIONAHA.114.011676>.
529. Lui C, Fraser 3rd CD, Zhou X, et al. Racial disparities in patients bridged to heart transplantation with left ventricular assist devices. *Ann Thorac Surg* 2019;108:1122-6. <https://doi.org/10.1016/j.athoracsur.2019.03.073>.
530. Davies RR, Russo MJ, Reinhartz O, et al. Lower socioeconomic status is associated with worse outcomes after both listing and transplanting children with heart failure. *Pedia Transplant* 2013;17:573-81. <https://doi.org/10.1111/ptr.12117>.
531. Amdani S, Tang A, Schold JD. Children from socioeconomically disadvantaged communities present in more advanced heart failure at the time of transplant listing. *J Heart Lung Transplant* 2023;42:150-5. <https://doi.org/10.1016/j.healun.2022.09.007>.
532. Dore-Stites D, Lopez MJ, Magee JC, et al. Health literacy and its association with adherence in pediatric liver transplant recipients and their parents. *Pediatr Transplant* 2020;24:e13726. <https://doi.org/10.1111/ptr.13726>.
533. Miller TA. Health literacy and adherence to medical treatment in chronic and acute illness: a meta-analysis. *Patient Educ Couns* 2016;99:1079-86.

534. Bahador Z, Dehghani SM, Bahador A, et al. Parents' education level and mortality and morbidity of children after liver transplantation. *Int J Organ Transplant Med* 2015;6:25-30.
535. Breathett K, Liu WG, Allen LA, et al. African Americans are less likely to receive care by a cardiologist during an intensive care unit admission for heart failure. *JACC Heart Fail* 2018;6:413-20. <https://doi.org/10.1016/j.jchf.2018.02.015>. Published correction appears in *JACC Heart Fail*. 2018 Jul;6:617.
536. Sabin J, Nosek BA, Greenwald A, Rivara FP. Physicians' implicit and explicit attitudes about race by MD race, ethnicity, and gender. *J Health Care Poor Under* 2009;20:896-913. <https://doi.org/10.1353/hpu.0.0185>.
537. Greenwald AG, Banaji MR. Implicit social cognition: attitudes, self-esteem, and stereotypes. *Psychol Rev* 1995;102:4-27. <https://doi.org/10.1037/0033-295x.102.1.4>.
538. Maina IW, Belton TD, Ginzberg S, Singh A, Johnson TJ. A decade of studying implicit racial/ethnic bias in healthcare providers using the implicit association test. *Soc Sci Med* 2018;199:219-29.
539. FitzGerald C, Hurst S. Implicit bias in healthcare professionals: a systematic review. *BMC Med Ethics* 2017;18:19. <https://doi.org/10.1186/s12910-017-0179-8>.
540. Amdani S, Conway J, Kleinmahon J, et al. Race and socioeconomic bias in pediatric cardiac transplantation. *JACC Heart Fail* 2023;11:19-26. <https://doi.org/10.1016/j.jchf.2022.08.021>.
541. Ashkenazi T, Berman M, Ben Ami S, Fadila A, Aravot D. A bridge between hearts: mutual organ donation by Arabs and Jews in Israel. *Transplantation* 2004;77:151-7. <https://doi.org/10.1097/01.TP.0000103722.79951.DE>.
542. Ali A, Ahmed T, Ayub A, et al. Organ donation and transplant: the Islamic perspective. *Clin Transpl* 2020;34:e13832. <https://doi.org/10.1111/ctr.13832>.
543. Sander S, Singer-Englar T, Nishihara K, et al. Heart transplant in Jehovah's Witness patients: a case-control study. *J Heart Lung Transplant* 2021;40:575-9. <https://doi.org/10.1016/j.healun.2021.03.014>.
544. Richards CT, Crawley LM, Magnus D. Use of neurodevelopmental delay in pediatric solid organ transplant listing decisions: inconsistencies in standards across major pediatric transplant centers. *Pediatr Transplant* 2009;13:843-50.
545. Papazoglou A, Jacobson LA, McCabe M, Kaufmann W, Zabel TA. To ID or not to ID? Changes in classification rates of intellectual disability using DSM-5. *Intellect Dev Disabil* 2014;52:165-74. <https://doi.org/10.1352/1934-9556-52.3.165>.
546. Tassé MJ, Schalock RL, Balboni G, et al. The construct of adaptive behavior: its conceptualization, measurement, and use in the field of intellectual disability. *Am J Intellect Dev Disabil* 2012;117:291-303. <https://doi.org/10.1352/1944-7558-117.4.291>.
547. Kates OS, Stohs EJ, Pergam SA, et al. The limits of refusal: an ethical review of solid organ transplantation and vaccine hesitancy. *Am J Transplant* 2021;21:2637-45. <https://doi.org/10.1111/ajt.16472>.
548. Ladd JM, Karkazis K, Magnus D. Parental refusal of vaccination and transplantation listing decisions: a nationwide survey. *Pediatr Transplant* 2013;17:244-50. <https://doi.org/10.1111/petr.12046>.
549. Green M, Blumberg EA, Danziger-Isakov L, Huprikar S, Kotton CN, Kumar D. Foreword: 4th edition of the American Society of Transplantation Infectious Diseases Guidelines. *Clin Transplant* 2019;33:e13642. <https://doi.org/10.1111/ctr.13642>.
550. Cajita MI, Baumgartner E, Berben L, et al. Heart transplant centers with multidisciplinary team show a higher level of chronic illness management - findings from the International BRIGHT Study. *Heart Lung* 2017;46:351-6. <https://doi.org/10.1016/j.hrtlng.2017.05.006>.
551. Schmidhauser M, Regamey J, Pilon N, et al. The impact of multidisciplinary care on early morbidity and mortality after heart transplantation. *Inter Cardiovasc Thorac Surg* 2017;25:384-90. <https://doi.org/10.1093/icvts/ivx151>.
552. Gattis WA, Hasselblad V, Whellan DJ, O'Connor CM. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) study. *Arch Intern Med* 1999;159:1939-45. <https://doi.org/10.1001/archinte.159.16.1939>.
553. Koshman SL, Charrois TL, Simpson SH, McAlister FA, Tsuyuki RT. Pharmacist care of patients with heart failure: a systematic review of randomized trials. *Arch Intern Med* 2008;168:687-94. <https://doi.org/10.1001/archinte.168.7.687>.
554. Dunn SP, Birtcher KK, Beavers CJ, et al. The role of the clinical pharmacist in the care of patients with cardiovascular disease. *J Am Coll Cardiol* 2015;66:2129-39. <https://doi.org/10.1016/j.jacc.2015.09.025>.
555. O'Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. *JAMA* 2009;301:1439-50. <https://doi.org/10.1001/jama.2009.454>.

556. Janaudis-Ferreira T, Mathur S, Deliva R, et al. Exercise for solid organ transplant candidates and recipients: a joint position statement of the Canadian Society of Transplantation and CAN-RESTORE. *Transplantation* 2019;103:e220-38. <https://doi.org/10.1097/TP.0000000000002806>.
557. Shoemaker MJ, Dias KJ, Lefebvre KM, Heick JD, Collins SM. Physical therapist clinical practice guideline for the management of individuals with heart failure. *Phys Ther* 2020;100:14-43. <https://doi.org/10.1093/ptj/pzz127>.
558. Dy SM, Shugarman LR, Lorenz KA, Mularski RA, Lynn J. RAND-Southern California Evidence-Based Practice Center. A systematic review of satisfaction with care at the end of life. *J Am Geriatr Soc* 2008;56:124-9. <https://doi.org/10.1111/j.1532-5415.2007.01507.x>.
559. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2021;42:3599-726. <https://doi.org/10.1093/eurheartj/ehab368>. Published correction appears in *Eur Heart J*. 2021 Oct 14.
560. Rosano GMC, Moura B, Metra M, et al. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2021;23:872-81. <https://doi.org/10.1002/ehfj.2206>.
561. Trachtenberg B, Cowger J, Jennings DL, et al. HFSA expert consensus statement on the medical management of patients on durable mechanical circulatory support. *J Card Fail* 2023;29:479-502. <https://doi.org/10.1016/j.cardfail.2023.01.009>. Published correction appears in *J Card Fail*. 2023 Sep;29:1342.
562. Brinkley Jr DM, Wang L, Yu C, Grandin EW, Kiernan MS. Impact of renin-angiotensin-aldosterone system inhibition on morbidity and mortality during long-term continuous-flow left ventricular assist device support: an IMACS report. *J Heart Lung Transplant* 2021;40:1605-13. <https://doi.org/10.1016/j.healun.2021.08.015>.
563. Schnettler JK, Roehrich L, Just IA, et al. Safety of contemporary heart failure therapy in patients with continuous-flow left ventricular assist devices. *J Card Fail* 2021;27:1328-36. <https://doi.org/10.1016/j.cardfail.2021.06.007>.
564. McCullough M, Caraballo C, Ravindra NG, et al. Neurohormonal blockade and clinical outcomes in patients with heart failure supported by left ventricular assist devices. *JAMA Cardiol* 2020;5:175-82. <https://doi.org/10.1001/jamacardio.2019.4965>.
565. Almazroa L, Mihajlovic V, Lawler PR, Luk A. Crossing the chasm: caution for use of angiotensin receptor-neprilysin inhibition in patients with cardiogenic shock- a case report. *Eur Heart J Case Rep* 2020;4:1-4. <https://doi.org/10.1093/ehjcr/ytac233>.
566. Cheng RK, Vasbinder A, Levy WC, et al. Lack of association between neurohormonal blockade and survival in transthyretin cardiac amyloidosis. *J Am Heart Assoc* 2021;10:e022859. <https://doi.org/10.1161/JAHA.121.022859>.
567. Tini G, Cappelli F, Biagini E, et al. Current patterns of beta-blocker prescription in cardiac amyloidosis: an Italian nationwide survey. *ESC Heart Fail* 2021;8:3369-74. <https://doi.org/10.1002/ehf2.13411>.
568. Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2019;21:137-55. <https://doi.org/10.1002/ehfj.1369>.
569. Felker GM, Ellison DH, Mullens W, Cox ZL, Testani JM. Diuretic therapy for patients with heart failure: JACC state-of-the-art review. *J Am Coll Cardiol* 2020;75:1178-95. <https://doi.org/10.1016/j.jacc.2019.12.059>.
570. Cox ZL, Hung R, Lenihan DJ, Testani JM. Diuretic strategies for loop diuretic resistance in acute heart failure: the 3T trial. *JACC Heart Fail* 2020;8:157-68. <https://doi.org/10.1016/j.jchf.2019.09.012>.
571. Mullens W, Daww J, Martens P, et al. Acetazolamide in acute decompensated heart failure with volume overload. *N Engl J Med* 2022;387:1185-95. <https://doi.org/10.1056/NEJMoa2203094>.
572. Bart BA, Boyle A, Bank AJ, et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. *J Am Coll Cardiol* 2005;46:2043-6. <https://doi.org/10.1016/j.jacc.2005.05.098>.
573. Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. *J Am Coll Cardiol* 2007;49:675-83. <https://doi.org/10.1016/j.jacc.2006.07.073>. Published correction appears in *J Am Coll Cardiol*. 2007 Mar 13;49:1136.
574. Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. *N Engl J Med* 2012;367:2296-304. <https://doi.org/10.1056/NEJMoa1210357>.
575. Wilson SR, Scirica BM, Braunwald E, et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. *J Am Coll Cardiol* 2009;53:1510-6. <https://doi.org/10.1016/j.jacc.2009.01.037>.
576. Fox K, Ford I, Steg PG, et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. *Eur Heart J* 2009;30:2337-45. <https://doi.org/10.1093/eurheartj/ehp358>.

577. Zhang L, Lu Y, Jiang H, et al. Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. *J Am Coll Cardiol* 2012;59:913-22. <https://doi.org/10.1016/j.jacc.2011.11.027>.
578. Tedford RJ, Hemnes AR, Russell SD, et al. PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. *Circ Heart Fail* 2008;1:213-9. <https://doi.org/10.1161/CIRCHEARTFAILURE.108.796789>.
579. Cao JY, Wales KM, Cordina R, Lau EMT, Celermajor DS. Pulmonary vasodilator therapies are of no benefit in pulmonary hypertension due to left heart disease: a meta-analysis. *Int J Cardiol* 2018;273:213-20. <https://doi.org/10.1016/j.ijcard.2018.09.043>.
580. Vachiéry JL, Delcroix M, Al-Hiti H, et al. Macitentan in pulmonary hypertension due to left ventricular dysfunction. *Eur Respir J* 2018;51:1701886. <https://doi.org/10.1183/13993003.01886-2017>.
581. Kaluski E, Cotter G, Leitman M, et al. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension—a multi-center randomized study. *Cardiology* 2008;109:273-80.
582. de Groote P, El Asri C, Fertin M, et al. Sildenafil in heart transplant candidates with pulmonary hypertension. *Arch Cardiovasc Dis* 2015;108:375-84. <https://doi.org/10.1016/j.acvd.2015.01.013>.
583. Pons J, Leblanc MH, Bernier M, et al. Effects of chronic sildenafil use on pulmonary hemodynamics and clinical outcomes in heart transplantation. *J Heart Lung Transplant* 2012;31:1281-7. <https://doi.org/10.1016/j.healun.2012.09.009>.
584. Ravichandran AK, LaRue SJ, Novak E, Joseph SA, Schilling JD. Sildenafil in left ventricular assist device is safe and well-tolerated. *ASAIO J* 2018;64:280-1. <https://doi.org/10.1097/MAT.0000000000000626>.
585. Papathanasiou M, Ruhparwar A, Kamler M, Rassaf T, Luedike P. Off-label use of pulmonary vasodilators after left ventricular assist device implantation: calling in the evidence. *Pharm Ther* 2020;214:107619. <https://doi.org/10.1016/j.pharmthera.2020.107619>.
586. Baker WL, Radojevic J, Gluck JA. Systematic review of phosphodiesterase-5 inhibitor use in right ventricular failure following left ventricular assist device implantation. *Artif Organs* 2016;40:123-8. <https://doi.org/10.1111/aor.12518>.
587. Desai K, Di Lorenzo M, Zuckerman WA, Emeruwa E, Krishnan US. Safety and efficacy of sildenafil for group 2 pulmonary hypertension in left heart failure. *Child (Basel)* 2023;10:270. <https://doi.org/10.3390/children10020270>.
588. Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. *Circulation* 2007;116:1555-62. <https://doi.org/10.1161/CIRCULATIONAHA.107.716373>.
589. Dumitrescu D, Seck C, Möhle L, Erdmann E, Rosenkranz S. Therapeutic potential of sildenafil in patients with heart failure and reactive pulmonary hypertension. *Int J Cardiol* 2012;154:205-6. <https://doi.org/10.1016/j.ijcard.2011.10.064>.
590. Wu X, Yang T, Zhou Q, Li S, Huang L. Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis. *Eur J Heart Fail* 2014;16:444-53. <https://doi.org/10.1002/ehjhf.47>.
591. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. *Circulation* 2011;124:164-74. <https://doi.org/10.1161/CIRCULATIONAHA.110.983866>.
592. Opitz CF, Hoeper MM, Gibbs JS, et al. Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum. *J Am Coll Cardiol* 2016;68:368-78. <https://doi.org/10.1016/j.jacc.2016.05.047>.
593. Kramer T, Dumitrescu D, Gerhardt F, et al. Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension. *Int J Cardiol* 2019;283:152-8. <https://doi.org/10.1016/j.ijcard.2018.12.078>.
594. Hoendermis ES, Liu LC, Hummel YM, et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. *Eur Heart J* 2015;36:2565-73. <https://doi.org/10.1093/eurheartj/ehv336>.
595. Cuker A, Burnett A, Triller D, et al. Reversal of direct oral anticoagulants: guidance from the Anticoagulation Forum. *Am J Hematol* 2019;94:697-709. <https://doi.org/10.1002/ajh.25475>.
596. Wanek MR, Hodges K, Persaud RA, et al. Prothrombin complex concentrates for warfarin reversal before heart transplantation. *Ann Thorac Surg* 2019;107:1409-15. <https://doi.org/10.1016/j.athoracsur.2018.10.032>.
597. Santibanez M, Lesch CA, Lin L, Berger K. Tolerability and effectiveness of 4-factor prothrombin complex concentrate (4F-PCC) for warfarin and non-warfarin reversals. *J Crit Care* 2018;48:183-90. <https://doi.org/10.1016/j.jcrc.2018.08.031>.
598. Gómez-Outes A, Alcubilla P, Calvo-Rojas G, et al. Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants. *J Am Coll Cardiol* 2021;77:2987-3001. <https://doi.org/10.1016/j.jacc.2021.04.061>.

599. White K, Faruqi U, Cohen AAT. New agents for DOAC reversal: a practical management review. *Br J Cardiol* 2022;29:1. <https://doi.org/10.5837/bjc.2022.001>.
600. Kulkarni A, Manek M. Interruption and reversal of direct oral anticoagulants in preprocedural and acute settings. *J Am Board Fam Med* 2018;31:817-27. <https://doi.org/10.3122/jabfm.2018.05.180007>.
601. Lichvar AB, Pierce DR, Salerno D, Klem P, Waldman G, Park JM. Utilization of direct-acting oral anticoagulation in solid organ transplant patients: a national survey of institutional practices. *Clin Transplant* 2020;34:e13853. <https://doi.org/10.1111/ctr.13853>.
602. Kalmanovich E, Battistella P, Rouviere P, et al. Idarucizumab (Praxbind®) for dabigatran reversal in patients undergoing heart transplantation: a cohort of ten patients. *Future Sci OA* 2021;7:FSO689. <https://doi.org/10.2144/foa-2020-0186>.
603. Van Keer JM, Vanassche T, Droogne W, et al. Idarucizumab for the reversal of dabigatran in patients undergoing heart transplantation. *Eur J Heart Fail* 2019;21:129-31. <https://doi.org/10.1002/ehf.1356>.
604. Crespo-Leiro MG, López-Vilella R, López Granados A, et al. Use of Idarucizumab to reverse the anticoagulant effect of dabigatran in cardiac transplant surgery. A multicentric experience in Spain. *Clin Transplant* 2019;33:e13748. <https://doi.org/10.1111/ctr.13748>.
605. Vuillienet T, Gebhard C, Bizzozero C, et al. Discontinuation of dual antiplatelet therapy and bleeding in intensive care in patients undergoing urgent coronary artery bypass grafting: a retrospective analysis. *Inter Cardiovasc Thorac Surg* 2019;28:665-73. <https://doi.org/10.1093/icvts/ivy330>.
606. Bertling A, Fender AC, Schüngel L, et al. Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor. *J Thromb Haemost* 2018;16:1089-98. <https://doi.org/10.1111/jth.14014>.
607. Bhatt DL, Pollack CV, Weitz JI, et al. Antibody-based ticagrelor reversal agent in healthy volunteers. *N Engl J Med* 2019;380:1825-33. <https://doi.org/10.1056/NEJMoa1901778>.
608. Laehn SJ, Feih JT, Saltzberg MT, Garner Rinka JR. Pharmacodynamic-guided cangrelor bridge therapy for orthotopic heart transplant. *J Cardiothorac Vasc Anesth* 2019;33:1054-8. <https://doi.org/10.1053/j.jvca.2018.06.027>.
609. Succar L, Lopez CN, Victor 3rd DW, et al. Perioperative cangrelor in patients with recent percutaneous coronary intervention undergoing liver transplantation: a case series. *Pharmacotherapy* 2022;42:263-7. <https://doi.org/10.1002/phar.2661>.
610. Halprin C, Czer LS, Cole R, et al. Diagnosing heparin-induced thrombocytopenia in mechanical circulatory support device patients. *J Heart Lung Transplant* 2022;41:80-5. <https://doi.org/10.1016/j.healun.2021.09.006>.
611. Sandoval E, Lozano M, Pereda D, et al. A combined approach to treat heparin-induced thrombocytopenia before heart transplant. *Inter Cardiovasc Thorac Surg* 2020;31:881-3. <https://doi.org/10.1093/icvts/ivaa196>.
612. Pamboukian SV, Ignaszewski AP, Ross HJ. Management strategies for heparin-induced thrombocytopenia in heart-transplant candidates: case report and review of the literature. *J Heart Lung Transplant* 2000;19:810-4. [https://doi.org/10.1016/s1053-2498\(00\)00133-9](https://doi.org/10.1016/s1053-2498(00)00133-9).
613. Choxi AA, Patel PA, Augoustides JG, et al. Bivalirudin for cardiopulmonary bypass in the setting of heparin-induced thrombocytopenia and combined heart and kidney transplantation-diagnostic and therapeutic challenges. *J Cardiothorac Vasc Anesth* 2017;31:354-64. <https://doi.org/10.1053/j.jvca.2016.07.009>.
614. Gellatly RM, Leet A, Brown KE. Fondaparinux: an effective bridging strategy in heparin-induced thrombocytopenia and mechanical circulatory support. *J Heart Lung Transplant* 2014;33:118. <https://doi.org/10.1016/j.healun.2013.07.015>.
615. Ezponda A, Alfonso A, Iribarren MJ, Rábago G, Páramo JA, Lecumberri R. Short-term heparin re-exposure during heart transplantation in patients with ventricular assist devices and acute heparin-induced thrombocytopenia. *Rev Esp Cardiol (Engl Ed)* 2015;68:638-40. <https://doi.org/10.1016/j.rec.2015.02.024>.
616. Buttar C, Lakhdar S, Pavankumar T, Guzman-Perez L, Mahmood K, Collura G. Heart transplantation in end-stage heart failure secondary to cardiac sarcoidosis: an updated systematic review. *Heart Fail Rev* 2023;28:961-6. <https://doi.org/10.1007/s10741-022-10284-0>.
617. Trivieri MG, Spagnolo P, Birnie D, et al. Challenges in Cardiac and Pulmonary Sarcoidosis: JACC State-of-the-Art Review. *J Am Coll Cardiol* 2020;76:1878-901. <https://doi.org/10.1016/j.jacc.2020.08.042>.
618. van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. *Br J Rheumatol* 1996;35:364-72. <https://doi.org/10.1093/rheumatology/35.4.364>.
619. Kraus MJ, Smits JM, Meyer AL, et al. Outcomes in patients with cardiac amyloidosis undergoing heart transplantation: the eurotransplant experience. *J Heart Lung Transplant* 2023;42:778-85. <https://doi.org/10.1016/j.healun.2023.01.001>.
620. Dispenzieri A, Kyle RA, Lacy MQ, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. *Blood* 2004;103:3960-3. <https://doi.org/10.1182/blood-2003-12-4192>.

621. Trachtenberg BH, Kamble RT, Rice L, et al. Delayed autologous stem cell transplantation following cardiac transplantation experience in patients with cardiac amyloidosis. *Am J Transplant* 2019;19:2900-9. <https://doi.org/10.1111/ajt.15487>.
622. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med* 2019;381:1995-2008. <https://doi.org/10.1056/NEJMoa1911303>.
623. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. *N Engl J Med* 2020;383:1413-24. <https://doi.org/10.1056/NEJMoa2022190>.
624. Schaffer JM, Chiu P, Singh SK, Oyer PE, Reitz BA, Mallidi HR. Heart and combined heart-kidney transplantation in patients with concomitant renal insufficiency and end-stage heart failure. *Am J Transplant* 2014;14:384-96. <https://doi.org/10.1111/ajt.12522>.
625. Hein AM, Scialla JJ, Edmonston D, Cooper LB, DeVore AD, Mentz RJ. Medical management of heart failure with reduced ejection fraction in patients with advanced renal disease. *JACC Heart Fail* 2019;7:371-82. <https://doi.org/10.1016/j.jchf.2019.02.009>.
626. Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ. PEARL-HF Investigators. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. *Eur Heart J* 2011;32:820-8. <https://doi.org/10.1093/eurheartj/ehq502>.
627. Pitt B, Bushinsky DA, Kitzman DW, et al. Evaluation of an individualized dose titration regimen of patiomer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease. *ESC Heart Fail* 2018;5:257-66. <https://doi.org/10.1002/ehf2.12265>.
628. Anker SD, Kosiborod M, Zannad F, et al. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. *Eur J Heart Fail* 2015;17:1050-6. <https://doi.org/10.1002/ejhf.300>.
629. Hoy SM. Sodium zirconium cyclosilicate: a review in hyperkalaemia. *Drugs* 2018;78:1605-13. <https://doi.org/10.1007/s40265-018-0991-6>.
630. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). *Am Heart J* 1997;134:44-54. [https://doi.org/10.1016/s0002-8703\(97\)70105-4](https://doi.org/10.1016/s0002-8703(97)70105-4).
631. Packer M, McMurray JJV, Krum H, et al. Long-term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure: primary results of the ENABLE trials. *JACC Heart Fail* 2017;5:317-26. <https://doi.org/10.1016/j.jchf.2017.02.021>.
632. Ahmed H, VanderPluym C. Medical management of pediatric heart failure. *Cardiovasc Diagn Ther* 2021;11:323-35. <https://doi.org/10.21037/cdt-20-358>.
633. Dipchand A. Status of pediatric heart transplantation. *Ann Cardiothorac Surg* 2018;7:31-55.3.
634. Dipchand AI, Naftel DC, Feingold B, et al. Outcomes of children with cardiomyopathy listed for transplant: a multi-institutional study. *J Heart Lung Transplant* 2009;28:1312-21. <https://doi.org/10.1016/j.healun.2009.05.019>.
635. Masarone D, Valente F, Rubino M, et al. Pediatric heart failure: a practical guide to diagnosis and management. *Pediatr Neonatol* 2017;58:303-12. <https://doi.org/10.1016/j.pedneo.2017.01.001>.
636. Loss KL, Shaddy RE, Kantor PF. Recent and upcoming drug therapies for pediatric heart failure. *Front Pediatr* 2021;9:681224. <https://doi.org/10.3389/fped.2021.681224>.
637. Shaddy R, Canter C, Halnon N, et al. Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study). *Am Heart J* 2017;193:23-34. <https://doi.org/10.1016/j.ahj.2017.07.006>.
638. Das BB, Scholl F, Vandale B, Chrisant M. Sacubitril/valsartan: potential treatment for paediatric heart failure. *Cardiol Young* 2018 Sep;28:1077-81. <https://doi.org/10.1017/S1047951118001014>.
639. Newland DM, Law YM, Albers EL, et al. Early Clinical Experience with Dapagliflozin in Children with Heart Failure. *Pediatr Cardiol* 2023;44:146-52. <https://doi.org/10.1007/s00246-022-02983-0>.
640. Broberg MCG, Cheifetz IM, Plummer ST. Current evidence for pharmacologic therapy following stage 1 palliation for single ventricle congenital heart disease. *Expert Rev Cardiovasc Ther* 2022;20:627-36. <https://doi.org/10.1080/14779072.2022.2103542>.
641. Truong DT, Menon SC, Lambert LM, et al. Digoxin use in infants with single ventricle physiology: secondary analysis of the pediatric heart network infant single ventricle trial public use dataset. *Pediatr Cardiol* 2018;39:1200-9. <https://doi.org/10.1007/s00246-018-1884-x>.
642. Brown DW, Mangeot C, Anderson JB, et al. Digoxin use is associated with reduced interstage mortality in patients with no history of arrhythmia after stage I palliation for single ventricle heart disease. *J Am Heart Assoc* 2016;5:e002376.

643. Kumar KR, Flair A, Thompson EJ, et al. Association between digoxin use and cardiac function in infants with single-ventricle congenital heart disease during the interstage period. *Pediatr Crit Care Med* 2022;23:453-63. <https://doi.org/10.1097/PCC.0000000000002946>.
644. Oster ME, Kelleman M, McCracken C, Ohye RG, Mahle WT. Association of digoxin with interstage mortality: results from the pediatric heart network single ventricle reconstruction trial public use dataset. *J Am Heart Assoc* 2016;5:e002566. <https://doi.org/10.1161/JAHA.115.002566>.
645. Lasa JJ, Gaies M, Bush L, et al. Epidemiology and outcomes of acute decompensated heart failure in children. *Circ Heart Fail* 2020;13:e006101. <https://doi.org/10.1161/CIRCHEARTFAILURE.119.006101>.
646. Blume ED, VanderPluym C, Lorts A, et al. Second annual Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs) report: pre-implant characteristics and outcomes. *J Heart Lung Transplant* 2018;37:38-45. <https://doi.org/10.1016/j.healun.2017.06.017>.
647. Amdani S, Boyle GJ, Cantor RS, et al. Significance of pre and post-implant MELD-XI score on survival in children undergoing VAD implantation. *J Heart Lung Transplant* 2021;40:1614-24. <https://doi.org/10.1016/j.healun.2021.08.013>.
648. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. *Eur Heart J* 2022;43:561-632. <https://doi.org/10.1093/eurheartj/ehab395>. Published correction appears in *Eur Heart J*. 2022 Feb 18.
649. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol* 2021;77:e25-197. <https://doi.org/10.1016/j.jacc.2020.11.018>. Published correction appears in *J Am Coll Cardiol*. 2021 Feb 2;77:509. Published correction appears in *J Am Coll Cardiol*. 2021 Mar 9;77:1275. Published correction appears in *J Am Coll Cardiol*. 2023 Aug 29;82:969.
650. Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure. *N Engl J Med* 2018;379:2307-18. <https://doi.org/10.1056/NEJMoa1806640>.
651. Giustino G, Lindenfeld J, Abraham WT, et al. NYHA functional classification and outcomes after transcatheter mitral valve repair in heart failure: the COAPT trial. *JACC Cardiovasc Inter* 2020;13:2317-28. <https://doi.org/10.1016/j.jcin.2020.06.058>.
652. Nishimura RA, Bonow RO. Percutaneous repair of secondary mitral regurgitation - a tale of two trials. *N Engl J Med* 2018;379:2374-6. doi:10.1056/NEJMe1812279.
653. Enriquez-Sarano M, Michelena HI, Grigioni F. Treatment of functional mitral regurgitation. *Circulation* 2019;139:2289-91. <https://doi.org/10.1161/CIRCULATIONAHA.118.038207>.
654. Godino C, Munafò A, Scotti A, et al. MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the International MitraBridge Registry. *J Heart Lung Transplant* 2020;39:1353-62. <https://doi.org/10.1016/j.healun.2020.09.005>.
655. Lurz P, Stephan von Bardeleben R, Weber M, et al. Transcatheter edge-to-edge repair for treatment of tricuspid regurgitation. *J Am Coll Cardiol* 2021;77:229-39. <https://doi.org/10.1016/j.jacc.2020.11.038>.
656. Sorajja P, Whisenant B, Hamid N, et al. Transcatheter repair for patients with tricuspid regurgitation. *N Engl J Med* 2023;388:1833-42. <https://doi.org/10.1056/NEJMoa2300525>.
657. Abraham WT, Stevenson LW, Bourge RC, et al. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. *Lancet* 2016;387:453-61. [https://doi.org/10.1016/S0140-6736\(15\)00723-0](https://doi.org/10.1016/S0140-6736(15)00723-0).
658. Lindenfeld J, Zile MR, Desai AS, et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. *Lancet* 2021;398:991-1001. [https://doi.org/10.1016/S0140-6736\(21\)01754-2](https://doi.org/10.1016/S0140-6736(21)01754-2).
659. Brugts JJ, Radhoe SP, Clephas PRD, et al. Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial. *Lancet* 2023;401:2113-23. [https://doi.org/10.1016/S0140-6736\(23\)00923-6](https://doi.org/10.1016/S0140-6736(23)00923-6). Published correction appears in *Lancet*. 2023 Jun 24;401:2112.
660. Vakil K, Duval S, Cogswell R, et al. Impact of implantable cardioverter-defibrillators on waitlist mortality among patients awaiting heart transplantation: an UNOS/OPTN analysis. *JACC Clin Electrophysiol* 2017;3:33-40. <https://doi.org/10.1016/j.jacep.2016.07.010>.
661. Lin AY, Duran JM, Sykes A, et al. Association between implantable cardioverter-defibrillator and survival in patients awaiting heart transplantation: a meta-analysis and systematic review. *Heart Rhythm O2* 2021;2:710-8. <https://doi.org/10.1016/j.hroo.2021.09.013>.
662. Klein HU, Meltendorf U, Reek S, et al. Bridging a temporary high risk of sudden arrhythmic death. Experience with the wearable cardioverter defibrillator (WCD). *Pacing Clin Electrophysiol* 2010;33:353-67. <https://doi.org/10.1111/j.1540-8159.2009.02590.x>.
663. Opreanu M, Wan C, Singh V, et al. Wearable cardioverter-defibrillator as a bridge to cardiac transplantation: a national database analysis. *J Heart Lung Transplant* 2015;34:1305-9. <https://doi.org/10.1016/j.healun.2015.04.004>.

664. Garcia R, Combes N, Defaye P, et al. Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study. *Europace* 2021;23:73-81. <https://doi.org/10.1093/europace/euaa268>.
665. Lindenfeld J, Feldman AM, Saxon L, et al. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. *Circulation* 2007;115:204-12. <https://doi.org/10.1161/CIRCULATIONAHA.106.629261>.
666. Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. *N Engl J Med* 2018;378:417-27. <https://doi.org/10.1056/NEJMoa1707855>.
667. Di Biase L, Mohanty P, Mohanty S, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC Multicenter Randomized Trial. *Circulation* 2016;133:1637-44. <https://doi.org/10.1161/CIRCULATIONAHA.115.019406>.
668. Sohns C, Zintl K, Zhao Y, et al. Impact of left ventricular function and heart failure symptoms on outcomes post ablation of atrial fibrillation in heart failure: CASTLE-AF trial. *Circ Arrhythm Electrophysiol* 2020;13:e008461. <https://doi.org/10.1161/CIRCEP.120.008461>.
669. Gopinathannair R, Chen LY, Chung MK, et al. Managing atrial fibrillation in patients with heart failure and reduced ejection fraction: a scientific statement from the American Heart Association. *Circ Arrhythm Electro* 2021;14:HAE000000000000078. <https://doi.org/10.1161/HAE.0000000000000078>. published correction appears in *Circ Arrhythm Electrophysiol*. 2021 Nov;14(11):e000080.
670. Kuck KH, Merkely B, Zahn R, et al. Catheter ablation versus best medical therapy in patients with persistent atrial fibrillation and congestive heart failure: the randomized AMICA trial. *Circ Arrhythm Electro* 2019;12:e007731. <https://doi.org/10.1161/CIRCEP.119.007731>.
671. Sohns C, Fox H, Marrouche NF, et al. Catheter ablation in end-stage heart failure with atrial fibrillation. *N Engl J Med* 2023;389:1380-9. <https://doi.org/10.1056/NEJMoa2306037>.
672. Khan MN, Jaïs P, Cummings J, et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. *N Engl J Med* 2008;359:1778-85. <https://doi.org/10.1056/NEJMoa0708234>.
673. Ganesan AN, Brooks AG, Roberts-Thomson KC, Lau DH, Kalman JM, Sanders P. Role of AV nodal ablation in cardiac resynchronization in patients with coexistent atrial fibrillation and heart failure a systematic review. *J Am Coll Cardiol* 2012;59:719-26. <https://doi.org/10.1016/j.jacc.2011.10.891>.
674. Brignole M, Pokushalov E, Pentimalli F, et al. A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS. *Eur Heart J* 2018;39:3999-4008. <https://doi.org/10.1093/eurheartj/ehy555>.
675. Tzou WS, Tung R, Frankel DS, et al. Ventricular tachycardia ablation in severe heart failure: an International Ventricular Tachycardia Ablation Center collaboration analysis. *Circ Arrhythm Electrophysiol* 2017;10:e004494. <https://doi.org/10.1161/CIRCEP.116.004494>. published correction appears in *Circ Arrhythm Electrophysiol*. 2018 Aug;11(8):e000029.
676. Santangeli P, Rame JE, Birati EY, Marchlinski FE. Management of ventricular arrhythmias in patients with advanced heart failure. *J Am Coll Cardiol* 2017;69:1842-60. <https://doi.org/10.1016/j.jacc.2017.01.047>.
677. Cooper LB, Mentz RJ, Edwards LB, et al. Amiodarone use in patients listed for heart transplant is associated with increased 1-year post-transplant mortality. *J Heart Lung Transplant* 2017;36:202-10. <https://doi.org/10.1016/j.healun.2016.07.009>.
678. Jennings DL, Baker WL. Pre-cardiac transplant amiodarone use is not associated with postoperative mortality: an updated meta-analysis. *Int J Cardiol* 2017;236:345-7. <https://doi.org/10.1016/j.ijcard.2017.02.045>.
679. Wright M, Takeda K, Mauro C, et al. Dose-dependent association between amiodarone and severe primary graft dysfunction in orthotopic heart transplantation. *J Heart Lung Transplant* 2017;36:1226-33. <https://doi.org/10.1016/j.healun.2017.05.025>.
680. Hoemann B, Takayama H, Jennings DL, et al. Discontinuing amiodarone treatment prior to heart transplantation lowers incidence of severe primary graft dysfunction. *Clin Transplant* 2020;34:e13779. <https://doi.org/10.1111/ctr.13779>.
681. Jennings DL, Vaishnavi Gadela N, Jaiswal A, Touch A, Baker WL. Pre-transplant amiodarone use does not affect long-term heart transplant survival. *Pharmacotherapy* 2021;41:1024-32. doi:10.1002/phar.2533s.
682. Writing Committee Members Shah MJ, Silka MJ, et al. 2021 PACES expert consensus statement on the indications and management of cardiovascular implantable electronic devices in pediatric patients. *Heart Rhythm* 2021;18:1888-924. <https://doi.org/10.1016/j.hrthm.2021.07.038>.
683. Peng DM, Koehl DA, Cantor RS, et al. Outcomes of children with congenital heart disease implanted with ventricular assist devices: an analysis of the Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs). *J Heart Lung Transplant* 2019;38:420-30. <https://doi.org/10.1016/j.healun.2018.10.008>. published correction appears in *J Heart Lung Transplant*. 2020 Dec;39:1512-1514.

684. Adachi I. Ventricular assist device support for complex congenital heart disease: inspiration from history of surgical evolution. *J Heart Lung Transplant* 2019;38:431-2. <https://doi.org/10.1016/j.healun.2019.02.007>.
685. Griselli M, Sinha R, Jang S, Perri G, Adachi I. Mechanical circulatory support for single ventricle failure. *Front Cardiovasc Med* 2018;5:115. <https://doi.org/10.3389/fcvm.2018.00115>.
686. Bharucha T, Lee KJ, Daubeney PE, et al. Sudden death in childhood cardiomyopathy: results from a long-term national population-based study. *J Am Coll Cardiol* 2015;65:2302-10. <https://doi.org/10.1016/j.jacc.2015.03.552>.
687. Motonaga KS, Dubin AM. Cardiac resynchronization therapy for pediatric patients with heart failure and congenital heart disease: a reappraisal of results. *Circulation* 2014;129:1879-91. <https://doi.org/10.1161/CIRCULATIONAHA.113.001383>.
688. Kharbanda RK, Moore JP, Lloyd MS, et al. Cardiac resynchronization therapy for adult patients with a failing systemic right ventricle: a multicenter study. *J Am Heart Assoc* 2022;11:e025121. <https://doi.org/10.1161/JAHA.121.025121>.
689. Chubb H, Rosenthal DN, Almond CS, et al. Impact of cardiac resynchronization therapy on heart transplant-free survival in pediatric and congenital heart disease patients. *Circ Arrhythm Electrophysiol* 2020;13:e007925. <https://doi.org/10.1161/CIRCEP.119.007925>.
690. Ahluwalia M, Jessup M, Forde KA, et al. Clinical utility of surveillance and clinically prompted right heart catheterization in patients listed for heart transplantation. *Catheter Cardiovasc Interv* 2020;95:28-34. <https://doi.org/10.1002/ccd.28272>.
691. Gonzalez MH, Wang Q, Yaranov DM, et al. Dynamic assessment of pulmonary artery pulsatility index provides incremental risk assessment for early right ventricular failure after left ventricular assist device. *J Card Fail* 2021;27:777-85. <https://doi.org/10.1016/j.cardfail.2021.02.012>.
692. Drakos SG, Wever-Pinzon O, Selzman CH, et al. Magnitude and time course of changes induced by continuous-flow left ventricular assist device unloading in chronic heart failure: insights into cardiac recovery. *J Am Coll Cardiol* 2013;61:1985-94. <https://doi.org/10.1016/j.jacc.2013.01.072>.
693. Wever-Pinzon O, Drakos SG, Kfoury AG, et al. Morbidity and mortality in heart transplant candidates supported with mechanical circulatory support: is reappraisal of the current United network for organ sharing thoracic organ allocation policy justified? *Circulation* 2013;127:452-62. <https://doi.org/10.1161/CIRCULATIONAHA.112.100123>.
694. Ruan DT, Farr M, Ning Y, et al. The Role of Serial Right Heart Catheterization Survey in Patients Awaiting Heart Transplant on Ventricular Assist Device. *ASAIO J* 2022;68(5):663-8. <https://doi.org/10.1097/MAT.0000000000001542>.
695. Al-Kindi SG, Farhoud M, Zacharias M, et al. Left ventricular assist devices or inotropes for decreasing pulmonary vascular resistance in patients with pulmonary hypertension listed for heart transplantation. *J Card Fail* 2017;23:209-15. <https://doi.org/10.1016/j.cardfail.2016.06.421>.
696. Schumer EM, Gallo M, Rogers MP, et al. The Development of pulmonary hypertension results in decreased post-transplant survival. *ASAIO J* 2018;64:508-14. <https://doi.org/10.1097/MAT.0000000000000682>.
697. Swank AM, Horton J, Fleg JL, et al. Modest increase in peak VO₂ is related to better clinical outcomes in chronic heart failure patients: results from heart failure and a controlled trial to investigate outcomes of exercise training. *Circ Heart Fail* 2012;5:579-85. <https://doi.org/10.1161/CIRCHEARTFAILURE.111.965186>.
698. Malhotra R, Bakken K, D'Elia E, Lewis GD. Cardiopulmonary exercise testing in heart failure. *JACC Heart Fail* 2016;4:607-16. <https://doi.org/10.1016/j.jchf.2016.03.022>.
699. Adamopoulos S, Corrà U, Laoutaris ID, et al. Exercise training in patients with ventricular assist devices: a review of the evidence and practical advice. A position paper from the Committee on Exercise Physiology and Training and the Committee of Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2019;21(1):3-13. <https://doi.org/10.1002/ejhf.1352>.
700. Kumar A, Howard A, Thomas CP. Estimated glomerular filtration rate at transplant listing and other predictors of post-heart transplant mortality and the development of ESRD. *Transplantation* 2020;104:2444-52. <https://doi.org/10.1097/TP.0000000000003159>.
701. Trivedi JR, Cheng A, Ising M, Lenneman A, Birks E, Slaughter MS. Heart transplant survival based on recipient and donor risk scoring: a UNOS database analysis. *ASAIO J* 2016;62:297-301. <https://doi.org/10.1097/MAT.0000000000000337>.
702. Blackstone EH, Rajeswaran J, Cruz VB, et al. Continuously updated estimation of heart transplant waitlist mortality. *J Am Coll Cardiol* 2018;72:650-9. <https://doi.org/10.1016/j.jacc.2018.05.045>.
703. Kato TS, Cheema FH, Yang J, et al. Preoperative serum albumin levels predict 1-year postoperative survival of patients undergoing heart transplantation. *Circ Heart Fail* 2013;6:785-91. <https://doi.org/10.1161/CIRCHEARTFAILURE.111.000358>.

- 704 https://www.isHLT.org/docs/default-source/default-document-library/2023-11-15-isHLT-ast-asts-joint-statement-covid19-vaccination.pdf?sfvrsn=383b0c3e_1. Last accessed June 2024.
705. Prenner S, Levitsky J. Comprehensive review on colorectal cancer and transplant. *Am J Transplant* 2017;17:2761-74. <https://doi.org/10.1111/ajt.14340>.
706. Becher E, Wang A, Lepor H. Prostate cancer screening and management in solid organ transplant candidates and recipients. *Rev Urol* 2019;21:85-92.
707. Chadban SJ, Ahn C, Axelrod DA, et al. Summary of the Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline on the evaluation and management of candidates for kidney transplantation. *Transplantation* 2020;104:708-14. <https://doi.org/10.1097/TP.0000000000003137>.
708. Serkies K, Dębska-Ślizień A, Kowalczyk A, Lizakowski S, Małyszko J. Malignancies in adult kidney transplant candidates and recipients: current status. *Nephrol Dial Transplant* 2023;38:1591-602. <https://doi.org/10.1093/ndt/gfac239>.
709. Acuna SA, Huang JW, Scott AL, et al. Cancer screening recommendations for solid organ transplant recipients: a systematic review of clinical practice guidelines. *Am J Transplant* 2017;17:103-14. <https://doi.org/10.1111/ajt.13978>.
710. Urwin HR, Jones PW, Harden PN, et al. Predicting risk of nonmelanoma skin cancer and premalignant skin lesions in renal transplant recipients. *Transplantation* 2009;87:1667-71. <https://doi.org/10.1097/TP.0b013e3181a5ce2e>.
711. Kojder PL, Jambusaria-Pahlajani ASkin, Neoplasia Transplant Risk Assessment UV. Calculator (SUNTRAC)-keeping solid organ transplant recipients on track for skin cancer screening. *JAMA Dermatol* 2023;159:17-8. <https://doi.org/10.1001/jamadermatol.2022.3498>.
712. Gómez-Tomás Á, Bouwes Bavinck JN, Genders R, et al. External validation of the skin and uv neoplasia transplant risk assessment calculator (SUNTRAC) in a large European solid organ transplant recipient cohort. *JAMA Dermatol* 2023;159:29-36. <https://doi.org/10.1001/jamadermatol.2022.4820>. Published correction appears in *JAMA Dermatol*. 2023 Sep 1;159(9):1014.
713. Sargen MR, Cahoon EK, Lynch CF, Tucker MA, Goldstein AM, Engels EA. Sebaceous carcinoma incidence and survival among solid organ transplant recipients in the United States, 1987-2017. *JAMA Dermatol* 2020;156:1307-14. <https://doi.org/10.1001/jamadermatol.2020.3111>.
714. Kuntz K, Weinland SR, Butt Z. Psychosocial challenges in solid organ transplantation. *J Clin Psychol Med Settings* 2015;22:122-35. <https://doi.org/10.1007/s10880-015-9435-6>.
715. Grady KL, Andrei AC, Shankel T, et al. Pediatric heart transplantation: transitioning to adult care (TRANSIT): feasibility of a pilot randomized controlled trial. *J Card Fail* 2019;25:948-58. <https://doi.org/10.1016/j.cardfail.2019.06.011>.
716. Levi ME, Montague BT, Thurstone C, et al. Marijuana use in transplantation: a call for clarity. *Clin Transplant* 2019;33:e13456. <https://doi.org/10.1111/ctr.13456>.
717. Lefkowitz DS, Fitzgerald CJ, Zelikovsky N, Barlow K, Wray J. Best practices in the pediatric pre-transplant psychosocial evaluation. *Pediatr Transplant* 2014;18:327-35. <https://doi.org/10.1111/petr.12260>.
718. Anthony SJ, Annunziato RA, Fairey E, Kelly VL, So S, Wray J. Waiting for transplant: physical, psychosocial, and nutritional status considerations for pediatric candidates and implications for care. *Pediatr Transplant* 2014;18:423-34. <https://doi.org/10.1111/petr.12305>.
719. Putschoegl A, Dipchand AI, Ross H, Chaparro C, Johnson JN. Transitioning from pediatric to adult care after thoracic transplantation. *J Heart Lung Transplant* 2017;36:823-9. <https://doi.org/10.1016/j.healun.2017.02.023>.
720. Korb-Savoldelli V, Sabatier B, Gillaizeau F, et al. Non-adherence with drug treatment after heart or lung transplantation in adults: a systematic review. *Patient Educ Couns* 2010;81:148-54. <https://doi.org/10.1016/j.pec.2010.04.013>.
721. Wurm F, McKeaveney C, Corr M, Wilson A, Noble H. The psychosocial needs of adolescent and young adult kidney transplant recipients, and associated interventions: a scoping review. *BMC Psychol* 2022;10:186. <https://doi.org/10.1186/s40359-022-00893-7>.
722. Anton CM, Anton K, Butts RJ. Preparing for transition: The effects of a structured transition program on adolescent heart transplant patients' adherence and transplant knowledge. *Pediatr Transplant* 2019;23:e13544. <https://doi.org/10.1111/petr.13544>.
723. Driggin E, Chung A, Concha D, et al. The impact of pre-transplant weight loss on survival following cardiac transplantation. *Clin Transplant* 2022;36:e14831. <https://doi.org/10.1111/ctr.14831>.
724. Driggin E, Cohen LP, Gallagher D, et al. Nutrition assessment and dietary interventions in heart failure: JACC review topic of the week. *J Am Coll Cardiol* 2022;79:1623-35. <https://doi.org/10.1016/j.jacc.2022.02.025>.
725. Barge-Caballero E, García-López F, Marzoa-Rivas R, et al. Prognostic value of the nutritional risk index in heart transplant recipients. *Rev Esp Cardiol (Engl Ed)* 2017;70:639-45. <https://doi.org/10.1016/j.rec.2017.01.005>.

726. Hersberger L, Dietz A, Bürgler H, et al. Individualized nutritional support for hospitalized patients with chronic heart failure. *J Am Coll Cardiol* 2021;77:2307-19. <https://doi.org/10.1016/j.jacc.2021.03.232>.
727. Lin H, Zhang H, Lin Z, Li X, Kong X, Sun G. Review of nutritional screening and assessment tools and clinical outcomes in heart failure. *Heart Fail Rev* 2016;21:549-65. <https://doi.org/10.1007/s10741-016-9540-0>.
728. Fernández-Pombo A, Rodríguez-Carnero G, Castro AI, et al. Relevance of nutritional assessment and treatment to counteract cardiac cachexia and sarcopenia in chronic heart failure. *Clin Nutr* 2021;40:5141-55. <https://doi.org/10.1016/j.clnu.2021.07.027>.
729. Vest AR, Chan M, Deswal A, et al. Nutrition, obesity, and cachexia in patients with heart failure: a consensus statement from the Heart Failure Society of America Scientific Statements Committee. *J Card Fail* 2019;25:380-400. <https://doi.org/10.1016/j.cardfail.2019.03.007>.
730. Macdonald P. Frailty of the heart recipient. *Transplantation* 2021;105:2352-61. <https://doi.org/10.1097/TP.0000000000003692>.
731. Kobashigawa J, Shah P, Joseph S, et al. Frailty in heart transplantation: report from the heart workgroup of a consensus conference on frailty. *Am J Transplant* 2021;21:636-44. <https://doi.org/10.1111/ajt.16207>.
732. Ayesta A, Valero Masa MJ, Vidán MT, et al. Prevalence and characterization of frailty, depression, and cognitive impairment in patients listed for heart transplantation: results of the FELICITAR prospective registry. *Clin Transplant* 2021;35:e14391. <https://doi.org/10.1111/ctr.14391>.
733. Tambur AR, Bestard O, Campbell P, et al. Sensitization in transplantation: assessment of risk 2022 Working Group Meeting Report. *Am J Transplant* 2023;23:133-49. <https://doi.org/10.1016/j.ajt.2022.11.009>. Published correction appears in *Am J Transplant*. 2023 May;23:694.
734. Kobashigawa J, Colvin M, Potena L, et al. The management of antibodies in heart transplantation: an ISHLT consensus document. *J Heart Lung Transplant* 2018;37:537-47. <https://doi.org/10.1016/j.healun.2018.01.1291>.
735. Halpin AM, Nahirniak S, Campbell PM, et al. HLA alloimmunization following ventricular assist device support across the age spectrum. *Transplantation* 2019;103:2715-24. <https://doi.org/10.1097/TP.0000000000002798>.
736. Meyer SR, Campbell PM, Rutledge JM, et al. Use of an allograft patch in repair of hypoplastic left heart syndrome may complicate future transplantation. *Eur J Cardiothorac Surg* 2005;27:554-60. <https://doi.org/10.1016/j.ejcts.2004.12.033>.
737. Mahle WT, Tresler MA, Edens RE, et al. Allosensitization and outcomes in pediatric heart transplantation. *J Heart Lung Transplant* 2011;30:1221-7. <https://doi.org/10.1016/j.healun.2011.06.005>.
738. Kumpati GS, Cook DJ, Blackstone EH, et al. HLA sensitization in ventricular assist device recipients: does type of device make a difference? *J Thorac Cardiovasc Surg* 2004;127:1800-7. <https://doi.org/10.1016/j.jtcvs.2004.01.014>.
739. Bouqueneau A, Loheac C, Aubert O, et al. Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: a systematic review and meta-analysis. *PLoS Med* 2018;15:e1002572. <https://doi.org/10.1371/journal.pmed.1002572>. Published correction appears in *PLoS Med*. 2018 Jul 27;15:e1002637.
740. Ionescu L, Urschel S. Memory B cells and long-lived plasma cells. *Transplantation* 2019;103:890-8. <https://doi.org/10.1097/TP.0000000000002594>.
741. Elkind J, Sobczyk J, Ostberg-Braun O, Silva Enciso J, Adler E, Morris GP. Factors influencing transfusion-associated HLA sensitization in patients bridged to heart transplantation using ventricular assist device. *Clin Transpl* 2020;34:e13772. <https://doi.org/10.1111/ctr.13772>.
742. Fong SW, Qaqundah BY, Taylor WF. Developmental patterns of ABO isoagglutinins in normal children correlated with the effects of age, sex, and maternal isoagglutinins. *Transfusion* 1974;14:551-9. <https://doi.org/10.1111/j.1537-2995.1974.tb04576.x>.
743. Urschel S, West LJ. ABO-incompatible heart transplantation. *Curr Opin Pediatr* 2016;28:613-9. <https://doi.org/10.1097/MOP.0000000000000398>.
744. Weinstock C, Schnaidt M. Human leucocyte antigen sensitisation and its impact on transfusion practice. *Transfus Med Hemother* 2019;46:356-69. <https://doi.org/10.1159/000502158>.
745. González A, Richards AM, de Boer RA, et al. Cardiac remodelling - part 1: from cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2022;24:927-43. <https://doi.org/10.1002/ehf.2493>. Published correction appears in *Eur J Heart Fail*. 2023 Mar;25:443. Published correction appears in *Eur J Heart Fail*. 2024 Jan;26:193.
746. MacGowan GA, Neely D, Peaston R, Wrightson N, Parry G. Evaluation of NT-proBNP to predict outcomes in advanced heart failure. *Int J Clin Pr* 2010;64:892-9. <https://doi.org/10.1111/j.1742-1241.2010.02388.x>.
747. Palmieri V, Amarelli C, Mattucci I, et al. Predicting major events in ambulatory patients with advanced heart failure awaiting heart transplantation: a pilot study. *J Cardiovasc Med (Hagerstown)* 2022;23:387-93. <https://doi.org/10.2459/JCM.0000000000001304>.

748. Guglin M, Zucker MJ, Borlaug BA, et al. Evaluation for heart transplantation and LVAD implantation: JACC council perspectives. *J Am Coll Cardiol* 2020;75:1471-87. <https://doi.org/10.1016/j.jacc.2020.01.034>.
749. Szczurek W, Szyguła-Jurkiewicz B, Zakliczyński M, Król B, Gąsior M, Zembala M. Prognostic utility of the N terminal prohormone of brain natriuretic peptide and the modified Model for End Stage Liver Disease in patients with end stage heart failure. *Pol Arch Intern Med* 2018;128:235-43. <https://doi.org/10.20452/pamw.4210>.
750. Naidu SS, Baran DA, Jentzer JC, et al. SCAI SHOCK Stage Classification Expert Consensus Update: a review and incorporation of validation studies: this statement was endorsed by the American College of Cardiology (ACC), American College of Emergency Physicians (ACEP), American Heart Association (AHA), European Society of Cardiology (ESC) Association for Acute Cardiovascular Care (ACVC), International Society for Heart and Lung Transplantation (ISHLT), Society of Critical Care Medicine (SCCM), and Society of Thoracic Surgeons (STS) in December 2021. *J Am Coll Cardiol* 2022;79:933-46. <https://doi.org/10.1016/j.jacc.2022.01.018>.
751. Hoercher KJ, Nowicki ER, Blackstone EH, et al. Prognosis of patients removed from a transplant waiting list for medical improvement: implications for organ allocation and transplantation for status 2 patients. *J Thorac Cardiovasc Surg* 2008;135:1159-66. <https://doi.org/10.1016/j.jtcvs.2008.01.017>.
752. ElAmm CA, Al-Kindi SG, Oliveira GH. Characteristics and outcomes of patients with myocarditis listed for heart transplantation. *Circ Heart Fail* 2016;9:e003259. <https://doi.org/10.1161/CIRCHEARTFAILURE.116.003259>.
753. Colvin MM, Smith JM, Ahn YS, et al. OPTN/SRTR 2021 annual data report: heart. *Am J Transplant* 2023;23(2 Suppl 1):S300-78. <https://doi.org/10.1016/j.ajt.2023.02.008>.
754. Birks EJ, Drakos SG, Patel SR, et al. Prospective multicenter study of myocardial recovery using left ventricular assist devices (RESTAGE-HF [Remission from Stage D Heart Failure]): medium-term and primary end point results. *Circulation* 2020;142:2016-28. <https://doi.org/10.1161/CIRCULATIONAHA.120.046415>.
755. Topkara VK, Garan AR, Fine B, et al. Myocardial recovery in patients receiving contemporary left ventricular assist devices: results from the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). *Circ Heart Fail* 2016;9:e003157. <https://doi.org/10.1161/CIRCHEARTFAILURE.116.003157>.
756. Wever-Pinzon J, Selzman CH, Stoddard G, et al. Impact of ischemic heart failure etiology on cardiac recovery during mechanical unloading. *J Am Coll Cardiol* 2016;68:1741-52. <https://doi.org/10.1016/j.jacc.2016.07.756>.
757. Kasper EK, Gerstenblith G, Hefter G, et al. A randomized trial of the efficacy of multidisciplinary care in heart failure outpatients at high risk of hospital readmission. *J Am Coll Cardiol* 2002;39:471-80. [https://doi.org/10.1016/s0735-1097\(01\)01761-2](https://doi.org/10.1016/s0735-1097(01)01761-2).
758. Bartling T, Oedingen C, Kohlmann T, Schrem H, Krauth C. Comparing preferences of physicians and patients regarding the allocation of donor organs: a systematic review. *Transpl Rev (Orlando)* 2020;34:100515. <https://doi.org/10.1016/j.trre.2019.100515>.
759. Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. *Am Heart J* 2007;154:260-6. <https://doi.org/10.1016/j.ahj.2007.01.041>.
760. Voors AA, Ouwerkerk W, Zannad F, et al. Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. *Eur J Heart Fail* 2017;19:627-34. <https://doi.org/10.1002/ehfj.785>.
761. Simpson J, Jhund PS, Lund LH, et al. Prognostic models derived in PARADIGM-HF and validated in ATMOSPHERE and the Swedish heart failure registry to predict mortality and morbidity in chronic heart failure. *JAMA Cardiol* 2020;5:432-41. <https://doi.org/10.1001/jamacardio.2019.5850>. Published correction appears in *JAMA Cardiol*. 2020 Mar 11.
762. Hanff TC, Browne A, Dickey J, et al. Heart waitlist survival in adults with an intra-aortic balloon pump relative to other Status 2, Status 1, and inotrope Status 3 patients. *J Heart Lung Transplant* 2023;42:368-76. <https://doi.org/10.1016/j.healun.2022.10.010>.
763. Tacon CL, McCaffrey J, Delaney A. Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials. *Intensive Care Med* 2012;38:359-67. <https://doi.org/10.1007/s00134-011-2435-6>.
764. Nizamic T, Murad MH, Allen LA, et al. Ambulatory inotrope infusions in advanced heart failure: a systematic review and meta-analysis. *JACC Heart Fail* 2018;6:757-67. <https://doi.org/10.1016/j.jchf.2018.03.019>.
765. Lee EC, McNitt S, Martens J, et al. Long-term milrinone therapy as a bridge to heart transplantation: safety, efficacy, and predictors of failure. *Int J Cardiol* 2020;313:83-8. <https://doi.org/10.1016/j.ijcard.2020.04.055>.
766. Brozena SC, Twomey C, Goldberg LR, et al. A prospective study of continuous intravenous milrinone therapy for status IB patients awaiting heart transplant at home. *J Heart Lung Transplant* 2004;23:1082-6. <https://doi.org/10.1016/j.healun.2003.08.017>.
767. Birnbaum BF, Simpson KE, Boschert TA, et al. Intravenous home inotropic use is safe in pediatric patients awaiting transplantation. *Circ Heart Fail* 2015;8:64-70. <https://doi.org/10.1161/CIRCHEARTFAILURE.114.001528>.

768. Aranda Jr JM, Schofield RS, Pauly DF, et al. Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial. *Am Heart J* 2003;145:324-9. <https://doi.org/10.1067/mhj.2003.50>.
769. Mathew R, Di Santo P, Jung RG, et al. Milrinone as compared with dobutamine in the treatment of cardiogenic shock. *N Engl J Med* 2021;385:516-25. <https://doi.org/10.1056/NEJMoa2026845>.
770. Dobarro D, Donoso-Trenado V, Solé-González E, et al. Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: the LEVO-D registry. *ESC Heart Fail* 2023;10:1193-204. <https://doi.org/10.1002/ehf2.14278>.
771. Ponz de Antonio I, de Juan Bagudá JS, Rodríguez Chaverri A, García-Cosío Carmena MD, Arribas Ynsaurriaga F, Delgado Jiménez JF. Levosimendan as bridge to transplant in patients with advanced heart failure. *Rev Esp Cardiol (Engl Ed)* 2020;73:422-4. <https://doi.org/10.1016/j.rec.2019.10.026>.
772. Thorvaldsen T, Benson L, Hagerman I, Dahlström U, Edner M, Lund LH. Planned repetitive use of levosimendan for heart failure in cardiology and internal medicine in Sweden. *Int J Cardiol* 2014;175:55-61. <https://doi.org/10.1016/j.ijcard.2014.04.243>.
773. Heringlake M, Alvarez J, Bettex D, et al. An update on levosimendan in acute cardiac care: applications and recommendations for optimal efficacy and safety. *Expert Rev Cardiovasc Ther* 2021;19:325-35. <https://doi.org/10.1080/14779072.2021.1905520>.
774. Masarone D, Kittleson MM, Pollesello P, et al. Use of levosimendan in patients with advanced heart failure: an update. *J Clin Med* 2022;11:6408. <https://doi.org/10.3390/jcm11216408>.
775. Masarone D, Kittleson MM, Martucci ML, et al. Levosimendan as a "bridge to optimization" in patients with advanced heart failure with reduced ejection-a single-center study. *J Clin Med* 2022;11:4227. <https://doi.org/10.3390/jcm11144227>.
776. Silveti S, Belletti A, Fontana A, Pollesello P. Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta-analysis of randomized trials. *ESC Heart Fail* 2017;4:595-604. <https://doi.org/10.1002/ehf2.12177>.
777. Altenberger J, Parissis JT, Costard-Jaeckle A, et al. Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial. *Eur J Heart Fail* 2014;16:898-906. <https://doi.org/10.1002/ejhf.118>.
778. Lelonek M, Stopczyńska I, Korościak E, Straburzyńska-Migaj E, Gruchała M. Multicenter experiences with levosimendan therapy and its safety in patients with decompensated advanced heart failure. *Adv Clin Exp Med* 2020;29:1305-12. <https://doi.org/10.17219/acem/126301>.
779. García-González MJ, Aldea Perona A, Lara Padron A, et al. Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study. *ESC Heart Fail* 2021;8:4820-31. <https://doi.org/10.1002/ehf2.13670>.
780. Comín-Colet J, Manito N, Segovia-Cubero J, et al. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. *Eur J Heart Fail* 2018;20:1128-36. <https://doi.org/10.1002/ejhf.1145>.
781. Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. *Lancet* 2011;377:658-66. [https://doi.org/10.1016/S0140-6736\(11\)60101-3](https://doi.org/10.1016/S0140-6736(11)60101-3). Published correction appears in *Lancet*. 2012 Feb 4;379:412.
782. Long EF, Swain GW, Mangi AA. Comparative survival and cost-effectiveness of advanced therapies for end-stage heart failure. *Circ Heart Fail* 2014;7:470-8. <https://doi.org/10.1161/CIRCHEARTFAILURE.113.000807>.
783. Assad-Kottner C, Chen D, Jahanyar J, et al. The use of continuous milrinone therapy as bridge to transplant is safe in patients with short waiting times. *J Card Fail* 2008;14:839-43. <https://doi.org/10.1016/j.cardfail.2008.08.004>.
784. Goff RR, Uccellini K, Lindblad K, et al. A change of heart: preliminary results of the US 2018 adult heart allocation revision. *Am J Transplant* 2020;20:2781-90. <https://doi.org/10.1111/ajt.16010>.
785. Gorodeski EZ, Chu EC, Reese JR, Shishehbor MH, Hsieh E, Starling RC. Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure. *Circ Heart Fail* 2009;2:320-4. <https://doi.org/10.1161/CIRCHEARTFAILURE.108.839076>.
786. Tehrani BN, Truesdell AG, Psotka MA, et al. A standardized and comprehensive approach to the management of cardiogenic shock. *JACC Heart Fail* 2020;8:879-91. <https://doi.org/10.1016/j.jchf.2020.09.005>.
787. Costa-Pinto R, Yong ZT, Yanase F, et al. A pilot, feasibility, randomised controlled trial of midodrine as adjunctive vasopressor for low-dose vasopressor-dependent hypotension in intensive care patients: the MAVERIC study. *J Crit Care* 2022;67:166-71. <https://doi.org/10.1016/j.jcrc.2021.11.004>.
788. Fernández-Fernández FJ, Ameneiros-Lago E, Sardina-Ferreiro R. Might midodrine be useful in patients with decompensated and worsening chronic heart failure. *Eur J Intern Med* 2022;105:104. <https://doi.org/10.1016/j.ejim.2022.08.031>.

789. Ho AH, Kinter CW, Wight J, Neelam AR, Krakow D. Droxidopa as an effective treatment for refractory neurogenic orthostatic hypotension and reflex bradycardia in amyloid light-chain amyloidosis: a case report. *J Med Case Rep* 2020;14:73. <https://doi.org/10.1186/s13256-020-02405-w>.
790. Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. *N Engl J Med* 2020;382:1883-93. <https://doi.org/10.1056/NEJMoa1915928>.
791. Armstrong PW, Zheng Y, Troughton RW, et al. Sequential evaluation of NT-proBNP in heart failure: insights into clinical outcomes and efficacy of vericiguat. *JACC Heart Fail* 2022;10:677-88. <https://doi.org/10.1016/j.jchf.2022.04.015>.
792. Butler J, Stebbins A, Melenovsky V, et al. Vericiguat and health-related quality of life in patients with heart failure with reduced ejection fraction: insights from the VICTORIA trial. *Circ Heart Fail* 2022;15:e009337. <https://doi.org/10.1161/CIRCHEARTFAILURE.121.009337>.
793. Jentzer JC, Bihorac A, Brusca SB, et al. Contemporary management of severe acute kidney injury and refractory cardiorenal syndrome: JACC council perspectives. *J Am Coll Cardiol* 2020;76:1084-101. <https://doi.org/10.1016/j.jacc.2020.06.070>. Published correction appears in *J Am Coll Cardiol*. 2021 Jan 5;77:107-109.
794. Rangaswami J, Bhalla V, Blair JEA, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. *Circulation* 2019;139:e840-78. <https://doi.org/10.1161/CIR.0000000000000664>.
795. Tang WHW, Kiang A. Acute cardiorenal syndrome in heart failure: from dogmas to advances. *Curr Cardiol Rep* 2020;22:143. <https://doi.org/10.1007/s11886-020-01384-0>.
796. Baran DA, Grines CL, Bailey S, et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock: this document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. *Catheter Cardiovasc Interv* 2019;94:29-37. <https://doi.org/10.1002/ccd.28329>.
797. Bansal S, Prasad A, Linas S. Right heart failure-unrecognized cause of cardiorenal syndrome. *J Am Soc Nephrol* 2018;29:1795-8. <https://doi.org/10.1681/ASN.2018020224>.
798. El Nihum LI, Manian N, Arunachalam P, Al Abri Q, Guha A. Renal dysfunction in patients with left ventricular assist device. *Methodist DeBakey Cardiovasc J* 2022;18:19-26. <https://doi.org/10.14797/mdcvj.1146>.
799. Atkins J, Hess NR, Fu S, et al. Outcomes in patients with LVADs undergoing simultaneous heart-kidney transplantation. *J Card Fail* 2022;28:1584-92. <https://doi.org/10.1016/j.cardfail.2022.04.016>.
800. Chang YK, Allen LA, McClung JA, et al. Criteria for referral of patients with advanced heart failure for specialized palliative care. *J Am Coll Cardiol* 2022;80:332-44. <https://doi.org/10.1016/j.jacc.2022.04.057>.
801. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2016;37:2129-200. <https://doi.org/10.1093/eurheartj/ehw128>. published correction appears in *Eur Heart J*. 2016 Dec 30.
802. Sobanski PZ, Alt-Epping B, Currow DC, et al. Palliative care for people living with heart failure: European Association for Palliative Care Task Force expert position statement. *Cardiovasc Res* 2020;116:12-27. <https://doi.org/10.1093/cvr/cvz200>.
803. Tomasoni D, Vishram-Nielsen JKK, Pagnesi M, et al. Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care. *ESC Heart Fail* 2022;9:1507-23. <https://doi.org/10.1002/ehf2.13859>.
804. Hill L, Prager Geller T, Baruah R, et al. Integration of a palliative approach into heart failure care: a European Society of Cardiology Heart Failure Association position paper. *Eur J Heart Fail* 2020;22:2327-39. <https://doi.org/10.1002/ejhf.1994>.
805. Lund LH, Edwards LB, Kucheryavaya AY, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-first official adult heart transplant report-2014; focus theme: retransplantation. *J Heart Lung Transplant* 2014;33:996-1008. <https://doi.org/10.1016/j.healun.2014.08.003>.
806. Chambers DC, Perch M, Zuckermann A, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-eighth adult lung transplantation report - 2021; focus on recipient characteristics. *J Heart Lung Transplant* 2021;40:1060-72. <https://doi.org/10.1016/j.healun.2021.07.021>.
807. Barghash MH, Pinney SP. Heart retransplantation: candidacy, outcomes, and management. *Curr Transplant Rep* 2020;7:12-7. <https://doi.org/10.1007/s40472-019-00257-y>.
808. Johnson MR, Aaronson KD, Canter CE, et al. Heart retransplantation. *Am J Transplant* 2007;7:2075-81. <https://doi.org/10.1111/j.1600-6143.2007.01902.x>.

809. Saito A, Novick RJ, Kiaii B, et al. Early and late outcomes after cardiac retransplantation. *Can J Surg* 2013;56:21-6. <https://doi.org/10.1503/cjs.012511>.
810. Potena L, Pellegrini C, Grigioni F, et al. Optimizing the safety profile of everolimus by delayed initiation in de novo heart transplant recipients: results of the prospective randomized study EVERHEART. *Transplantation* 2018;102:493-501. <https://doi.org/10.1097/TP.0000000000001945>.
811. Chambers DC, Cherikh WS, Goldfarb SB, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-fifth adult lung and heart-lung transplant report-2018; focus theme: multiorgan transplantation. *J Heart Lung Transplant* 2018;37:1169-83. <https://doi.org/10.1016/j.healun.2018.07.020>.
812. Stehlik J, Chambers DC, Zuckermann A, Mehra MR, Khush KK. Increasing complexity of thoracic transplantation and the rise of multiorgan transplantation around the world: insights from the International Society for Heart and Lung Transplantation Registry. *J Heart Lung Transplant* 2018;37:1145-54. <https://doi.org/10.1016/j.healun.2018.07.016>.
813. Kirklin JK, Pearce FB, Dabal RJ, Carlo WF, Mauchley DC. Challenges of cardiac transplantation following the Fontan procedure. *World J Pediatr Congenit Heart Surg* 2017;8:480-6. <https://doi.org/10.1177/2150135117714460>.
814. Singh TP, Cherikh WS, Hsieh E, et al. The International thoracic organ transplant registry of the international society for heart and lung transplantation: twenty-fifth pediatric heart transplantation report-2022; focus on infant heart transplantation. *J Heart Lung Transplant* 2022;41:1357-65. <https://doi.org/10.1016/j.healun.2022.07.019>.
815. Das BB, Pruitt E, Molina K, et al. The impact of flow PRA on outcome in pediatric heart recipients in modern era: an analysis of the Pediatric Heart Transplant Study database. *Pediatr Transplant* 2018;22:e13087. <https://doi.org/10.1111/ptr.13087>.
816. Edwards JJ, Seliktar N, White R, et al. Impact and predictors of positive response to desensitization in pediatric heart transplant candidates. *J Heart Lung Transplant* 2019;38:1206-13. <https://doi.org/10.1016/j.healun.2019.08.018>.
817. Webber S, Zeevi A, Mason K, et al. Pediatric heart transplantation across a positive crossmatch: first year results from the CTOTC-04 multi-institutional study. *Am J Transplant* 2018;18:2148-62. <https://doi.org/10.1111/ajt.14876>.
818. Jaffray J, Mahajerin A, Branchford B, et al. A new risk assessment model for hospital-acquired venous thromboembolism in critically ill children: a report from the children's hospital-acquired thrombosis consortium. *Pediatr Crit Care Med* 2022;23:e1-9. <https://doi.org/10.1097/PCC.0000000000002826>.
819. Atchison CM, Amankwah E, Wilhelm J, et al. Risk factors for hospital-associated venous thromboembolism in critically ill children following cardiothoracic surgery or therapeutic cardiac catheterisation. *Cardiol Young* 2018;28:234-42. <https://doi.org/10.1017/S1047951117001755>.
820. Urschel S, Bond GY, Dinu IA, et al. Neurocognitive outcomes after heart transplantation in early childhood. *J Heart Lung Transplant* 2018;37:740-8. <https://doi.org/10.1016/j.healun.2017.12.013>.
821. Garcia Guerra G, Bond GY, Joffe AR, et al. Health-related quality of life after pediatric heart transplantation in early childhood. *Pediatr Transplant* 2020;24:e13822. <https://doi.org/10.1111/ptr.13822>.
822. Quinlan K, Auerbach S, Bearl DW, et al. The impact of psychiatric disorders on outcomes following heart transplantation in children. *Pediatr Transplant* 2020;24:e13847. <https://doi.org/10.1111/ptr.13847>.
823. Stone D, Banerjee M, Dupuis J, Leleszi J, Allasio D, Singh TP. Association of parental pre-transplant psychosocial assessment with post-transplant morbidity in pediatric heart transplant recipients. *Pediatr Transplant* 2006;10:602-7. <https://doi.org/10.1111/j.1399-3046.2006.00543.x>.
824. Dipchand AI, Honjo O, Alonso-Gonzalez R, McDonald M, Roche SL. Heart transplant indications, considerations, and outcomes in fontan patients: age-related nuances, transplant listing, and disease-specific indications. *Can J Cardiol* 2022;38:1072-85. <https://doi.org/10.1016/j.cjca.2022.02.019>.
825. Greenway SC, Crossland DS, Hudson M, et al. Fontan-associated liver disease: implications for heart transplantation. *J Heart Lung Transplant* 2016;35:26-33. <https://doi.org/10.1016/j.healun.2015.10.015>.
826. Reardon LC, DePasquale EC, Tarabay J, et al. Heart and heart-liver transplantation in adults with failing Fontan physiology. *Clin Transplant* 2018;32:e13329. <https://doi.org/10.1111/ctr.13329>.
827. Burton CE, Sester M, Robinson JL, Eurich DT, Preiksaitis JK, Urschel S. Assigning cytomegalovirus status in children awaiting organ transplant: viral shedding, CMV-specific T cells, and CD27-CD28-CD4+ T cells. *J Infect Dis* 2018;218:1205-9. <https://doi.org/10.1093/infdis/jiy309>.
828. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Available at: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglit2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious>. Accessed February 10, 2023.

829. Haider L, Hugon-Vallet E, Constantin JP, Riad Z, Sebbag L, Mewton N. ARNI pre-operative use and vasoplegic syndrome in patients undergoing heart transplantation or left ventricular assist device surgery. *Med Sci (Basel)* 2021;10:2. <https://doi.org/10.3390/medsci10010002>.
830. Kransdorf EP, Kittleson MM, Patel JK, Pando MJ, Steidley DE, Kobashigawa JA. Calculated panel-reactive antibody predicts outcomes on the heart transplant waiting list. *J Heart Lung Transplant* 2017;36:787-96. <https://doi.org/10.1016/j.healun.2017.02.015>.
831. Nwakanma LU, Williams JA, Weiss ES, Russell SD, Baumgartner WA, Conte JV. Influence of pre-transplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. *Ann Thorac Surg* 2007;84:1556-63. <https://doi.org/10.1016/j.athoracsur.2007.05.095>.
832. Kobashigawa JA, Patel JK, Kittleson MM, et al. The long-term outcome of treated sensitized patients who undergo heart transplantation. *Clin Transplant* 2011;25:E61-7. <https://doi.org/10.1111/j.1399-0012.2010.01334.x>.
833. Vo AA, Choi J, Cisneros K, et al. Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients. *Transplantation* 2014;98:312-9. <https://doi.org/10.1097/TP.000000000000064>.
834. Pisani BA, Mullen GM, Malinowska K, et al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. *J Heart Lung Transplant* 1999;18:701-6. [https://doi.org/10.1016/s1053-2498\(99\)00022-4](https://doi.org/10.1016/s1053-2498(99)00022-4).
835. John R, Lietz K, Burke E, et al. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. *Circulation* 1999;100(19 Suppl):II229-35. https://doi.org/10.1161/01.cir.100.suppl_2.ii-229.
836. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. *N Engl J Med* 2008;359:242-51. <https://doi.org/10.1056/NEJMoa0707894>.
837. Patel J, Everly M, Chang D, Kittleson M, Reed E, Kobashigawa J. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation. *J Heart Lung Transplant* 2011;30:1320-6. <https://doi.org/10.1016/j.healun.2011.08.009>.
838. Khuu T, Cadeiras M, Wisniewski N, Reed EF, Deng MC. Reduced HLA class II antibody response to proteasome inhibition in heart transplantation. *J Heart Lung Transplant* 2015;34:863-5. <https://doi.org/10.1016/j.healun.2015.01.982>.
839. Philogene MC, Sikorski P, Montgomery RA, Leffell MS, Zachary AA. Differential effect of bortezomib on HLA class I and class II antibody. *Transplantation* 2014;98:660-5. <https://doi.org/10.1097/TP.0000000000000132>.
840. Colvin MM, Cook JL, Chang PP, et al. Sensitization in heart transplantation: emerging knowledge: a scientific statement from the American Heart Association. *Circulation* 2019;139:e553-78. <https://doi.org/10.1161/CIR.0000000000000598>.
841. Chang DH, Youn JC, Diliberto D, Patel JK, Kobashigawa JA. Heart transplant immunosuppression strategies at Cedars-Sinai Medical Center. *Int J Heart Fail* 2020;3:15-30. <https://doi.org/10.36628/ijhf.2020.0034>.
842. DeFilippis EM, Kransdorf EP, Jaiswal A, et al. Detection and management of HLA sensitization in candidates for adult heart transplantation. *J Heart Lung Transplant* 2023;42:409-22. <https://doi.org/10.1016/j.healun.2022.12.019>.
843. Holt DB, Lublin DM, Phelan DL, et al. Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing peri-operative plasmapheresis and cytolytic therapy. *J Heart Lung Transplant* 2007;26:876-82. <https://doi.org/10.1016/j.healun.2007.07.011>.
844. Lick SD, Beckles DL, Piovesana G, et al. Transplantation of high panel-reactive antibody left ventricular assist device patients without crossmatch using on-bypass pheresis and alemtuzumab. *Ann Thorac Surg* 2011;92:1428-34.
845. Abbo LM, Grossi PA. AST ID Community of Practice. Surgical site infections: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. *Clin Transplant* 2019;33:e13589. <https://doi.org/10.1111/ctr.13589>.
846. Graziano E, Peghin M, Grossi PA. Perioperative antibiotic stewardship in the organ transplant setting. *Transpl Infect Dis* 2022;24:e13895. <https://doi.org/10.1111/tid.13895>.
847. Soave R. Prophylaxis strategies for solid-organ transplantation. *Clin Infect Dis* 2001;33(Suppl 1):S26-31. <https://doi.org/10.1086/320901>.
848. Steinberg JP, Braun BI, Hellinger WC, et al. Timing of antimicrobial prophylaxis and the risk of surgical site infections: results from the Trial to Reduce Antimicrobial Prophylaxis Errors. *Ann Surg* 2009;250:10-6. <https://doi.org/10.1097/SLA.0b013e3181ad5fca>.
849. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology* 2018;67:1560-99. <https://doi.org/10.1002/hep.29800>.
850. Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. *Hepatol Int* 2016;10:1-98. <https://doi.org/10.1007/s12072-015-9675-4>.

851. Huprikar S, Danziger-Isakov L, Ahn J, et al. Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management. *Am J Transplant* 2015;15:1162-72. <https://doi.org/10.1111/ajt.13187>.
852. Chen YC, Chuang MK, Chou NK, et al. Twenty-four year single-center experience of hepatitis B virus infection in heart transplantation. *Transplant Proc* 2012;44:910-2. <https://doi.org/10.1016/j.transproceed.2012.03.040>.
853. Shin HS, Cho HJ, Jeon ES, et al. The impact of hepatitis B on heart transplantation: 19 years of national experience in Korea. *Ann Transplant* 2014;19:182-7. <https://doi.org/10.12659/AOT.889680>.
854. Mahboobi N, Tabatabaei SV, Blum HE, Alavian SM. Renal grafts from anti-hepatitis B core-positive donors: a quantitative review of the literature. *Transpl Infect Dis* 2012;14:445-51. <https://doi.org/10.1111/j.1399-3062.2012.00782.x>.
855. Pinney SP, Cheema FH, Hammond K, Chen JM, Edwards NM, Mancini D. Acceptable recipient outcomes with the use of hearts from donors with hepatitis-B core antibodies. *J Heart Lung Transplant* 2005;24:34-7. <https://doi.org/10.1016/j.healun.2003.09.036>.
856. Dhillion GS, Levitt J, Mallidi H, et al. Impact of hepatitis B core antibody positive donors in lung and heart-lung transplantation: an analysis of the United Network For Organ Sharing Database. *Transplantation* 2009;88:842-6. <https://doi.org/10.1097/TP.0b013e3181b4e1fd>.
857. Shitrit AB, Kramer MR, Bakal I, Morali G, Ben Ari Z, Shitrit D. Lamivudine prophylaxis for hepatitis B virus infection after lung transplantation. *Ann Thorac Surg* 2006;81:1851-2. <https://doi.org/10.1016/j.athoracsur.2005.12.026>.
858. Department of Health and Human Services. Request for information: regarding revisions to the PHS guideline for reducing human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) through organ transplantation. Available at: <https://www.federalregister.gov/documents/2019/08/27/2019-17759/request-for-information-regarding-revisions-to-the-phs-guideline-for-reducing-human-immunodeficiency>.
859. Seem DL, Lee I, Umscheid CA, Kuehnert MJ. United States Public Health Service. PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation. *Public Health Rep* 2013;128:247-343. <https://doi.org/10.1177/003335491312800403>.
860. Ghany MG, Morgan TR. AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. *Hepatology* 2020;71:686-721. <https://doi.org/10.1002/hep.31060>.
861. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. *J Hepatol* 2018;69:461-511. <https://doi.org/10.1016/j.jhep.2018.03.026>.
862. Schlendorf KH, Zalawadiya S, Shah AS, et al. Expanding heart transplant in the era of direct-acting antiviral therapy for hepatitis C. *JAMA Cardiol* 2020;5:167-74. <https://doi.org/10.1001/jamacardio.2019.4748>.
863. Woolley AE, Singh SK, Goldberg HJ, et al. Heart and lung transplants from HCV-infected donors to uninfected recipients. *N Engl J Med* 2019;380:1606-17. <https://doi.org/10.1056/NEJMoa1812406>.
864. Aslam S, Grossi P, Schlendorf KH, et al. Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: an ISHLT expert consensus statement. *J Heart Lung Transplant* 2020;39:418-32. <https://doi.org/10.1016/j.healun.2020.03.004>.
865. Levitsky J, Formica RN, Bloom RD, et al. The American Society of Transplantation Consensus Conference on the use of hepatitis C viremic donors in solid organ transplantation. *Am J Transplant* 2017;17:2790-802. <https://doi.org/10.1111/ajt.14381>.
866. Guidance from the International Society of Heart and Lung Transplantation regarding the SARS-CoV-2 pandemic; update February 2021. Available at: https://ishlt.org/ishlt/media/documents/SARS-CoV-2_Guidance-for-Cardiothoracic-Transplant-and-VAD-center.pdf.
867. Organ Procurement Transplantation Network Ad Hoc Disease Transmission Advisory Committee. Summary of current evidence and information—donor SARS-CoV-2 testing and organ recovery from donors and a history of COVID-19; 2022. Available at: <https://optn.transplant.hrsa.gov/media/4424/sars-cov-2-summary-of-evidence.pdf>. Accessed November 14, 2022.
868. Schold JD, Koval CE, Wee A, Eltemamy M, Poggio ED. Utilization and outcomes of deceased donor SARS-CoV-2-positive organs for solid organ transplantation in the United States. *Am J Transplant* 2022;22:2217-27. <https://doi.org/10.1111/ajt.17126>.
869. Romagnoli R, Gruttadauria S, Tisone G, et al. Liver transplantation from active COVID-19 donors: a lifesaving opportunity worth grasping? *Am J Transplant* 2021;21:3919-25. <https://doi.org/10.1111/ajt.16823>.
870. Eichenberger EM, Coniglio AC, Milano C, et al. Transplanting thoracic COVID-19 positive donors: an institutional protocol and report of the first 14 cases. *J Heart Lung Transplant* 2022;41:1376-81. <https://doi.org/10.1016/j.healun.2022.06.018>.
871. Perlin DV, Dymkov IN, Terentiev AV, Perlina AV. Is kidney transplantation from a COVID-19-positive deceased donor safe for the recipient? *Transplant Proc* 2021;53:1138-42. <https://doi.org/10.1016/j.transproceed.2021.01.025>.

872. La Hoz RM, Mufti AR, Vagefi PA. Short-term liver transplant outcomes from SARS-CoV-2 lower respiratory tract NAT positive donors. *Transpl Infect Dis* 2022;24:e13757. <https://doi.org/10.1111/tid.13757>.
873. Bock MJ, Vaughn GR, Chau P, Berumen JA, Nigro JJ, Ingulli EG. Organ transplantation using COVID-19-positive deceased donors. *Am J Transpl* 2022;22:2203-16. <https://doi.org/10.1111/ajt.17145>.
874. Martinez-Reviejo R, Tejada S, Cipriano A, Karakoc HN, Manuel O, Rello J. Solid organ transplantation from donors with recent or current SARS-CoV-2 infection: a systematic review. *Anaesth Crit Care Pain Med* 2022;41:101098. <https://doi.org/10.1016/j.accpm.2022.101098>.
875. Goldman JD, Pouch SM, Woolley AE, et al. Transplant of organs from donors with positive SARS-CoV-2 nucleic acid testing: a report from the organ procurement and transplantation network ad hoc disease transmission advisory committee. *Transpl Infect Dis* 2023;25:e14013. <https://doi.org/10.1111/tid.14013>.
876. Summary of Current Evidence and Information–Donor SARS-CoV-2 Testing & Organ Recovery from Donors with a History of COVID-19. Available at: <https://optn.transplant.hrsa.gov/media/kkhn1wah/sars-cov-2-summary-of-evidence.pdf>.
877. TID Recommendations for Organ Donation and Transplantation after COVID-19 – October 2022, American Society of Transplantation; SARS-CoV-2: Recommendations and Guidance for Organ Donor Testing and Evaluation, updated January 18, 2023.
878. COVIDSurg Collaborative; GlobalSurg Collaborative. Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study. *Anaesthesia* 2021;76:748-58. <https://doi.org/10.1111/anae.15458>.
879. Deng JZ, Chan JS, Potter AL, et al. The risk of postoperative complications after major elective surgery in active or resolved COVID-19 in the United States. *Ann Surg* 2022;275:242-6. <https://doi.org/10.1097/SLA.0000000000005308>.
880. Rohatgi N, Smilowitz NR, Reejhsinghani R. Perioperative cardiovascular considerations prior to elective noncardiac surgery in patients with a history of COVID-19. *JAMA Surg* 2022;157:187-8. <https://doi.org/10.1001/jamasurg.2021.6953>.
881. Locke JE, Gustafson S, Mehta S, et al. Survival benefit of kidney transplantation in HIV-infected patients. *Ann Surg* 2017;265:604-8. <https://doi.org/10.1097/SLA.0000000000001761>.
882. Locke JE, Durand C, Reed RD, et al. Long-term outcomes after liver transplantation among human immunodeficiency virus-infected recipients. *Transplantation* 2016;100:141-6. <https://doi.org/10.1097/TP.0000000000000829>.
883. Doberne JW, Jawitz OK, Raman V, Bryner BS, Schroder JN, Milano CA. Heart transplantation survival outcomes of HIV positive and negative recipients. *Ann Thorac Surg* 2021;111:1465-71. <https://doi.org/10.1016/j.athoracsur.2020.06.120>.
884. Koval CE, Farr M, Krisl J, et al. Heart or lung transplant outcomes in HIV-infected recipients. *J Heart Lung Transplant* 2019;38:1296-305. <https://doi.org/10.1016/j.healun.2019.09.011>.
885. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at: <https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf>. Accessed April 16, 2023.
886. Durand CM, Florman S, Motter JD, et al. HOPE in action: a prospective multicenter pilot study of liver transplantation from donors with HIV to recipients with HIV. *Am J Transplant* 2022;22:853-64. <https://doi.org/10.1111/ajt.16886>.
887. Durand CM, Zhang W, Brown DM, et al. A prospective multicenter pilot study of HIV-positive deceased donor to HIV-positive recipient kidney transplantation: HOPE in action. *Am J Transplant* 2021;21:1754-64. <https://doi.org/10.1111/ajt.16205>.
888. Frassetto LA, Browne M, Cheng A, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. *Am J Transplant* 2007;7:2816-20. <https://doi.org/10.1111/j.1600-6143.2007.02007.x>.
889. Costanzo MR, Dipchand A, Starling R, et al. The International Society of Heart and Lung Transplantation guidelines for the care of heart transplant recipients. *J Heart Lung Transplant* 2010;29:914-56. <https://doi.org/10.1016/j.healun.2010.05.034>.
890. Bergenfeldt H, Stehlik J, Höglund P, Andersson B, Nilsson J. Donor-recipient size matching and mortality in heart transplantation: influence of body mass index and gender. *J Heart Lung Transplant* 2017;36:940-7. <https://doi.org/10.1016/j.healun.2017.02.002>.
891. Gong TA, Joseph SM, Lima B, et al. Donor predicted heart mass as predictor of primary graft dysfunction. *J Heart Lung Transplant* 2018;37:826-35. <https://doi.org/10.1016/j.healun.2018.03.009>.
892. Kransdorf EP, Kittleson MM, Benck LR, et al. Predicted heart mass is the optimal metric for size match in heart transplantation. *J Heart Lung Transplant* 2019;38:156-65. <https://doi.org/10.1016/j.healun.2018.09.017>.
893. Miller RJH, Hedman K, Amsellem M, et al. Donor and recipient size matching in heart transplantation with predicted heart and lean body mass. *Semin Thorac Cardiovasc Surg* 2022;34:158-67. <https://doi.org/10.1053/j.semtcvs.2021.01.001>.

894. Shah M, Saeed O, Shin J, et al. Predicted heart mass-based size matching among recipients with moderate pulmonary hypertension: outcomes and sex effect. *J Heart Lung Transplant* 2020;39:648-56. <https://doi.org/10.1016/j.healun.2020.01.1339>.
895. Khush KK, Kubo JT, Desai M. Influence of donor and recipient sex mismatch on heart transplant outcomes: analysis of the International Society for Heart and Lung Transplantation Registry. *J Heart Lung Transplant* 2012;31:459-66. <https://doi.org/10.1016/j.healun.2012.02.005>.
896. Kaczmarek I, Meiser B, Beiras-Fernandez A, et al. Gender does matter: gender-specific outcome analysis of 67,855 heart transplants. *Thorac Cardiovasc Surg* 2013;61:29-36. <https://doi.org/10.1055/s-0032-1331467>.
897. Conway J, Ballweg JA, Fenton M, et al. Review of the impact of donor characteristics on pediatric heart transplant outcomes. *Pediatr Transplant* 2020;24:e13680. <https://doi.org/10.1111/petr.13680>. published correction appears in *Pediatr Transplant*. 2021 Nov;25(7):e14081.
898. Kanani M, Hoskote A, Carter C, Burch M, Tsang V, Kostolny M. Increasing donor-recipient weight mismatch in pediatric orthotopic heart transplantation does not adversely affect outcome. *Eur J Cardiothorac Surg* 2012;41:427-34. <https://doi.org/10.1016/j.ejcts.2011.04.042>.
899. Rossano JW, Singh TP, Cherikh WS, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: twenty-second pediatric heart transplantation report - 2019; focus theme: donor and recipient size match. *J Heart Lung Transplant* 2019;38:1028-41. <https://doi.org/10.1016/j.healun.2019.08.002>.
900. Szugye NA, Shuler JM, Pradhan S, et al. Echocardiography provides a reliable estimate of total cardiac volume for pediatric heart transplantation. *J Am Soc Echocardiogr* 2023;36:224-32. <https://doi.org/10.1016/j.echo.2022.08.014>.
901. Plasencia JD, Kamarianakis Y, Ryan JR, et al. Alternative methods for virtual heart transplant-Size matching for pediatric heart transplantation with and without donor medical images available. *Pediatr Transplant* 2018;22:e13290. <https://doi.org/10.1111/petr.13290>.
902. Szugye NA, Lorts A, Zafar F, Taylor M, Morales DLS, Moore RA. Can virtual heart transplantation via 3-dimensional imaging increase the maximum acceptable donor size? *J Heart Lung Transplant* 2019;38:331-3. <https://doi.org/10.1016/j.healun.2018.12.014>.
903. Szugye NA, Zafar F, Ollberding NJ, et al. A novel method of donor-recipient size matching in pediatric heart transplantation: A total cardiac volume-predictive model. *J Heart Lung Transplant* 2021;40:158-65. <https://doi.org/10.1016/j.healun.2020.11.002>.
904. Kirklin JK, Carlo WF, Pearce FB. Current expectations for cardiac transplantation in patients with congenital heart disease. *World J Pediatr Congenit Heart Surg* 2016;7:685-95. <https://doi.org/10.1177/2150135116660701>.
905. Kirklin JK, Pearce FB, Dabal RJ, Carlo W, McGiffin DC. Cardiac transplantation and mechanical support for functional single ventricle. *World J Pediatr Congenit Heart Surg* 2012;3:183-93. <https://doi.org/10.1177/2150135111435342>.
906. Alshawabkeh L, Opatowsky AR, Carter KD, et al. Disparities in wait-list outcomes for adults with congenital heart disease listed for heart transplantation before and since revision of status I listing. *Am J Cardiol* 2018;122:1761-4. <https://doi.org/10.1016/j.amjcard.2018.08.013>.
907. Foreman C, Gruenwald C, West L. ABO-incompatible heart transplantation: a perfusion strategy. *Perfusion* 2004;19:69-72. <https://doi.org/10.1191/0267659104pf708oa>.
908. Ethics Committee, Organ Procurement and Transplantation Network (OPTN), Ethical Principles in the Allocation of Human Organs, Adopted 1992, Revised 2010. Available at: <https://optn.transplant.hrsa.gov/resources/ethics/ethical-principles-in-the-allocation-of-human-organs>. Accessed April 2, 2024.
909. Kuczewski M, Wasson K, Hutchison PJ, Dilling DF. Putting ethics and clinical decision making before politics: requiring COVID-19 immunization for Solid Organ Transplantation (SOT) Candidates and their Support Team. *J Heart Lung Transplant* 2022;41:17-9. <https://doi.org/10.1016/j.healun.2021.10.001>.
910. Belmont, Informe. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report, Ethical Principles and Guidelines for the protection of human research subjects; 1978. Available at: <https://www.hhs.gov/ohrp/regulations-and-policy/belmont-report/index.html>. Accessed April 2, 2024.
911. Yuzefpolskaya M, Schroeder SE, Houston BA, et al. The Society of Thoracic Surgeons Intermacs 2022 annual report: focus on the 2018 heart transplant allocation system. *Ann Thorac Surg* 2023;115:311-27. <https://doi.org/10.1016/j.athoracsur.2022.11.023>.
912. Goodwin ML, Kagawa H, Selzman CH. The good, the bad, the ugly: optimal left ventricular assist device duration in bridge to transplantation. *JTCVS Open* 2021;8:116-20. <https://doi.org/10.1016/j.xjon.2021.10.013>.
913. Pagani FD, Mehra MR, Cowger JA, et al. Clinical outcomes and healthcare expenditures in the real world with left ventricular assist devices - the CLEAR-LVAD study. *J Heart Lung Transplant* 2021;40:323-33. <https://doi.org/10.1016/j.healun.2021.02.010>.
914. Starling RC, Estep JD, Horstmanhof DA, et al. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: the ROADMAP study 2-year results. *JACC Heart Fail* 2017;5:518-27. <https://doi.org/10.1016/j.jchf.2017.02.016>.

915. de By TMMH, Mohacsi P, Gahl B, et al. The European Registry for Patients with Mechanical Circulatory Support (EUROMACS) of the European Association for Cardio-Thoracic Surgery (EACTS): second report. *Eur J Cardiothorac Surg* 2018;53:309-16. <https://doi.org/10.1093/ejcts/ezx320>.
916. de By TMMH, Schoenrath F, Veen KM, et al. The European Registry for Patients with Mechanical Circulatory Support of the European Association for Cardio-Thoracic Surgery: third report. *Eur J Cardiothorac Surg* 2022;62:ezac032. <https://doi.org/10.1093/ejcts/ezac032>. Published correction appears in *Eur J Cardiothorac Surg*. 2022 Jun 15;62.
917. Drakos SG, Pagani FD, Lundberg MS, Baldwin TJ. Advancing the science of myocardial recovery with mechanical circulatory support: a Working Group of the National, Heart, Lung, and Blood Institute. *J Thorac Cardiovasc Surg* 2017;154:165-70. <https://doi.org/10.1016/j.jtcvs.2017.03.033>.
918. Mehra MR, Uriel N, Naka Y, et al. A fully magnetically levitated left ventricular assist device - final report. *N Engl J Med* 2019;380:1618-27. <https://doi.org/10.1056/NEJMoa1900486>.
919. Rogers JG, Pagani FD, Tatroles AJ, et al. Intrapericardial left ventricular assist device for advanced heart failure. *N Engl J Med* 2017;376:451-60. <https://doi.org/10.1056/NEJMoa1602954>.
920. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. *N Engl J Med* 2009;361:2241-51. <https://doi.org/10.1056/NEJMoa0909938>. Published correction appears in *N Engl J Med*. 2018 Aug 16;379:697.
921. Kormos RL, Cowger J, Pagani FD, et al. The Society of Thoracic Surgeons Intermacs database annual report: evolving indications, outcomes, and scientific partnerships. *J Heart Lung Transplant* 2019;38:114-26. <https://doi.org/10.1016/j.healun.2018.11.013>.
922. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. *N Engl J Med* 2001;345:1435-43. <https://doi.org/10.1056/NEJMoa012175>.
923. Rogers JG, Butler J, Lansman SL, et al. Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial. *J Am Coll Cardiol* 2007;50:741-7. <https://doi.org/10.1016/j.jacc.2007.03.063>.
924. Estep JD, Starling RC, Horstmanhof DA, et al. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: results from the ROADMAP study. *J Am Coll Cardiol* 2015;66:1747-61. <https://doi.org/10.1016/j.jacc.2015.07.075>.
925. Wever-Pinzon O, Drakos SG, McKellar SH, et al. Cardiac recovery during long-term left ventricular assist device support. *J Am Coll Cardiol* 2016;68:1540-53. <https://doi.org/10.1016/j.jacc.2016.07.743>.
926. Goldstein DJ, Naka Y, Horstmanhof D, et al. Association of clinical outcomes with left ventricular assist device use by bridge to transplant or destination therapy intent: the multicenter study of MagLev technology in patients undergoing mechanical circulatory support therapy with HeartMate 3 (MOMENTUM 3) randomized clinical trial. *JAMA Cardiol* 2020;5:411-9. <https://doi.org/10.1001/jamacardio.2019.5323>.
927. Knierim J, Heck R, Pieri M, et al. Outcomes from a recovery protocol for patients with continuous-flow left ventricular assist devices. *J Heart Lung Transplant* 2019;38:440-8. <https://doi.org/10.1016/j.healun.2018.11.001>.
928. Birks EJ, George RS, Hedger M, et al. Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study. *Circulation* 2011;123:381-90. <https://doi.org/10.1161/CIRCULATIONAHA.109.933960>.
929. Antonides CFJ, Schoenrath F, de By TMMH, et al. Outcomes of patients after successful left ventricular assist device explantation: a EUROMACS study. *ESC Heart Fail* 2020;7:1085-94. <https://doi.org/10.1002/ehf2.12629>.
930. Goldstein DJ, Maybaum S, MacGillivray TE, et al. Young patients with nonischemic cardiomyopathy have higher likelihood of left ventricular recovery during left ventricular assist device support. *J Card Fail* 2012;18:392-5. <https://doi.org/10.1016/j.cardfail.2012.01.020>.
931. Diakos NA, Taleb I, Kyriakopoulos CP, et al. Circulating and myocardial cytokines predict cardiac structural and functional improvement in patients with heart failure undergoing mechanical circulatory support. *J Am Heart Assoc* 2021;10:e020238. <https://doi.org/10.1161/JAHA.120.020238>.
932. Butler J, Khadim G, Paul KM, et al. Selection of patients for heart transplantation in the current era of heart failure therapy. *J Am Coll Cardiol* 2004;43:787-93. <https://doi.org/10.1016/j.jacc.2003.08.058>.
933. Mehra MR, Nayak A, Morris AA, et al. Prediction of survival after implantation of a fully magnetically levitated left ventricular assist device. *JACC Heart Fail* 2022;10:948-59. <https://doi.org/10.1016/j.jchf.2022.08.002>.
934. Yancy CW, Januzzi Jr JL, Allen LA, et al. 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. *J Am Coll Cardiol* 2018;71:201-30. <https://doi.org/10.1016/j.jacc.2017.11.025>. Published correction appears in *J Am Coll Cardiol*. 2018 Nov 13;72:2549.

935. Kalogeropoulos AP, Kelkar A, Weinberger JF, et al. Validation of clinical scores for right ventricular failure prediction after implantation of continuous-flow left ventricular assist devices. *J Heart Lung Transplant* 2015;34:1595-603. <https://doi.org/10.1016/j.healun.2015.05.005>.
936. Arabia FA, Cantor RS, Koehl DA, et al. Interagency registry for mechanically assisted circulatory support report on the total artificial heart. *J Heart Lung Transplant* 2018;37:1304-12. <https://doi.org/10.1016/j.healun.2018.04.004>.
937. Kirklin JK, Pagani FD, Goldstein DJ, et al. (Editors), American Association for Thoracic Surgery/International Society for Heart and Lung Transplantation guidelines on selected topics in mechanical circulatory support. *J Heart Lung Transplant*. 2020;39:187-219. <https://doi.org/10.1016/j.healun.2020.01.1329>.
938. Yancy CW, Jessup M, Bozkurt B, et al. WRITING COMMITTEE MEMBERS. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *Circulation* 2013;128:e240-327. <https://doi.org/10.1161/CIR.0b013e31829e8776>.
939. Goldstein DJ, Meyns B, Xie R, et al. Third Annual Report From the ISHLT Mechanically Assisted Circulatory Support Registry: a comparison of centrifugal and axial continuous-flow left ventricular assist devices. *J Heart Lung Transplant* 2019;38:352-63. <https://doi.org/10.1016/j.healun.2019.02.004>.
940. Vierecke J, Gahl B, de By TMMH, et al. Results of primary biventricular support: an analysis of data from the EUROMACS registry. *Eur J Cardiothorac Surg* 2019;56:1037-45. <https://doi.org/10.1093/ejcts/ezz173>.
941. Lorts A, Smyth L, Gajarski RJ, et al. The Creation of a pediatric health care learning network: the ACTION quality improvement collaborative. *ASAIO J* 2020;66:441-6. <https://doi.org/10.1097/MAT.0000000000001133>.
942. Rossano JW, Shaddy RE. Heart failure in children: etiology and treatment. *J Pediatr* 2014;165:228-33. <https://doi.org/10.1016/j.jpeds.2014.04.055>.
943. Adachi I, Peng DM, Hollander SA, et al. Sixth Annual Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs) Report: the Society Of Thoracic Surgeons Pedimacs Annual Report. *Ann Thorac Surg* 2023;115:1098-108. <https://doi.org/10.1016/j.athoracsur.2022.10.042>.
944. Rossano JW, Cherikh WS, Chambers DC, et al. The Registry of the International Society for Heart and Lung Transplantation: twentieth pediatric heart transplantation report-2017; focus theme: allograft ischemic time. *J Heart Lung Transpl* 2017;36:1060-9. <https://doi.org/10.1016/j.healun.2017.07.018>.
945. Edelson JB, Huang Y, Griffis H, et al. The influence of mechanical Circulatory support on post-transplant outcomes in pediatric patients: a multicenter study from the International Society for Heart and Lung Transplantation (ISHLT) Registry. *J Heart Lung Transplant* 2021;40:1443-53. <https://doi.org/10.1016/j.healun.2021.06.003>.
946. Zafar F, Castleberry C, Khan MS, et al. Pediatric heart transplant waiting list mortality in the era of ventricular assist devices. *J Heart Lung Transplant* 2015;34:82-8. <https://doi.org/10.1016/j.healun.2014.09.018>.
947. Sutcliffe DL, Pruitt E, Cantor RS, et al. Post-transplant outcomes in pediatric ventricular assist device patients: a PediMACS-Pediatric Heart Transplant Study linkage analysis. *J Heart Lung Transplant* 2018;37:715-22. <https://doi.org/10.1016/j.healun.2017.12.004>.
948. Morales DLS, Rossano JW, VanderPluym C, et al. Third Annual Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs) report: preimplant characteristics and outcomes. *Ann Thorac Surg* 2019;107:993-1004. <https://doi.org/10.1016/j.athoracsur.2019.01.038>.
949. Almond CS, Morales DL, Blackstone EH, et al. Berlin Heart EXCOR pediatric ventricular assist device for bridge to heart transplantation in US children. *Circulation* 2013;127:1702-11. <https://doi.org/10.1161/CIRCULATIONAHA.112.000685>.
950. Friedland-Little JM, Hong BJ, Gossett JG, et al. Changes in renal function after left ventricular assist device placement in pediatric patients: a Pedimacs analysis. *J Heart Lung Transplant* 2018;37:1218-25. <https://doi.org/10.1016/j.healun.2018.06.016>.
951. Dipchand AI, Mahle WT, Tresler M, et al. Extracorporeal membrane oxygenation as a bridge to pediatric heart transplantation: effect on post-listing and post-transplantation outcomes. *Circ Heart Fail* 2015;8:960-9. <https://doi.org/10.1161/CIRCHEARTFAILURE.114.001553>.
952. Mathew J, Villa CR, Morales D, et al. Favorable waitlist and post-transplant outcomes in children and adolescent patients supported with durable continuous-flow ventricular assist devices. *Am J Transplant* 2016;16:2352-9. <https://doi.org/10.1111/ajt.13745>.
953. Castleberry C, Zafar F, Thomas T, et al. Allosensitization does not alter post-transplant outcomes in pediatric patients bridged to transplant with a ventricular assist device. *Pedia Transplant* 2016;20:559-64. <https://doi.org/10.1111/ptr.12706>.
954. Rao V, Oz MC, Flannery MA, Catanese KA, Argenziano M, Naka Y. Revised screening scale to predict survival after insertion of a left ventricular assist device. *J Thorac Cardiovasc Surg* 2003;125:855-62. <https://doi.org/10.1067/mtc.2003.111>.
955. Lietz K, Long JW, Kfoury AG, et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. *Circulation* 2007;116:497-505. <https://doi.org/10.1161/CIRCULATIONAHA.107.691972>.

956. Schaffer JM, Allen JG, Weiss ES, et al. Evaluation of risk indices in continuous-flow left ventricular assist device patients. *Ann Thorac Surg* 2009;88:1889-96. <https://doi.org/10.1016/j.athoracsur.2009.08.011>.
957. Teuteberg JJ, Ewald GA, Adamson RM, et al. Risk assessment for continuous flow left ventricular assist devices: does the destination therapy risk score work? An analysis of over 1,000 patients. *J Am Coll Cardiol* 2012;60:44-51. <https://doi.org/10.1016/j.jacc.2012.02.032>.
958. Cowger J, Sundareswaran K, Rogers JG, et al. Predicting survival in patients receiving continuous flow left ventricular assist devices: the HeartMate II risk score. *J Am Coll Cardiol* 2013;61:313-21. <https://doi.org/10.1016/j.jacc.2012.09.055>.
959. Kanwar MK, Lohmueller LC, Kormos RL, et al. A Bayesian model to predict survival after left ventricular assist device implantation. *JACC Heart Fail* 2018;6:771-9. <https://doi.org/10.1016/j.jchf.2018.03.016>.
960. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. *N Engl J Med* 1991;325:1468-75. <https://doi.org/10.1056/NEJM199111213252103>.
961. Thomas R, Huntley A, Mann M, et al. Specialist clinics for reducing emergency admissions in patients with heart failure: a systematic review and meta-analysis of randomised controlled trials. *Heart* 2013;99:233-9. <https://doi.org/10.1136/heartjnl-2012-302313>.
962. Uribarri A, Rojas SV, Hanke JS, et al. Prognostic value of the nutritional risk index in candidates for continuous flow left ventricular assist device therapy. *Rev Esp Cardiol (Engl Ed)* 2019;72:608-15. <https://doi.org/10.1016/j.rec.2018.05.029>.
963. Aggarwal A, Kumar A, Gregory MP, et al. Nutrition assessment in advanced heart failure patients evaluated for ventricular assist devices or cardiac transplantation. *Nutr Clin Pr* 2013;28:112-9. <https://doi.org/10.1177/0884533612457948>.
964. Yost G, Tatoes A, Bhat G. Preoperative nutritional assessment with the prognostic nutrition index in patients undergoing left ventricular assist device implantation. *ASAIO J* 2018;64:52-5. <https://doi.org/10.1097/MAT.0000000000000625>.
965. Holdy K, Dembitsky W, Eaton LL, et al. Nutrition assessment and management of left ventricular assist device patients. *J Heart Lung Transplant* 2005;24:1690-6. <https://doi.org/10.1016/j.healun.2004.11.047>.
966. Critsinelis AC, Kurihara C, Kawabori M, Sugiura T, Civitello AB, Morgan JA. Preoperative prealbumin level as a predictor of outcomes in patients who underwent left ventricular assist device implantation. *Am J Cardiol* 2017;120:1998-2002. <https://doi.org/10.1016/j.amjcard.2017.08.004>.
967. Gopal DJ, Hanff TC, Mazurek JA, et al. Prognostic implications of changes in albumin following left ventricular assist device implantation in patients with severe heart failure. *Am J Cardiol* 2017;120:2003-7. <https://doi.org/10.1016/j.amjcard.2017.08.005>.
968. Imamura T, Combs P, Siddiqi U, et al. Perioperative improvement in serum albumin level in patients with left ventricular assist device. *J Card Surg* 2020;35:3070-7. <https://doi.org/10.1111/jocs.14995>.
969. Asleh R, Briasoulis A, Schettle SD, et al. Impact of diabetes mellitus on outcomes in patients supported with left ventricular assist devices: a single institutional 9-year experience. *Circ Heart Fail* 2017;10:e004213. <https://doi.org/10.1161/CIRCHEARTFAILURE.117.004213>.
970. Kogan A, Frogel J, Ram E, et al. The impact of diabetes on short-, intermediate- and long-term mortality following left ventricular assist device implantation. *Eur J Cardiothorac Surg* 2022;61:1432-7. <https://doi.org/10.1093/ejcts/ezab575>.
971. Dimitrov K, Zimpfer D. The bittersweet consequences of diabetes on mortality following left ventricular assist device implantation. *Eur J Cardiothorac Surg* 2022;61:1438-9. <https://doi.org/10.1093/ejcts/ezac093>.
972. Zhu T, Dufendach KA, Hong Y, Thoma FW, Kilic A. Infectious complications following contemporary left ventricular assist device implantation. *J Card Surg* 2022;37:2297-306. <https://doi.org/10.1111/jocs.16545>.
973. Ascione R, Rogers CA, Rajakaruna C, Angelini GD. Inadequate blood glucose control is associated with in-hospital mortality and morbidity in diabetic and nondiabetic patients undergoing cardiac surgery. *Circulation* 2008;118:113-23. <https://doi.org/10.1161/CIRCULATIONAHA.107.706416>.
974. Székely A, Levin J, Miao Y, et al. Impact of hyperglycemia on perioperative mortality after coronary artery bypass graft surgery. *J Thorac Cardiovasc Surg* 2011;142:430-437.e1. <https://doi.org/10.1016/j.jtcvs.2011.03.009>.
975. Kotagal M, Symons RG, Hirsch IB, et al. Perioperative hyperglycemia and risk of adverse events among patients with and without diabetes. *Ann Surg* 2015;261:97-103. <https://doi.org/10.1097/SLA.0000000000000688>.
976. Yalcin YC, Muslem R, Veen KM, et al. Impact of preoperative liver dysfunction on outcomes in patients with left ventricular assist devices. *Eur J Cardiothorac Surg* 2020;57:920-8. <https://doi.org/10.1093/ejcts/ezz337>.
977. Sargent JE, Dardas TF, Smith JW, et al. Periportal fibrosis without cirrhosis does not affect outcomes after continuous flow ventricular assist device implantation. *J Thorac Cardiovasc Surg* 2016;151:230-5. <https://doi.org/10.1016/j.jtcvs.2015.08.073>.

978. George TJ, Van Dinter T, Rawitscher D, DiMaio JM, Kabra N, Afzal A. Impact of preoperative liver function on short-term HeartMate 3 outcomes. *Am J Cardiol* 2022;183:62-9. <https://doi.org/10.1016/j.amjcard.2022.07.029>.
979. Critsinelis A, Kurihara C, Volkovich N, et al. Model of End-Stage Liver Disease-eXcluding International Normalized Ratio (MELD-XI) scoring system to predict outcomes in patients who undergo left ventricular assist device implantation. *Ann Thorac Surg* 2018;106:513-9. <https://doi.org/10.1016/j.athoracsur.2018.02.082>.
980. Loforte A, Gliozzi G, Mariani C, Cavalli GG, Martin-Suarez S, Pacini D. Ventricular assist devices implantation: surgical assessment and technical strategies. *Cardiovasc Diagn Ther* 2021;11:277-91. <https://doi.org/10.21037/cdt-20-325>.
981. Papathanasiou M, Tsourelis L, Pizanis N, et al. Resternotomy does not adversely affect outcome after left ventricular assist device implantation. *Eur J Med Res* 2017;22:46. <https://doi.org/10.1186/s40001-017-0289-2>.
982. Ayers BC, Wood K, McNitt S, et al. Association of previous cardiac surgery with outcomes in left ventricular assist device patients. *Inter Cardiovasc Thorac Surg* 2020;31:1-8. <https://doi.org/10.1093/icvts/ivaa055>.
983. Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. *Circulation* 2004;110:1202-8. <https://doi.org/10.1161/01.CIR.0000140675.85342.1B>.
984. Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. *J Am Coll Cardiol* 2011;57:672-84. <https://doi.org/10.1016/j.jacc.2010.10.029>.
985. Smith PK, Goodnough LT, Levy JH, et al. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. *J Am Coll Cardiol* 2012;60:388-96. <https://doi.org/10.1016/j.jacc.2012.03.030>.
986. Hansson EC, Jidéus L, Åberg B, et al. Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study. *Eur Heart J* 2016;37:189-97. <https://doi.org/10.1093/eurheartj/ehv381>.
987. Tomšič A, Schotborgh MA, Manshanden JS, Li WW, de Mol BA. Coronary artery bypass grafting-related bleeding complications in patients treated with dual antiplatelet treatment. *Eur J Cardiothorac Surg* 2016;50:849-56. <https://doi.org/10.1093/ejcts/ezw149>.
988. Psychosocial Outcomes Workgroup of the Nursing and Social Sciences Council of the International Society for Heart and Lung Transplantation, Cupples S, Dew MA, et al. Report of the Psychosocial Outcomes Workgroup of the Nursing and Social Sciences Council of the International Society for Heart and Lung Transplantation: present status of research on psychosocial outcomes in cardiothoracic transplantation: review and recommendations for the field. *J Heart Lung Transplant* 2006;25:715-25. <https://doi.org/10.1016/j.healun.2006.02.005>.
989. Eshelman AK, Mason S, Nemeh H, Williams C. LVAD destination therapy: applying what we know about psychiatric evaluation and management from cardiac failure and transplant. *Heart Fail Rev* 2009;14:21-8. <https://doi.org/10.1007/s10741-007-9075-5>.
990. Lee DH, Butth KJ, Martin BJ, Yip AM, Hirsch GM. Frail patients are at increased risk for mortality and prolonged institutional care after cardiac surgery. *Circulation* 2010;121:973-8. <https://doi.org/10.1161/CIRCULATIONAHA.108.841437>.
991. Afilalo J, Eisenberg MJ, Morin JF, et al. Gait speed as an incremental predictor of mortality and major morbidity in elderly patients undergoing cardiac surgery. *J Am Coll Cardiol* 2010;56(20):1668-76. <https://doi.org/10.1016/j.jacc.2010.06.039>.
992. Fried LP, Xue QL, Cappola AR, et al. Nonlinear multisystem physiological dysregulation associated with frailty in older women: implications for etiology and treatment. *J Gerontol A Biol Sci Med Sci* 2009;64:1049-57. <https://doi.org/10.1093/gerona/glp076>.
993. Salzberg SP, Lachat ML, von Harbou K, Zünd G, Turina MI. Normalization of high pulmonary vascular resistance with LVAD support in heart transplantation candidates. *Eur J Cardiothorac Surg* 2005;27:222-5. <https://doi.org/10.1016/j.ejcts.2004.11.001>.
994. Torre-Amione G, Southard RE, Loebe MM, et al. Reversal of secondary pulmonary hypertension by axial and pulsatile mechanical circulatory support. *J Heart Lung Transplant* 2010;29:195-200. <https://doi.org/10.1016/j.healun.2009.05.030>.
995. Nair PK, Kormos RL, Teuteberg JJ, et al. Pulsatile left ventricular assist device support as a bridge to decision in patients with end-stage heart failure complicated by pulmonary hypertension. *J Heart Lung Transplant* 2010;29:201-8. <https://doi.org/10.1016/j.healun.2009.09.013>.
996. Gulati G, Ruthazer R, Denofrio D, Vest AR, Kent D, Kiernan MS. Understanding longitudinal changes in pulmonary vascular resistance after left ventricular assist device implantation. *J Card Fail* 2021;27:552-9. <https://doi.org/10.1016/j.cardfail.2021.01.004>.
997. Grupper A, Mazin I, Faierstein K, et al. Hemodynamic changes after left ventricular assist device implantation among heart failure patients with and without elevated pulmonary vascular resistance. *Front Cardiovasc Med* 2022;9:875204. <https://doi.org/10.3389/fcvm.2022.875204>.

998. Zimpfer D, Zrunek P, Sandner S, et al. Post-transplant survival after lowering fixed pulmonary hypertension using left ventricular assist devices. *Eur J Cardiothorac Surg* 2007;31:698-702. <https://doi.org/10.1016/j.ejcts.2006.12.036>.
999. Alba AC, Rao V, Ross HJ, et al. Impact of fixed pulmonary hypertension on post-heart transplant outcomes in bridge-to-transplant patients. *J Heart Lung Transplant* 2010;29:1253-8. <https://doi.org/10.1016/j.healun.2010.06.002>.
1000. Lampert BC, Teuteberg JJ. Right ventricular failure after left ventricular assist devices. *J Heart Lung Transplant* 2015;34:1123-30. <https://doi.org/10.1016/j.healun.2015.06.015>.
1001. Kormos RL, Teuteberg JJ, Pagani FD, et al. Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. *J Thorac Cardiovasc Surg* 2010;139:1316-24. <https://doi.org/10.1016/j.jtcvs.2009.11.020>.
1002. Nakanishi K, Homma S, Han J, et al. Usefulness of tricuspid annular diameter to predict late right sided heart failure in patients with left ventricular assist device. *Am J Cardiol* 2018;122:115-20. <https://doi.org/10.1016/j.amjcard.2018.03.01>.
1003. Aymami M, Amsellem M, Adams J, et al. The incremental value of right ventricular size and strain in the risk assessment of right heart failure post - left ventricular assist device implantation. *J Card Fail* 2018;24:823-32. <https://doi.org/10.1016/j.cardfail.2018.10.012>.
1004. Konstam MA, Kiernan MS, Bernstein D, et al. Evaluation and management of right-sided heart failure: a scientific statement from the American Heart Association. *Circulation* 2018;137:e578-622. <https://doi.org/10.1161/CIR.0000000000000560>.
1005. Houston BA, Brittain EL, Tedford RJ. Right ventricular failure. *N Engl J Med* 2023;388:1111-25. <https://doi.org/10.1056/NEJMra2207410>.
1006. Bellavia D, Iacovoni A, Scardulla C, et al. Prediction of right ventricular failure after ventricular assist device implant: systematic review and meta-analysis of observational studies. *Eur J Heart Fail* 2017;19:926-46. <https://doi.org/10.1002/ehf.73>.
1007. Lampert BC. Perioperative management of the right and left ventricles. *Cardiol Clin* 2018;36:495-506. <https://doi.org/10.1016/j.ccl.2018.06.004>.
1008. Salna M, Shudo Y, Teuteberg JJ, et al. Planned concomitant left and right ventricular assist device insertion to avoid long-term bi-ventricular mechanical support: bridge to right ventricular recovery. *Heart Surg Forum* 2018;21:E412-4. <https://doi.org/10.1532/hcf.2035>.
1009. Shehab S, Rao S, Macdonald P, et al. Outcomes of venopulmonary arterial extracorporeal life support as temporary right ventricular support after left ventricular assist implantation. *J Thorac Cardiovasc Surg* 2018;156:2143-52. <https://doi.org/10.1016/j.jtcvs.2018.05.077>.
1010. Raichlin E, Baibhav B, Lowes BD, et al. Outcomes in patients with severe preexisting renal dysfunction after continuous-flow left ventricular assist device implantation. *ASAIO J* 2016;62:261-7. <https://doi.org/10.1097/MAT.0000000000000330>.
1011. Hasin T, Topilsky Y, Schirger JA, et al. Changes in renal function after implantation of continuous-flow left ventricular assist devices. *J Am Coll Cardiol* 2012;59:26-36. <https://doi.org/10.1016/j.jacc.2011.09.038>.
1012. Kirklin JK, Pagani FD, Kormos RL, et al. Eighth annual INTERMACS report: special focus on framing the impact of adverse events. *J Heart Lung Transplant* 2017;36:1080-6. <https://doi.org/10.1016/j.healun.2017.07.005>.
1013. Doshi R, Taha M, Pisipati S, et al. Impact of chronic kidney disease on in-hospital outcomes following left ventricular assist device placement: a national perspective. *Heart Lung* 2020;49:48-53. <https://doi.org/10.1016/j.hrtlng.2019.05.013>.
1014. Bansal N, Hailpern SM, Katz R, et al. Outcomes associated with left ventricular assist devices among recipients with and without end-stage renal disease. *JAMA Intern Med* 2018;178:204-9. <https://doi.org/10.1001/jamainternmed.2017.4831>.
1015. Pasrija C, Tran D, George P, et al. Left ventricular assist device implantation may be feasible in appropriately selected patients with severe renal insufficiency. *J Thorac Cardiovasc Surg* 2020;159:1307-1319.e2. <https://doi.org/10.1016/j.jtcvs.2019.03.098>.
1016. Kilic A, Chen CW, Gaffey AC, Wald JW, Acker MA, Atluri P. Preoperative renal dysfunction does not affect outcomes of left ventricular assist device implantation. *J Thorac Cardiovasc Surg* 2018;156:1093-1101.e1. <https://doi.org/10.1016/j.jtcvs.2017.12.044>.
1017. Potapov EV, Antonides C, Crespo-Leiro MG, et al. 2019 EACTS Expert Consensus on long-term mechanical circulatory support. *Eur J Cardiothorac Surg* 2019;56:230-70. <https://doi.org/10.1093/ejcts/ezz098>.
1018. Chan JL, Patel DC, Megna D, et al. Use of durable mechanical circulatory support on outcomes of heart-kidney transplantation. *Inter Cardiovasc Thorac Surg* 2018;27:773-7. <https://doi.org/10.1093/icvts/ivy156>.
1019. Zalawadiya SK, Wigger M, DiSalvo T, Haglund N, Maltais S, Lindenfeld J. Mechanical circulatory support and simultaneous heart-kidney transplantation: an outcome analysis. *J Heart Lung Transplant* 2016;35:203-12. <https://doi.org/10.1016/j.healun.2015.10.007>.

1020. Gaffey AC, Chen CW, Chung J, et al. Bridge with a left ventricular assist device to a simultaneous heart and kidney transplant: review of the United Network for Organ Sharing database. *J Card Surg* 2017;32:209-14. <https://doi.org/10.1111/jocs.13105>.
1021. Melehy A, Sanchez JE, Nemeth SK, et al. National outcomes of bridge to multiorgan cardiac transplantation using mechanical circulatory support. *J Thorac Cardiovasc Surg* 2023;165:168-182.e11. <https://doi.org/10.1016/j.jtcvs.2021.01.114>.
1022. VanderPluym CJ, Cedars A, Eghtesady P, et al. Outcomes following implantation of mechanical circulatory support in adults with congenital heart disease: an analysis of the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). *J Heart Lung Transplant* 2018;37:89-99. <https://doi.org/10.1016/j.healun.2017.03.005>.
1023. Conway J, St Louis J, Morales DLS, Law S, Tjossem C, Humpl T. Delineating survival outcomes in children < 10 kg bridged to transplant or recovery with the Berlin Heart EXCOR Ventricular Assist Device. *JACC Heart Fail* 2015;3:70-7. <https://doi.org/10.1016/j.jchf.2014.07.011>.
1024. Morales DLS, Zafar F, Almond CS, et al. Berlin Heart EXCOR use in patients with congenital heart disease. *J Heart Lung Transplant* 2017;36:1209-16. <https://doi.org/10.1016/j.healun.2017.02.003>.
1025. Lorts A, Conway J, Schweiger M, et al. ISHLT consensus statement for the selection and management of pediatric and congenital heart disease patients on ventricular assist devices Endorsed by the American Heart Association. *J Heart Lung Transplant* 2021;40:709-32. <https://doi.org/10.1016/j.healun.2021.04.015>.
1026. Feldman D, Pamboukian SV, Teuteberg JJ, et al. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. *J Heart Lung Transplant* 2013;32:157-87. <https://doi.org/10.1016/j.healun.2012.09.013>.
1027. Gelow JM, Song HK, Weiss JB, Mudd JO, Broberg CS. Organ allocation in adults with congenital heart disease listed for heart transplant: impact of ventricular assist devices. *J Heart Lung Transplant* 2013;32:1059-64. <https://doi.org/10.1016/j.healun.2013.06.024>.
1028. Maxwell BG, Wong JK, Sheikh AY, Lee PH, Lobato RL. Heart transplantation with or without prior mechanical circulatory support in adults with congenital heart disease. *Eur J Cardiothorac Surg* 2014;45:842-6. <https://doi.org/10.1093/ejcts/ezt498>.
1029. Adachi I, Williams E, Jeewa A, Elias B, McKenzie ED. Mechanically assisted Fontan completion: a new approach for the failing Glenn circulation due to isolated ventricular dysfunction. *J Heart Lung Transplant* 2016;35:1380-1. <https://doi.org/10.1016/j.healun.2016.09.011>.
1030. Weinstein S, Bello R, Pizarro C, et al. The use of the Berlin Heart EXCOR in patients with functional single ventricle. *J Thorac Cardiovasc Surg* 2014;147:697-705. <https://doi.org/10.1016/j.jtcvs.2013.10.030>.
1031. Irving CA, Cassidy JV, Kirk RC, Griselli M, Hasan A, Crossland DS. Successful bridge to transplant with the Berlin Heart after cavo-pulmonary shunt. *J Heart Lung Transplant* 2009;28:399-401. <https://doi.org/10.1016/j.healun.2008.12.009>.
1032. Wells D, Villa CR, Simón Morales DL. The 50/50 cc total artificial heart trial: extending the benefits of the total artificial heart to underserved populations. *Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu* 2017;20:16-9. <https://doi.org/10.1053/j.pcsu.2016.09.004>.
1033. Fung E, Shaw RJ. Pediatric Transplant Rating Instrument - a scale for the pre-transplant psychiatric evaluation of pediatric organ transplant recipients. *Pediatr Transplant* 2008;12:57-66. <https://doi.org/10.1111/j.1399-3046.2007.00785.x>.
1034. Lefkowitz DS, Fitzgerald CJ. Mobile health technology for adolescent transplant recipients: what's h'app'ening in adherence promotion? *Pediatr Transplant* 2016;20:11-2. <https://doi.org/10.1111/ptr.12634>.
1035. Khoshbin E, Schueler S. Pre-transplant ventricular assist device explant. *Ann Cardiothorac Surg* 2018;7:160-8. <https://doi.org/10.21037/acs.2018.01.04>.
1036. Al-Naamani A, Fahr F, Khan A, et al. Minimally invasive ventricular assist device implantation. *J Thorac Dis* 2021;13:2010-7. <https://doi.org/10.21037/jtd-20-1492>.
1037. Jawad K, Nozdrzykowski M, Borger MA, Saeed D. Less invasive assist device implantation in patients with history of previous cardiac procedures: how i teach it. *Ann Thorac Surg* 2022;114:383-6. <https://doi.org/10.1016/j.athoracsur.2022.03.081>.
1038. Saeed D, Muslem R, Rasheed M, et al. Less invasive surgical implant strategy and right heart failure after LVAD implantation. *J Heart Lung Transplant* 2021;40:289-97. <https://doi.org/10.1016/j.healun.2021.01.005>.
1039. Jawad K, Sipahi F, Koziarz A, et al. Less-invasive ventricular assist device implantation: a multicenter study. *J Thorac Cardiovasc Surg* 2022;164:1910-1918.e4. <https://doi.org/10.1016/j.jtcvs.2020.12.043>.
1040. Gilkeson RC, Markowitz AH, Ciancibello L. Multisection CT evaluation of the reoperative cardiac surgery patient. *Radiographics* 2003;23:S3-17. <https://doi.org/10.1148/rg.23si035505>.

1041. Khan NU, Yonan N. Does preoperative computed tomography reduce the risks associated with re-do cardiac surgery. *Inter Cardiovasc Thorac Surg* 2009;9:119-23. <https://doi.org/10.1510/icvts.2008.189506>.
1042. Imran Hamid U, Digney R, Soo L, Leung S, Graham AN. Incidence and outcome of re-entry injury in redo cardiac surgery: benefits of preoperative planning. *Eur J Cardiothorac Surg* 2015;47:819-23. <https://doi.org/10.1093/ejcts/ezu261>.
1043. Kirmani BH, Brazier A, Sriskandarajah S, Azzam R, Keenan DJ. A meta-analysis of computerized tomography scan for reducing complications following repeat sternotomy for cardiac surgery. *Inter Cardiovasc Thorac Surg* 2016;22:472-9. <https://doi.org/10.1093/icvts/ivv367>.
1044. Mehra MR, Goldstein DJ, Cleveland JC, et al. Five-year outcomes in patients with fully magnetically levitated vs axial-flow left ventricular assist devices in the MOMENTUM 3 randomized trial. *JAMA* 2022;328:1233-42. <https://doi.org/10.1001/jama.2022.16197>.
1045. Mehra MR, Cleveland Jr JC, Uriel N, et al. Primary results of long-term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implants. *Eur J Heart Fail* 2021;23:1392-400. <https://doi.org/10.1002/ehf.2211>.
1046. Uriel MH, Clerkin KJ, Takeda K, et al. Bridging to transplant with HeartMate 3 left ventricular assist devices in the new heart organ allocation system: an individualized approach. *J Heart Lung Transplant* 2023;42:124-33. <https://doi.org/10.1016/j.healun.2022.08.022>.
1047. Truby LK, Farr MA, Garan AR, et al. Impact of bridge to transplantation with continuous-flow left ventricular assist devices on post-transplantation mortality. *Circulation* 2019;140:459-69. <https://doi.org/10.1161/CIRCULATIONAHA.118.036932>.
1048. Hariri IM, Dardas T, Kanwar M, et al. Long-term survival on LVAD support: device complications and end-organ dysfunction limit long-term success. *J Heart Lung Transplant* 2022;41:161-70. <https://doi.org/10.1016/j.healun.2021.07.011>.
1049. Kormos RL, Antonides CFJ, Goldstein DJ, et al. Updated definitions of adverse events for trials and registries of mechanical circulatory support: a consensus statement of the mechanical circulatory support academic research consortium. *J Heart Lung Transplant* 2020;39:735-50. <https://doi.org/10.1016/j.healun.2020.03.010>.
1050. Varshney AS, DeFilippis EM, Cowger JA, Netuka I, Pinney SP, Givertz MM. Trends and outcomes of left ventricular assist device therapy: JACC Focus Seminar. *J Am Coll Cardiol* 2022;79:1092-107.
1051. Uriel N, Pak SW, Jorde UP, et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. *J Am Coll Cardiol* 2010;56:1207-13.
1052. Leal-Noval SR, Rincon-Ferrari MD, Garcia-Curiel A, et al. Transfusion of blood components and postoperative infection in patients undergoing cardiac surgery. *Chest* 2001;119:1461-8.
1053. Murphy PJ, Connery C, Hicks Jr. GL, Blumberg N. Homologous blood transfusion as a risk factor for postoperative infection after coronary artery bypass graft operations. *J Thorac Cardiovasc Surg* 1992;104:1092-9.
1054. Miller RJH, Gregory AJ, Kent W, Banerjee D, Hiesinger W, Clarke B. Predicting transfusions during left ventricular assist device implant. *Semin Thorac Cardiovasc Surg* 2020;32:747-55.
1055. Kirklin JK, Naftel DC, Kormos RL, et al. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device. *J Heart Lung Transplant* 2014;33:12-22. <https://doi.org/10.1016/j.healun.2013.11.001>. Published correction appears in *J Heart Lung Transplant*. 2015 Oct;34:1356. Timothy Baldwin, J [corrected to Baldwin, J T].
1056. Badiye A, Hernandez GA, Chaparro S. Argatroban as novel therapy for suspected thrombosis in patients with continuous-flow left ventricle assist device and hemolysis. *ASAIO J* 2014;60:361-5. <https://doi.org/10.1097/MAT.0000000000000067>.
1057. Wert L, Hanke JS, Dogan G, et al. Argatroban administration as therapy for thrombosis in patients with continuous-flow ventricular assist devices. *J Thorac Dis* 2018;10(Suppl 15):S1720-7. <https://doi.org/10.21037/jtd.2017.10.164>.
1058. Weeks P, Sieg A, Rajapreyar I, et al. Bivalirudin for left ventricular assist device thrombosis. *J Thromb Thrombolysis* 2018;46:496-501. <https://doi.org/10.1007/s11239-018-1725-z>.
1059. Levin AP, Uriel N, Takayama H, et al. Device exchange in HeartMate II recipients: long-term outcomes and risk of thrombosis recurrence. *ASAIO J* 2015;61:144-9. <https://doi.org/10.1097/MAT.0000000000000170>.
1060. Urban M, Um J, Moulton M, et al. Recurrent pump thrombosis is common after axial continuous-flow left ventricular assist device exchange. *Int J Artif Organs* 2020;43:109-18. <https://doi.org/10.1177/0391398819876293>.
1061. Barac YD, Wojnarski CM, Junpaparp P, et al. Early outcomes with durable left ventricular assist device replacement using the HeartMate 3. *J Thorac Cardiovasc Surg* 2020;160:132-139.e1. <https://doi.org/10.1016/j.jtcvs.2019.09.151>.

1062. Rich JD, Gosev I, Patel CB, et al. The incidence, risk factors, and outcomes associated with late right-sided heart failure in patients supported with an axial-flow left ventricular assist device. *J Heart Lung Transplant* 2017;36:50-8. <https://doi.org/10.1016/j.healun.2016.08.010>.
1063. Ali HR, Kiernan MS, Choudhary G, et al. Right ventricular failure post-implantation of left ventricular assist device: prevalence, pathophysiology, and predictors. *ASAIO J* 2020;66:610-9. <https://doi.org/10.1097/MAT.0000000000001088>.
1064. Takeda K, Takayama H, Colombo PC, et al. Incidence and clinical significance of late right heart failure during continuous-flow left ventricular assist device support. *J Heart Lung Transplant* 2015;34:1024-32. <https://doi.org/10.1016/j.healun.2015.03.011>.
1065. Takeda K, Naka Y, Yang JA, et al. Outcome of unplanned right ventricular assist device support for severe right heart failure after implantable left ventricular assist device insertion. *J Heart Lung Transplant* 2014;33:141-8. <https://doi.org/10.1016/j.healun.2013.06.025>.
1066. Yoshioka D, Takayama H, Garan RA, et al. Contemporary outcome of unplanned right ventricular assist device for severe right heart failure after continuous-flow left ventricular assist device insertion. *Inter Cardiovasc Thorac Surg* 2017;24:828-34. <https://doi.org/10.1093/icvts/ivw409>.
1067. Shad R, Fong R, Quach N, et al. Long-term survival in patients with post-LVAD right ventricular failure: multi-state modelling with competing outcomes of heart transplant. *J Heart Lung Transplant* 2021;40:778-85. <https://doi.org/10.1016/j.healun.2021.05.002>.
1068. Pirlamarla P, Rame E, Hoopes C, Rajapreyar I. Pulmonary vasodilator use in continuous-flow left ventricular assist device management. *Ann Transl Med* 2021;9:522. <https://doi.org/10.21037/atm-20-4710>.
1069. Kusne S, Mooney M, Danziger-Isakov L, et al. An ISHLT consensus document for prevention and management strategies for mechanical circulatory support infection. *J Heart Lung Transplant* 2017;36:1137-53. <https://doi.org/10.1016/j.healun.2017.06.007>.
1070. Agrawal S, Garg L, Shah M, et al. Thirty-day readmissions after left ventricular assist device implantation in the United States: insights from the Nationwide Readmissions Database. *Circ Heart Fail* 2018;11:e004628. <https://doi.org/10.1161/CIRCHEARTFAILURE.117.004628>.
1071. Trachtenberg BH, Cordero-Reyes AM, Aldeiri M, et al. Persistent blood stream infection in patients supported with a continuous-flow left ventricular assist device is associated with an increased risk of cerebrovascular accidents. *J Card Fail* 2015;21:119-25. <https://doi.org/10.1016/j.cardfail.2014.10.019>.
1072. Cho SM, Lee T, Starling RC, Thompson NR, Uchino K. The impact of infection and elevated INR in LVAD-associated intracranial hemorrhage: a case-crossover study. *ASAIO J* 2019;65:545-9. <https://doi.org/10.1097/MAT.0000000000000887>.
1073. Kanjanahattakij N, Horn B, Abdulhadi B, Wongjarupong N, Mezue K, Rattanawong P. Blood stream infection is associated with cerebrovascular accident in patients with left ventricular assist device: a systematic review and meta-analysis. *J Artif Organs* 2018;21:271-7. <https://doi.org/10.1007/s10047-018-1034-5>.
1074. Goldstein DJ, Naftel D, Holman W, et al. Continuous-flow devices and percutaneous site infections: clinical outcomes. *J Heart Lung Transplant* 2012;31:1151-7. <https://doi.org/10.1016/j.healun.2012.05.004>.
1075. Tattevin P, Flécher E, Auffret V, et al. Risk factors and prognostic impact of left ventricular assist device-associated infections. *Am Heart J* 2019;214:69-76. <https://doi.org/10.1016/j.ahj.2019.04.021>.
1076. Zhou S, Yang G, Zhang M, et al. Mortality following durable left ventricular assist device implantation by timing and type of first infection. *J Thorac Cardiovasc Surg* 2023;166:570-579.e4. <https://doi.org/10.1016/j.jtcvs.2021.10.056>.
1077. Tong MZ, Smedira NG, Soltesz EG, et al. Outcomes of heart transplant after left ventricular assist device specific and related infection. *Ann Thorac Surg* 2015;100:1292-7. <https://doi.org/10.1016/j.athoracsur.2015.04.047>.
1078. Esquer Garrigos Z, Castillo Almeida NE, Gurram P, et al. Management and outcome of left ventricular assist device infections in patients undergoing cardiac transplantation. *Open Forum Infect Dis* 2020;7:ofaa303. <https://doi.org/10.1093/ofid/ofaa303>.
1079. Chahal D, Sepehry AA, Nazzari H, Wright AJ, Toma M. The impact of left ventricular assist device infections on postcardiac transplant outcomes: a systematic review and meta-analysis. *ASAIO J* 2019;65:827-36. <https://doi.org/10.1097/MAT.0000000000000921>.
1080. Salerno CT, Hayward C, Hall S, et al. HVAD to HeartMate 3 left ventricular assist device exchange: best practices recommendations. *Eur J Cardiothorac Surg* 2022;62:ezac169. <https://doi.org/10.1093/ejcts/ezac169>.
1081. Moayedi Y, Multani A, Bunce PE, et al. Outcomes of patients with infection related to a ventricular assist device after heart transplantation. *Clin Transpl* 2019;33:e13692. <https://doi.org/10.1111/ctr.13692>.
1082. Angus DC, van der Poll T. Severe sepsis and septic shock. *N Engl J Med* 2013;369:840-51. <https://doi.org/10.1056/NEJMra1208623>. Published correction appears in *N Engl J Med*. 2013 Nov 21;369:2069.

1083. Imamura T. How to manage left ventricular assist device-related infection to improve clinical outcomes following heart transplantation. *J Card Surg* 2022;37:705. <https://doi.org/10.1111/jocs.16177>.
1084. Acharya D, Loyaga-Rendon R, Morgan CJ, et al. INTERMACS analysis of stroke during support with continuous-flow left ventricular assist devices: risk factors and outcomes. *JACC Heart Fail* 2017;5:703-11. <https://doi.org/10.1016/j.jchf.2017.06.014>.
1085. Kirklin JK, Naftel DC, Myers SL, Pagani FD, Colombo PC. Quantifying the impact from stroke during support with continuous flow ventricular assist devices: an STS INTERMACS analysis. *J Heart Lung Transplant* 2020;39:782-94. <https://doi.org/10.1016/j.healun.2020.04.006>.
1086. Shah P, Birk SE, Cooper LB, et al. Stroke and death risk in ventricular assist device patients varies by ISHLT infection category: an INTERMACS analysis. *J Heart Lung Transplant* 2019;38:721-30. <https://doi.org/10.1016/j.healun.2019.02.006>.
1087. Cho SM, Mehaffey JH, Meyers SL, et al. Cerebrovascular events in patients with centrifugal-flow left ventricular assist devices: propensity score-matched analysis from the InterMACS Registry. *Circulation* 2021;144(10):763-72. <https://doi.org/10.1161/CIRCULATIONAHA.121.055716>. Published correction appears in *Circulation*. 2021 Sep 7;144:e200.
1088. Colombo PC, Mehra MR, Goldstein DJ, et al. Comprehensive analysis of stroke in the long-term cohort of the MOMENTUM 3 Study. *Circulation* 2019;139:155-68. <https://doi.org/10.1161/CIRCULATIONAHA.118.037231>.
1089. Cornwell 3rd WK, Ambardekar AV, Tran T, et al. Stroke incidence and impact of continuous-flow left ventricular assist devices on cerebrovascular physiology. *Stroke* 2019;50:542-8. <https://doi.org/10.1161/STROKEAHA.118.022967>.
1090. Milano CA, Rogers JG, Tatroles AJ, et al. HVAD: the ENDURANCE supplemental trial. *JACC Heart Fail* 2018;6:792-802. <https://doi.org/10.1016/j.jchf.2018.05.012>.
1091. Raasch H, Jensen BC, Chang PP, et al. Epidemiology, management, and outcomes of sustained ventricular arrhythmias after continuous-flow left ventricular assist device implantation. *Am Heart J* 2012;164:373-8. <https://doi.org/10.1016/j.ahj.2012.06.018>.
1092. Andersen M, Videbaek R, Boesgaard S, Sander K, Hansen PB, Gustafsson F. Incidence of ventricular arrhythmias in patients on long-term support with a continuous-flow assist device (HeartMate II). *J Heart Lung Transplant* 2009;28:733-5. <https://doi.org/10.1016/j.healun.2009.03.011>.
1093. Anderson RD, Lee G, Virk S, et al. Catheter ablation of ventricular tachycardia in patients with a ventricular assist device: a systematic review of procedural characteristics and outcomes. *JACC Clin Electro* 2019;5:39-51. <https://doi.org/10.1016/j.jacep.2018.08.009>.
1094. Liang JJ, Canterbury A, Kancharla K, Santangeli P. Catheter and surgical ablation for ventricular tachycardia in patients with left ventricular assist devices. *Heart Rhythm* 2023;20:927-32. <https://doi.org/10.1016/j.hrthm.2023.03.004>.
1095. Tankut S, Gosev I, Yoruk A, et al. Intraoperative ventricular tachycardia ablation during left ventricular assist device implantation in high-risk heart failure patients. *Circ Arrhythm Electro* 2022;15:e010660. <https://doi.org/10.1161/CIRCEP.121.010660>.
1096. Friedel N, Viazis P, Schiessler A, et al. Recovery of end-organ failure during mechanical circulatory support. *Eur J Cardiothorac Surg* 1992;6:519-23. [https://doi.org/10.1016/1010-7940\(92\)90001-e](https://doi.org/10.1016/1010-7940(92)90001-e).
1097. Farrar DJ, Hill JD. Recovery of major organ function in patients awaiting heart transplantation with Thoratec ventricular assist devices. Thoratec Ventricular Assist Device Principal Investigators. *J Heart Lung Transplant* 1994;13:1125-32.
1098. John R, Boyle A, Pagani F, Miller L. Physiologic and pathologic changes in patients with continuous-flow ventricular assist devices. *J Cardiovasc Transl Res* 2009;2:154-8. <https://doi.org/10.1007/s12265-009-9092-y>.
1099. Grimm JC, Magruder JT, Do N, et al. Modified Model for End-Stage Liver Disease eXcluding INR (MELD-XI) score predicts early death after pediatric heart transplantation. *Ann Thorac Surg* 2016;101:730-5. <https://doi.org/10.1016/j.athoracsur.2015.06.063>.
1100. Alsoufi B, Kozik D, Lambert AN, et al. Associated factors and impact of persistent renal dysfunction in pediatric heart transplantation. *Ann Thorac Surg* 2024;117:136-42. <https://doi.org/10.1016/j.athoracsur.2023.01.003>.
1101. Hollander SA, Cantor RS, Sutherland SM, et al. Renal injury and recovery in pediatric patients after ventricular assist device implantation and cardiac transplant. *Pedia Transpl* 2019;23:e13477. <https://doi.org/10.1111/petr.13477>.
1102. May LJ, Montez-Rath ME, Yeh J, et al. Impact of ventricular assist device placement on longitudinal renal function in children with end-stage heart failure. *J Heart Lung Transplant* 2016;35:449-56. <https://doi.org/10.1016/j.healun.2015.10.039>.
1103. Gupta D, Bansal N, Jaeger BC, et al. Prolonged hospital length of stay after pediatric heart transplantation: a machine learning and logistic regression predictive model from the Pediatric Heart Transplant Society. *J Heart Lung Transpl* 2022;41:1248-57. <https://doi.org/10.1016/j.healun.2022.05.016>.

1104. Alexopoulos SP, Wu WK, Ziogas IA, et al. Adult combined heart-liver transplantation: the United States experience. *Transpl Int* 2022;35:10036. <https://doi.org/10.3389/ti.2021.10036>.
1105. Dani A, Price N, Thangappan K, et al. Heart-kidney listing is better than isolated heart listing for pediatric heart transplant candidates with significant renal insufficiency. *J Thorac Cardiovasc Surg* 2022;164:2019-31. <https://doi.org/10.1016/j.jtcvs.2021.10.082>.
1106. George AN, Hsia TY, Schievano S, Bozkurt S. Complications in children with ventricular assist devices: systematic review and meta-analyses. *Heart Fail Rev* 2022;27:903-13. <https://doi.org/10.1007/s10741-021-10093-x>.
1107. Dipchand AI, Kirk R, Naftel DC, et al. Ventricular assist device support as a bridge to transplantation in pediatric patients. *J Am Coll Cardiol* 2018;72:402-15. <https://doi.org/10.1016/j.jacc.2018.04.072>.
1108. Auerbach SR, Cantor RS, Bradford TT, et al. The effect of infectious complications during ventricular assist device use on outcomes of pediatric heart transplantation. *ASAIO J* 2022;68:287-96. <https://doi.org/10.1097/MAT.0000000000001442>.
1109. Crespo-Leiro MG. Heart Transplantation in Spain: a review of the heart transplant programme in Spain from its beginning in 1984 by Marisa Crespo-Leiro MD. *Eur Heart J* 2017;38:3414-6. <https://doi.org/10.1093/eurheartj/ehx699>.
1110. Jasseron C, Lebreton G, Cantrelle C, et al. Impact of heart transplantation on survival in patients on venoarterial extracorporeal membrane oxygenation at listing in France. *Transplantation* 2016;100:1979-87. <https://doi.org/10.1097/TP.0000000000001265>.
1111. Gonzalez MH, Acharya D, Lee S, et al. Improved survival after heart transplantation in patients bridged with extracorporeal membrane oxygenation in the new allocation system. *J Heart Lung Transplant* 2021;40:149-57. <https://doi.org/10.1016/j.healun.2020.11.004>.
1112. Araj FG. Temporary mechanical circulatory support devices and post-transplant outcome: not all devices are created equal. *J Heart Lung Transplant* 2019;38:1323. <https://doi.org/10.1016/j.healun.2019.09.014>.
1113. Baran DA, Jaiswal A, Hennig F, Potapov E. Temporary mechanical circulatory support: devices, outcomes, and future directions. *J Heart Lung Transplant* 2022;41:678-91. <https://doi.org/10.1016/j.healun.2022.03.018>.
1114. Barge-Caballero E, Almenar-Bonet L, Gonzalez-Vilchez F, et al. Clinical outcomes of temporary mechanical circulatory support as a direct bridge to heart transplantation: a nationwide Spanish registry. *Eur J Heart Fail* 2018;20:178-86. <https://doi.org/10.1002/ejhf.956>.
1115. Reich H, Ramzy D, Moriguchi J, et al. Acceptable post-heart transplant outcomes support temporary MCS prioritization in the New OPTN|UNOS Heart Allocation Policy. *Transpl Proc* 2021;53(1):353-7. <https://doi.org/10.1016/j.transproceed.2020.04.1819>.
1116. Šipuš D, Krželj K, Đurić Ž, et al. Veno-arterial extracorporeal membrane oxygenation as a bridge to heart transplant-change of paradigm. *J Clin Med* 2022;11:7101. <https://doi.org/10.3390/jcm11237101>.
1117. Urban M, Siddique A, Merritt-Genore H, Um J. What are the results of venoarterial extracorporeal membrane oxygenation bridging to heart transplantation? *Inter Cardiovasc Thorac Surg* 2019;29:632-4. <https://doi.org/10.1093/icvts/ivz096>.
1118. Yin MY, Wever-Pinzon O, Mehra MR, et al. Post-transplant outcome in patients bridged to transplant with temporary mechanical circulatory support devices. *J Heart Lung Transplant* 2019;38:858-69. <https://doi.org/10.1016/j.healun.2019.04.003>.
1119. Shore S, Golbus JR, Aaronson KD, Nallamothu BK. Changes in the United States adult heart allocation policy: challenges and opportunities. *Circ Cardiovasc Qual Outcomes* 2020;13:e005795. <https://doi.org/10.1161/CIRCOUTCOMES.119.005795>.
1120. Network. CCT; November 9, 2021 Available at: www.efaidnbmnnnibpcajpcgclefindmkaj/https://ccs.ca/app/uploads/2022/01/StatusListingRevision_November9_2021.pdf.
1121. Eurotransplant. Chapter 6: ET Thoracic Allocation System (ETAS). Available at: <https://www.eurotransplant.org/allocation/eurotransplant-manual/>.
1122. Fiorentino M, Suarez SM, Botta L, et al. Cardiac Transplantation Italian Allocation System analysis: single center results. *J Heart Lung Transplant* 2022;41(4 Suppl):S366.
1123. POL229/9-Heart Transplantation: Selection Criteria and Recipient Registration. Available at: <https://nhsbt.dbe.blob.core.windows.net/umbraco-assets-corp/26637/pol229.pdf>.
1124. Clerkin KJ, Salako O, Fried JA, et al. Impact of temporary percutaneous mechanical circulatory support before transplantation in the 2018 Heart Allocation System. *JACC Heart Fail* 2022;10:12-23. <https://doi.org/10.1016/j.jchf.2021.08.003>.
1125. Salter BS, Gross CR, Weiner MM, et al. Temporary mechanical circulatory support devices: practical considerations for all stakeholders. *Nat Rev Cardiol* 2023;20:263-77. <https://doi.org/10.1038/s41569-022-00796-5>.
1126. Ouyang D, Gulati G, Ha R, Banerjee D. Incidence of temporary mechanical circulatory support before heart transplantation and impact on post-transplant outcomes. *J Heart Lung Transplant* 2018;37:1060-6. <https://doi.org/10.1016/j.healun.2018.04.008>.

1127. Rousse N, Juthier F, Pinçon C, et al. ECMO as a bridge to decision: Recovery, VAD, or heart transplantation? *Int J Cardiol* 2015;187:620-7. <https://doi.org/10.1016/j.ijcard.2015.03.283>.
1128. Hernandez-Montfort J, Sinha SS, Thayer KL, et al. Clinical outcomes associated with acute mechanical circulatory support utilization in heart failure related cardiogenic shock. *Circ Heart Fail* 2021;14:e007924. <https://doi.org/10.1161/CIRCHEARTFAILURE.120.007924>.
1129. van Diepen S, Katz JN, Albert NM, et al. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. *Circulation* 2017;136:e232-68. <https://doi.org/10.1161/CIR.0000000000000525>.
1130. Lauridsen MD, Gammelager H, Schmidt M, et al. Acute kidney injury treated with renal replacement therapy and 5-year mortality after myocardial infarction-related cardiogenic shock: a nationwide population-based cohort study. *Crit Care* 2015;19:452. <https://doi.org/10.1186/s13054-015-1170-8>.
1131. Adler C, Reuter H, Seck C, Hellmich M, Zobel C. Fluid therapy and acute kidney injury in cardiogenic shock after cardiac arrest. *Resuscitation* 2013;84:194-9. <https://doi.org/10.1016/j.resuscitation.2012.06.013>.
1132. Singh S, Kanwar A, Sundaragiri PR, et al. Acute kidney injury in cardiogenic shock: an updated narrative review. *J Cardiovasc Dev Dis* 2021;8:88. <https://doi.org/10.3390/jcdd8080088>.
1133. Zalawadiya S, Fudim M, Bhat G, Cotts W, Lindenfeld J. Extracorporeal membrane oxygenation support and post-heart transplant outcomes among United States adults. *J Heart Lung Transplant* 2017;36:77-81. <https://doi.org/10.1016/j.healun.2016.10.008>.
1134. Cho YH, Yang JH, Sung K, et al. Extracorporeal life support as a bridge to heart transplantation: importance of organ failure in recipient selection. *ASAIO J* 2015;61:139-43. <https://doi.org/10.1097/MAT.0000000000000171>.
1135. Fukuhara S, Takeda K, Kurlansky PA, Naka Y, Takayama H. Extracorporeal membrane oxygenation as a direct bridge to heart transplantation in adults. *J Thorac Cardiovasc Surg* 2018;155:1607-1618.e6. <https://doi.org/10.1016/j.jtcvs.2017.10.152>.